<SEC-DOCUMENT>0001558370-24-014767.txt : 20241107
<SEC-HEADER>0001558370-24-014767.hdr.sgml : 20241107
<ACCEPTANCE-DATETIME>20241107083530
ACCESSION NUMBER:		0001558370-24-014767
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		45
CONFORMED PERIOD OF REPORT:	20240930
FILED AS OF DATE:		20241107
DATE AS OF CHANGE:		20241107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aprea Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001781983
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39069
		FILM NUMBER:		241433375

	BUSINESS ADDRESS:	
		STREET 1:		3805 OLD EASTON ROAD
		CITY:			DOYLESTOWN
		STATE:			PA
		ZIP:			18902
		BUSINESS PHONE:		617-463-9385

	MAIL ADDRESS:	
		STREET 1:		3805 OLD EASTON ROAD
		CITY:			DOYLESTOWN
		STATE:			PA
		ZIP:			18902
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>apre-20240930x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.8.0.95 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 11/5/2024 12:12:55 PM -->
<!-- iXBRL Library version: 1.0.9027.2259 -->
<!-- iXBRL Service Job ID: 32dc9683-b0ce-49ed-b2cb-1d11e48203ad -->
<html xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:apre="http://aprea.com/20240930" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" xs:nil="true" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" name="us-gaap:CommitmentsAndContingencies" id="Hidden_-zPpJ3bRgkyQ0nxFFzF5lw"/><ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" xs:nil="true" contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg" name="us-gaap:CommitmentsAndContingencies" id="Hidden_GlMZNwmHW0qzOUsp9CRjlg"/><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="dei:EntityCentralIndexKey" id="Tc_XKnPpj0gkkCLXqbRAjdmRA_1_1">0001781983</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="dei:CurrentFiscalYearEndDate" id="Tc_napIRieUEU25LorZQCOpFA_2_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="dei:DocumentFiscalYearFocus" id="Tc_CwTW4B8KwEOKj1yJhkVIpw_3_1">2024</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="dei:DocumentFiscalPeriodFocus" id="Tc_GrlxfBf1qEet2t2j3Gc_lQ_4_1">Q3</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="dei:AmendmentFlag" id="Tc_XX9aeEqGc0uSOa5ZWi8sjw_5_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_81GrG1sLMEy1hqocEcqz_A">5434903</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_RER4QCFRiEqM4rJJHJIF8Q">3736673</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="As_Of_9_30_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_vRazHx54bUee8EgCl6bZxg" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_T0es8AYRy0ahzFENb_YA5A">56227</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_m1QoLrlDGE-p35iHaQN70A" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_CwFh2Lkz30mFTRIyKnV_og">56227</ix:nonFraction><ix:nonNumeric contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g" name="ecd:Rule10b51ArrAdoptedFlag" id="Hidden_crGT9flIcE6p7KBQXNYKVQ">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g" name="ecd:NonRule10b51ArrAdoptedFlag" id="Hidden_bgQIm2SdUki9zLB3cPayVA">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g" name="ecd:Rule10b51ArrTrmntdFlag" id="Hidden_iA1bmvAgEkabBTZ1yPfd7g">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g" name="ecd:NonRule10b51ArrTrmntdFlag" id="Hidden_gT6Ck3ksFUm3M-K_GoMkjg">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" decimals="0" name="apre:LesseeOperatingLeaseAnnualBaseRentObligationAfterCurrentYear" id="Hidden_dXY0fqi6LUqjrBt7mcO_tw">0</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="apre-20240930.xsd"/></ix:references><ix:resources><xbrli:context id="As_Of_9_30_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8visgBbaHUi1WL8smvF9Lg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">apre:ConvertiblePreferredStockSeriesaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_vRazHx54bUee8EgCl6bZxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">apre:ConvertiblePreferredStockSeriesaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_MQGoU-f5K02GZ9PlM-yOkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">apre:ConvertiblePreferredStockSeriesaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_liwNe_OrZkuTHNDpnZcmag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">apre:ConvertiblePreferredStockSeriesaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_7IVaogKI6UuHMaADrJkhsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">apre:ConvertiblePreferredStockSeriesaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_m1QoLrlDGE-p35iHaQN70A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">apre:ConvertiblePreferredStockSeriesaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_7gGY2uLNAUOrIeOyl0Yu3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">apre:ConvertiblePreferredStockSeriesaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_R6HjfKfj2kC0Dts-tFsRHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">apre:ConvertiblePreferredStockSeriesaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_rhWtSSOwCkCaEzpIAh-drA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">apre:ConvertiblePreferredStockSeriesaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8CsMqAUtn0GBba1hxVBFiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">apre:ConvertiblePreferredStockSeriesaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_Paz762NlyEuz8le-TUK-tw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_oHdcOW4hiEyfgESy4f5Jzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uk8mlSyVokKTP3XSCE6G2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bnRcQIiX2Eip-CUgrzN4Ag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SIsBYxIs2kWHjyNmgCyPrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_sqNgwBmbiUi7e68XTiWaJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GS2DrbBqyE-0nKgeaspqPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7APo5uzuAUeE_AwHD_aDyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_w6HcF2RyJ0OwVohdYcyrWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_mLJ_odBxZ0OgdXDNP5Doaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3OjBHmrFdEqql1a9Qd1d4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_z5h7zepvB0S3yMqUDLxYRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_kRMbWJwEh0W2ZdxtrlSp2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ZePgtrw-B0izH24xd1d8mw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wfx449lO0kKvBkD-ftLx7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Wi8LbADSoE6H9bs8u0MVsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_lCnJPy7l60uydEVcNxwm6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_Zvq5nTZZy0aWnnp0Yr_H1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mNt4s5ToekueR3QLxsxleQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GQCbRqVK3kuaSwxkX6qMKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_yLYKKEjvoUy7Hx5o25CtFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ibhlFLDIRka5MzPbpPpzAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6rGZcRyRUEmEmilgCL28PA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Ezbxq8ZdSkqMSQnvf2yPiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mlp_Zv_4RkCOvMMVab-nCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_yt6vg4-7Hk-CNT47e35gSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_VtyWAB_w50KEUnNv-Oaekg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_Lr_RTA-Vhk-vAvhygDZlMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_XHftf8DOMkW2QPF25BFt1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_DvSHu5RNCU269rSppFYYgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3R6cMW1KKUK6IIoYqDNzqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_slQjcR-CEUatMT3-GnhwQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_-el1flLwfkGvk1hb4s7jRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_X-C6_R8tJE29iS3my5-mwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fJbOuezCP0ukeyIR7_AUvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Omg5HL2Zk0iyUrhlyHkYzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_pTVYFBxdF0KO7SAVt4uiIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BOEuDXy_ZUeMtyMb1W31eg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tUhQ63t-YU-t2nhI1MP0bg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jAvkAIbuQECJ-En9TI9QOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5KgXuLcFS0y6eld2ApcJhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jLLZztnJSEaM57oF94_7xQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ep_zwMxd8Uy2Rb83GGZtEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_apre_ShelfRegistrationStatementMember_UBxEuMVTak-jJ5nG9mM16A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:ShelfRegistrationStatementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2023_To_2_28_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_apre_ShelfRegistrationStatementMember_LaEYUb2hjkW2KGU-74xlQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:ShelfRegistrationStatementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_fSqftKDYcEGIBNux4uAuoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_wNRC8dghckiqZHMJ2Qab2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fmrXxlAg8k2LTPqbZsdqQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_alO13T8cuE2PUKMnkFcK4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ZYusih75WEqqXs5jfU46kA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_BnvW7lwu70SqT0ZU3Hyn2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ZDYsshJEZkqk3c9XgeoP5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jqM4BFBbeUqa02lyUgxwnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_SbTatJBJOUiFH1taEFtwHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_pA-2oAPYMEqk86sHU18u8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_JK8xHrjZfkqa45FOBphUpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_NMOLLFp0TUWc89OurulIXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hNmUQDanvk2hr1a2pdyeMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_WAR5SHVFkE6tbDGoKuqOZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_Do28_zwKEkmVihgrJpKe5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_XHHJ56Sb40GzY2_iFyVSmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_8FQi5hYCckGx-AAVXCTMIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_18zK2B__vkKA8IrK9I5aKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_BniNzMIFNESCAEERHrL4Qg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_lWBjcVjr5UKoPSricaY5kw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_-xdRwU9xSUiPNwUETulTXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_V6BVG1ivukSZDtIV_eHuyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_I-_Nu9K7KEKrfxHT-XiE6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_z_oRFQwZ_U2_FPccUncU4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ddh4E4AbBEerRzR7f0tdRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_00YNAPouPUS3eodKEdKUZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_fAYnBVLhzUG8aJvV8WQWcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JmDXfNDeoU-A7sBdCGSkpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_k6qmi3YCyUeoj4EzQWmoYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_44A8CawaA0CwnlBa7i0axg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5LQIj-xrt0am4-0q7OB9Gw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_P0QiqJFu3ku16O4sijWHpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_60CYeoJMNkOFtTQ-EB4jYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_zTcMywQwh0-rXqoAlfNCWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_7_2024_rCC5Lx28V0yL1CVfxqJ0aQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_12_2020_us-gaap_SubsidiarySaleOfStockAxis_apre_ShelfRegistrationStatementMember_ARwQ47H460ieVrWA3BWUnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:ShelfRegistrationStatementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice9.1125PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_G-a6RTBX2E2Sy0VISZQI2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:PreFundedWarrantsExercisePrice9.1125PerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice7.29PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_lx_pDgysWkWXlV3jLs59hg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:PreFundedWarrantsExercisePrice7.29PerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_srt_StatementScenarioAxis_apre_AtEventOfElectionOfHolderMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_jryn2JxtuUiScam-ie0pMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">apre:AtEventOfElectionOfHolderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_5KoUULH39EatBTbigzb7Nw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice9.1125PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_zOEchtkouU6yqqanDoFo6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:PreFundedWarrantsExercisePrice9.1125PerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-11</xbrli:startDate><xbrli:endDate>2024-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice7.29PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_2erKOwIbbU-vg-0HBwM-Ew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:PreFundedWarrantsExercisePrice7.29PerShareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-11</xbrli:startDate><xbrli:endDate>2024-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_NhXjTaJGO0qzpt50WX1aQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-11</xbrli:startDate><xbrli:endDate>2024-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_26_2024_srt_CounterpartyNameAxis_apre_HCWainrightCoLlcMember_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarket2024OfferingMember_M05-gKo8P0qhKNNnCJ2ynA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:HCWainrightCoLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:AtMarket2024OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_26_2024_us-gaap_SubsidiarySaleOfStockAxis_apre_ShelfRegistrationStatement2024Member_hof9NYm7h0ub2MpXywHosA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:ShelfRegistrationStatement2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_12_2020_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_gmVaaYo2B0i-Fejiwesclg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_12_2020_To_11_12_2020_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_MJWqDGoHuUiO0gnEMhlZUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:AtMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-12</xbrli:startDate><xbrli:endDate>2020-11-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001781983</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_psC0V7jouEy1pdZ9EBR0Hw"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Vote_xLAtZ3mDNEadoQnTSpr_cQ"><xbrli:measure>apre:Vote</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_lease_uug6S_kQsEij919rCVEEeQ"><xbrli:measure>apre:lease</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_44ea2a96_ba19_40ae_9fad_78d162cc0ded"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:2.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="dei:DocumentType" id="Narr_3EyfGtKt4keo4c6_fk73Ow"><b style="font-weight:bold;">10-Q</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="dei:DocumentQuarterlyReport" id="Narr_w0gcbDq8Y0-lDVN_QGJFAQ"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b></ix:nonNumeric>&#160;&#160;&#160;<b style="font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the quarterly period ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="dei:DocumentPeriodEndDate" id="Narr_sB7B1yXT1Eqi7OUmWRRDtQ"><b style="font-weight:bold;">September&#160;30,&#160;2024</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="dei:DocumentTransitionReport" id="Narr_G22wCT5rC025ytYgtEnqmw"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></ix:nonNumeric>&#160;&#160;&#160;<b style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:center;margin:0pt;"><b style="font-size:10pt;font-weight:bold;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Commission File Number </b><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="dei:EntityFileNumber" id="Narr_PSzfweh-q0CmlEk6Zbmp8Q"><b style="font-weight:bold;">001-39069</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="dei:EntityRegistrantName" id="Narr_ojBHyRfuIU-yLfD0HkKXaQ"><b style="font-weight:bold;">Aprea Therapeutics, Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_92220628_6373_4a36_bcb6_b2cb3c249e79"></a><a id="Tc_jZGsVZu3hEq0KOce4fX2bw_2_0"></a><a id="Tc_9yTVd0aGK0qhYRhv0E8vSw_2_1"></a><a id="Tc_-z-oegBxfkKzkQ7FzdnOog_5_0"></a><a id="Tc_rYOM6FEX8UCKz2vHU2KgHQ_6_0"></a><a id="Tc__4RA4N3ZQkS8fAUcinlQkA_6_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="dei:EntityIncorporationStateCountryCode" id="Tc_6ssEvX4HFUyAOw6CPms7vA_1_0"><b style="font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="dei:EntityTaxIdentificationNumber" id="Tc_Gu69SdIOok67RdkC-ejIiQ_1_1"><b style="font-size:9pt;font-weight:bold;">84-2246769</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(State or other jurisdiction of incorporation or organization)</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(I.R.S. Employer Identification No.)</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="dei:EntityAddressAddressLine1" id="Tc_wzLS2aVhnEC2xb4qSAXwGQ_4_0"><b style="font-size:9pt;font-weight:bold;">3805 Old Easton Road</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="dei:EntityAddressCityOrTown" id="Narr_y41Qg7TG1kWkTvWB3OXf6w"><b style="font-size:9pt;font-weight:bold;">Doylestown</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="dei:EntityAddressStateOrProvince" id="Narr_wJasxAZpW0S0wgLumzRR_Q"><b style="font-size:9pt;font-weight:bold;">Pennsylvania</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;"> </b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="dei:EntityAddressPostalZipCode" id="Tc_8vVtiqNlCE2DSygFL1Kpqg_5_1"><b style="font-size:9pt;font-weight:bold;">18902</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="dei:CityAreaCode" id="Narr_QKJzOCR1TU-hJgn6stk4AA"><b style="font-size:9pt;font-weight:bold;">617</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="dei:LocalPhoneNumber" id="Narr_9_TxHZu_NUyLDP9q1WS0aQ"><b style="font-size:9pt;font-weight:bold;">463-9385</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Registrant&#8217;s telephone number, including area code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Not Applicable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Former name, former address and former fiscal year, if changed since last report)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Securities registered pursuant to Section&#160;12(b) of the Act: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_305fe040_d707_41e3_b170_24d9f468bc1f"></a><a id="Tc_0kMXwS2uNUKeayGia3amGQ_0_0"></a><a id="Tc_zLg5cNBgkUCmJKsNwlskQQ_0_2"></a><a id="Tc_xxcDvqGgC0Cuuk-srTq0qQ_0_4"></a><a id="Tc_XIe2KtOLH0KbaPFZUGtdUA_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:38.54%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class </b></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:16.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol&#160;</b></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:38.54%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of exchange on which registered: </b></p></td></tr><tr><td style="vertical-align:bottom;width:38.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="dei:Security12bTitle" id="Tc_P-tu_nVO6kWUmpn-GsQfsQ_1_0"><span style="font-size:8pt;">Common stock, par value $0.001 per share</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:16.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="dei:TradingSymbol" id="Tc_PhsGREJQbEa0tMgS88zNvg_1_2"><span style="font-size:8pt;">APRE</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:38.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="dei:SecurityExchangeName" id="Narr_rCNJGzOx60WSYn1O8RinCw"><span style="font-size:8pt;">The NASDAQ</span></ix:nonNumeric><span style="font-size:8pt;"> Stock Market LLC</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160; </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="dei:EntityCurrentReportingStatus" id="Narr_GiAzFkMRv0qtBZ8AX32WkQ"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160;&#160;No&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="dei:EntityInteractiveDataCurrent" id="Narr_iJmIp6IRTU2w2xJCdKj7yQ"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160;&#160;No&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.&#160; See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:72pt;text-align:center;text-indent:-72pt;margin:0pt;">Large accelerated filer&#160;<span style="font-family:'Times New Roman';">&#9723;</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:36pt;text-indent:-36pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;">Accelerated filer&#160;<span style="font-family:'Times New Roman';">&#9723;</span></p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;padding-left:36pt;text-indent:-36pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:72pt;text-align:center;text-indent:-72pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="dei:EntityFilerCategory" id="Narr_qba514AAzU67n8DjTcaNXQ"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric><span style="font-size:8pt;">&#160;</span><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:36pt;text-indent:-36pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;"><span style="font-size:8pt;">Smaller reporting company&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="dei:EntitySmallBusiness" id="Narr_yc7KsLwGeEmXF9XOThvrWg"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b></ix:nonNumeric></p></td></tr><tr style="height:5.35pt;"><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;padding-left:36pt;text-indent:-36pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:36pt;text-indent:-36pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt;"><span style="font-size:8pt;">Emerging growth company&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="dei:EntityEmergingGrowthCompany" id="Narr_Xq-YVpI1VUWxoJlez3dpfw"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="dei:EntityExTransitionPeriod" id="Narr_Yzrqj7RULESeNk-F_INK8Q"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160; Yes&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="dei:EntityShellCompany" id="Narr_R4epJb8DE0CZFJUxC-6_vg"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;No&#160;</span><span style="font-family:'Times New Roman';">&#8999;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">There were <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_11_7_2024_rCC5Lx28V0yL1CVfxqJ0aQ" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_W0_o68Wrn06Hp7RFBRwVVA">5,434,903</ix:nonFraction> shares of the registrant&#8217;s common stock, $0.001 par value, outstanding as of November 7, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="TOC"></a><a id="_9ff45271_8c07_4ea9_abfc_4cb68154b955"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Aprea Therapeutics,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Quarterly Report on Form&#160;10-Q</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">For the Quarter Ended September&#160;30,&#160;2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PartIFinancialInformation_655269"><span style="font-style:normal;font-weight:normal;">PART&#160;I</span><span style="font-family:'Symbol';font-style:normal;font-weight:normal;">:</span><span style="font-style:normal;font-weight:normal;"> FINANCIAL INFORMATION</span></a></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><a href="#Item1FinancialStatements_974418"><span style="font-style:normal;font-weight:normal;">Item 1. Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">16</p></td></tr><tr><td style="vertical-align:top;width:92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><a href="#Item3Quantitativeandqualitativedisclosur"><span style="font-style:normal;font-weight:normal;">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">28</p></td></tr><tr><td style="vertical-align:top;width:92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><a href="#Item4ControlsandProcedures_266"><span style="font-style:normal;font-weight:normal;">Item 4. Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIIOTHERINFORMATION_907842"><span style="font-style:normal;font-weight:normal;">PART&#160;II</span><span style="font-family:'Symbol';font-style:normal;font-weight:normal;">:</span><span style="font-style:normal;font-weight:normal;"> OTHER INFORMATION</span></a></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><a href="#Item1LegalProceedings_809320"><span style="font-style:normal;font-weight:normal;">Item 1. Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><a href="#Item1ARiskFactors"><span style="font-style:normal;font-weight:normal;">Item 1A. Risk Factors</span></a></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">30</p></td></tr><tr><td style="vertical-align:top;width:92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-style:normal;font-weight:normal;">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">88</p></td></tr><tr><td style="vertical-align:top;width:92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><a href="#Item3DefaultsUponSeniorSecurities_753349"><span style="font-style:normal;font-weight:normal;">Item 3. Defaults Upon Senior Securities</span></a></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">88</p></td></tr><tr><td style="vertical-align:top;width:92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><a href="#Item4MineSafetyDisclosures_869418"><span style="font-style:normal;font-weight:normal;">Item 4. Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">88</p></td></tr><tr><td style="vertical-align:top;width:92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><a href="#Item5OtherInformation_682434"><span style="font-style:normal;font-weight:normal;">Item 5. Other Information</span></a></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">88</p></td></tr><tr><td style="vertical-align:top;width:92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><a href="#Item6Exhibits_309671"><span style="font-style:normal;font-weight:normal;">Item 6. Exhibits</span></a></p></td><td style="vertical-align:bottom;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">89</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_d4745fd7_ddcc_438d_a181_ade60fbbec91"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">This Quarterly Report on Form&#160;10-Q includes statements that are, or may be deemed, &#8220;forward-looking statements.&#8221; In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;designed,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;approximately&#8221; or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. They appear in a number of places throughout this Quarterly Report on Form&#160;10-Q and include statements regarding our current intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ongoing and planned clinical trials, including for ATRN-119, our ongoing and planned IND-enabling studies, including for APR-1051, our ongoing and planned development, prospects for commercialization, and market uptake of our potential product candidates, the strength and breadth of our intellectual property, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, the legal and regulatory landscape impacting our business, the degree of clinical utility of our product candidates, particularly in specific patient populations, expectations regarding clinical trial data, our development and validation of manufacturing capabilities, our results of operations, financial condition, liquidity, prospects, growth and strategies, the length of time that we will be able to continue to fund our operating expenses and capital expenditures, our expected financing needs and sources of financing, the industry in which we operate and the trends that may affect the industry or us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">By their nature, forward-looking statements involve risks and uncertainties because they relate to future events, competitive dynamics, and healthcare, regulatory and scientific developments and depend on economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We caution you that forward-looking statements are not guarantees, or predictive, of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this Quarterly Report on Form&#160;10-Q.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Some of the factors that we believe could cause actual results to differ from those anticipated or predicted include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">estimates of our expenses, capital requirements and our needs for additional financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">business interruptions, including delays in enrollment, patient follow-up and data collection of clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prospects of our product candidates, all of which are still in development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outcome and results of ongoing or future preclinical studies and clinical trials of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations regarding our ability to identify, discover or acquire additional suitable product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the design of our ongoing and planned clinical trials, including the sample size, trial duration, endpoint definition, event rate assumptions and eligibility criteria;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to enroll patients in clinical trials, to timely and successfully complete those trials and to receive necessary regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations regarding the timing of initiation of data readout from our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market acceptance or commercial success of any product candidate we develop and the degree of acceptance among physicians, patients, patient advocacy groups, healthcare payors and the medical community;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations regarding competition, potential market size, the size of the patient populations for our product candidates, if approved for commercial use, and market acceptance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain regulatory approval of our product candidates, and any restrictions, limitations and/or warnings in their labels, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential claims relating to our intellectual property and third-party intellectual property;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the duration of our intellectual property estate that will provide protection for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments relating to our competitors and our industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our sales, marketing or distribution capabilities and our ability to commercialize our product candidates, if we obtain regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">current and future agreements with third parties in connection with conducting clinical trials, as well as the manufacturing of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations regarding the ability of our current contract manufacturing partners to produce our product candidates in the quantities and timeframe that we will require;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations regarding our future costs of goods;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to attract, retain and motivate key personnel and increase the size of our organization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish collaborations in lieu of obtaining additional financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of government laws and regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our financial performance; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations regarding the time during which we will be an emerging growth company under the JOBS Act or a smaller reporting company under the Exchange Act.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10.5pt 0pt;">Any forward-looking statements that we make in this Quarterly Report on Form&#160;10-Q speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this Quarterly Report on Form&#160;10-Q. You should also read carefully the factors described in the &#8220;Risk Factors&#8221; included in Part&#160;II,&#160;Item&#160;1A of this Quarterly Report, in Part I and in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December&#160;31,&#160;<span style="white-space:pre-wrap;">2023 to better understand significant risks and uncertainties inherent in our business and underlying any forward-looking statements.  As a result of these factors, we cannot assure you that the forward-looking statements in this Quarterly Report on Form&#160;10-Q will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified timeframe, or at all.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10.5pt 0pt;">This Quarterly Report on Form&#160;10-Q includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe these industry publications and third-party research, surveys and studies are reliable, we have not independently verified such data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10.5pt 0pt;">We qualify all of our forward-looking statements by these cautionary statements. In addition, with respect to all of our forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This Form&#160;10-Q may include trademarks, tradenames, and service marks that are the property of other organizations. Solely for convenience, our trademarks and tradenames referred to in this Form&#160;10-Q may appear without the &#174; and &#8482; symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of the applicable licensor to these trademarks and tradenames.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_6f9f2a5c_9f8b_49f7_969d_77f01ac91066"></a><a id="PartIFinancialInformation_655269"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Part I &#8211; Financial Information </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Item1FinancialStatements_974418"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Item 1.  Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aprea Therapeutics, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Balance Sheets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">(Unaudited)</b></p><a id="_ca1467be_1284_4528_8de3_99d1c6e1fa34"></a><a id="Tc_tZKygW_vW0aX_TeGMPYd0w_1_2"></a><a id="Tc_JLUXz2k4b0yVWBRNYik5pQ_1_5"></a><a id="Tc_pT89_Ik2QkW38TdRfsuNmA_2_2"></a><a id="Tc_3QHm9f4sJEup7P7bDm8rsw_2_5"></a><a id="Tc_9HuH7lTYQkOGYSGCpvythg_3_0"></a><a id="Tc_bIfIFY2uVE2dawgCFcOKBg_4_0"></a><a id="Tc_9R3aVuWJo0G6ztkh-EoYLQ_5_0"></a><a id="Tc_umgGf44zT0ubuZbSsnhyfw_5_2"></a><a id="Tc_gmB2O2IER0y34Bf-Amzzlw_5_5"></a><a id="Tc_Xyo7-u-ytUC6mjG7LMvQsw_6_0"></a><a id="Tc_zz_sink4jku3KbboLYu94w_7_0"></a><a id="Tc_q_Wcl-C2Okqqw5TkRKpwvw_8_0"></a><a id="Tc_JwhqV4_LnkSCk5dN_fXK0Q_9_0"></a><a id="Tc_WASL0-jMOEy0daxWSS7gxA_10_0"></a><a id="Tc_xO0SDX9kXUaPR74DjSVn7A_10_6"></a><a id="Tc_U9F-rUTTPka0ZNUL9J5Y-A_11_0"></a><a id="Tc_PRi4qnbryUaIydscHz7a8Q_11_2"></a><a id="Tc_bNEJyg3nGkG4PVA6RVGkvg_11_5"></a><a id="Tc_cJp4FXrrEUOjP75lTJJKfQ_12_0"></a><a id="Tc_Dv98H97-7Uu8dB_XRjdA9Q_13_0"></a><a id="Tc_NMzCkBhtPEaxdUyRCSjVfg_14_0"></a><a id="Tc_09bQXoQ2ZkConhnXt2lRHQ_14_2"></a><a id="Tc_e3R0sGFkUku54CPF1jObLg_14_5"></a><a id="Tc_fzMZkKdXBkCRB0dtgz9-Ig_15_0"></a><a id="Tc_nVAdW5gqFUmV68HVd9kypQ_16_0"></a><a id="Tc_Wfd5I_tkbkWoWoyfr8miVg_16_3"></a><a id="Tc_uReTfO0HMUOjHMOrxZG5NA_17_0"></a><a id="Tc_GnLqDx4P2E2-5_zKcIWj9A_18_0"></a><a id="Tc_GT4S107CcUy5mJn8pBkfAg_19_0"></a><a id="_f49108ad_0a1d_49f7_925b_2a7c25332901"></a><a id="_f49108ad_0a1d_49f7_925b_2a7c25332901_2"></a><a id="_f49108ad_0a1d_49f7_925b_2a7c25332901_3"></a><a id="Tc_oOGrIbPHWU6B52vF4DK1EQ_20_0"></a><a id="Tc_6lUEKOc5HUyTFHGmGgcnNw_21_0"></a><a id="Tc_qkBI-u1HJk-5igHLfcRBLA_22_0"></a><a id="Tc_qj6r6PMX-kqbVDwr7bZA-w_23_0"></a><a id="Tc_9PNEth_Eo02SERn3Agb9OQ_24_0"></a><a id="Tc_d66lMu9LS0Kp4CxKYr4XyA_25_0"></a><a id="Tc_Mn26jqfrd0WjW5ugViNofg_26_0"></a><a id="Tc_s6Aon7y4G0aL__FW4JYqOw_26_2"></a><a id="Tc_tJJMNpRhf02RRs1U-b0s-g_26_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:68.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:68.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:68.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:68.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_xwW35TRHikG2gd6kqiwslg_5_3">26,249,625</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_6hmNAX_vfUypXc_dxTxKjw_5_6">21,606,820</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_GpJBH-ibME6L-u3Ws7q0aA_6_3">234,195</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_3VirJ-6dL0-b7By9btMguw_6_6">914,275</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_-HQ_7mI41kepF7tIDOMqaA_7_3">26,483,820</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_jX2RmYFcFE6K8PsTZ6lanA_7_6">22,521,095</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_1q29ya2eskWzxSky3GfJEA_8_3">86,950</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_66ZnmiQRqUee3WJnATLdgg_8_6">88,362</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="0" id="Tc_sGmvdS1hlUuxk6d_MEa-ng_9_3">41,537</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="0" id="Tc_SobIJs2yb06zlLhf3Kvv0A_9_6">40,717</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other noncurrent assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="Tc_CMsk6td60Ea1lYvFIXuT-Q_10_3">281,662</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:68.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_L9XfP9CCb0mieKdOOVB_Zg_11_3">26,893,969</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_610Ua_jG1UWQ53-i2cBZ0g_11_6">22,650,174</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and Stockholders&#8217; Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:68.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:68.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_G8SMTKHz-EC9CD1sUoSmtw_14_3">1,153,880</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_j2RnaRuAiUSIXNpDgE-yNg_14_6">1,670,369</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" decimals="0" format="ixt:numdotdecimal" name="apre:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_DvCf-6xvzUSkG_4mtHOv9A_15_3">2,482,008</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg" decimals="0" format="ixt:numdotdecimal" name="apre:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_WPDBb7I7_kiVHr1GMM2HBQ_15_6">2,186,262</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Deferred grant revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="0" id="Tc_syxRxJg3KEaTYZIRFop_DQ_16_6">528,974</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_nWTxQJptnUe7nDNsE5KWmA_17_3">3,635,888</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_kLb6H9SqkU6vWVGatza3_A_17_6">4,385,605</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commitments and contingencies (Note&#160;7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:68.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Series A convertible preferred stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A" contextRef="As_Of_9_30_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_vRazHx54bUee8EgCl6bZxg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr__V9i4AW9_k6mRdXL-u5v2g"><ix:nonFraction unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_m1QoLrlDGE-p35iHaQN70A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_ww2NYHLCo02p73H7Zokt4g">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="As_Of_9_30_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_vRazHx54bUee8EgCl6bZxg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_fIcmEaL62Eee5WP5DnxjeQ"><ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_m1QoLrlDGE-p35iHaQN70A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_T_CcTl9AsEilG_lqrjgXlw">40,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="As_Of_9_30_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_vRazHx54bUee8EgCl6bZxg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Narr_Q-UyHMcmO0SXkeRavtxDKw"><ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_m1QoLrlDGE-p35iHaQN70A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Narr_AMl_s0_W7EKGp5DesUOxDQ">56,227</ix:nonFraction></ix:nonFraction> shares issued and outstanding at September&#160;30,&#160;2024 and December&#160;31,&#160;2023.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_vRazHx54bUee8EgCl6bZxg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_7EHv4_rGN0aztZpi02rVYQ_19_3">1,311,063</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_m1QoLrlDGE-p35iHaQN70A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_FRVEsfynN0S5OW42AsVqgg_19_6">1,311,063</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stockholders&#8217; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:68.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_IzFUVydXVEqY14-FurjyBw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A" contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_sRx6OH7OEUyR4jywFXrn9A">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_RHAFHvIrg0e4XRZ15Fw_sA"><ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_Utdo9x2l8Eq0_JHzixqffg">400,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_CeoWckkCGkC6kFFbaqU6Xg">5,434,903</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_02rt8iZOK0WyuG6e8v9Xvg">3,736,673</ix:nonFraction> shares <span style="-sec-ix-hidden:Hidden_RER4QCFRiEqM4rJJHJIF8Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_81GrG1sLMEy1hqocEcqz_A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> at September&#160;30,&#160;2024 and December&#160;31,&#160;2023, respectively.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_IB9CDappAUeSQeUyuvd7rw_21_3">5,435</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_hn7wXOOUmEy1bRtO2pQVMw_21_6">3,736</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_p82MmbT6-0-t28Gb2HJ1lw_22_3">350,693,403</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_k9oFhNleUkynEB1A7rfDjw_22_6">335,644,204</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accumulated other comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="0" id="Tc_UDrU77dll0uPN7MBnSPaXQ_23_3">10,604,747</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="0" id="Tc_x8t1Lq8Evk20wrORScWGKA_23_6">10,611,273</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:68.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_R8mtH81G00-s4AqKkVIK9g_24_3">318,147,073</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_Ia9vhyWi8kCx5yEU55i_IA_24_6">308,083,161</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:68.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_MyabgoqC40S8zY8Uqwhf_Q_25_3">21,947,018</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_kqyHzXa8WUKQi1oMbl84wQ_25_6">16,953,506</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total liabilities and stockholders' equity </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_G6d0rDvyI06c4U_RnSaZEg_26_3">26,893,969</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_dhYvgRCBnkue2QssJiEqQg_26_6">22,650,174</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">See accompanying notes to unaudited condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_8c1ccf6e_a8e1_415e_aba9_b85571826bb7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aprea Therapeutics, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Operations and Comprehensive Loss</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Unaudited)</b></p><a id="_20238986_9cfd_4330_bfd9_91d737ca6b3f"></a><a id="_32c216e9_7942_477c_8dae_f11303642b8d"></a><a id="Tc_hT_b6P_Sq0acEgyxtHb5-Q_1_2"></a><a id="Tc_CcVZQ8ymiUWjKQxlp0texw_1_8"></a><a id="Tc_zOmAGQWLsEOIfOAtwwSNfA_2_2"></a><a id="Tc_RtU0xCmVWkqisFS8AtvJmQ_2_5"></a><a id="Tc_BPBguRmrSEi92z-5EG97Bw_2_8"></a><a id="Tc_d1hRtcaN0USvTBHShVtncA_2_11"></a><a id="Tc_DSbhPPfPWEq1NgCP6KXCYQ_3_0"></a><a id="Tc_2id-C3-IUkOB3s3tQ3VC3g_3_2"></a><a id="Tc_uZ9AVdNi1U6VqNQ07yoz5Q_3_5"></a><a id="Tc_s5IefLEkAUWu75NXz2IDWg_3_8"></a><a id="Tc_1uXlSxpgEUGlJXeZIRrPnA_3_11"></a><a id="Tc_c9eXV_r4X0iLvUh9vC0RNA_4_0"></a><a id="Tc_1L2NWiVCAkGngyYGD2U3Yw_5_0"></a><a id="Tc_Y28Z2VWaFEOWbtswSVyMdg_6_0"></a><a id="Tc_UE0nIT2pF0yJvQnp4I7NGA_7_0"></a><a id="Tc_GitVtwYQzUWGTImDVe6hqg_8_0"></a><a id="Tc_MGMNRNVDRkOlPHhyUrIhFw_9_0"></a><a id="Tc_-H8lX__u00ygjzC_qFDFuA_10_0"></a><a id="Tc_FdIbeXJ6rkeQuMuWVE8M0g_11_0"></a><a id="Tc_xXbkDzoYqEqJybSb28-NmA_12_0"></a><a id="Tc_nOdGaQ7zU02ST2AqKpcdLg_13_0"></a><a id="Tc_BMgDup5N1UKNX5tjLnT8BA_13_2"></a><a id="Tc_wj2BQoZOdEmIMEQdX-bfew_13_5"></a><a id="Tc_-zDd_jf-bUGa_S76cRn3Hw_13_8"></a><a id="Tc_jlLTa3WQfkOyijYNVKZEoQ_13_11"></a><a id="Tc_Har5ICWEQ0yL6R8EueQS8A_14_0"></a><a id="Tc_ovKFpxMSGkqGUhNY8Nr08A_15_0"></a><a id="Tc_kEqvWraVzEi4p-nrUlhxwg_16_0"></a><a id="Tc_0oSUWON6PkCgxKfNHwODlA_17_0"></a><a id="Tc_cWCl-aXXOkyIPpE4XeeEvA_17_2"></a><a id="Tc_-HF_0-m9QUmSXOx7849KzQ_17_5"></a><a id="Tc_fFcyCb1GrUCUhUVMgLyagg_17_8"></a><a id="Tc_zQM21UwvLEC0-dTwrNDVGg_17_11"></a><a id="Tc_F0_Vr_K_qka9q7qLBNZ1gw_18_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:44.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:44.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="0" id="Tc_7y_Xx6ROoEuyq-rLuifFIQ_3_3">354,621</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="0" id="Tc_ddvt6rKo4kKAztQ5EVTCcQ_3_6">319,468</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="0" id="Tc_ZJCmpVXFWUKB0E2md9d5lQ_3_9">1,296,764</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="0" id="Tc_s6oBQp0UJ06rQNpG8kmt3g_3_12">569,156</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:44.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:44.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="0" id="Tc_yITcHZEuqk-fAY00aoF2bg_5_3">2,846,399</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="0" id="Tc_oOoDLeUmzE-e81Mihua7hQ_5_6">2,122,603</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="0" id="Tc_YzR9eCMJTkODSf5km1tJIQ_5_9">7,004,451</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="0" id="Tc_EQl2UFcYo0eq5ymgj675kg_5_12">5,581,802</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:44.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_iQkcGfVGTU-p2_dxc0jAnw_6_3">1,605,238</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_3e0K-4Cqs0qO8ANBNNFHhw_6_6">1,719,715</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_Rb8ynzCUYk2bjmG-pfr-mA_6_9">5,385,923</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_Y7VuOiY1E0Oln5mHOe0wLA_6_12">6,784,388</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:44.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_pJ0Swk21b0qyxkjlB4FUrQ_7_3">4,451,637</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_vGqvNxYTQkam4wsOmgxbHA_7_6">3,842,318</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_6PD9TGIr10Wy_K7_jDWmyQ_7_9">12,390,374</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_Twcp66QJG06omA2ntD4KSw_7_12">12,366,190</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:44.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_cACtO86oEE-nb6IbfvgyTg_8_3">4,097,016</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_GiSotAG6ZkmOxUyLeQFNuQ_8_6">3,522,850</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_GORYa6gDJkC-7STYIRofeg_8_9">11,093,610</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_jcbyP1wD0UWshqU1k_2AUQ_8_12">11,797,034</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:44.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:44.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" id="Tc_lQ4wsYYrGEuW_RQ2_j9ulw_10_3">348,741</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" id="Tc_teuSu4Qnk0CKYgS_O78cPw_10_6">321,215</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" id="Tc_PnU4y0h67kKwJphCx8_fAg_10_9">1,014,518</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" id="Tc_EneG2cUihkSjL1BnOAxjIw_10_12">913,846</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:44.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Foreign currency (loss) gain</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" sign="-" scale="0" id="Tc_r0pOf9nJskmUOmyZEcVzBA_11_3">35,494</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" sign="-" scale="0" id="Tc_5wR7RpAhP0K8Ez-W50MOsA_11_6">2,880</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" id="Tc_DHm_G4UGbkyashh7Isyjvw_11_9">15,180</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" id="Tc_bT7QhfdONkqJlfvZRp-ptQ_11_12">39,686</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:44.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="Tc_yAnRuydnYkyb0CGyPXQbug_12_3">313,247</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="Tc_-7vTNQR0FEmjqKxWgDSaiA_12_6">318,335</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="Tc_XCKY8Z0E00mY9z6bUhCuoQ_12_9">1,029,698</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" id="Tc_nm0lEou1OECjoHCHEUFynw_12_12">953,532</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:44.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_Gjx7df3vpESV5TgwiUz1uQ_13_3">3,783,769</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_-a1dYDSGp0GuU331YUjksA_13_6">3,204,515</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_d31DbBKb3kGC94AfWlFjIg_13_9">10,063,912</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_JFuC-qrg_UKGciO0ZaSHgA_13_12">10,843,502</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:44.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other comprehensive income (loss):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:44.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Foreign currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="Tc_SYY3bec_dUWcbhBEYcY-1w_15_3">23,557</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="0" id="Tc_w0unpQdUKkiylkn65epYNg_15_6">1,002</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="Tc_GIeEB23lDUiwYoYF0da5KQ_15_9">6,526</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="0" id="Tc_q8rhOJU62kmU7GPxJ8IyWw_15_12">12,466</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:44.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="0" id="Tc__MEf_cTHNEu_Hl2hpPslMQ_16_3">3,760,212</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="0" id="Tc_uNjUnw3Ve0ez35gYCOxGeg_16_6">3,205,517</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="0" id="Tc_YMyG7bqgdE2bpYpgNdy_Kg_16_9">10,057,386</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="0" id="Tc_u47a4RwY5U2VFB_zGIw70w_16_12">10,855,968</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:44.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share attributable to common stockholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A" contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_BYOISHvoVUGifAaOX-50UQ_17_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A" contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_BYOISHvoVUGifAaOX-50UQ_17_3_2">0.64</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A" contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_M413Etpf_k2VfBcfXzr6xg_17_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A" contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_M413Etpf_k2VfBcfXzr6xg_17_6_2">0.86</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_a1vxov7CUkqlRXZkxgJWhA_17_9"><ix:nonFraction unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_a1vxov7CUkqlRXZkxgJWhA_17_9_2">1.88</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A" contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_uFaRapRVrkaHM6IeJFMuzQ_17_12"><ix:nonFraction unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A" contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_uFaRapRVrkaHM6IeJFMuzQ_17_12_2">3.03</ix:nonFraction></ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:44.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_CCzNvXdEUUiLCd_TvgLd7Q_18_3"><ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_CCzNvXdEUUiLCd_TvgLd7Q_18_3_2">5,939,755</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_WW9VMFFrZk-O6AyGbnvl8w_18_6"><ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_WW9VMFFrZk-O6AyGbnvl8w_18_6_2">3,735,176</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_F7BRbzPD80S8-oz_3y-hnQ_18_9"><ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_F7BRbzPD80S8-oz_3y-hnQ_18_9_2">5,360,579</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_BnLGV-j-R0-7QFwEjdrhJg_18_12"><ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_BnLGV-j-R0-7QFwEjdrhJg_18_12_2">3,577,482</ix:nonFraction></ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">See accompanying notes to unaudited condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:8%;padding-right:8%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_e97947dc_73c2_44f3_935f_aef5f3adf274"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aprea Therapeutics, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Unaudited)</b></p><a id="_3a84d363_42ee_4c4a_86ec_529867559813"></a><a id="Tc_uYoD5f7krE6ZI7r1mH9AYw_1_12"></a><a id="Tc_ofwXck1FPESilS5TdNYzWA_1_15"></a><a id="Tc_KKcaXZKNjE-5gHv4UGqIMw_2_2"></a><a id="Tc_S5mvBtk6wkqAHzEsVl8KxQ_2_7"></a><a id="Tc_zQnXtxsHQ02EbwA8wAhi-Q_2_12"></a><a id="Tc_S49fJ7duckyVyg9gtKJEwA_2_15"></a><a id="Tc_Wu_AaNQuLUaaH0wnXxUXmg_2_18"></a><a id="Tc_nOzgJzjcE0WqXXn9N_vgJg_2_21"></a><a id="Tc_nKLxUZfsmkiIvc7xw0UM0g_3_2"></a><a id="Tc_AvwnNbfDjUqt9uqYYrcYMw_3_4"></a><a id="Tc_DRuMbJka8kC6CaPopxlhLQ_3_7"></a><a id="Tc_RxB0OaVI-EO8lWwuXtkc9w_3_9"></a><a id="Tc_nhFkpPQYmUiCnEHNGQ7qSw_3_12"></a><a id="Tc_BYo3-7-IB0ag3205zFwh9w_3_15"></a><a id="Tc_EjHRBWVC5kOdffaSMi8vkw_3_18"></a><a id="Tc_ZL9_Lc7NMUSkm_rsFh9arQ_3_22"></a><a id="Tc_47KJcEl6a0WAi0XGICjjvA_5_0"></a><a id="Tc_OxZ2ARcYbUqE6EeKNRRmXg_5_4"></a><a id="Tc_LDkG9CAJ1kemMM3C9L9wqQ_5_9"></a><a id="Tc_xvq2QwEzWUW1YSO5sO_dHA_5_12"></a><a id="Tc_HL6FzBokuEeuuVptlgZ1hA_5_15"></a><a id="Tc_yIUz5JWS50K3yQRlwayb6Q_5_18"></a><a id="Tc_IoSEQss_uEy_qKuKc5FXEQ_5_21"></a><a id="Tc_btFkrE92T06zZ4oSe1q-iA_6_0"></a><a id="Tc_ZHyc_VAsMkCy-Ta_blaoHg_6_2"></a><a id="Tc_slYN8-lx1ESICsBKmA52MA_6_5"></a><a id="Tc_zo66ZOPnYkyGaRzORX9BEQ_6_16"></a><a id="Tc_OncNaeLBZ0GB_wG1-3ZeRg_6_19"></a><a id="Tc_wRs8KD6USUe6x9NRasm8zA_7_0"></a><a id="Tc_MG-7CzWXnUyOls4FgsYsJA_7_2"></a><a id="Tc_2tfT4I7XFU-cKtUtYXyIZA_7_5"></a><a id="Tc_sF-cbkdacUiZiDdDrbl3hg_7_16"></a><a id="Tc_sFI4B0HS2UydUXLVgmScXA_7_19"></a><a id="Tc_iB6DJ4UmbEOJYssfshME8A_8_0"></a><a id="Tc_nCKfz9WEwUCyAyFGsKjYyw_8_2"></a><a id="Tc_MZGQ9gm46kyKnqIZAPwH8w_8_5"></a><a id="Tc_PMZSG8WymECjcZvibSH3Sg_8_7"></a><a id="Tc_WyHd56FEgUyegW1zPWY8PQ_8_10"></a><a id="Tc_WYLj0mNhaEWKtJ7LuKbSEg_8_16"></a><a id="Tc_J4biOOrn-UmR9pn_jt8UCQ_8_19"></a><a id="Tc_UaQwoV-jSkK--1x55ToeSA_9_0"></a><a id="Tc_4WcibJC38kuNOGLqtB8C0A_9_2"></a><a id="Tc_FRB2ldwgdECu3Tm9k56I4g_9_5"></a><a id="Tc_etPa34iuyUivFO7Iyti-Vw_9_7"></a><a id="Tc_jygUtO7Rs0yasotjCRW3dQ_9_10"></a><a id="Tc_7orSwJQl-0i1WPZ5v3WivA_9_13"></a><a id="Tc_NOVYDqIPyUWR6KMlSjF1pw_9_19"></a><a id="Tc_RWw-ozjSmU2my0kPpc8sXg_10_0"></a><a id="Tc_6XEHkVdN9kaugUaC6tCA6g_10_2"></a><a id="Tc_45H3LQOhd0iWg6SeCn6XmQ_10_5"></a><a id="Tc_akUWXNwI2UahyuEiWTKVRg_10_7"></a><a id="Tc_AcOW2KpE7ECcmngekWUslA_10_10"></a><a id="Tc_t_SETZ8o3E-Umgt33wn7jg_10_13"></a><a id="Tc_xAoEsEKDQEOzT6rGOQ7QCw_10_16"></a><a id="Tc_gDgS6n2zMUOSpe9qMYSTkg_11_0"></a><a id="Tc_eUzDoGZXbkqhxLvI_qa2qw_11_4"></a><a id="Tc_fMTdvvjFQUyHl6YIhuL3EA_11_9"></a><a id="Tc_VMAcETkxwUOgjT_-IIqzKA_11_12"></a><a id="Tc_myr0W1MbKkqwmVlvfN2PuQ_11_15"></a><a id="Tc_k7RehrqttUiAWGU8hZZs8g_11_18"></a><a id="Tc_V9dJjW8EZ0CdUexojdX6uw_11_21"></a><a id="Tc_Kp42mAPsQUGoMnrxo9U0Hg_13_0"></a><a id="Tc_15BUGMQV-UCqhiqKGbKWeA_13_2"></a><a id="Tc_1-HQPVas_Ey5aVZ961lL6Q_13_5"></a><a id="Tc_O2I-u9wdXEi9IHseIYdFrg_13_7"></a><a id="Tc_ot7MIMpzv0Sn2zIFpno7zQ_13_10"></a><a id="Tc_2jkjS6X7CUGJSWewIBXZLg_13_16"></a><a id="Tc_c59CwCBOpE6z0VhMHaI3sw_13_19"></a><a id="Tc_-Tesv1pRjEWv78ENKS_2Eg_14_0"></a><a id="Tc_yZEm5Gb4MkC9L38GwssmFQ_14_2"></a><a id="Tc_pA63Zvk--ES-muWr8m3M6w_14_5"></a><a id="Tc_UKnR8JZsB02SzEDnmCfpSg_14_7"></a><a id="Tc_gE_M6dpcPU6cR7rPx4ZW4A_14_10"></a><a id="Tc_4ERGAeTH20GbSpy6PHHGFg_14_13"></a><a id="Tc_ROFsBPBz2U6mWHlnTi6txA_14_19"></a><a id="Tc_21D_zPWmdUW2BVIeVHYkuw_15_0"></a><a id="Tc_l-xUEolNRkaEJCj2iM2WEQ_15_2"></a><a id="Tc_xosSFEkraUiLHZpHJJfGmw_15_5"></a><a id="Tc_FmexDeBMzEOAqrDqJynQKg_15_7"></a><a id="Tc_wP3tultXKUGLxtF4pE_5eA_15_10"></a><a id="Tc_W9SB7ktvrEu9-Jj-93xvWQ_15_13"></a><a id="Tc_KJs7axoYK0KsIM6De9Yg7Q_15_16"></a><a id="Tc__a53TktyWk2FveFyQB9Lcg_16_0"></a><a id="Tc_oG2nk7uDlUea46RuU_o2Qw_16_4"></a><a id="Tc_OlN8ak2az0-f-qR9G_EUzw_16_9"></a><a id="Tc_K2_32R-r8kmUGSAEjA_W1A_16_12"></a><a id="Tc_axLh3ZNfE0y6fz4Vcudt7g_16_15"></a><a id="Tc_vuU7EZgYt0aNSrKv1R2nlg_16_18"></a><a id="Tc_IuBAyDg1V0Oi4xMFC3-AXQ_16_21"></a><a id="Tc_1Yr2Q7D4-EeXerPdpvPeNA_18_0"></a><a id="Tc_Sd8Nz7EJR0WYahq5klfVlA_18_2"></a><a id="Tc_8voP5D_6GkCIhtcI1Kwtwg_18_5"></a><a id="Tc_M43b7UvAvESG8eIGmj4UCQ_18_16"></a><a id="Tc_ytn-ZL_p4Uana2cDgMll3Q_18_19"></a><a id="Tc_IJS5TQvrEUGMyQGo6S2wWw_18_22"></a><a id="Tc_SSSArN_nVEWnfIRh7XWJCA_19_0"></a><a id="Tc_LAxz3CNlFkyej7_VMgTj_Q_19_2"></a><a id="Tc_9H_b3BJxdEyX1x-KjoZW2Q_19_5"></a><a id="Tc_bv088j5xo0-obN0OycitMw_19_7"></a><a id="Tc_zw49cTAeP0yWbiGlBQKGTg_19_10"></a><a id="Tc_ex-NinpkKUCicIL9INMR2w_19_16"></a><a id="Tc_1TC_HLeB5USsOCNqq84O5A_19_19"></a><a id="Tc_KgxWr7hMOE25XY8_sNjAOQ_20_0"></a><a id="Tc_xJV85pxSykaB_subaBTdAw_20_2"></a><a id="Tc_ytIpVq7z5UGpXz1otTgMKQ_20_5"></a><a id="Tc_887BcbbIZ0WvIflDHTjpmQ_20_7"></a><a id="Tc_c-W6JhYQOkK293puUPlepg_20_10"></a><a id="Tc_ujuMIYn_LUqKZ3jHv78URA_20_13"></a><a id="Tc_Dt0mSW8JN0ihoXIU33B3Lg_20_19"></a><a id="Tc_aNO2gZtnXUeo8xAZZ16ykA_21_0"></a><a id="Tc_wQqwz85htEKL2FPQoowDcw_21_2"></a><a id="Tc_VW4PVQSKG0aziRy8dcH7Kw_21_5"></a><a id="Tc_apCmqY_pcUKcHFwG5qRSZA_21_7"></a><a id="Tc_ebK6aaFQFE2d7zi168s1Sg_21_10"></a><a id="Tc_NmPr_36fxkmPkTvymH2w7A_21_13"></a><a id="Tc_-LHUjLVqLkm_ihTe8k5r_g_21_16"></a><a id="Tc_dzvw-o_uck2GrF-Jk4yp3Q_22_0"></a><a id="Tc_ft4VG54hxk6HG_ZNwBfFhQ_22_4"></a><a id="Tc_7ZL11fdqnkuVrUOXkD8_dA_22_9"></a><a id="Tc_60eLEhUd6ECS6B5eI1NjAg_22_12"></a><a id="Tc_ikiJAyvUiU26v769daQPVg_22_15"></a><a id="Tc_29HKPrZvmEemi58zJhsnWQ_22_18"></a><a id="Tc_VDgwd20-XUGvMHqeVOIO5g_22_21"></a><a id="Tc_AOrONlcofkirWH7jBE7jJA_24_0"></a><a id="Tc_bLb-uPDhPEKTLvCKKVqY_w_24_4"></a><a id="Tc_K99Jswz7zk-54FYtVw7gfw_24_9"></a><a id="Tc_Bb2J1pNGl0isaIlRrm9sSA_24_12"></a><a id="Tc_An-ml7gLt0afjlJ7ZpaasQ_24_15"></a><a id="Tc_wuUjDB46x0-BkcpsHoftTA_24_18"></a><a id="Tc_-oQEV34RyUi09R5IoOhXvA_24_21"></a><a id="Tc_YEtGvAkrbkCnGf-eVWQt7Q_25_0"></a><a id="Tc_rzOIjUbyr0Wfdz7CjKyg-g_25_2"></a><a id="Tc_OfLSmzEKlEOodR8zxq4r6w_25_5"></a><a id="Tc_j0Dp-853bkiwHfWqlmhUFQ_25_16"></a><a id="Tc_739-mHiLOkq4lMq5vpp9wA_25_19"></a><a id="Tc_4h2lQhgfSkS2NLr0vanMiw_26_0"></a><a id="Tc_VSbqYDBGa0SNJeH4qIG2ww_26_16"></a><a id="Tc_eWwYvdDH8kyqGMvmTBa8Fg_26_19"></a><a id="Tc_JRPUFqna0k65YQvx_pIVaA_26_22"></a><a id="Tc_jDEAVl8jP0mhsQbB5iuU-A_27_0"></a><a id="Tc_awj3e0leXEu-eD6hxbJ8XQ_27_2"></a><a id="Tc_3bzPkcjrvEuHKa1gWfziWg_27_5"></a><a id="Tc_zR1gSYQih0OWLX4b3SnyLQ_27_7"></a><a id="Tc_1xdo9tm-jUae9ABXCoMjbA_27_10"></a><a id="Tc_-iO_q5rWaUGyMsEPQDmrpw_27_16"></a><a id="Tc_gZ7rh-XQB0yHQrd5SlEqnQ_27_19"></a><a id="Tc_KSiISvkO7ES0zjJl77oYYw_28_0"></a><a id="Tc_bA_ZUSJhQk2h5fwq591UtQ_28_2"></a><a id="Tc_GLItrcHQ3Eq6Rco8DC9qZw_28_5"></a><a id="Tc_YG0DPej2n0Gw_a2HQtpF6Q_28_7"></a><a id="Tc_-2VxZ_kdlU6nHkKoTJZ1aQ_28_10"></a><a id="Tc_gX4_6RsIkEe1-Or37gy7yA_28_13"></a><a id="Tc_Wb-3hTtkhkaW5jBOzO_R-g_28_19"></a><a id="Tc_ZkeIsiJpuEK4kGVbwbwXqw_29_0"></a><a id="Tc_B4CJsIgGaUKo7LRgKDKVqA_29_2"></a><a id="Tc__nVf5h1fu0GZIXXO7m8O-A_29_5"></a><a id="Tc_Va6wtbMqSUCtHXrwMWCUDQ_29_7"></a><a id="Tc_6WaqKh1vE0-ADJhCtuxCYg_29_10"></a><a id="Tc_nhHvdGH780CIxnVDmLLoiQ_29_13"></a><a id="Tc_CZLt3nwaAEyDHrVhIgvpdw_29_16"></a><a id="Tc_irFal_z0Tkqy-gc8OuKrdg_30_0"></a><a id="Tc_zsg4b-eQNU6Be1DWR8-1uA_30_4"></a><a id="Tc_W9EgHQLvFES_4GNcXeqx-A_30_9"></a><a id="Tc_ufyScal8W0aR-NGxhhPCrQ_30_12"></a><a id="Tc_MOP-0uJ17kiHEN0_dCjl4w_30_15"></a><a id="Tc_2RnqhV9NAUi4A0S6SsIqZQ_30_18"></a><a id="Tc_Qh4kckUmO0Cq_0KmJue0RA_30_21"></a><a id="Tc_JbLJY5xOJE-sZ-r6wppx8w_32_0"></a><a id="Tc_-xD9A0lf70uxwWsVrLLPSg_32_2"></a><a id="Tc_iwwNdJueAUOTgoE1MydPTg_32_5"></a><a id="Tc_Kn2jg373fkq4UCCnPpZReA_32_7"></a><a id="Tc_cIocpWc_qkCGQnvxLIfuqg_32_10"></a><a id="Tc_jmSgty15h0eaDCXuCFs30Q_32_16"></a><a id="Tc_7-GEcnvE9Ui9K-xiRIWRrw_32_19"></a><a id="Tc_0A9fpxQg40-1p3k2S4u62Q_33_0"></a><a id="Tc_VjUa6_ChsE6a3b_SgAEQKw_33_2"></a><a id="Tc_DIFClnPDyUKnhT8JYZ8v5w_33_5"></a><a id="Tc_n6ZWXc4ovEa4l0xz8yY60g_33_7"></a><a id="Tc_RgrsVFHdgkKOAOcwVhBnkQ_33_10"></a><a id="Tc_K6UWAp3EykWwmZnL4XsKKg_33_16"></a><a id="Tc_m86Hlo-3X0OrAYs8ahvRFQ_33_19"></a><a id="Tc_YPqOqa-_v0iI0nsbiIy4tw_34_0"></a><a id="Tc_HweO4ZwiVkmZKkc_U1FUig_34_2"></a><a id="Tc_QcgLFhhJWkGvK21ZiY6K6Q_34_5"></a><a id="Tc_MDqzMZMCCkq3PmoLULAjzw_34_7"></a><a id="Tc_ajGpognR8EWYIGSQitNWsA_34_10"></a><a id="Tc_qzCFElV9UUyTp6K8w1qZ0Q_34_13"></a><a id="Tc_jV7xLEUPF0-Q9JRNlF63hg_34_19"></a><a id="Tc_tLL6V1XnUUys4gQMQU1uQg_35_0"></a><a id="Tc_WjuaOJgQI0uddt6gpeOtzw_35_2"></a><a id="Tc_6BEk_oeAAESSWXKtuHABOQ_35_5"></a><a id="Tc_K_dE_h7MZUKZ9gv3jEa4IA_35_7"></a><a id="Tc_leq9XkzOYkmYXkGu8RxV7Q_35_10"></a><a id="Tc_f9wvKoChmkK92YtQm_Dlrg_35_13"></a><a id="Tc_SSCl6tP2sUOPLiV_Kk_vOA_35_16"></a><a id="Tc_RTSB9tmGEEyPSY3wINCEQQ_36_0"></a><a id="Tc_EsrI_4pQ802pl8Q9SLGItQ_36_4"></a><a id="Tc_PHBzvHzOkUCXscLpcho-qQ_36_9"></a><a id="Tc__AiG-9zHhkCBn6mB6OdlUQ_36_12"></a><a id="Tc_C8XundA18U2jncwG-FBKqw_36_15"></a><a id="Tc_iIW2Z1IeYkmEfdgLxZATuQ_36_18"></a><a id="Tc_jW4rrMETrkCHGD2G4nXl0Q_36_21"></a><a id="Tc_XQJlN2rVhUivY6di7n0-Qg_38_0"></a><a id="Tc_38VLfSk0U0KJ1ggW4mwTmg_38_2"></a><a id="Tc_rhqrNPxRhUqFNKN-XgGeRA_38_5"></a><a id="Tc_qSGLRS_0GECJWBZ_H1ln8A_38_7"></a><a id="Tc_Wa4gAWXCeEaWi0VGOV4fUQ_38_10"></a><a id="Tc_9vBQkFCPGkWeKldivZYNgA_38_16"></a><a id="Tc_QcnTB1GtWE2P9J2TtF37GA_38_19"></a><a id="Tc_bDse5RlBfUWjMPM9ZbUuQw_39_0"></a><a id="Tc_LAx_QDa6f0SCpvTxHyvA-Q_39_2"></a><a id="Tc_RBZsQ8zXOEWWOfS5aE3KKg_39_5"></a><a id="Tc_9kbb8gZmt02wsUjunjsrgg_39_16"></a><a id="Tc_qiROa781hkCDNwXuadVqSA_39_19"></a><a id="Tc_9kw1_vfoEES9esXr_FcUqg_39_22"></a><a id="Tc_7qo7ATuwvUGiYDpsHT1yjA_40_0"></a><a id="Tc_s83RBehB3ECIM7AvdYWWeQ_40_2"></a><a id="Tc_V2ijV9RglEe0vPO09gb03A_40_5"></a><a id="Tc_A3neuugbE0ulgqQkEwyWYA_40_7"></a><a id="Tc_gNyt5Dltm0-Tp9DobWG2Cg_40_10"></a><a id="Tc_-IMPkwaJlU-lSEuY2bTD3Q_40_16"></a><a id="Tc_rPF0ANbpEkeT7X0h29E7eA_40_19"></a><a id="Tc_vN-p_milU0C0aD23d207rw_41_0"></a><a id="Tc_MlCQ9gR9TU2dynJ7uNe77A_41_2"></a><a id="Tc_Y9jnlqwIoUi8L6ylouGnlw_41_5"></a><a id="Tc_TbNd7_MDPU6Pc_WpIBphwA_41_7"></a><a id="Tc_w1-8yLEWbUijnIM7vWW0aA_41_10"></a><a id="Tc_p65jfM-7lUWkXE_DD1NAcw_41_13"></a><a id="Tc_B4NJuYTL-kONd8K9r35CfA_41_19"></a><a id="Tc_kz1IPbFMk0GVxm2zunIdKg_42_0"></a><a id="Tc_TtMWM3iRMUOlxI4PFmNxJw_42_2"></a><a id="Tc_uTa0T8nx00iV74ib3CxGCQ_42_5"></a><a id="Tc_2xecEdUaQUyJQnQnUkFGYw_42_7"></a><a id="Tc_T7QX9uRohEqjZ7v1uqFzlw_42_10"></a><a id="Tc_zeLh5W9b30ucCdnMU6a5Kw_42_13"></a><a id="Tc_aUjSlJfFpEm9BKEmASkfPQ_42_16"></a><a id="Tc_HqXr7PzIc0eG73yZ5vZGuw_43_0"></a><a id="Tc_VQJboL3RxEqnRkTE-zZkdQ_43_4"></a><a id="Tc_ED1Yu2zoy0u0t_Be-8cAfA_43_9"></a><a id="Tc_116k31pZfEmEnhokOneV1w_43_12"></a><a id="Tc_5RGjnNlSs0KtkTm6Kq0s4g_43_15"></a><a id="Tc_TpXpokDyp0O3iOzAvnzoqg_43_18"></a><a id="Tc_b95aKcBGR0mO_KSnE26lRA_43_21"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:28.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:28.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:14.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Series&#160;A Convertible Preferred Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid</b><b style="font-weight:bold;">&#8209;</b><b style="font-weight:bold;">in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:28.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:28.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:28.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Balance, December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8CsMqAUtn0GBba1hxVBFiQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_rYJnYlIKmUKtoEbZyzKBIA_5_2">56,227</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8CsMqAUtn0GBba1hxVBFiQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_N2MD-RF8jkSpkz38eNGJfg_5_5">1,311,063</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ep_zwMxd8Uy2Rb83GGZtEA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_gJby4NOGZECrbmsenrs6PQ_5_7">2,655,269</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ep_zwMxd8Uy2Rb83GGZtEA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_-2Om3geWA0O1M_K-ORrjNQ_5_10">2,655</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_X-C6_R8tJE29iS3my5-mwA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_9d9ygiS_w0y1W6tg8g9UoA_5_13">330,060,836</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fJbOuezCP0ukeyIR7_AUvw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_slq1pKZNUEODjk_BsxvddA_5_16">10,623,408</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_-el1flLwfkGvk1hb4s7jRQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_8YssXp_NaUKhCTUE3tMH2w_5_19">293,796,405</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_12_31_2022_XHHJ56Sb40GzY2_iFyVSmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_lZUwz_OJNU-XfcXFiyAjjQ_5_22">25,643,678</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Issuance of common stock, net </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GS2DrbBqyE-0nKgeaspqPg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_Gl5Jw6b1K0KaOQ8gfa6YJg_6_7">1,050,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GS2DrbBqyE-0nKgeaspqPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_2H0ieNUHA0q_5h48fejfrg_6_10">1,050</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_60CYeoJMNkOFtTQ-EB4jYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_TZGzhsoFyUqSuIhx-dmeng_6_13">4,870,815</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_3_31_2023_zTcMywQwh0-rXqoAlfNCWw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_AKXS8MAmZ0WBIBzv2VmRNg_6_22">4,871,865</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:28.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Issuance of common stock pursuant to at-the-market stock sales, net </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_sqNgwBmbiUi7e68XTiWaJg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_UdVYTxVTSUaEMpC70fC7XA_7_7">26,302</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_sqNgwBmbiUi7e68XTiWaJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_V18kTdRnZkmMl77TRVVV-w_7_10">26</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_Paz762NlyEuz8le-TUK-tw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_-iXtGOiaNkWLa6jCfJkx_A_7_13">268,099</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_oHdcOW4hiEyfgESy4f5Jzw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_EaFVj2x9mkCxNURHwrwVpg_7_22">268,125</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:28.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Stock&#8209;based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_60CYeoJMNkOFtTQ-EB4jYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_PFH4BHd6h0KJBkzIKaqf_Q_8_13">16,244</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_3_31_2023_zTcMywQwh0-rXqoAlfNCWw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_dJWMkckVaUmdBOl875FRtg_8_22">16,244</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:28.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Foreign currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ZDYsshJEZkqk3c9XgeoP5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="Tc_SjPP6aTTgkS05x-qSm5NPw_9_16">61,956</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_3_31_2023_zTcMywQwh0-rXqoAlfNCWw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="Tc_VkER0-aLIUevgH2-CvS-RA_9_22">61,956</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:28.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hNmUQDanvk2hr1a2pdyeMA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_5o2H9TRwxEOqgQHM-B2SFQ_10_19">4,379,890</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_3_31_2023_zTcMywQwh0-rXqoAlfNCWw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_TGKL6ZusVE2f7rzg231IRA_10_22">4,379,890</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:28.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Balance, March&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_rhWtSSOwCkCaEzpIAh-drA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_ax8xvdRxF0eHxkNWD0mZug_11_2">56,227</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_rhWtSSOwCkCaEzpIAh-drA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_cQZrGvEYBkywD5SKZwTOQA_11_5">1,311,063</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jLLZztnJSEaM57oF94_7xQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_weAIF-6ElkeBrm7XfK_mdw_11_7">3,731,571</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jLLZztnJSEaM57oF94_7xQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_Aovzn_X7FEafSPcd28Iheg_11_10">3,731</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_DvSHu5RNCU269rSppFYYgw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_Fc8IdYziZESdPJaa3i_m_A_11_13">335,215,994</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3R6cMW1KKUK6IIoYqDNzqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_xE8GTP80uUyDk_lWj8c_Dg_11_16">10,561,452</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_XHftf8DOMkW2QPF25BFt1A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_RiDIs5sja0GNKeUHXdcZqQ_11_19">298,176,295</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_3_31_2023_slQjcR-CEUatMT3-GnhwQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_goFTpJ-bqkyAM_WDqnuJmw_11_22">26,481,978</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:28.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:28.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Stock&#8209;based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5LQIj-xrt0am4-0q7OB9Gw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_58jUGNEagEePu-xAEliPWQ_13_13">269,323</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_4_1_2023_To_6_30_2023_P0QiqJFu3ku16O4sijWHpw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_LQlZ1Ff090Sb8U08__ehcg_13_22">269,323</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:28.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Foreign currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_BnvW7lwu70SqT0ZU3Hyn2A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="0" id="Tc_QKPz9QPc-EWM_xmRZPegug_14_16">73,420</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_4_1_2023_To_6_30_2023_P0QiqJFu3ku16O4sijWHpw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="0" id="Tc_Zjqu9LP7fESb5GM0eZCUnQ_14_22">73,420</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:28.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_NMOLLFp0TUWc89OurulIXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_qh0QxN4nCUuFwMDwCEC93Q_15_19">3,259,097</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_4_1_2023_To_6_30_2023_P0QiqJFu3ku16O4sijWHpw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_AQclITxQsUKS2bY7XStwoQ_15_22">3,259,097</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:28.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Balance, June&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_R6HjfKfj2kC0Dts-tFsRHg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_Qy7_somJ9kKqceTu_sFS_Q_16_2">56,227</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_R6HjfKfj2kC0Dts-tFsRHg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_SOUY8tHo50y9PZTec3oyQQ_16_5">1,311,063</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5KgXuLcFS0y6eld2ApcJhw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_iwUFYWVYbkef2rSENk55tQ_16_7">3,731,571</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5KgXuLcFS0y6eld2ApcJhw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_3jR6znR6CEyW92w2SpPLXw_16_10">3,731</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_yt6vg4-7Hk-CNT47e35gSQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_UPhKSI5wqk68OoCsIE0Exg_16_13">335,485,317</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_VtyWAB_w50KEUnNv-Oaekg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_To-LrBbqL0SntT7i3xuKKg_16_16">10,634,872</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mlp_Zv_4RkCOvMMVab-nCw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_gr3nUHCt-U-ndU61DuXAEA_16_19">301,435,392</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_6_30_2023_Lr_RTA-Vhk-vAvhygDZlMw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_Zws_CVYYuUuctysOk2rndw_16_22">23,418,784</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:28.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:28.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Vesting of restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bnRcQIiX2Eip-CUgrzN4Ag" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Tc_1zUeHAdhj0-Zb-qnnmj17Q_18_7">5,102</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bnRcQIiX2Eip-CUgrzN4Ag" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" id="Tc_aHEyEDRYaUaN1TSGso7f9g_18_10">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_44A8CawaA0CwnlBa7i0axg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" sign="-" scale="0" id="Tc_EdHlBaf9RUCC3xuEnz1kaQ_18_13">5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:28.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Stock&#8209;based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_44A8CawaA0CwnlBa7i0axg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_lpYT2VV7mUitWgULN5vpyw_19_13">76,031</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_XSvVt1gRd0ap1cQ-G4yzrw_19_22">76,031</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:28.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Foreign currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ZYusih75WEqqXs5jfU46kA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="0" id="Tc_YZYNCDMUyUSAWi0suFHm0g_20_16">1,002</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="0" id="Tc_PW4wOvLU30K9RhNyQnKXEw_20_22">1,002</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:28.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_JK8xHrjZfkqa45FOBphUpw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_qJ3gZrut5kODQ9BzObcRbQ_21_19">3,204,515</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_a9x6kAVYFk-FmQhtDTAznQ_21_22">3,204,515</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:28.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Balance, September&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="As_Of_9_30_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_7gGY2uLNAUOrIeOyl0Yu3Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_SxJCi4wonUywZFiHkOj65w_22_2">56,227</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_7gGY2uLNAUOrIeOyl0Yu3Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_dB85EOhWdUKHn2B12msSww_22_5">1,311,063</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jAvkAIbuQECJ-En9TI9QOw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_63Oo28tpwkuX4A7n0YEvHA_22_7">3,736,673</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jAvkAIbuQECJ-En9TI9QOw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_jsnxbIRC7Ua8ifbTRgTt0A_22_10">3,736</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6rGZcRyRUEmEmilgCL28PA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_eanh1mR0qkK6ozZ6En7NFw_22_13">335,561,343</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Ezbxq8ZdSkqMSQnvf2yPiw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_IpgLjsbQLUuxkhSv45w_jw_22_16">10,635,874</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ibhlFLDIRka5MzPbpPpzAQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_uhMDXllJwkuNE8kTdLPO-g_22_19">304,639,907</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2023_8FQi5hYCckGx-AAVXCTMIQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_EI6K793eBkOT5QzbaLq78g_22_22">20,289,298</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:28.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Balance, December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_7IVaogKI6UuHMaADrJkhsA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_is5H_HkXDEaQRTyApAsJpA_24_2">56,227</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_7IVaogKI6UuHMaADrJkhsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_uuBemZZmx0-T-IZKni1PEA_24_5">1,311,063</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tUhQ63t-YU-t2nhI1MP0bg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_f7UbBznXp0qSGFYOYeo8GQ_24_7">3,736,673</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tUhQ63t-YU-t2nhI1MP0bg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_502LkiTAOEKLfBBnRit3_g_24_10">3,736</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GQCbRqVK3kuaSwxkX6qMKA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_NEUS4kCIkUGCZtK1Mf_Tpw_24_13">335,644,204</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_yLYKKEjvoUy7Hx5o25CtFw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_TuZyCX6LekSK3FcKPUk9rw_24_16">10,611,273</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mNt4s5ToekueR3QLxsxleQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_eRzrSu0qVkmXSE4wCmwm8Q_24_19">308,083,161</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_txOc2BkAQE-746oI_IigeA_24_22">16,953,506</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Issuance of common stock and pre-funded warrants, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SIsBYxIs2kWHjyNmgCyPrQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_JtN92iCFXE253ZvLNvCs-Q_25_7">1,687,712</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SIsBYxIs2kWHjyNmgCyPrQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_-GtKXuNoJES_Oh2l543NGQ_25_10">1,688</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JmDXfNDeoU-A7sBdCGSkpw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_b_2Cc4onAka7mYa8yZwnlg_25_13">14,708,017</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_3_31_2024_k6qmi3YCyUeoj4EzQWmoYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_CQO3rWVbEEqYhkFz0y0Wgw_25_22">14,709,705</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:28.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Vesting of restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SIsBYxIs2kWHjyNmgCyPrQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Tc_s0BkeOazmkKLs1_bilfYGA_26_7">5,830</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SIsBYxIs2kWHjyNmgCyPrQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" id="Tc_bEuV6eerHE-8_rmot_Vjrw_26_10">6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JmDXfNDeoU-A7sBdCGSkpw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" sign="-" scale="0" id="Tc_J_NnGop33ECcL-Xis1lrnw_26_13">6</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:28.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Stock&#8209;based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JmDXfNDeoU-A7sBdCGSkpw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_bi9HuC2pqkSj4H9A3i-OdQ_27_13">85,830</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_3_31_2024_k6qmi3YCyUeoj4EzQWmoYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_INs23ZkBr0-bnLHKk2E2PA_27_22">85,830</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:28.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Foreign currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_alO13T8cuE2PUKMnkFcK4Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="0" id="Tc_C1p-HqRkqUSsh96ddf9OfQ_28_16">15,083</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_3_31_2024_k6qmi3YCyUeoj4EzQWmoYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="0" id="Tc_2V0hjTGqFUWHA66-afbUUw_28_22">15,083</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:28.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_pA-2oAPYMEqk86sHU18u8Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_mLcBVJw9GEqM14aB6TRuig_29_19">2,810,091</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_3_31_2024_k6qmi3YCyUeoj4EzQWmoYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_RwnYD04C0UCmTyultyETnw_29_22">2,810,091</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:28.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Balance, March&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="As_Of_3_31_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_liwNe_OrZkuTHNDpnZcmag" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_oLxASaoHiUKHeXnWnCoU0A_30_2">56,227</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_3_31_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_liwNe_OrZkuTHNDpnZcmag" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_DF0PTZU_uUOh0BIzg2vv9w_30_5">1,311,063</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BOEuDXy_ZUeMtyMb1W31eg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_Rj-Ucl0f0UqsJHArFKZaEQ_30_7">5,430,215</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BOEuDXy_ZUeMtyMb1W31eg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_20TxZIpBJkaaB6UW_Yq-Tw_30_10">5,430</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Wi8LbADSoE6H9bs8u0MVsQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_dIBOXoQAdEOW1r7iaUqwVQ_30_13">350,438,045</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_lCnJPy7l60uydEVcNxwm6g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_PhGDturCZka3LhawtgdD8A_30_16">10,626,356</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wfx449lO0kKvBkD-ftLx7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_wDHGrFlnkUWT9q0ee9t9_g_30_19">310,893,252</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_3_31_2024_Zvq5nTZZy0aWnnp0Yr_H1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_cetyQA1NdkCwYjZHJJ2_6A_30_22">28,923,867</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:28.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_00YNAPouPUS3eodKEdKUZQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="0" id="Tc_ELSTK5OGVkiepBqLX7gHfw_32_13">21,060</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_4_1_2024_To_6_30_2024_fAYnBVLhzUG8aJvV8WQWcQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="0" id="Tc_W2OCHiciskGAx_Q-smyp3Q_32_22">21,060</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:28.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Stock&#8209;based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_00YNAPouPUS3eodKEdKUZQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_gXw8mwKWlU6LRhsTVFXIXw_33_13">128,488</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_4_1_2024_To_6_30_2024_fAYnBVLhzUG8aJvV8WQWcQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_oLJpawGesESlVmuxgjoobQ_33_22">128,488</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:28.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Foreign currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fmrXxlAg8k2LTPqbZsdqQw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="0" id="Tc_rLRxlXmfTE228VQibOQ7yw_34_16">1,948</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_4_1_2024_To_6_30_2024_fAYnBVLhzUG8aJvV8WQWcQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="0" id="Tc_VFM1Q7atxk-LyWeIYbwflg_34_22">1,948</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:28.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_SbTatJBJOUiFH1taEFtwHQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_BCgAz4PX8ECdxHIomRtlxA_35_19">3,470,052</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_4_1_2024_To_6_30_2024_fAYnBVLhzUG8aJvV8WQWcQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_8nlOTVObRUS7svFJ1WkXqg_35_22">3,470,052</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:28.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Balance, June&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="As_Of_6_30_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_MQGoU-f5K02GZ9PlM-yOkA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_ZQVfN2jzY0SChWCPBqkOBA_36_2">56,227</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_6_30_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_MQGoU-f5K02GZ9PlM-yOkA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_VeHMKDZVnUmYYxij1Wcpkg_36_5">1,311,063</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_pTVYFBxdF0KO7SAVt4uiIg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_qbk8jpjWNUOgI4Jd3e59hg_36_7">5,430,215</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_pTVYFBxdF0KO7SAVt4uiIg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_90JYYeMYKkOEwkLiE6Bl7Q_36_10">5,430</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_z5h7zepvB0S3yMqUDLxYRQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_DrECCqGVS0eKehXfyfAH4g_36_13">350,545,473</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_kRMbWJwEh0W2ZdxtrlSp2g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_3oaFCXqwJESVIWVbw8TU9w_36_16">10,628,304</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3OjBHmrFdEqql1a9Qd1d4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_aRs8y1oe6k606zdmcjwkeQ_36_19">314,363,304</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_6_30_2024_ZePgtrw-B0izH24xd1d8mw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_nAUYZ59yN0ixEdyV6uq6yQ_36_22">25,559,295</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:28.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ddh4E4AbBEerRzR7f0tdRQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="0" id="Tc_qqTVArkW_EKD6wDcc49_XA_38_13">1,155</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="0" id="Tc_SfxR5orYmkqu1C1xYuuu_A_38_22">1,155</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:28.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Vesting of restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uk8mlSyVokKTP3XSCE6G2g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Tc_KIwqepWFSEurnCt61t_htw_39_7">4,688</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uk8mlSyVokKTP3XSCE6G2g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" id="Tc_N1-gr3wjUUmZQzopvK7AVA_39_10">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ddh4E4AbBEerRzR7f0tdRQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" sign="-" scale="0" id="Tc_dbn6qIPNeUm-k-GoeJjxkw_39_13">5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:28.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Stock&#8209;based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ddh4E4AbBEerRzR7f0tdRQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_sJUng0xS1kWa26TT1ttK8g_40_13">149,090</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_uO2DP1y5Tk-o8k77X6k_rA_40_22">149,090</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:28.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Foreign currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_wNRC8dghckiqZHMJ2Qab2A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="Tc_ihOf5Z-JdkmitOkqCugwUQ_41_16">23,557</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="Tc_LhSz1FXEFEquHwmIJr070Q_41_22">23,557</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:28.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jqM4BFBbeUqa02lyUgxwnw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_CBja0fVZhUirP3pnJa70jQ_42_19">3,783,769</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_5yPaoXcW1U2U5_FrMmwTfw_42_22">3,783,769</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:28.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">Balance, September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="As_Of_9_30_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8visgBbaHUi1WL8smvF9Lg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_SIU0NfKtAUOJYofxOJx4eQ_43_2">56,227</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8visgBbaHUi1WL8smvF9Lg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_LNQK1zSDK0OCFEMWQmA5RA_43_5">1,311,063</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Omg5HL2Zk0iyUrhlyHkYzQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_zhjCrA09TkGlEH4SzdYCvQ_43_7">5,434,903</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Omg5HL2Zk0iyUrhlyHkYzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_wOdablRwJUWW1ykGVWhTqw_43_10">5,435</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_w6HcF2RyJ0OwVohdYcyrWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_i3KFprF0gE-ftkZJfLVbng_43_13">350,693,403</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_mLJ_odBxZ0OgdXDNP5Doaw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_NlitUHHPYUmQZl-ab1S4HQ_43_16">10,604,747</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7APo5uzuAUeE_AwHD_aDyQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_BxTBDTKQBU2fhKBuLA1bXw_43_19">318,147,073</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_iwwPbiox6E2qUizsV8Yl0A_43_22">21,947,018</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">See accompanying notes to unaudited condensed consolidated financial statements.</p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:84%;border:0;margin:30pt 8% 30pt 8%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_87755d22_4d34_4f27_b7a9_296abaf79b15"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aprea Therapeutics, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Unaudited)</b></p><a id="_4c190804_d140_4231_a9d8_23a563a01004"></a><a id="Tc_aEJMB8zxOEWIQyGGUOhu8A_1_2"></a><a id="Tc_IFIJz_4Gm0GsGRQXhDKkRQ_2_2"></a><a id="Tc_4IHRCPGA806UfnJxz13d4A_2_5"></a><a id="Tc_RGleXWwvT0CVblbipfP_fA_3_0"></a><a id="Tc_f6czOnuZzk68VEpok2_cGA_4_0"></a><a id="Tc_z_mgR2oeRkG6MoLo5431xw_4_2"></a><a id="Tc_rwjZir1-MUaHC0XYHQMkOQ_4_5"></a><a id="Tc_HFpZu7EnLk2OtlhkL8IHWg_5_0"></a><a id="Tc_znRZSuTTiUuiHQZTD8rDcA_6_0"></a><a id="Tc_bDAt7XkMIkGHBJPTm3c5Fw_7_0"></a><a id="Tc_jB9B4RRjF0KGHq8G9ZkHiw_8_0"></a><a id="Tc_Q6RZXDcawkO8KwfbT4hPjw_9_0"></a><a id="Tc_3cM-LwyqbEmqnvIo9pyw5w_10_0"></a><a id="Tc_vIDUxJCScU6T5AAriMCV8Q_11_0"></a><a id="Tc_0UYb5WlIbUG-X6dVX8zcLw_12_0"></a><a id="Tc_L4pHQ7b_mE2_ffIh5OeQSw_13_0"></a><a id="Tc_qysqX9zjCU69NEe4P_LBDg_13_6"></a><a id="Tc_X3riTE4KcEmnsV2jcfmyMg_14_0"></a><a id="Tc_SspIIEVL30y0gT8g-sncVQ_15_0"></a><a id="Tc_X7afIV-Rk028EpAPJDTVIg_16_0"></a><a id="Tc_ojsYRJS3EECQZGxbndJgvw_17_0"></a><a id="Tc_1-3YxbGpSUiJ7lmoOxftuQ_18_0"></a><a id="Tc__T0mftGyl0eBcD0aBzHxqw_19_0"></a><a id="Tc_TOX1F9L94UOZlmqdmU2Z9w_20_0"></a><a id="Tc_cGnsedfgjU2zQriy-1iwWg_21_0"></a><a id="Tc_1E6CUwYIZE63qTe1qE_6BQ_22_0"></a><a id="Tc_95Nfnvyd3ky5YSL5ew0sQA_23_0"></a><a id="Tc_2bUg5cFZMUmkZ4_aA8QuVg_24_0"></a><a id="Tc_ixqj0_KSY0y3IAltFSfg0w_25_0"></a><a id="Tc_05GJZmiC4k-P_7eGyW_x3Q_25_2"></a><a id="Tc_RVfe57vpeki_qev-wdltJQ_25_5"></a><a id="Tc_LqkUoEY8jUK8MpMJMTmUVA_27_0"></a><a id="Tc__yltJRqChE2myq2EePpjbA_28_0"></a><a id="Tc_BfX62PQdgkauITVqqcj-Xw_28_2"></a><a id="Tc_fGeAD4L3o0aQKc0nsuzJBA_28_5"></a><a id="Tc_-osc4sko8kCCbvgkmQQTYQ_29_0"></a><a id="Tc_KL2RzSajFEG7ltREAPxM4g_30_0"></a><a id="Tc_KN6ZZu72FEuVoDp3J9lj1w_30_2"></a><a id="Tc_6t9EkPkmM0-tnbez51wOhw_30_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:68.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from operating activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_E6xUcTdyakuJbGtov2eIaQ_4_3">10,063,912</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_R8Knvky9EkOReX2iuNX-Sw_4_6">10,843,502</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="Tc_wMC1oh2qE067hY-7gf47rA_6_3">16,890</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="Tc_xS-cmM5RcUS6z8RB_9K7Yg_6_6">2,066</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Stock&#8209;based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash" scale="0" id="Tc_aVimeM__bkaUhjnF6upm7g_7_3">363,408</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash" scale="0" id="Tc_kKNvnMy8x0uaejvkej2ROw_7_6">361,598</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Foreign currency (gain) loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" id="Tc_2lEC7ksPrUKDtpBfD3ZASw_8_3">15,180</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" id="Tc_a6O_7wYhrUaO65kKAbyF_w_8_6">39,686</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="0" id="Tc_9Koi3yWe_USOujYy23nyPQ_10_3">398,531</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="0" id="Tc_ayc7qxDpnEKDSC5haHJWdQ_10_6">1,077,138</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="0" id="Tc_FhjMNFpPz0e5xD4cv5Dt_w_11_3">515,964</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" id="Tc_Ax9FROEw6ECueY8hxbjq6Q_11_6">21,873</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" id="Tc_7_eNzTsIt0qa4nCVgVJyqA_12_3">299,387</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" id="Tc_nxvdP25JkU6kzIxvJtWHlw_12_6">982,563</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Deferred grant revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" sign="-" scale="0" id="Tc_VMKFVvl94EGcyanBhHOfhA_13_3">528,974</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_8aSI2cRW3UCU6SvDW6g-Zw_14_3">10,045,814</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_9WMCVT0CI0idQDC1mHVacA_14_6">8,437,950</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from investing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Purchases of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="Tc_3078a0AMJ0C8aLuZa9QkEA_16_3">15,478</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="Tc_MdnOIdkB7EK9gdtXOoHzAw_16_6">85,943</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="0" id="Tc_FU9-x1wnV0WLjyoZb-pZBw_17_3">15,478</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="0" id="Tc_RFVoCFxkGU2TQ3j9JoeLQw_17_6">85,943</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Proceeds from issuance of common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Tc_ve8iv9D9zkGM_KbOpDeNDw_19_3">15,999,598</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Tc_XP4SmZ4CUESJJjMRIlad_w_19_6">5,788,918</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Common stock issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="Tc_GS2eKvY0fEWLSDcEcQ1Mtg_20_3">1,312,108</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="Tc_KS-TISJsBEiIHaB_SGxApA_20_6">648,928</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_21HEAg_oS0KpYh-nYm0rzw_21_3">14,687,490</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_EGEHlyoq_UClxeF8W2oVAg_21_6">5,139,990</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="0" id="Tc_xnNRDbyUMUmYGC_A9nLvVw_22_3">4,626,198</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" sign="-" scale="0" id="Tc_NFXWDFP4S0SwJCYnDSSWjQ_22_6">3,383,903</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effect of exchange rate changes on cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" id="Tc_UA3AZJRhdEqDwmW_ntNd5Q_23_3">17,427</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" sign="-" scale="0" id="Tc_0WZZc6xVk0SJNu6k35WfOA_23_6">8,782</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash, cash equivalents and restricted cash&#8212;beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_YLm40TYIEkO4yUUHoxni2w_24_3">21,647,537</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_12_31_2022_XHHJ56Sb40GzY2_iFyVSmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_17qOXeXOCEqBkufiqi0gXA_24_6">28,786,647</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash, cash equivalents and restricted cash&#8212;end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_ah3Z_wHXtEaEG75XmY6pGA_25_3">26,291,162</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2023_8FQi5hYCckGx-AAVXCTMIQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_lQa3zhiJ-EufanUosTfIPA_25_6">25,393,962</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Reconciliation of cash, cash equivalents and restricted cash</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_uAH4rAPjEkqvT0PBo0s8Hw_28_3">26,249,625</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2023_8FQi5hYCckGx-AAVXCTMIQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_UM7ZHtXWS0mDfmePnNEbvg_28_6">25,353,513</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="0" id="Tc_yGKDC_AP3E2LwXJ8z5IrkA_29_3">41,537</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2023_8FQi5hYCckGx-AAVXCTMIQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="0" id="Tc_Ty6yjJITAE6QaPW7lZFd8w_29_6">40,449</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:68.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_a6qNa-ezyEGLWn3I4HZiQw_30_3">26,291,162</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2023_8FQi5hYCckGx-AAVXCTMIQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_e09gepk1Uk2wKqkDYeH13w_30_6">25,393,962</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">See accompanying notes to unaudited condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aprea Therapeutics, Inc. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes&#160;to Condensed Consolidated Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Unaudited)</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_4hMiYW5Kv0uZlXk3aNT0EQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Nature of business and basis of presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Nature of business</b><span style="white-space:pre-wrap;">&#8212;Aprea Therapeutics, Inc. (the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company began principal operations in 2006 and is headquartered in Doylestown, Pennsylvania.  Prior to the acquisition of Atrin Pharmaceuticals Inc. (&#8220;Atrin&#8221;) in May 2022, the Company was engaged in the clinical development of cancer therapeutics that reactivate the mutant p53 tumor suppressor protein. In December 2020, the Company announced that its pivotal Phase 3 myelodysplastic syndromes trial failed to meet its predefined primary endpoint of complete remission (CR) rate. Given these results, FDA feedback and the costs of continuing the APR-246 development program, the Company shifted focus of its activities to the assets acquired in the May 2022 acquisition of Atrin. The Company&#8217;s two clinical programs are a novel oral macrocyclic ATR inhibitor, ATRN-119, and our next-generation oral inhibitor of the WEE1 kinase, APR-1051. Both programs are the cornerstones of our pipeline of synthetic lethality-based cancer therapeutics and were internally discovered, developed, and evaluated by our dedicated team of chemists, scientists, and clinicians.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Basis of presentation and management plans</b>&#8212;The accompanying financial statements are prepared in conformity with accounting principles generally accepted in the United States (&#8220;U.S.&#160;GAAP&#8221;). The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Since its inception, the Company has devoted substantially all of its efforts to business planning, clinical operations, research and development, recruiting management, technical staff, raising capital and has financed its operations through the issuance of convertible preferred stock and common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks common to companies in the biopharmaceutical industry. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be maintained, that any therapeutic products developed will obtain required regulatory approval or that any approved or consumer products will be commercially viable. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will generate significant product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company believes that the September&#160;30,&#160;2024 cash balance of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="Narr_qFKatj8cIEOKUvJPAYFZcw">26.2</ix:nonFraction> million will be sufficient to fund the Company&#8217;s operating expenses and capital expenditure requirements through at least twelve months from the date of issuance of these condensed consolidated financial statements. In the event that additional funds are not available thereafter, management would expect to significantly reduce expenditures to conserve cash, which would involve scaling back or curtailing new development activity.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_V89E-hcq5k2vWo_LtPPkEA" continuedAt="Tb_V89E-hcq5k2vWo_LtPPkEA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Summary of significant accounting policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company's complete listing of significant accounting policies are described in Note 2 to the Company's audited consolidated financial statements as of December&#160;31,&#160;2023 included in its annual report on Form 10-K filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;).</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="us-gaap:ConsolidationPolicyTextBlock" id="Tb_XjMNNj98okKG-FrxmVh3Vw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Principles of consolidation</b>&#8212;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries Aprea Therapeutics AB, which was incorporated in May 2009, Aprea US,&#160;Inc., which was incorporated in June&#160;2016 and ATR Pharmaceuticals LLC which was incorporated in May 2022. Management has concluded it has a single reporting segment for purposes of reporting financial condition and results of operations. All intercompany transactions and balances have been eliminated.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="apre:UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock" id="Tb_aC6XweIQFEalESnViFaknA" continuedAt="Tb_aC6XweIQFEalESnViFaknA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Unaudited interim consolidated financial statements</b>&#8212;The accompanying unaudited interim condensed consolidated financial statements have been prepared by the Company in accordance with U.S. GAAP for interim information and pursuant to the rules and regulations of the SEC for reporting on Form 10-Q. Accordingly, certain information and footnote disclosure normally included in financial statements prepared in accordance with U.S. GAAP have been </p></ix:nonNumeric></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aprea Therapeutics, Inc. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes&#160;to Condensed Consolidated Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Unaudited)</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_V89E-hcq5k2vWo_LtPPkEA_cont1" continuedAt="Tb_V89E-hcq5k2vWo_LtPPkEA_cont2"><ix:continuation id="Tb_aC6XweIQFEalESnViFaknA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">condensed or omitted pursuant to such rules and regulations. These unaudited condensed interim financial statements should be read in conjunction with the audited financial statements and related notes included in the Company&#8217;s annual report on Form 10-K for the year ended December&#160;31,&#160;2023 filed with the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The unaudited interim consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements, and in management&#8217;s opinion, include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of the financial information for the interim periods have been made. The results of operations for the three and nine months ended September&#160;30,&#160;2024 are not necessarily indicative of the results to be expected for the full fiscal year or any future period.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="us-gaap:UseOfEstimates" id="Tb_vFBQmcYH-0mD_l3znCrj0g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of estimates</b>&#8212;The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses as of and during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates. Significant items subject to such estimates and assumptions, are used for, but not limited to, include stock-based compensation and accounting for research and development costs.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="Tb_M96s1MFyGk6iJYD7hgzl5A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Foreign currency and currency translation</b>&#8212;The functional currency for Aprea Therapeutics AB is the Swedish Krona. Assets and liabilities of Aprea Therapeutics AB are translated into United States dollars at the exchange rate in effect on the balance sheet date. Operating expenses are translated at the average exchange rate in effect during the period. Unrealized translation gains and losses are recorded as a cumulative translation adjustment, which is included in the consolidated statements of stockholders&#8217; equity as a component of accumulated other comprehensive loss. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other income, net in the condensed consolidated statements of operations and comprehensive loss as incurred.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="Tb_L73sOzHNz0230_5eTcJZgQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cash and cash equivalents&#8212; </b>The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Restricted cash&#8212; </b>The Company has restricted cash of $<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="0" id="Narr_fWqVjhkG50uqb4ZLcr9rgQ">41,537</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="0" id="Narr_Qbo363oR2UquJ4T9znP7Iw">40,717</ix:nonFraction> at September&#160;30,&#160;2024 and December&#160;31,&#160;2023, respectively, that is securing the Company&#8217;s credit card program.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Tb_yhFNXp6ewkCvQnkSJAGsgQ" continuedAt="Tb_yhFNXp6ewkCvQnkSJAGsgQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Fair value of financial instruments</b>&#8212;The accounting standard for fair value measurements provides a framework for measuring fair value and requires expanded disclosures regarding fair value measurements. Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic 820, Fair Value Measurement (&#8220;ASC 820&#8221;), establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The hierarchy defines three levels of valuation inputs, of which the first two are considered observable and the last is considered unobservable:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;1 inputs: Quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;2 inputs: Inputs other than quoted prices included within Level&#160;1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;3 inputs: Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use in pricing the asset or liability.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in </p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aprea Therapeutics, Inc. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes&#160;to Condensed Consolidated Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Unaudited)</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_V89E-hcq5k2vWo_LtPPkEA_cont2" continuedAt="Tb_V89E-hcq5k2vWo_LtPPkEA_cont3"><ix:continuation id="Tb_yhFNXp6ewkCvQnkSJAGsgQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial instruments consist of cash, cash equivalents, restricted cash, accounts payable and accrued expenses. The carrying amount of accounts payable and accrued expenses is considered a reasonable estimate of fair value due to the short-term maturity.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="apre:TemporaryEquityPolicyTextBlock" id="Tb_Z4sTgrNbjUWp3QuFbuEz6g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Series A Convertible Preferred Stock</b>&#8212;The Company classifies the Series A Preferred Stock as temporary equity outside of stockholders&#8217; equity on the accompanying condensed consolidated balance sheets&#160;due to certain events that are not within the Company's control.&#160;The Series A Preferred Stock was recorded at fair value upon the acquisition of Atrin in May 2022.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_tXkYhFMRikGB5pdJMLjmsw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Accounting for leases</b>&#8212;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified asset(s), if any, and the Company&#8217;s control over the use of the identified asset(s), if applicable. Operating lease liabilities and their corresponding right of use assets are recorded based on the present value of future lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;">The Company has elected not to separate lease and non-lease components as a single component. Operating leases are recognized on the balance sheet as right of use (ROU) lease assets, lease liabilities current and lease liabilities non-current. Fixed rents are included in the calculation of the lease balances while variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis. The Company has also elected the short-term lease exemption for all leases with an original term of less than 12&#160;months.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_lm-LuDqijkiPbw8RMSQdug" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Research and development costs</b>&#8212;Research and development costs are charged to expense as incurred. Research and development expenses incurred in performing research and development activities, include salaries and benefits, materials and supplies, preclinical expenses, stock-based compensation expense, depreciation of equipment, contract services, and other outside expenses. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development. Deposits made by the Company with certain service providers that are to be applied to future payments due under the service agreements or returned to the Company if not utilized are recorded in the consolidated balance sheets.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="Tb_6e7awdMBe0iNuaPD1_vpOA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Revenue recognition</b>&#8212; The Company&#8217;s revenue is primarily generated through grants from government and non-government organizations. Grant revenue is recognized during the period that the reimbursable research and development services occur, as qualifying expenses are incurred or conditions of the grants are met. Grant revenue received in advance is recorded as deferred grant revenue and recognized as revenue once the conditions for revenue recognition are met. Associated expenses are recognized when incurred as research and development expenses. The Company concluded that payments received under these grants represent conditional, nonreciprocal contributions, as described in ASC&#160;<i style="font-style:italic;">958,</i><i style="font-style:italic;">&#160;</i>Not-for-Profit Entities, and that the grants are&#160;<i style="font-style:italic;">not</i>&#160;within the scope of ASC&#160;<i style="font-style:italic;">606,</i>&#160;Revenue from Contracts with Customers, as the organizations providing the grants do&#160;<i style="font-style:italic;">not</i>&#160;meet the definition of a customer. </p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_i7F0ViNjwUaJAIef_wiDOQ" continuedAt="Tb_i7F0ViNjwUaJAIef_wiDOQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stock-based compensation</b>&#8212;The Company measures stock options and other stock-based awards granted to employees and directors based on their fair value on the date of the grant and recognize compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective award. The Company applies the straight-line method of expense recognition to all awards with only service based vesting conditions.</p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aprea Therapeutics, Inc. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes&#160;to Condensed Consolidated Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Unaudited)</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_fd468b0c_ce39_408b_8820_6d44645df365"></a><a id="Tc_4INJAFsM80el3I9bt8p30g_1_2"></a><a id="Tc_36vQIjm6_UOta40II2U52A_2_2"></a><a id="Tc__SbSODccZEOJ3RGkcgY4Sg_2_4"></a><a id="Tc_rDp1lZ9SlU2UO2q7JbtTdw_3_0"></a><a id="Tc_Lvqd8Isr60Od_uW7o_ZEBQ_4_0"></a><a id="Tc_I8BbhwxpAk2CwZSkzwTWiQ_5_0"></a><a id="Tc_ILRMW7nLAUScNaU59YGTiA_5_4"></a><a id="Tc_HJ86gyqsSEeBkU0p8FCEEw_6_0"></a><a id="Tc_pRkAGr4lQ0SGxMC4zhG2oA_7_0"></a><ix:continuation id="Tb_V89E-hcq5k2vWo_LtPPkEA_cont3"><ix:continuation id="Tb_i7F0ViNjwUaJAIef_wiDOQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For stock-based awards granted to non-employees, compensation expense is recognized over the period during which services are rendered by such non-employees until completed in accordance with ASC 718. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company estimates the fair value of each stock option grant on the date of grant using the Black Scholes option pricing model, which uses as inputs the fair value of the Company&#8217;s common stock and assumptions the Company makes for the volatility of its common stock, the expected term of its stock options, the risk-free interest rate for a period that approximates the expected term of its stock options and its expected dividend yield. The Company elects to account for forfeitures when they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company also awards restricted stock units (&#8220;RSUs&#8221;) to employees and directors. RSUs are generally subject to forfeiture if employment terminates prior to the completion of the vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse.<span style="font-size:12pt;"> </span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_4sz1AHPQj02e79BwnX2c1A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Net loss per share</b>&#8212;The Company has reported losses since inception and has computed basic net loss per share attributable to common stockholders by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company computes diluted net loss per common share after giving consideration to all potentially dilutive common shares, including options to purchase common stock, outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential common shares have been anti-dilutive and basic and diluted loss per share have been the same. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Included within weighted average common shares outstanding for the three and nine months ended September&#160;30,&#160;2024 are <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_WAR5SHVFkE6tbDGoKuqOZg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_WzzAmbQQGESkqcjHWta9AQ"><ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_WAR5SHVFkE6tbDGoKuqOZg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_Spd-Nyl6QEmiwb8CTG_pqQ">507,076</ix:nonFraction></ix:nonFraction> common shares issuable upon the exercise of certain warrants, which are exercisable at any time for nominal consideration, and as such, the shares are considered outstanding for the purpose of calculating basic and diluted net loss per share attributable to common stockholders.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_A5FgWA2sNUSG2-wLVEygCA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine months ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:67.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Convertible preferred stock (as converted)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_-xdRwU9xSUiPNwUETulTXA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_dHoO9S3DAECwCnBMMTXB5Q_3_2">28,112</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_z_oRFQwZ_U2_FPccUncU4Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_o140uOgmv069dOK6ee9zdQ_3_4">28,112</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:67.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_lWBjcVjr5UKoPSricaY5kw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_EJnzFr7X3kqmucT6tZvArQ_4_2">734,131</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_I-_Nu9K7KEKrfxHT-XiE6A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_EFqoR1A6_U-vWv_yDW79GQ_4_4">582,641</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:67.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_18zK2B__vkKA8IrK9I5aKw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_oXG3Z3xwREOFxQ2-PiiVVg_5_2">2,194,788</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:67.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_BniNzMIFNESCAEERHrL4Qg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_nrY1GN7oEEu_BxDU8Kj6rw_6_2">36,442</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_V6BVG1ivukSZDtIV_eHuyA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_I69oiOiFkUi7kZL6Ogdakw_6_4">23,870</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:67.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total shares of common stock equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_8gN_vzHN7U6p34LPk7lgxQ_7_2">2,993,473</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_SGtdBuQN8ketXUU79aHE2g_7_4">634,623</ix:nonFraction></p></td></tr></table></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_xynWj9Ix50madTBHF8oxtg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently issued accounting pronouncements&#8212;<span style="font-weight:normal;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies that the Company adopts as of the specified effective date. </span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 will improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses on an interim and annual basis. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods after December 15, 2024, with early adoption permitted. The adoption of this standard is not expected to have a material impact on the Company&#8217;s condensed financial statements at adoption date.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aprea Therapeutics, Inc. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes&#160;to Condensed Consolidated Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Unaudited)</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="apre:LeaseDisclosureTextBlock" id="Tb_F7z5NAA9wE-bn6V8JqcErw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3. Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is party to <ix:nonFraction unitRef="Unit_Standard_lease_uug6S_kQsEij919rCVEEeQ" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" decimals="INF" format="ixt-sec:numwordsen" name="apre:LesseeOperatingLeaseNumberOfOperatingLeases" scale="0" id="Narr_7vN6DwcjMEOnCWtuLC2ucw">one</ix:nonFraction> operating lease for office and laboratory space. The Company&#8217;s finance leases are immaterial both individually and in the aggregate. The Company has elected to apply the short-term lease exception to all leases of one&#160;year or less. Rent expense for each of the three months ended September&#160;30,&#160;2024 and 2023 was $<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="0" id="Narr_Whqcbb5tk0KBJ6hKx611qg"><ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="0" id="Narr_HY4MxuLRdE-GswImWSQseA">19,998</ix:nonFraction></ix:nonFraction>. Rent expense for each of the nine months ended September&#160;30,&#160;2024 and 2023 was $<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="0" id="Narr_VWvYSTE2V0i-e_rU9Jc1kA"><ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="0" id="Narr_Elt3eS_utEK_FEpLO9T9kw">59,993</ix:nonFraction></ix:nonFraction>, which is included in operating expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company has an annual operating lease for office and laboratory space in Doylestown, Pennsylvania which was amended in October 2024 and is currently set to expire on October 31, 2025. Rent expense under this lease is $<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" decimals="INF" format="ixt:numdotdecimal" name="apre:LesseeOperatingLeaseAnnualBaseRent" scale="0" id="Narr_3zlvYhneYkWYPGssS7s8GA">110,000</ix:nonFraction> annually and the Company has applied the short-term exception to this lease. The Company has <span style="-sec-ix-hidden:Hidden_dXY0fqi6LUqjrBt7mcO_tw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no</span></span> lease obligations beyond October 2025.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Tc_MkpTm41z0kuXX-ilTxVgsw_1_2"></a><a id="Tc_KFMBWW8XSECLMhtXaXNtxQ_1_5"></a><a id="Tc_D9GeRsQTS0OqInYY2QVTOw_2_2"></a><a id="Tc_Cp0rBeejg0yo9eUM_ny50g_2_5"></a><a id="Tc_WPvaIitA0EGumxz6eOHyVQ_3_0"></a><a id="Tc_nqh9tb-h_kuC21YF8Zn2oQ_3_2"></a><a id="Tc_qh-fq7Q3-kORPcUnI7tx-w_3_5"></a><a id="Tc_EyjKNJLZeEG2jLg-eRwO1g_4_0"></a><a id="Tc_nRLXyAOweEaoPzME0ONVLQ_5_0"></a><a id="Tc_u--_sKPz3UiT1HKdEZyipw_6_0"></a><a id="Tc_hnfEI0AOZkSBPCK_mIvvTg_7_0"></a><a id="Tc_g3Mc1st7E0-1Xjss_4PZaQ_7_2"></a><a id="Tc_qOKrvc9oB0yYfRS43tT-9w_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Tb_7eXRpuTclUSB76UXwctvbQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">4. Accrued expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Accrued expenses consist of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_TwTWdpTvXUuVN41oDaz6HQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:72.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Professional&#160;fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" id="Tc_fM_CVDb7rEy1tSk0OnYIbA_3_3">168,225</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" id="Tc_Ylr8QPMDZEGCIte88zu-rQ_3_6">138,601</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Compensation, severance&#160;and&#160;benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_4Jg9WbXbDkeSRmVoe68acg_4_3">673,322</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_9eGEWAt5PUS6HynRPdoCZg_4_6">1,016,960</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research&#160;and&#160;development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" decimals="0" format="ixt:numdotdecimal" name="apre:ResearchAndDevelopmentRelatedLiabilitiesCurrent" scale="0" id="Tc_mHNN4GwhSUu5HhEZBFEAOg_5_3">1,582,173</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg" decimals="0" format="ixt:numdotdecimal" name="apre:ResearchAndDevelopmentRelatedLiabilitiesCurrent" scale="0" id="Tc_97GjH06PP0eOzkF486ilYA_5_6">856,575</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" id="Tc_dd9dHVwueECnV8Aq34xfJw_6_3">58,288</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" id="Tc_AOpvp2KcPkactpQuCCiNmg_6_6">174,126</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total&#160;accrued&#160;expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" decimals="0" format="ixt:numdotdecimal" name="apre:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_HyqeikMXYUaB-pwOnNQvfA_7_3">2,482,008</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg" decimals="0" format="ixt:numdotdecimal" name="apre:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_trDCJsT1yUmhOicnSSKvRg_7_6">2,186,262</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="apre:CommonStockTextBlock" id="Tb_vmWvwuyPH0ONwH5iVSZSTA" continuedAt="Tb_vmWvwuyPH0ONwH5iVSZSTA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">5. Stockholders&#8217; equity </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The total number of shares of all classes of capital stock that the Company is authorized to issue is <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" decimals="INF" format="ixt:numdotdecimal" name="apre:StockSharesAuthorized" scale="0" id="Narr_QZu8urIr0EKJ73whMmVbWQ">440,000,000</ix:nonFraction> shares, consisting of <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_vWWwbpaaskOTtXoi4trUVQ">400,000,000</ix:nonFraction> shares of common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_8g71vJPrp0yKNCir8EBPOA">0.001</ix:nonFraction> per share and <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_0VZTxjGcAEafGLd55Aa7RQ">40,000,000</ix:nonFraction> shares of preferred stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_p_ZjpFsgdkK5t5w5imxgZQ">0.001</ix:nonFraction> per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Series A Preferred Stock</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of September&#160;30,&#160;2024, a total of <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="As_Of_9_30_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_vRazHx54bUee8EgCl6bZxg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr_KtspceqDQUm0dDTGuRkVwQ">56,227</ix:nonFraction> shares of Series A Preferred Stock remained outstanding, which are convertible into <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" id="Narr_snotvY5h1ku8ujGfCZdjkg">28,112</ix:nonFraction> shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;font-weight:normal;">Common Stock</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The holders of common stock are entitled to <ix:nonFraction unitRef="Unit_Standard_Vote_xLAtZ3mDNEadoQnTSpr_cQ" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" decimals="INF" format="ixt-sec:numwordsen" name="apre:CommonStockNumberOfVotingRightsPerShare" scale="0" id="Narr_cvQRoMHp8UyckKt0jJx4KA">one</ix:nonFraction><span style="white-space:pre-wrap;"> vote for each share of common stock.  In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, after the payment or provision for payment of all debts and liabilities of the Company, the holders of common stock shall be entitled to share in the remaining assets of the Company available for distribution, if any.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Shelf Registration Statement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On November 12, 2020, the Company filed a universal shelf registration statement with the SEC for the issuance of common stock, preferred stock, warrants, rights, debt securities and units up to an aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_11_12_2020_us-gaap_SubsidiarySaleOfStockAxis_apre_ShelfRegistrationStatementMember_ARwQ47H460ieVrWA3BWUnQ" decimals="-5" format="ixt:numdotdecimal" name="apre:UniversalShelfRegistrationMaximumAmountToBeIssued" scale="6" id="Narr_sn82W6G5wk6A1GjKXlNT3w">350.0</ix:nonFraction> million (the &#8220;2020 Shelf Registration Statement&#8221;). On November 30, 2020, the 2020 Shelf Registration Statement was declared effective by the SEC and on November 30, 2023, the 2020 Shelf Registration Statement expired. The 2020 Shelf Registration Statement included an at-the-market offering program with SVB Leerink LLC (the &#8220;SVB ATM Program&#8221;) and the Company filed a Prospectus Supplement dated September 2, 2022, for the sale of up to $<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_11_12_2020_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_gmVaaYo2B0i-Fejiwesclg" decimals="INF" format="ixt:numdotdecimal" name="apre:AtMarketOfferingProgramMaximumAmountToBeIssued" scale="0" id="Narr_1ZfIWiluHEu6pMHUQ5eB_w">14,744,728</ix:nonFraction> of shares of the Company&#8217;s common stock pursuant to its ATM offering program. The Company agreed to pay a commission of <ix:nonFraction unitRef="Unit_Standard_pure_psC0V7jouEy1pdZ9EBR0Hw" contextRef="Duration_11_12_2020_To_11_12_2020_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_MJWqDGoHuUiO0gnEMhlZUg" decimals="2" format="ixt:numdotdecimal" name="apre:AtMarketOfferingCommissionPayableAsPercentageOfGrossProceedsFromSaleOfCommonStock" scale="-2" id="Narr_yLVhCbvlWUayp8flg4Digg">3</ix:nonFraction>% </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aprea Therapeutics, Inc. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes&#160;to Condensed Consolidated Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Unaudited)</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_vmWvwuyPH0ONwH5iVSZSTA_cont1" continuedAt="Tb_vmWvwuyPH0ONwH5iVSZSTA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">of the gross proceeds of any common stock sold in connection with the SVB ATM Program. During the nine months ended September&#160;30,&#160;2023, the Company issued and sold <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_fSqftKDYcEGIBNux4uAuoQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_b0paR4ld40ilt31kP6SzFA">26,302</ix:nonFraction> shares of common stock under the ATM offering program resulting in net proceeds to the Company of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_fSqftKDYcEGIBNux4uAuoQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_imHQ-IOC_0mefw3cDDrwug">0.3</ix:nonFraction> million after deducting approximately $<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_fSqftKDYcEGIBNux4uAuoQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="Narr_0qKLOh0FtU6_6MENb7UI1Q">8,000</ix:nonFraction> in issuance costs. The SVB ATM Program has terminated and is no longer effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In February 2023, the Company issued and sold <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="Duration_2_1_2023_To_2_28_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_apre_ShelfRegistrationStatementMember_LaEYUb2hjkW2KGU-74xlQw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_ZSDuAEh0REmQHqLohaG8Mw">1,050,000</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A" contextRef="As_Of_2_28_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_apre_ShelfRegistrationStatementMember_UBxEuMVTak-jJ5nG9mM16A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="Narr_qBB9itCmnEuwYlzcsSU3nw">5.25</ix:nonFraction> per share pursuant to the 2020 Shelf Registration Statement resulting in net proceeds to the Company of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_2_1_2023_To_2_28_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_apre_ShelfRegistrationStatementMember_LaEYUb2hjkW2KGU-74xlQw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_U_HoenttBk61_BfGqwFoRA">4.9</ix:nonFraction> million, after deducting underwriting discounts and offering expenses of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_2_1_2023_To_2_28_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_apre_ShelfRegistrationStatementMember_LaEYUb2hjkW2KGU-74xlQw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_RFTZsCEQwUy89T7mDosMVw">0.6</ix:nonFraction> million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On January 26, 2024, the Company filed a new shelf registration statement (the &#8220;2024 Shelf Registration Statement&#8221;) with the SEC for issuance of common stock, preferred stock, warrants, rights, debt securities and units up to an aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_1_26_2024_us-gaap_SubsidiarySaleOfStockAxis_apre_ShelfRegistrationStatement2024Member_hof9NYm7h0ub2MpXywHosA" decimals="-6" format="ixt:numdotdecimal" name="apre:UniversalShelfRegistrationMaximumAmountToBeIssued" scale="6" id="Narr_sBAc6OcYNE6jYYAH-E1Lpw">150</ix:nonFraction> million, including a prospectus for the sale of $<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_1_26_2024_us-gaap_SubsidiarySaleOfStockAxis_apre_ShelfRegistrationStatement2024Member_hof9NYm7h0ub2MpXywHosA" decimals="-6" format="ixt:numdotdecimal" name="apre:AtMarketOfferingProgramMaximumAmountToBeIssued" scale="6" id="Narr_lsBrLnDOcEqQ1yP5-if3QQ">1</ix:nonFraction><span style="white-space:pre-wrap;"> million of shares of our common stock under the ATM Agreement, as defined below, which was declared effective on February 2, 2024.  The Company subsequently filed a prospectus supplement to the 2024 Shelf Registration Statement for the sale of up to </span>$<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_1_26_2024_us-gaap_SubsidiarySaleOfStockAxis_apre_ShelfRegistrationStatement2024Member_hof9NYm7h0ub2MpXywHosA" decimals="-6" format="ixt:numdotdecimal" name="apre:AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement" scale="6" id="Narr_c-Tt8ZOo8kmqoQWYAjmGrw">2</ix:nonFraction><span style="white-space:pre-wrap;"> million of shares of common stock pursuant to the ATM Agreement.  On January 26, 2024, the Company entered into an At the Market Offering Agreement (the &#8220;ATM Agreement&#8221;) with H.C. Wainwright &amp; Co., LLC (&#8220;HCW&#8221;).  Pursuant to the ATM Agreement and the prospectus supplement filed in connection therewith, the Company was able, from time to time, in its sole discretion, to issue and sell through HCW, acting as sales agent and/or principal, up to </span>$<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_1_26_2024_srt_CounterpartyNameAxis_apre_HCWainrightCoLlcMember_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarket2024OfferingMember_M05-gKo8P0qhKNNnCJ2ynA" decimals="-6" format="ixt:numdotdecimal" name="apre:AtMarketOfferingProgramMaximumAmountToBeIssued" scale="6" id="Narr_XASu58PP4kyxjQqTBSzJHg">2</ix:nonFraction><span style="white-space:pre-wrap;"> million of shares of common stock.  The Company did not make any sales under the ATM Agreement and in March 2024, the Company terminated the ATM Agreement with HCW.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">March 2024 Private Placement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On March 11, 2024, the Company entered into a securities purchase agreement with certain purchasers (the &#8220;Purchasers&#8221;) pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement offering exempt from registration under the Securities Act of 1933, as amended, or the Securities Act, and the Purchasers agreed to purchase from the Company (i) <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_NhXjTaJGO0qzpt50WX1aQA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_4wFMh3Hm2UygYmc1PEXfqg">1,687,712</ix:nonFraction> shares of the Company&#8217;s common stock at a purchase price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A" contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_5KoUULH39EatBTbigzb7Nw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_Yp2Mt13lBEyYGrKXOdKJ6w">7.29</ix:nonFraction> per share (the &#8220;Shares&#8221;), (ii) pre-funded common stock purchase warrants at a purchase price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A" contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_Do28_zwKEkmVihgrJpKe5A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_AZ5Dpst84UWfBana4ROO-w">7.289</ix:nonFraction> to purchase an aggregate of up to <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_Do28_zwKEkmVihgrJpKe5A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_lx37ipP1b02rqdR6Z8INuQ">507,076</ix:nonFraction> shares of the Company&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A" contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_5KoUULH39EatBTbigzb7Nw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_72NJDpCz7USaaz6wsBzS9g">0.001</ix:nonFraction> per share (the &#8220;Pre-Funded Shares&#8221;), (iii) tranche A common stock purchase warrants to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice7.29PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_lx_pDgysWkWXlV3jLs59hg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_RAohUyRidUKVs6iN0m9iYQ">1,097,394</ix:nonFraction> shares of the Company&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A" contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice7.29PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_lx_pDgysWkWXlV3jLs59hg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_X7wiODn4hk2MZSWCnVKRoA">7.29</ix:nonFraction> per share (the &#8220;Tranche A Warrants&#8221;), and (iv) tranche B common stock purchase warrants to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg" contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice7.29PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_lx_pDgysWkWXlV3jLs59hg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_kQePR8Xab0q-qctPB6rCoQ">1,097,394</ix:nonFraction> shares of the Company&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A" contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice9.1125PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_G-a6RTBX2E2Sy0VISZQI2A" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_AgXIBW9IcEaeX1oG-9R8rA">9.1125</ix:nonFraction> per share (the &#8220;Tranche B Warrants&#8221;). The Tranche A Warrants will be exercisable until the earlier of (i) the <ix:nonNumeric contextRef="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice7.29PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_2erKOwIbbU-vg-0HBwM-Ew" format="ixt-sec:durwordsen" name="apre:StockIssuanceAnniversaryPeriod" id="Narr_NIqIXRlCR0i6UddLUmfLIw">three-year</ix:nonNumeric> anniversary of issuance and (ii) <ix:nonNumeric contextRef="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice7.29PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_2erKOwIbbU-vg-0HBwM-Ew" format="ixt-sec:durwordsen" name="apre:NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119" id="Narr_VtxT4GNeg02rOqDHIebX5g">30 days</ix:nonNumeric> after the Company announces the recommended Phase 2 dose for ATRN-119, and, following such announcement, the daily volume weighted average price of the Company&#8217;s common stock equals or exceeds $<ix:nonFraction unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A" contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice7.29PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_lx_pDgysWkWXlV3jLs59hg" decimals="2" format="ixt:numdotdecimal" name="apre:SharesIssuedVolumeWeightedAveragePricePerShare" scale="0" id="Narr_jsDtz-sRGEOwaEsCBMo4xA">14.58</ix:nonFraction> for <ix:nonNumeric contextRef="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice7.29PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_2erKOwIbbU-vg-0HBwM-Ew" format="ixt-sec:durday" name="apre:NumberOfConsecutiveTradingDays" id="Narr_A7s7oYjDF0KbKhhYrIfc-w">30</ix:nonNumeric> consecutive trading days. The Tranche B Warrants will be exercisable until the earlier of (i) the <ix:nonNumeric contextRef="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice9.1125PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_zOEchtkouU6yqqanDoFo6w" format="ixt-sec:durwordsen" name="apre:StockIssuanceAnniversaryPeriod" id="Narr_DkqjriLx8k6iqOz3dgG4Dg">five-year</ix:nonNumeric> anniversary of issuance and (ii) <ix:nonNumeric contextRef="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice9.1125PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_zOEchtkouU6yqqanDoFo6w" format="ixt-sec:durwordsen" name="apre:NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119" id="Narr_vtgg1lGcikipppKDmlc6JQ">30 days</ix:nonNumeric> after the Company announces the recommended Phase 2 dose for APR-1051 and, following such announcement, the daily volume weighted average price of the Company&#8217;s common stock equals or exceeds $<ix:nonFraction unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A" contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice9.1125PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_G-a6RTBX2E2Sy0VISZQI2A" decimals="3" format="ixt:numdotdecimal" name="apre:SharesIssuedVolumeWeightedAveragePricePerShare" scale="0" id="Narr_lFPeZfyx7kSjJnvGa89kJA">18.225</ix:nonFraction> for <ix:nonNumeric contextRef="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice7.29PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_2erKOwIbbU-vg-0HBwM-Ew" format="ixt-sec:durday" name="apre:NumberOfConsecutiveTradingDays" id="Narr_9vckXgciA0mQLpDGZlttAg">30</ix:nonNumeric> consecutive trading days. To the extent that the exercise of a Tranche A Warrant or Tranche B Warrant would result in the holder beneficially owning greater than <ix:nonFraction unitRef="Unit_Standard_pure_psC0V7jouEy1pdZ9EBR0Hw" contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_5KoUULH39EatBTbigzb7Nw" decimals="4" format="ixt:numdotdecimal" name="apre:PercentageOfOutstandingShares" scale="-2" id="Narr_Kjbh-J4pRkulaOG2Dy-fJg">4.99</ix:nonFraction>% (or, at the election of the holder, greater than <ix:nonFraction unitRef="Unit_Standard_pure_psC0V7jouEy1pdZ9EBR0Hw" contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_srt_StatementScenarioAxis_apre_AtEventOfElectionOfHolderMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_jryn2JxtuUiScam-ie0pMg" decimals="4" format="ixt:numdotdecimal" name="apre:PercentageOfOutstandingShares" scale="-2" id="Narr_Pu_2GbairkqlQHmRuKKjfQ">9.99</ix:nonFraction>%) of the Company&#8217;s outstanding common stock immediately following such exercise, the holder will instead receive pre-funded warrants in substantially the same form as the pre-funded warrants issued at closing. The aggregate upfront gross proceeds from the issuance of common stock and pre-funded common stock purchase warrants totaled approximately $<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_NhXjTaJGO0qzpt50WX1aQA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="Narr_eZPhhR4d6ESEXBadaj8FfA">16.0</ix:nonFraction> million, before deducting placement agent fees and offering costs of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_NhXjTaJGO0qzpt50WX1aQA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_OYO4Wf_YGk-fw3yvMsEY7w">1.3</ix:nonFraction> million. The gross proceeds from potential future warrant cash exercises are expected to be up to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_NhXjTaJGO0qzpt50WX1aQA" decimals="-5" format="ixt:numdotdecimal" name="apre:ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise" scale="6" id="Narr_acup2Ik8kUWCtIzB_WGojg">18.0</ix:nonFraction> million, before deducting placement agent fees. In April 2024, we registered on Form S-3 the resale of the Shares, the Pre-Funded Shares and the shares underlying the Tranche A Warrants and Tranche B Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company evaluated the terms of the warrants issued and determined that they should be classified as equity instruments within additional paid-in capital. As of September&#160;30,&#160;2024, <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ProceedsFromWarrantExercises" scale="0" id="Narr_I1JD4_la00-3mgUZfCT_sQ">none</ix:nonFraction> of the pre-funded warrants, Tranche A Warrants or Tranche B Warrants have been exercised.</p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aprea Therapeutics, Inc. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes&#160;to Condensed Consolidated Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Unaudited)</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_vmWvwuyPH0ONwH5iVSZSTA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Stock-Based Compensation Expense</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company recorded stock-based compensation expense of $<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_f_VG65IQw0SMk3rq4pDEGw">149,090</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_nHJyNfPc20a4o26OgXbB4g">76,031</ix:nonFraction> for the three months ended September&#160;30,&#160;2024 and 2023, respectively. The Company recorded stock-based compensation expense of $<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_Fn9k7rW7XEC5fB1GMDzHxg">363,408</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_gTjEYJTPVkOZQkvXavuVlQ">361,598</ix:nonFraction> for the nine months ended September&#160;30,&#160;2024 and 2023, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_sHCYOpUYgU2woPy89oquTQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">6. Income Taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="Narr_KnJrh0lZN0KcN0pU3Q4VNQ"><ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="Narr_C769ns_V-EqYxrvi4Y2_Pg"><ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="Narr_v6TxUCPxwkaqej36HDME1Q"><ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="Narr_ceYO5sEWcEW_VYwb9WNYQw">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> income tax expense due to operating losses incurred for the three and nine months ended September&#160;30,&#160;2024 and 2023. The Company has provided a valuation allowance for the full amount of the net deferred tax assets as, based on all available evidence, it is considered more likely than not that all the recorded deferred tax assets will not be realized in a future period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Realization of the future tax benefits is dependent on may factors, including the Company&#8217;s ability to generate taxable income within the net operating loss carryforward period.  Under the provisions of the U.S. Internal Revenue Code and Sweden tax law, certain substantial changes in the Company&#8217;s ownership, including a sale of the Company or significant changes in ownership due to sales of equity, may have limited, or may limit in the future, the amount of net operating loss carryforwards that could be used annually to offset future taxable income.  For U.S. and Swedish income tax purposes, the Company has not completed a study to assess whether a change of control has occurred or whether there have been changes of control since the Company&#8217;s formation due to the complexity and cost associated with such study and because there could be additional changes of control in the future.  As a result, the Company is not able to estimate the effect of the change in control, if any, on the Company&#8217;s ability to utilize U.S. or Swedish net operating losses or other tax attribute carryforwards in the future.  For Swedish income tax purposes, the Company&#8217;s net operating losses may be subject to limitations in accordance with the country&#8217;s group contribution restriction laws.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company files tax returns in Sweden, the United States, Massachusetts and Pennsylvania. Income tax returns prior to 2020 in the United States and Massachusetts are no longer subject to examination and income tax returns prior to 2017 are no longer subject to examination in Sweden. The Company is not currently under examination by the IRS or any other jurisdictions for any tax years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As tax law is complex and often subject to varied interpretations, it is uncertain whether some of the Company&#8217;s tax positions will be sustained upon examination. Tax liabilities associated with uncertain tax positions represent unrecognized tax benefits, which arise when the estimated benefit recorded in the Company&#8217;s financial statements differs from the amounts taken or expected to be taken in a tax return because of the uncertainties described above. Substantially all of these unrecognized tax benefits, if recognized, would benefit the Company&#8217;s effective income tax rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of September&#160;30,&#160;2024 and December&#160;31,&#160;2023, the Company had approximately $<ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" scale="6" id="Narr_2QEUnkXDnUyMdKnyJ8zKKQ"><ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" scale="6" id="Narr_5i_WbmqNC0OS_71tYUhsNg">0.1</ix:nonFraction></ix:nonFraction> million of liabilities related to uncertain tax positions. As the Company&#8217;s uncertain tax positions can be offset by available net operating losses, the Company did not recognize interest and penalties for 2024 and 2023.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_6XdxMGekK0eoUYSC-W2INw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">7. Commitments and contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company records a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. As of September&#160;30,&#160;2024, the Company has <ix:nonFraction unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw" contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyAccrualProvision" scale="0" id="Narr_QIzVBwuwjEuF-USauq9oag">no</ix:nonFraction>t recorded a provision for any contingent losses.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_26a67239_c64e_4393_b87b_66e74e2e9d27"></a><a id="Item2ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Item 2.  Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with the unaudited financial information and notes thereto included in this Quarterly Report on Form&#160;</i><i style="font-style:italic;white-space:pre-wrap;">10-Q. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business and related financing, including forward-looking statements that involve risks and uncertainties.  As a result of many factors, including those factors set forth in the &#8220;Risk Factors&#8221; section of this Quarterly Report and in our Annual Report on Form 10-K for the year ended December 31, 2023, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. Our approach is built upon a platform of integrated discovery technologies to enrich our pipeline with novel targets in synthetic lethality and cancer treatment. Together with our expertise in small molecule drug discovery, we are applying the capabilities of our discovery platform to the development of new precision oncology therapies and the identification of patient populations most likely to benefit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Aprea Therapeutics AB was originally incorporated in 2002 and commenced principal operations in 2006. On September 20, 2019, we consummated a reorganization, pursuant to which all of the issued and outstanding stock and options of Aprea Therapeutics AB were exchanged for common stock, preferred stock or options, as applicable, of Aprea Therapeutics, Inc. As a result, Aprea Therapeutics AB became a wholly owned subsidiary of Aprea Therapeutics, Inc. Prior to the acquisition of Atrin Pharmaceuticals Inc. (&#8220;Atrin&#8221;), in May 2022, we were engaged in the clinical development of cancer therapeutics that reactivate the mutant p53 tumor suppressor protein. In December 2020, we announced that our pivotal Phase 3 myelodysplastic syndromes trial failed to meet its predefined primary endpoint of complete remission (&#8220;CR&#8221;) rate. Given these results, FDA feedback and the costs of continuing the APR-246 development program, we shifted focus of our activities to the assets acquired in the May 2022 acquisition of Atrin. Our two clinical programs are a novel oral macrocyclic ATR inhibitor, ATRN-119, and our next-generation oral inhibitor of the WEE1 kinase, APR-1051. Both programs are the cornerstones of our pipeline of synthetic lethality-based cancer therapeutics and were internally discovered, developed, and evaluated by our dedicated team of chemists, scientists, and clinicians. We do not currently have any significant ongoing preclinical studies or any clinical trials involving APR-246, our reactivators of mutant p53. Our primary pre-clinical focus is on the discovery and development of molecules targeting DDR pathways in oncology through synthetic lethality.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We believe that synthetic lethality has the potential to impact patients&#8217; lives and treatment strategies for a wide range of cancer types. We aspire to become a leader in this emerging field and are establishing a pipeline of clinical and preclinical programs that we believe may have broad application to cancer treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our most advanced synthetic lethality product candidate is ATRN-119, a clinical-stage oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR. The ATR kinase is a master regulator of the DNA damage response, with key roles in cell cycle control and DNA repair following replication stress. Aprea Therapeutics has developed ATRN-119, the first oral macrocyclic ATR inhibitor to enter clinical trials. We are enrolling patients into ABOYA-119, a Phase 1/2a clinical trial to evaluate ATRN-119 under an investigational new drug (&#8220;IND&#8221;) application. The first five dose cohorts have been completed, with the sixth cohort currently enrolling. The primary endpoint of this Phase 1 part is to evaluate the tolerability and pharmacokinetics of ATRN-119 when administered orally on a continuous, once-daily schedule. We observed preliminary signs of clinical benefit in the early stages of development, and based on the interim data from our ongoing first-in-human phase study, ATRN-119 has demonstrated the ability to be safe and well tolerated, with no dose-limiting toxicities and no signs of significant hematological toxicity reported. We recently amended the study protocol to 1) add up to four additional groups of patients who will receive ATRN-119 twice a day (BID); 2), add an additional, higher dose level of 1,500mg once a day (QD) and 3) investigate the effect of food on ATRN-119 absorption and drug exposure in blood. Under the current new protocol, we anticipate potential efficacy data readout in second half 2025.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our second clinical program is a WEE1 inhibitor, APR-1051. WEE1 is a protein kinase that inhibits premature cell cycle progression. Specifically, WEE1 prevents the premature entry of cells into both the DNA synthetic phase of the cell cycle and the phase in which cells divide after the DNA is duplicated. Through these roles, WEE1 prevents loss of genome stability, particularly in CCNE1-overexpressing cancer cells. APR-1051 is an orally bioavailable, highly potent, and selective small molecule inhibitor of WEE1. APR-1051 has demonstrated in vivo anti-proliferative activity in multiple cancer cell lines. Importantly, the pharmacodynamic properties of APR-1051 include lower off-target inhibition of three members of the PLK family of kinases (PLK1, PLK2, and PLK3), which may improve its therapeutic value. In March 2024, the FDA cleared our IND application for APR-1051 and in the second quarter of 2024 we enrolled the first patient into ACESOT-1051. A total of 8 cohorts are planned for ACESOT-1051 that will evaluate doses of 10 mg to 150 mg once daily. As of November 4, 2024, we are enrolling cohort 4 for ACESOT-1051 to evaluate a subtherapeutic dose of 50 mg once daily. Preliminary results indicate APR-1051 is safe and well-tolerated with no hematologic toxicity and one possible treatment-related grade 1 adverse event (abdominal distention) at the dose levels assessed. Active enrollment is ongoing at three sites in the U.S. (NCT06260514) with additional sites planned. We expect open-label safety/efficacy data in the first half of 2025. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We also have an early preclinical research program, which is currently in the lead optimization stage, for an undisclosed DDR target.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition to development of these drugs as single agents, we are also evaluating potential expansion opportunities for our product candidates through combination with other agents where we believe a combination of therapeutic agents may enhance efficacy. Importantly, we are also evaluating combination opportunities within our pipeline, including pre-clinical research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute (&#8220;NCI&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have assembled a team with extensive experience in the discovery, development and commercialization of oncology drugs to support our mission of developing novel synthetic lethality-based cancer therapeutics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have devoted substantially all of our resources to developing our product candidates, building our intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. To date, we have financed our operations primarily through the net proceeds received from the initial public offering of our common stock and sales of common stock through public and private offerings. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Components of our results of operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Grant revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;">We have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the near future. If our development efforts for any of our product candidates are successful and result in marketing approval or collaboration or license agreements with third parties, we may generate revenue in the future from a combination of product sales or payments from collaboration or license agreements that we may enter into with third parties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">Our revenue is primarily generated through grants from government and non-government organizations. Grant revenue is recognized during the period that the research and development services occur, as qualifying expenses are incurred or conditions of the grants are met. Associated expenses are recognized when incurred as research and development expense. We concluded that payments received under these grants represent conditional, nonreciprocal contributions, as described in ASC&#160;958,<i style="font-style:italic;">&#160;</i>Not<i style="font-style:italic;">-</i>for-Profit Entities, and that the grants are&#160;not&#160;within the scope of ASC&#160;606,&#160;Revenue from Contracts with Customers, as the organizations providing the grants do&#160;not&#160;meet the definition of a customer. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Operating expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our expenses since inception have consisted solely of research and development costs and general and administrative costs.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Research and development expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts, and the development of our product candidates, and include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses incurred under agreements with third parties, including contract research organizations, or CROs, that conduct clinical trials, research and preclinical activities on our behalf as well as contract manufacturing organizations, or CMOs, that manufacture our product candidates for use in our preclinical and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">salaries, benefits and other related costs, including stock-based compensation expense, for personnel engaged in research and development functions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs of outside consultants, including their fees, stock-based compensation and related travel expenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs of laboratory supplies and acquiring, developing and manufacturing preclinical study and clinical trial materials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses related to compliance with regulatory requirements; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We expense research and development costs as incurred. We recognize costs for certain development activities, such as clinical trials, based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided to us by our vendors and our clinical investigative sites. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our financial statements as prepaid or accrued research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We typically use our employee and infrastructure resources across our development programs. We track outsourced development costs and payments made to our research partners by product candidate or development program, but we do not allocate personnel costs or other internal costs to specific development programs or product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will continue to increase for the foreseeable future as we initiate clinical trials for ATRN-119, APR-1051 and other product candidates and continue to discover and develop additional product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We cannot determine with certainty the duration and costs of planned clinical trials of our product candidates or if, when, or to what extent we will generate revenue from the commercialization and sale of any our product candidates for which we obtain marketing approval. We may never succeed in obtaining marketing approval for any of our product candidates. The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, rate of progress, expense and results of any future clinical trials of our product candidates and other research and development activities that we may conduct;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">uncertainties in clinical trial progression, patient enrollment and response rates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant and changing government regulation and regulatory guidance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and receipt of, and any limitations imposed by regulatory bodies on, any marketing approvals; and</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expense of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the U.S. Food and Drug Administration, or FDA, or another regulatory authority in a foreign jurisdiction were to require us to conduct clinical trials beyond the scope we currently anticipate, or additional clinical trials beyond those that we anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant trial delays due to patient enrollment or other reasons, we would be required to expend significant additional financial resources and time on the completion of clinical development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">General and administrative expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in our executive, finance, corporate and business development and administrative functions. General and administrative expenses also include legal fees relating to patent and corporate matters; professional fees for accounting, auditing, tax and consulting services; insurance costs; travel expenses; and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We expect that our general and administrative expenses will increase in the future as we increase our headcount to support personnel in research and development and to support our operations generally, and as we increase our activities related to the potential commercialization of our product candidates. We also expect to continue to incur increased expenses associated with being a public company, including costs of accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with exchange listing and SEC requirements; director and officer insurance costs; and investor and public relations costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other income and expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Interest income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Interest income consists of income earned on our cash and cash equivalents. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Foreign currency gain (loss)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our consolidated financial statements are presented in U.S. dollars, which is our reporting currency. The financial position and results of operations of our subsidiary Aprea AB is measured using the foreign subsidiary&#8217;s local currency as the functional currency. Aprea AB cash accounts holding U.S. dollars are remeasured based upon the exchange rate at the date of remeasurement with the resulting gain or loss included in the consolidated statement of operations and comprehensive loss. Expenses of such subsidiaries have been translated into U.S. dollars at average exchange rates prevailing during the period. Assets and liabilities have been translated at the rates of exchange on the consolidated balance sheet date. The resulting translation gain and loss adjustments are recorded directly as a separate component of stockholders&#8217; equity and as other comprehensive loss on the consolidated statement of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have not recorded any U.S. federal, state or foreign income tax expense or benefits for the net losses we have incurred in any year, due to our uncertainty of realizing a benefit from those items. We have provided a valuation allowance for the full amount of the net deferred tax assets as, based on all available evidence, it is considered more likely than not that all the recorded deferred tax assets will not be realized in a future period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Critical accounting policies and use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The preparation of our financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, costs and expenses in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">While our significant accounting policies are described in more detail in the notes to our financial statements, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Accrued research and development expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As part of the process of preparing our financial statements, we are required to estimate our accrued research and development expenses at each balance sheet date. This process involves reviewing open contract and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated costs incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. The majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met; however, some require advanced payments. We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us at that time. Examples of estimated accrued research and development expenses include fees billed by:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">CRO's in connection with performing research activities on our behalf and conducting preclinical studies and clinical trials on our behalf;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">investigative sites or other service providers in connection with clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">vendors in connection with preclinical and clinical development activities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">vendors related to product manufacturing and development and distribution of preclinical and clinical supplies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We base our expenses related to preclinical studies and clinical trials on our estimates of the services received and efforts expended pursuant to quotes and contracts with CROs that conduct and manage preclinical studies and clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Payments under some of these contracts are fee for service or depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing fees, we estimate the time period over which services will be performed, and multiple factors including enrollment of patients, number of sites activated and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or amount of prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in us reporting amounts that are too high or too low in any particular period. To date, we have not made any material adjustments to our prior estimates of accrued research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We measure stock options and other stock-based awards granted to employees and directors based on their fair value on the date of the grant and recognize compensation expense of those awards, over the requisite service period, which is generally the vesting period of the respective award. We apply the straight-line method of expense recognition to all awards with only service-based vesting conditions and apply the graded-vesting method to all awards with performance-based vesting conditions or to awards with both service-based and performance-based vesting conditions.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For stock-based awards granted to non employees, compensation expense is recognized over the period during which services are rendered by such non employees until completed in accordance with ASC 718.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We estimate the fair value of each stock option grant on the date of grant using the Black-Scholes option-pricing model, which uses as inputs the fair value of our common stock and assumptions we make for the volatility of our common stock, the expected term of our stock options, the risk-free interest rate for a period that approximates the expected term of our stock options and our expected dividend yield.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We also award restricted stock units (&#8220;RSUs&#8221;) to employees and directors. RSUs are generally subject to forfeiture if employment terminates prior to completion of the vesting restrictions. We expense the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Emerging growth company and smaller reporting company status</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are an emerging growth company (&#8220;EGC&#8221;), as defined in the JOBS Act. Under this act, emerging growth companies are permitted to delay adopting new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may remain classified as an EGC until the end of the fiscal year in which the fifth anniversary of our IPO occurs, which is December 31, 2024, although if the market value of our common stock that is held by non-affiliates exceeds $700&#160;million as of the last trading day of the second quarter before that time, which it did not at June 30, 2024, or if we have annual gross revenues of $1.235&#160;billion or more in any fiscal year, we would cease to be an EGC as of December&#160;31 of the applicable year. We also would cease to be an EGC if we issue more than $1&#160;billion of non-convertible debt over a three-year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are also a &#8220;smaller reporting company,&#8221; as such term is defined in Rule&#160;12b-2 of the Exchange Act, meaning that the market value of our common stock held by non-affiliates is less than $700 million and our annual revenue is less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i)&#160;the market value of our common stock held by non-affiliates is less than $250 million or (ii)&#160;our annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our common stock held by non-affiliates is less than $700 million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form&#160;10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;">Comparison of the three months ended September&#160;30,&#160;2024 and 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:55.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:55.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 354,621</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 319,468</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 35,153</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:55.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:55.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,846,399</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,122,603</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 723,796</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:55.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,605,238</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,719,715</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (114,477)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:55.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,451,637</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,842,318</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 609,319</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:55.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (4,097,016)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (3,522,850)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (574,166)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:55.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:55.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 348,741</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 321,215</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 27,526</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:55.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Foreign currency loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (35,494)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2,880)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (32,614)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:55.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 313,247</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 318,335</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (5,088)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:55.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (3,783,769)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (3,204,515)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (579,254)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;">Grant revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Grant revenue primarily from the National Cancer Institute of the National Institutes of Health (&#8220;NIH&#8221;) for the three months ended September&#160;30,&#160;2024 and 2023 was approximately $0.4 million and $0.3 million, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;">Research and development expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:55.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:55.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">APR-246</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,113</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18,023</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (15,910)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:55.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ATRN-119</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,420,238</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 426,585</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 993,653</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:55.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">APR-1051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 875,236</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,198,574</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (323,338)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:55.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other early-stage development programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 91,783</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 89,760</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,023</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:55.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unallocated research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 457,029</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 389,661</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 67,368</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:55.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,846,399</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,122,603</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 723,796</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses for the three months ended September&#160;30,&#160;2024 were approximately $2.8 million, compared to approximately $2.1&#160;million for the three months ended September&#160;30,&#160;2023. The overall increase of $0.7&#160;million was primarily due to the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase of $1.0 million related to the ABOYA-119 clinical trial to evaluate ATRN-119, our clinical-stage oral small molecule inhibitor of ATR.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The above increases were offset in part by the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a decrease of $0.3 million related to IND enabling studies for ATRN-1051, our small molecule WEE1 inhibitor, in the third quarter of 2023. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 11pt 0pt;">General and administrative expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">General and administrative expenses for the three months ended September&#160;30,&#160;2024 were approximately $1.6&#160;million, compared to approximately $1.7&#160;million for the three months ended September&#160;30,&#160;2023. The decrease of $0.1 million was primarily due to a decrease of $0.1 million in insurance costs.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 11pt 0pt;">Other income </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">Foreign currency loss for the three months ended September&#160;30,&#160;2024 was $35,494 compared to a foreign currency loss of $2,880 for the three months ended September&#160;30,&#160;2023. The change in the foreign currency of $32,614 was primarily due to a weakening of the U.S. dollar against the Swedish Krona during the three months ended September&#160;30,&#160;2024 as compared to the three months ended September&#160;30,&#160;2023. Interest income, net for the three months ended September&#160;30,&#160;2024 and 2023 primarily consisted of interest income on our cash and cash equivalents. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><span style="font-style:italic;font-weight:bold;">Comparison of the nine months ended September&#160;30,&#160;2024 and 2023</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:54.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine months ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:top;width:54.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,296,764</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 569,156</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 727,608</span></p></td></tr><tr><td style="vertical-align:top;width:54.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:54.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,004,451</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,581,802</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,422,649</span></p></td></tr><tr><td style="vertical-align:top;width:54.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,385,923</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,784,388</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,398,465)</span></p></td></tr><tr><td style="vertical-align:top;width:54.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,390,374</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,366,190</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 24,184</span></p></td></tr><tr><td style="vertical-align:top;width:54.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (11,093,610)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (11,797,034)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 703,424</span></p></td></tr><tr><td style="vertical-align:top;width:54.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:54.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,014,518</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 913,846</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 100,672</span></p></td></tr><tr><td style="vertical-align:top;width:54.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Foreign currency gain</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 15,180</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 39,686</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (24,506)</span></p></td></tr><tr><td style="vertical-align:top;width:54.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,029,698</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 953,532</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 76,166</span></p></td></tr><tr><td style="vertical-align:top;width:54.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (10,063,912)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (10,843,502)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 779,590</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;">Grant revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">Grant revenue primarily from the National Cancer Institute of the National Institutes of Health (&#8220;NIH&#8221;) for the nine months ended September&#160;30,&#160;2024 and 2023 was approximately $1.3 million and $0.6 million, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;">Research and development expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:57.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine months ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:top;width:57.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">APR-246</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 106,316</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 29,678</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 76,638</span></p></td></tr><tr><td style="vertical-align:top;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">ATRN-119</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,915,224</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,182,904</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 732,320</span></p></td></tr><tr><td style="vertical-align:top;width:57.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">APR-1051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,393,628</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,940,080</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 453,548</span></p></td></tr><tr><td style="vertical-align:top;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other early-stage development programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 198,284</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 278,112</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (79,828)</span></p></td></tr><tr><td style="vertical-align:top;width:57.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unallocated research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,390,999</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,151,028</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 239,971</span></p></td></tr><tr><td style="vertical-align:top;width:57.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,004,451</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,581,802</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,422,649</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses for the nine months ended September&#160;30,&#160;2024 were approximately $7.0 million, compared to approximately $5.6&#160;million for the nine months ended September&#160;30,&#160;2023. The overall increase of $1.4&#160;million was primarily due to the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase of $0.5 million related to the initiation of our second clinical trial program for APR-1051, our small molecule WEE1 inhibitor, in preparation for enrollment of first patient into ACESOT-1051, our Phase 1 dose-escalation study, in the second quarter of 2024;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase of $0.7 million related to the ABOYA-119 clinical trial to evaluate ATRN-119, our clinical-stage oral small molecule inhibitor of ATR; and</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase of $0.3 million in personnel costs.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The above increases were offset in part by the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a decrease of $0.1 million in other clinical programs. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 11pt 0pt;">General and administrative expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">General and administrative expenses for the nine months ended September&#160;30,&#160;2024 were approximately $5.4&#160;million, compared to approximately $6.8&#160;million for the nine months ended September&#160;30,&#160;2023. The decrease of $1.4 million was primarily due to a decrease of $1.3 million in personnel costs primarily related to severance expense for former executives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 11pt 0pt;">Other income </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">Foreign currency gain for the nine months ended September&#160;30,&#160;2024 was $15,180 compared to a foreign currency gain of $39,686 for the nine months ended September&#160;30,&#160;2023. The change in the foreign currency of $24,506 was primarily due to a weakening of the U.S. dollar against the Swedish Krona during the nine months ended September&#160;30,&#160;2024 as compared to the nine months ended September&#160;30,&#160;2023. Interest income, net for the nine months ended September&#160;30,&#160;2024 and 2023 primarily consisted of interest income on our cash and cash equivalents. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">Liquidity and capital resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">Since our inception, we have incurred significant losses on an aggregate basis. We have not yet commercialized any of our product candidates, which are in various phases of preclinical and clinical development, and we do not expect to generate revenue from sales of any products for several years, if at all. Our ability to generate product revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of one or more of our product candidates. Since 2019, our primary source of funds has been from the public sales of our common stock. As of September&#160;30,&#160;2024, we had cash and cash equivalents of $26.2&#160;million. We believe that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements through at least twelve months from the date of issuance of these condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">Our net losses were $10.1 million and $10.8 million for the nine months ended September&#160;30,&#160;2024 and 2023, respectively. As of September&#160;30,&#160;2024, we had an accumulated deficit of $318.1 million. These losses have resulted primarily from costs incurred in connection with research and development activities, patent investment, and general and administrative costs associated with our operations. We expect to continue to incur significant expenses and increasing operating losses for at least the next several years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 11pt 0pt;">Cash flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following table summarizes our sources and uses of cash for each of the periods presented:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.11%;"><tr style="height:1pt;"><td style="vertical-align:top;width:64.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:0.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine months ended September&#160;30,&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:64.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash provided by (used in):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:0.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:64.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (10,045,814)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (8,437,950)</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:64.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (15,478)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (85,943)</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:0.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:64.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,687,490</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,139,990</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:64.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,626,198</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,383,903)</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:0.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Operating activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash used in operating activities resulted primarily from our net losses adjusted for non-cash charges and changes in components of working capital. Net cash used in operating activities was $10.0 million for the nine months ended September&#160;30,&#160;2024 compared to $8.4&#160;million for the nine months ended September&#160;30,&#160;2023. The increase in cash used </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">in operating activities of $1.6&#160;million was primarily attributable to a change in operating assets and liabilities of $2.4 million, partially offset by a decrease in our net loss of $0.8 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Investing activities<span style="font-style:normal;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Cash used in investing activities of $15,478 for the nine months ended September&#160;30,&#160;2024 was for the purchase of property and equipment. No cash was used in or provided by investing activities for the nine months ended September&#160;30,&#160;2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Financing activities<span style="font-style:normal;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities was $14.7 million for the nine months ended September&#160;30,&#160;2024. Cash provided by financing activities for the nine months ended September&#160;30,&#160;2024 was attributable to the net proceeds of $14.7 million, after deducting underwriting discounts and offering expenses of approximately $1.3 million, received from the sale of 1,687,712 shares of common stock, 507,076 pre-funded common stock purchase warrants, 1,097,394 tranche A common stock purchase warrants and 1,097,394 tranche B common stock purchase warrants in March 2024.<span style="background:#ffffff;">&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Net c</span>ash provided by financing activities of $5.1 million for the nine months ended September&#160;30,&#160;2023<span style="background:#ffffff;"> was attributable to the net proceeds </span>of $4.9 million, after deducting underwriting discounts and offering expenses of approximately $0.6 million, received from the sale of 1,050,000 shares of common stock in February 2023 and the net proceeds of approximately $0.3 million, after deducting approximately $8,000 in issuance costs, received from sales of common stock under our ATM program<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Funding requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We expect our expenses to increase in connection with our ongoing and planned development activities. In addition, we have incurred and continue to incur additional costs associated with operating as a public company. We expect that our expenses will increase substantially if and as we:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiate and conduct clinical trials and additional preclinical research for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek to identify and develop additional product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek marketing approvals for any of our product candidates that successfully complete clinical trials, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish a sales, marketing, manufacturing and distribution infrastructure to commercialize any products for which we may obtain marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require the manufacture of larger quantities of our product candidates for clinical development and potentially commercialization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintain, expand, protect and enforce our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquire or in-license other drugs and technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">defend against any claims of infringement, misappropriation or other violation of third-party intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hire and retain additional clinical, quality control and scientific personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">build out new facilities or expand existing facilities to support our ongoing development activity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">add operational, financial and management information systems and personnel, including personnel to support our drug development and any future commercialization efforts; and</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue to operate as a public company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of September&#160;30,&#160;2024, we had cash and cash equivalents of $26.2 million. We believe that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements through at least twelve months from the date of issuance of these condensed consolidated financial statements. We have based this estimate on assumptions that may prove to be inaccurate, and we could exhaust our available capital resources sooner than we expect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Because of the numerous risks and uncertainties associated with the development of our product candidates and programs and because the extent to which we may enter into collaborations with third parties for development of our product candidates is unknown, we are unable to estimate the timing and amounts of increased capital outlays and operating expenses associated with completing the research and development of our product candidates. Our future capital requirements will depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, results and costs of our planned clinical trials, drug discovery and preclinical research for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of future product candidates that we pursue and their development requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs, timing and outcome of regulatory review of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which we acquire or invest in businesses, products and technologies, including entering into or maintaining licensing or collaboration arrangements for product candidates on favorable terms, and although we may explore such opportunities from time to time during the normal course of business, we currently have no commitments or agreements to complete any such transactions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of future commercialization activities, including drug sales, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval, to the extent that such sales, marketing, manufacturing and distribution are not the responsibility of any collaborator that we may have at such time;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the amount of revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of preparing, filing and prosecuting patent applications, maintaining, protecting and enforcing our intellectual property rights and defending intellectual property-related claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our headcount growth and associated costs as we expand our business operations and our research and development activities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of operating as a public company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As a result, we will need additional financing to support our continuing operations. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity or debt financings or other sources, which may include collaborations with third parties and grants from government and other (non-government) organizations. We may be unable to raise additional funds or enter into other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our product candidates. In addition, our ability to engage in certain types of capital raising transactions may be limited by the Listing Rules of the Nasdaq Stock Market and/or General Instruction I.B.6 of Form S-3 if the market value of our common stock held by non-affiliates is ever below $75 million at a time we seek to utilize our effective registration statement on Form S-3.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Developing drug products, including conducting preclinical studies and clinical trials, is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval for any product candidates or generate revenue from the sale of any products for which we may obtain marketing approval. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of drugs that we do not expect to be commercially available for many years, if ever. Accordingly, we will need to obtain substantial additional funds to achieve our business objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Adequate additional funds may not be available to us on acceptable terms, or at all. We do not currently have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, ownership interests in our securities may be diluted, and the terms of these securities may include liquidation or other preferences and anti-dilution protections that could adversely affect the rights of our common stockholders. Additional debt or preferred equity financing, if available, may involve agreements that include restrictive covenants that may limit our ability to take specific actions, such as incurring debt, making capital expenditures or declaring dividends, which could adversely impact our ability to conduct our business, and may require the issuance of warrants, which could potentially dilute existing ownership interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technology, future revenue streams, research programs, or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or collaborations, strategic alliances or licensing arrangements with third parties when needed, we may be required to delay, limit, reduce and/or terminate our product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Contractual obligations and commitments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For additional details regarding our contractual obligations, see Note&#160;3&#160;&#8220;Leases&#8221; to our condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form&#160;10-Q.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Equity Financings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">On November 12, 2020, we filed a universal shelf registration statement with the SEC for the issuance of common stock, preferred stock, warrants, rights and debt securities and units up to an aggregate of $350.0 million, or the 2020 Shelf Registration Statement.  On November 30, 2020, the Shelf Registration Statement was declared effective by the SEC and expired on November 30, 2023. The universal shelf registration statement included an at-the-market offering program and we filed a Prospectus Supplement dated September 2, 2022 for the sale of up to $14,744,728 of shares of our common stock pursuant to our ATM offering program. During the nine months ended September&#160;30,&#160;2023, we issued and sold 26,302 shares of common stock under the ATM offering program resulting in net proceeds of approximately $0.3 million after deducting approximately $8,000 in issuance costs. The ATM offering program has terminated and is no longer effective.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In February 2023, we issued and sold 1,050,000 shares of common stock at a public offering price of $5.25 per share pursuant to the 2020 Shelf Registration Statement resulting in net proceeds of approximately $4.9 million, after deducting underwriting discounts and offering expenses of approximately $0.6 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On January 26, 2024, we filed a shelf registration statement, or the 2024 Shelf Registration Statement, with the SEC for the issuance of common stock, preferred stock, warrants, rights and debt securities and units up to an aggregate of $150 </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">million, including a prospectus for the sale of $1 million of shares of our common stock under the ATM Agreement, as discussed below, which was declared effective on February 2, 2024.  We subsequently filed a prospectus supplement to the 2024 Shelf Registration Statement for the sale of up to $2 million of shares of our common stock pursuant to the ATM Agreement.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On January 26, 2024, we entered into an At the Market Offering Agreement, or the ATM Agreement, with H.C. Wainwright &amp; Co., LLC, or HCW.  Pursuant to the ATM Agreement and the prospectus supplement to the 2024 Shelf Registration Statement filed in connection therewith, we were able, from time to time, in our sole discretion, to issue and sell through HCW, acting as sales agent and/or principal, up to $2 million of shares of our common stock.  We have not made any sales under the ATM Agreement to date.  In March 2024, we terminated the ATM Agreement with HCW.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On March 11, 2024, we entered into a securities purchase agreement with certain purchasers, or the Purchasers, pursuant to which we agreed to issue and sell to the Purchasers in a private placement offering exempt from registration under the Securities Act, and the Purchasers agreed to purchase from us (i) 1,687,712 shares of our common stock at a purchase price of $7.29 per share (the &#8220;Shares&#8221;), (ii) pre-funded common stock purchase warrants at a purchase price of $7.289 to purchase an aggregate of up to 507,076 shares of our common stock at an exercise price of $0.001 per share (the &#8220;Pre-Funded Shares&#8221;), (iii) tranche A common stock purchase warrants to purchase up to 1,097,394 shares of our common stock at an exercise price of $7.29 per share, or the Tranche A Warrants, and (iv) tranche B common stock purchase warrants to purchase up to 1,097,394 shares of our common stock at an exercise price of $9.1125 per share, or the Tranche B Warrants. The Tranche A Warrants will be exercisable until the earlier of (i) the three-year anniversary of issuance and (ii) 30 days after we announce the recommended Phase 2 dose for ATRN-119, and, following such announcement, the daily volume weighted average price of our common stock equals or exceeds $14.58 for 30 consecutive trading days. The Tranche B Warrants will be exercisable until the earlier of (i) the five-year anniversary of issuance and (ii) 30 days after we announce the recommended Phase 2 dose for APR-1051 and, following such announcement, the daily volume weighted average price of our common stock equals or exceeds $18.225 for 30 consecutive trading days. To the extent that the exercise of a Tranche A Warrant or Tranche B Warrant would result in the holder beneficially owning greater than 4.99% (or, at the election of the holder, greater than 9.99%) of our outstanding common stock immediately following such exercise, the holder will instead receive pre-funded warrants in substantially the same form as the pre-funded warrants issued at closing. The aggregate gross proceeds from the issuance of common stock and warrants totaled approximately $16.0 million, before deducting placement agent fees and offering costs of approximately $1.3 million, and the gross proceeds from potential future warrant cash exercises is expected to be up to approximately $18.0 million, before deducting placement agent fees. In April 2024, we registered on Form S-3 the resale of the Shares, the Pre-Funded Shares and the shares underlying the Tranche A Warrants and Tranche B Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Recent accounting pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies that we adopt as of the specified effective date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We do not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Off-balance sheet arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules&#160;and regulations of the SEC.</p><a id="_3e714400_25ca_46cb_8e5b_af2faaa3b871"></a><a id="Item3Quantitativeandqualitativedisclosur"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 3. Quantitative and Qualitative Disclosures About Market Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Interest Rate Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We are exposed to market risk related changes in interest rates. As of September&#160;30,&#160;2024, our cash equivalents consisted of bank deposits and money market accounts. Our primary exposure to market risk is interest income </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">sensitivity, which is affected by changes in the general level of U.S. interest rates. However, historical fluctuations in interest income have not been significant for us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Foreign Currency Exchange Rate Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We face market risk to the extent that changes in foreign currency exchange rates affect our non-U.S. dollar functional currency foreign subsidiaries&#8217; revenues, expenses, assets and liabilities. The financial position and results of operations of our subsidiary Aprea AB is measured using the foreign subsidiary&#8217;s local currency as the functional currency. Aprea AB cash accounts holding U.S. dollars are remeasured based upon the exchange rate at the date of remeasurement with the resulting gain or loss included in the consolidated statement of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our investments in foreign subsidiaries with a functional currency other than the U.S. dollar are generally considered long-term. In addition, we do not believe that we currently have any significant direct foreign exchange risk. Accordingly, we have not used any derivative financial instruments to hedge exposure to such risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Inflation</span><b style="font-weight:bold;">&#160;</b><span style="font-style:italic;font-weight:bold;">Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Inflation generally affects us by increasing our cost of labor and pricing of contracts. We do not believe that inflation has had a material effect on our business, financial condition, or results of operations during the nine months ended September&#160;30,&#160;2024.</p><a id="_5f98c7ac_57d1_4a0e_b640_bf23fdb0506c"></a><a id="Item4ControlsandProcedures_266"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 4. Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Disclosure Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures as of September&#160;30,&#160;2024. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Exchange Act, mean controls and other procedures of a company that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules&#160;and forms. Disclosure controls include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company on the reports that it files or submits under the Exchange Act is accumulated and communicated to management, including, our principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgement in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of September&#160;30,&#160;2024, our chief executive officer and chief financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable level.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in Internal Control</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There has been no change in our internal control over financial reporting as such term is defined in Rules&#160;13a-15(f)&#160;and 15d-15(f)&#160;under the Exchange Act during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p><a id="_417626c6_f8a4_4d89_94f8_6efcc4bb3b0b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;visibility:hidden;">&#8203;</span></p><a id="PARTIIOTHERINFORMATION_907842"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;<b style="font-weight:bold;white-space:pre-wrap;">II:  OTHER INFORMATION</b></p><a id="Item1LegalProceedings_809320"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Item 1.   Legal Proceedings.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are not currently subject to any material legal proceedings.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_85e7511b_a0a1_4fea_ada5_c9e5b11e0965"></a><a id="Item1ARiskFactors"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 1A. Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Our business is subject to substantial risks and uncertainties. Investing in our common stock involves a high degree of risk. You should carefully consider the risk factors below, together with the information contained elsewhere in this Quarterly Report on Form 10-Q, including Part I, Item 1 &#8220;Financial Statements&#8221; and Part I, Item 2. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and in our other public filings in evaluating our business, including our Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on March 26, 2024. Any of the risks and uncertainties described below and in our other filings with the SEC, either alone or taken together, could materially and adversely affect our business, financial condition, results of operations, prospects for growth, and the value of an investment in our common stock. In addition, these risks and uncertainties could cause actual results to differ materially from those expressed or implied by forward looking statements contained in this Form 10-Q (please read the Cautionary Note Regarding Forward-Looking Statements in this Form 10-Q).</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;background:#ffffff;">We have marked with an asterisk (*) those risk factors below that reflect a substantive change from the risk factors included in our Annual Report on Form&#160;10-K filed with the SEC on March 26, 2024.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman;font-weight:bold;">Risk Factor Summary</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">An investment in our securities is subject to various risks, these risks include, among others, the brief bulleted list of our principal risk factors set forth below that make an investment in our company speculative or risky.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-family:'Times New Roman;font-weight:bold;">Risks related to our financial position and the need for additional capital</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">We have incurred significant losses in each year since inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability. We have never generated commercial revenues and may never be profitable.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">We will need substantial additional funding, which may not be available to us on acceptable terms or at all. If we are unable to raise capital when needed, we may be forced to delay, reduce and/or eliminate our research and drug development programs or future commercialization efforts.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults or non-performance by financial institutions or transactional counterparties, could adversely affect our current and projected business operations and our financial condition and results of operations.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-family:'Times New Roman;font-weight:bold;">Risks related to the discovery, development and commercialization of our product candidates</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">We are substantially dependent on the success of our lead product candidate, ATRN-119 and APR-1051, which are currently in clinical development. Our clinical trials of ATRN-119 and APR-1051 may not be successful. If we are unable to obtain approval for and commercialize ATRN-119 and/or APR-1051 or experience significant delays in doing so, our business will be materially harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">We are in the early stages of testing ATRN-119 and APR-1051 in clinical trials. The results of preclinical studies and early-stage clinical trials may not be predictive of future results in later studies or trials. Initial success in clinical trials may not be indicative of results obtained when these trials are completed or in later-stage clinical trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">We may not be able to file INDs or IND amendments to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">We have limited experience as a company conducting clinical trials and may be unable to complete clinical trials for any product candidates we may develop.</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">We may find it difficult to enroll patients in our clinical trials. If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary marketing approvals could be delayed or prevented.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">If serious adverse or unacceptable side effects are identified during the development of our product candidates or we observe limited efficacy of our product candidates, we may need to abandon or limit the development of one or more of our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, interim results of a clinical trial do not necessarily predict final results, and the results of our clinical trials may not satisfy the requirements of the FDA or comparable foreign regulatory authorities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">If, in the future, we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates, we may not be successful in commercializing our product candidates if and when they are approved.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-family:'Times New Roman;font-weight:bold;">Risks related to our dependence on third parties</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">We rely on third parties to conduct our clinical trials and some aspects of our research and preclinical studies, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research and studies.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-family:'Times New Roman;font-weight:bold;">Risks related to our intellectual property</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">If we are unable to obtain and maintain intellectual property protection for our product candidates or for our technology, our competitors could develop and commercialize products or technology similar or identical to ours, and our ability to successfully commercialize any product candidates we may develop, and our technology may be adversely affected.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">Issued patents covering our product candidates and other technologies could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">We may be subject to other claims challenging the inventorship of our patents and other intellectual property.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-family:'Times New Roman;font-weight:bold;">Risks related to regulatory and marketing approval and other legal compliance matters</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">We have never obtained marketing approval for a product candidate and we may be unable to obtain, or may be delayed in obtaining, marketing approval for any of our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us, or any future collaborators, from obtaining approvals for the commercialization of some or all of our product candidates. As a result, we cannot predict when or if, and in which territories, we, or any future collaborators, will obtain marketing approval to commercialize a product candidate.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">Failure to obtain marketing approval in foreign jurisdictions would prevent our product candidates from being marketed abroad. Any approval we are granted for our product candidates in the United States would not assure approval of our product candidates in foreign jurisdictions.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">The FDA&#8217;s and other comparable regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates, which would impact our ability to generate commercial revenue.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">Recently enacted and future legislation, and any change in existing government regulations and policies, may increase the difficulty and cost for us and our future collaborators to obtain marketing approval of and commercialize our product candidates and affect the prices we, or they, may obtain.</span></td></tr></table><div style="margin-top:6pt;"></div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman;font-weight:bold;">Risks related to employee matters and managing growth</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">Our future success depends on our ability to retain executive officers and to attract, retain and motivate qualified personnel.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">We expect to expand our development and regulatory capabilities and potentially our sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman;font-weight:bold;">Risks related to tax matters</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">We have significant deferred tax assets, which may become devalued if we do not generate sufficient future taxable income, applicable corporate tax rates are reduced or if we experience an ownership change.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-family:'Times New Roman;font-weight:bold;">Risks related to our common stock</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">Our executive officers, directors and principal stockholders may have substantial influence over matters submitted to stockholders for approval.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">Our certificate of incorporation designates the state courts in the State of Delaware or, if no state court located within the State of Delaware has jurisdiction, the federal court for the District of Delaware, as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could discourage lawsuits against the company and our directors, officers and employees.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">We are required to meet the Nasdaq Stock Market, or Nasdaq, continued listing requirements and other Nasdaq rules, and if we fail to meet such rules and requirements, we may be subject to delisting.</span></td></tr></table><div style="margin-top:6pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">The summary risk factors described above should be read together with the text of the full risk factors below in this section entitled &#8220;</span><i style="font-family:'Times New Roman;font-style:italic;">Risk Factors</i><span style="font-family:'Times New Roman;">&#8221; and the other information set forth in this Quarterly Report on Form 10-Q. The risks summarized above or described in full below are not the only risks that we face. Additional risks and uncertainties not precisely known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, results of operations and future growth prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks related to our financial position and need for additional capital</b></p><a id="_Hlk111125083"></a><a id="_Hlk110770684"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We have incurred significant losses in each year since inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability.*</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Since our inception, we have incurred significant losses on an aggregate basis. Our net loss was $10.1 million for the nine months ended September&#160;30,&#160;2024, and $14.3 million, $112.7 million and $37.1 million for the years ended December 31, 2023, 2022 and 2021, respectively. Our accumulated deficit was $318.1 million and $308.1 million as of September&#160;30,&#160;2024 and December&#160;31,&#160;2023, respectively. We have not generated any commercial revenue to date from sales of any drugs and have financed our operations principally through private placements of our preferred stock and the net proceeds received from the initial public offering (IPO) of our common stock and private placement of our common stock and warrants in March 2024. We have devoted substantially all of our efforts to research and development. Our lead product candidate ATRN-119 and APR-1051 are currently in clinical development. We expect that it will be several years, if ever, before we have any product candidates ready for commercialization. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. The net losses we incur may fluctuate significantly from quarter to quarter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Hlk111125210"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">To become and remain profitable, we must develop, obtain approval for and eventually commercialize a drug or drugs with significant market potential, either on our own or with a collaborator. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of our product candidates, obtaining marketing approval for these product candidates, manufacturing, marketing and selling those drugs for which we may obtain marketing approval and establishing and managing any collaborations for the development, marketing and/or commercialization of our product candidates. We may never succeed in these activities and, even if we do, may </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">never generate revenues that are significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business and/or continue our operations. A decline in the value of our company could also cause our stockholders to lose all or part of their investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Even if we succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development and other expenditures to develop and market additional product candidates. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;">Our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of drugs that we do not expect to be commercially available for many years, if at all. If we are unable to obtain product approvals or generate significant commercial revenues, our business will be materially harmed.<span style="font-style:italic;font-weight:bold;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability. We have never generated commercial revenues and may never be profitable.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">We are an early-stage company. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, developing our product candidates, identifying potential product candidates, conducting preclinical studies of our product candidates and conducting clinical trials of our product candidates. Our lead product candidates, ATRN-119 and APR-1051 are in clinical development, and our other product candidates are in preclinical development. We have not yet demonstrated our ability to successfully complete large-scale, pivotal clinical trials, obtain marketing approvals, manufacture commercial-scale drug products, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful drug commercialization. Typically, it takes about six to ten years to develop a new drug from the time it is in Phase&#160;1 clinical trials to when it is approved for treating patients, but in many cases it may take longer. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">In addition, as a business with a limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We may need to transition from a company with a research focus to a company capable of supporting commercial activities. We may not be successful in such a transition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">As we continue to build our business, we expect our financial condition and operating results may fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any particular quarterly or annual periods as indications of future operating performance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We will need substantial additional funding, which may not be available to us on acceptable terms or at all. If we are unable to raise capital when needed, we may be forced to delay, reduce and/or eliminate our research and drug development programs or future commercialization efforts.*</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">Developing drug products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. We expect our expenses to increase in connection with our ongoing activities, particularly as we conduct clinical trials of, and seek marketing approval for our product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to drug sales, marketing, manufacturing and distribution to the extent that such sales, marketing, manufacturing and distribution are not the responsibility of any collaborator that we may have at such time for any such product candidate. Furthermore, since the completion of our IPO, we have incurred and expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. The recent uncertainty and volatility in financial markets which in turn may make raising additional funds even more difficult or impossible for us. If we are unable to </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">raise capital when needed or on attractive terms, we may be forced to delay, reduce and/or eliminate our research and drug development programs or future commercialization efforts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We believe that our existing cash and cash equivalents as of September&#160;30,&#160;2024 will enable us to fund our operating expenses and capital expenditure requirements through at least twelve months from the date of issuance of these condensed consolidated financial statements. Our estimate as to how long we expect our existing cash and cash equivalents to be able to continue to fund our operations is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Further, changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned. Our future capital requirements will depend on many factors, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, results and costs of our current and future clinical trials of ATRN-119, APR-1051 and our other product candidates for our current targeted indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, results and costs of drug discovery, preclinical research and clinical trials for ATRN-119, APR-1051 and our other product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">the number of future product candidates that we pursue and their development requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">the costs, timing and outcome of regulatory review of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">the extent to which we acquire or invest in businesses, products and technologies, including entering into or maintaining licensing or collaboration arrangements for product candidates on favorable terms, although we currently have no commitments or agreements to complete any such transactions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of future commercialization activities, including drug sales, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval, to the extent that such sales, marketing, manufacturing and distribution are not the responsibility of any collaborator that we may have at such time;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">the amount of revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">the costs of preparing, filing and prosecuting patent applications, maintaining, defending and enforcing our intellectual property rights and defending intellectual property-related claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">our headcount growth and associated costs as we expand our business operations and our research and development activities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">the costs of operating as a public company.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Raising additional capital may cause dilution to our stockholders and restrict our operations or require us to relinquish rights to our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">We expect our expenses to increase in connection with our planned operations. Until such time, if ever, as we can generate substantial revenues from the sale of drugs, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and/or licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, ownership interests in our securities may be diluted, and the terms of these securities could include liquidation or other preferences and anti-dilution protections that could adversely affect the rights of our common stockholders. In addition, debt financing, if available, would result in fixed payment obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures, creating liens, redeeming stock or declaring dividends, that could adversely impact our ability to conduct our business. In addition, securing financing could require a substantial amount of time and attention from our management and may divert a disproportionate amount of their attention away from day-to-day activities, which may adversely affect our management&#8217;s ability to oversee the development of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technology, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, reduce and/or eliminate our product candidate development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We are currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability, an ongoing military conflict between Russia and Ukraine, Israel and Hamas and record inflation</span><b style="font-weight:bold;">.</b><span style="font-style:italic;font-weight:bold;">&#160;Our business, financial condition and results of operations could be materially adversely affected by any negative impact on the global economy and capital markets resulting from the conflict in&#160;Ukraine, the Middle East, geopolitical tensions or record inflation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. and global markets are experiencing volatility and disruption following the escalation of geopolitical tensions and the start of the military conflict between Russia and&#160;Ukraine. On February 24, 2022, a full-scale military invasion of&#160;Ukraine&#160;by Russian troops was reported. Although the length and impact of the ongoing military conflict is highly unpredictable, the conflict in&#160;Ukraine&#160;could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions, which has led to record inflation globally. We are continuing to monitor inflation, the situation in&#160;Ukraine&#160;and global capital markets and assessing the potential impacts on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The global economy has been, and may continue to be, negatively impacted by Russia&#8217;s invasion of Ukraine. As a result of Russia's invasion of Ukraine, the U.S., the European Union, the United Kingdom, and other G7 countries, among other countries, have imposed substantial financial and economic sanctions on certain industry sectors and parties in Russia. Broad restrictions on exports to Russia have also been imposed. These measures include: (i) comprehensive financial sanctions against major Russian banks; (ii) additional designations of Russian individuals with significant business interests and government connections; (iii) designations of individuals and entities involved in Russian military activities; and (iv) enhanced export controls and trade sanctions limiting Russia's ability to import various goods. Russian military actions and the resulting sanctions could continue to adversely affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets, potentially making it more difficult for us to obtain additional funds. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">There are current geopolitical tensions with China. Recently, the Biden administration has signed multiple executive orders regarding China. One particular executive order titled Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy&#160;signed on September 12, 2022 will likely impact the pharmaceutical industry to encourage U.S. domestic manufacturing of pharmaceutical products. Any additional executive orders or potential sanctions with China could materially impact our current manufacturing partners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In addition, on October 7, 2023, Hamas militants and members of other terrorist organizations infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of terror attacks on civilian and military targets. Thereafter, Hamas launched extensive rocket attacks on Israeli population and industrial centers located along the Israeli border with the Gaza Strip. Shortly following the attack, Israel&#8217;s security cabinet declared war against Hamas and launched an aerial bombardment of various targets within the Gaza Strip. Recently, other terrorist organizations joined the hostilities as well, including Hezbollah in Lebanon, the Houthi in Yemen and it is possible that Palestinian military organizations in the West Bank will also join, resulting in a widening of the conflict. The intensity and duration of Israel&#8217;s current war against Hamas, Hezbollah and the Houthi&#8217;s is difficult to predict as are such war&#8217;s economic implications on the global economy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Although our business has not been materially impacted by the ongoing military conflict between Russia and&#160;Ukraine, Israel and Hamas, Hezbollah and the Houthi&#8217;s geopolitical tensions, or record inflation&#160;to date, it is impossible to predict the extent to which our operations, or those of our suppliers and manufacturers, will be impacted in the short and long term, or the ways in which the conflict may impact our business. The extent and duration of the conflict in Ukraine, the Middle East, geopolitical tensions, record inflation, sanctions and resulting market disruptions are impossible to predict, but could be substantial. Any such disruptions may also magnify the impact of other risks described herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_Hlk129787972"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults or non-performance by financial institutions or transactional counterparties, could adversely affect our current and projected business operations and our financial condition and results of operations.&#160;&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. Recently, some banks have experienced financial distress. For example, on March 8, 2023, the California Department of Financial Protection and Innovation (&#8220;DFPI&#8221;) announced that Silvergate Bank had entered voluntary liquidation, and on March 10, 2023, Silicon Valley Bank, (&#8220;SVB&#8221;), was closed by the DFPI, which appointed the FDIC, as receiver. Similarly, on March 12, 2023, the New York Department of Financial Services took possession of Signature Bank and appointed the FDIC as receiver. A joint statement by the Department of the Treasury, the Federal Reserve and the FDIC on March 12, 2023, stated that depositors in Signature and&#160;SVB&#160;will have access to all of their funds, including funds held in deposit accounts, in excess of the insured amount. On May 1, 2023, First Republic Bank was closed by the California Department of Financial Protection and Innovation, which appointed the FDIC as receiver. Following a bidding process, the FDIC entered into a purchase and assumption agreement with JPMorgan Chase Bank, National Association, to acquire the substantial majority of the assets and assume certain liabilities of First Republic Bank from the FDIC.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">Inflation and rapid increases in interest rates have led to a decline in the trading value of previously issued government securities with interest rates below current market interest rates. Although the U.S. Department of Treasury, FDIC and Federal Reserve Board have announced a program to provide up to $25 billion of loans to financial institutions secured by certain of such government securities held by financial institutions to mitigate the risk of potential losses on the sale of such instruments, widespread demands for customer withdrawals or other liquidity needs of financial institutions for immediately liquidity may exceed the capacity of such program. There is no guarantee that the U.S. Department of Treasury, FDIC and Federal Reserve Board will provide access to uninsured funds in the future in the event of the closure of other banks or financial institutions, or that they would do so in a timely fashion.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">Although we assess our banking relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect us, the financial institutions with which we have arrangements directly, or the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry. These factors could involve financial institutions or financial services industry companies with which we have financial or business relationships, but could also include factors involving financial markets or the financial services industry generally.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations, result in breaches of our financial and/or contractual obligations or result in violations of federal or state wage and hour laws. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our liquidity and our current and/or projected business operations and financial condition and results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">In addition, any further deterioration in the macroeconomic economy or financial services industry could lead to losses or defaults by parties with whom we conduct business, which in turn, could have a material adverse effect on our current and/or projected business operations and results of operations and financial condition. For example, a party with whom we conduct business may fail to make payments when due, default under their agreements with us, become insolvent or declare bankruptcy. Any bankruptcy or insolvency, or the failure to make payments when due, of any counterparty of </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">ours, or the loss of any significant relationships, could result in material losses to us and may material adverse impacts on our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Risks related to the discovery, development and commercialization of our product candidates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We are substantially dependent on the success of our lead product candidate, ATRN-119 and APR-1051, which are in clinical development. Our clinical trials of ATRN-119 and APR-1051 may not be successful. If we are unable to obtain approval for and commercialize ATRN-119 and APR-1051 or experience significant delays in doing so, our business will be materially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">We have no products approved for sale. Our future success is substantially dependent on our ability to timely obtain marketing approval for, and then successfully commercialize, ATRN-119 and APR-1051, our lead product candidates. We are investing a majority of our efforts and financial resources in the research and development of ATRN-119 and APR-1051. Our business depends entirely on the successful development and commercialization of our product candidates. We currently have no drugs approved for sale and generate no revenues from sales of any products, and we may never be able to develop a marketable product.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Our product candidates will require additional clinical development, evaluation of clinical, preclinical and manufacturing activities, marketing approval in multiple jurisdictions, substantial investment and significant marketing efforts before we generate any revenues from product sales. We are not permitted to market or promote any of our product candidates before we receive marketing approval from the FDA and comparable foreign regulatory authorities, and we may never receive such marketing approvals. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">The success of ATRN-119 and APR-1051 will depend on several factors, including the following:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">successful progression, successful patient enrollment and timely completion of clinical trials of ATRN-119 and APR-1051;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">successful initiation and successful patient enrollment and completion of additional clinical trials, for ATRN-119, APR-1051 or our other product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">our ability to demonstrate ATRN-119 and APR-1051&#8217;s safety, tolerability and efficacy to the FDA or any comparable foreign regulatory authority for marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">timely receipt of marketing approvals for ATRN-119 and APR-1051;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining patent protection, trade secret protection and regulatory exclusivity, both in the United States and internationally;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">successfully defending and enforcing our rights in our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">avoiding and successfully defending against any claims that we have infringed, misappropriated or otherwise violated any intellectual property of any third party;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">the performance of our future collaborators, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">the extent of, and our ability to timely complete, any required post-marketing approval commitments imposed by FDA or other applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">successfully developing a companion diagnostic test on a timely and cost-effective basis;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">establishment of supply arrangements with third-party raw materials and drug product suppliers and manufacturers who are able to manufacture clinical trial and commercial quantities of ATRN-119 and APR-</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">1051 drug substance and drug product and to develop, validate and maintain a commercially viable manufacturing process that is compliant with current good manufacturing practices, or cGMP, at a scale sufficient to meet anticipated demand and over time enable us to reduce our cost of manufacturing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">successful formulation for all of our products</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">establishment of scaled production arrangements with third-party manufacturers to obtain finished products that are compliant with cGMP and appropriately packaged for sale;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">successful launch of commercial sales following any marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">a continued acceptable safety profile following any marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">commercial acceptance by patients, the medical community and third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">the availability of coverage and adequate reimbursement and pricing by third-party payors and government authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">the availability, perceived advantages, relative cost, relative safety and relative efficacy of alternative and competing treatments; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">our ability to compete with other therapies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">We do not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing, distribution and sales efforts of any future collaborator. Accordingly, we cannot assure you that we will ever be able to generate revenue through the sale of our product candidates. If we are not successful in commercializing ATRN-119 and/or APR-1051, or are significantly delayed in doing so, our business will be materially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We are in the early stages of testing ATRN-119 and APR-1051 in clinical trials. The results of preclinical studies and early-stage clinical trials may not be predictive of future results in later studies or trials. Initial success in clinical trials may not be indicative of results obtained when these trials are completed or in later-stage clinical trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">We are in the early stages of testing ATRN-119 and APR-1051 in clinical trials. The results of preclinical studies, whether or not conducted by us, may not be predictive of the results of clinical trials, and the results of any early-stage clinical trials that we are conducting today and that we may commence in the future may not be predictive of the results of the later-stage clinical trials. For example, even if successful, the results of our Phase 1 clinical trials of our product candidates ATRN-119 and APR-1051 and other product candidates may not be predictive of the results of further clinical trials of these product candidates or any of our other product candidates. In addition, initial success in clinical trials may not be indicative of results obtained when such trials are completed in later stage clinical trials. In particular, the small number of patients in our current and planned early clinical trials may make the results of these trials less predictive of the outcome of later clinical trials. Moreover, preclinical and clinical data often are susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless have failed to obtain marketing licensure of their product candidates. Our current clinical trials for ATRN-119 and APR-1051 may not ultimately be successful or support further clinical development. There is a high failure rate for product candidates proceeding through clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving encouraging results in earlier studies. Any such setbacks in our clinical development could materially harm our business, results of operations, financial condition and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to file INDs or IND amendments to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">We have filed IND&#8217;s for ATRN-119 and APR-1051, but we may not be able to file INDs for our other product candidates on the timelines we expect. For example, we may experience manufacturing delays or other delays with IND-enabling studies. Moreover, we cannot be sure that submission of an IND will result in the FDA allowing further clinical trials to begin, or that, once begun, issues will not arise that lead FDA, IRBs, or other authorities to suspend, terminate, or require changes to our clinical trials. Additionally, even if such regulatory and other authorities agree with the design and implementation of the clinical trials set forth in an IND, we cannot guarantee that such regulatory authorities will not change their requirements in the future. These considerations also apply to new clinical trials or changes to existing clinical trials we may submit as amendments to existing INDs or to a new IND. Any failure to file INDs on the timelines we expect or to obtain regulatory clearance or approvals for our trials may prevent us from completing our clinical trials or commercializing our products on a timely basis, if at all.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Hlk132636686"></a><a id="_Hlk132636668"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We&#160;have&#160;limited&#160;experience&#160;as&#160;a&#160;company&#160;conducting&#160;clinical&#160;trials&#160;and may be unable to complete pivotal clinical trials for any product candidates we may develop.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">Our success is dependent upon our ability to initiate and successfully complete clinical trials and obtain regulatory approval for and commercialization of our product candidates. We have not demonstrated an ability to perform the functions necessary for the approval or successful commercialization of any product candidate. The successful commercialization of any product candidate may require us to perform a variety of functions, including:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">continuing to undertake preclinical development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">obtaining approval to commence clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">successfully planning and enrolling subjects in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">participating in regulatory approval processes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">formulating and manufacturing products; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">conducting sales and marketing activities</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">We have limited experience designing, conducting and enrolling subjects in clinical trials. While certain members of our management and staff have significant experience in conducting clinical trials, to date, we have not completed any clinical trials as a company. Our operations to date provide a limited basis to assess our ability to develop and commercialize our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">Because of this lack of experience, any future clinical trials we may conduct may not be completed on time, if at all. Large-scale trials require significant additional financial and management resources, monitoring and oversight, and reliance on third-party clinical investigators, consultants or contract research organizations, or CROs. Relying on third-party clinical investigators, CROs and manufacturers, which are all also subject to governmental oversight and regulations, may also cause us to encounter delays that are outside of our control. Failure to commence or complete, or delays in, clinical trials, could prevent us from or delay us in commercializing our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may find it difficult to enroll patients in our clinical trials. If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary marketing approvals could be delayed or prevented.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or comparable foreign regulatory authorities. Patient enrollment is a significant factor in the timing of clinical trials and our ability to enroll eligible patients may be limited or may result in slower enrollment than we anticipate. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">Patient enrollment may be affected if our competitors have ongoing clinical trials for product candidates that are under development for the same indications as our product candidates, and patients who would otherwise be eligible for our </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">clinical trials instead enroll in clinical trials of our competitors&#8217; product candidates. Patient enrollment may also be affected by other factors, including</span>:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">size and nature of the patient population;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">severity of the disease under investigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">availability and efficacy of approved drugs for the disease under investigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patient eligibility criteria for the trial in question;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patients&#8217; and clinicians&#8217; perceived risks and benefits of the product candidate under study;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competing clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">efforts to facilitate timely enrollment in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">physicians&#8217; attitudes and practices with respect to clinical trial enrollment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to monitor patients adequately during and after treatment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">proximity and availability of clinical trial sites for prospective patients; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continued enrollment of prospective patients by clinical trial sites.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Leveraging synthetic lethality in therapeutic targeting of DDR represents an emerging strategy to treat a broad spectrum of cancers, and negative perceptions of the efficacy, safety, or tolerability of this class of targets, including any that we develop, could adversely affect our ability to conduct our business, advance our product candidates or obtain regulatory approvals. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman;">Aside from PARP inhibitors, such as Lynparza, Rubraca, Zejula and Talzenna, no synthetic lethality small molecule inhibitor therapeutics have been approved to date by the FDA. Pamiparib, a PARP inhibitor developed by Beigene, was approved in 2021 in China. Adverse events in future clinical trials of our product candidates or in clinical trials of other similar products and the resulting publicity, as well as any other adverse events in the field of synthetic lethality and DDR, or any adverse events involving other products that are perceived to be similar to DDR, such as those related to gene therapy or gene editing, could result in a decrease in the perceived benefit of one or more of our programs, increased regulatory scrutiny, decreased confidence by healthcare professionals, patients and CROs in our product candidates, difficulties and delays in regulatory clearance or approval for, enrollment of patients in, and conduct of, our clinical trials, and less demand for any product that we may develop. Synthetic lethality is a very competitive space with many companies developing programs for different targets in the field. Our pipeline of product candidates could result in a greater quantity of reportable adverse events or other reportable negative clinical outcomes, manufacturing reportable events or material clinical events that could lead to clinical delays or holds by the FDA or applicable regulatory authority or other clinical delays, any of which could negatively impact the perception of one or more of our product development programs, as well as our business as a whole. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman;">In addition, responses by U.S. federal or foreign governments to adverse events or negative public perception may result in new legislation or regulations that could limit our ability to develop any product candidates or commercialize any approved products, obtain or maintain regulatory approval, or otherwise achieve profitability. More restrictive statutory regimes, government regulations, or negative public opinion would have an adverse effect on our business, financial condition, results of operations, and prospects, and may delay or impair the development of our product candidates and commercialization of any approved products or demand for any products we may develop.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If serious adverse or unacceptable side effects are identified during the development of our product candidates or we observe limited efficacy of our product candidates, we may need to abandon or limit the development of one or more of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">Adverse events or unacceptable side effects caused by, or other unexpected properties of, our product candidates could cause us, any future collaborators, an institutional review board, or IRB, or regulatory authorities to interrupt, delay or halt clinical trials of one or more of our product candidates and could result in the (i)&#160;delay or denial of marketing approval by the FDA or comparable foreign regulatory authorities, (ii)&#160;approval with significant restrictions on distribution or use or (iii)&#160;required labeling information regarding safety concerns, if approved.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">In general, our clinical trials of ATRN-119 and APR-1051 will include cancer patients who are very sick and whose health is deteriorating. We expect that patients may experience adverse events, serious adverse events or may die during their participation in our future clinical trials for ATRN-119 and APR-1051, or other product candidates. We cannot predict with certainty what adverse events may occur in our clinical trials. Any adverse events, serious adverse events, or deaths occurring in our clinical trials, whether related to our product candidates or not, could affect perceptions relating to our product candidates. In addition, our previous clinical trials of eprenetapopt include cancer patients who were very sick and whose health is deteriorating, and we expect that additional clinical trials of eprenetapopt and our other product candidates will include similar patients with deteriorating health. Multiple patients in these trials have experienced adverse events. The most commonly reported adverse events include nausea, vomiting, constipation, dizziness, fatigue, and neutropenia. Some patients in these trials have experienced serious adverse events. The most common serious adverse events include febrile neutropenia, pneumonia, sepsis, and pyrexia.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">In addition, if any of our product candidates are associated with adverse events or undesirable side effects or have properties that are unexpected, our trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. We, or any future collaborators, may abandon development or limit development of that product candidate to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, results of operations, financial condition and prospects significantly.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, interim results of a clinical trial do not necessarily predict final results, and the results of our clinical trials may not satisfy the requirements of the FDA or comparable foreign regulatory authorities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">We currently have no drugs approved for sale and we cannot guarantee that we will ever have marketable drugs. Clinical failure can occur at any stage of clinical development. Clinical trials may produce negative or inconclusive results, and we or any future collaborators may decide, or regulators may require us, to conduct additional clinical trials or preclinical studies. We will be required to demonstrate with substantial evidence through adequate and well-controlled clinical trials that our product candidates are safe and effective for use in treating specific conditions in order to obtain marketing approvals for their commercial sale. Success in preclinical studies and early-stage clinical trials does not mean that future larger registration clinical trials will be successful because product candidates in later-stage clinical trials may fail to demonstrate safety and efficacy to the satisfaction of the FDA and non-U.S. regulatory authorities despite having progressed through preclinical studies and early-stage clinical trials. Product candidates that have shown promising results in preclinical studies and early-stage clinical trials may still suffer significant setbacks in subsequent registration clinical trials. Additionally, the outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later-stage clinical trials. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">From time to time, we may publish or report interim or preliminary data from our clinical trials. Interim or preliminary data from clinical trials that we may conduct may not be indicative of the final results of the trial and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Interim or preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the interim or preliminary data. As a result, interim or preliminary data should be viewed with caution until the final data are available.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">In addition, the design of a clinical trial can determine whether its results will support approval of a drug and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. We have limited experience in designing clinical trials and may be unable to design and conduct a clinical trial to support marketing approval. Further, if our product candidates are found to be unsafe or lack efficacy, we will not be able to obtain marketing approval for them and our business would be harmed. A number of companies in the pharmaceutical industry, including those with greater resources and experience than us, have suffered significant setbacks in advanced clinical trials, even after obtaining promising results in preclinical studies and earlier clinical trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">In some instances, there can be significant variability in safety and efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial protocols, differences in size and type of the patient populations, differences in and adherence to the dosing regimen and other trial protocols and the rate of dropout among clinical trial participants. We do not know whether any clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety sufficient to obtain marketing approval to market our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">In addition, in the event that an adverse safety issue, clinical hold, or other adverse finding occurs in one of our clinical trials, that event could adversely affect any other clinical trials for the same product candidate. Moreover, there is a relatively limited safety data set for product candidates with the same mechanism of action as ATRN-119 or APR-1051 or our other product candidates. An adverse safety issue or other adverse finding in a clinical trial conducted by a third party with a similar mechanism of action could adversely affect clinical trials involving ATRN-119 or APR-1051 or our other product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Further, our product candidates may not be approved even if they achieve their primary endpoints in clinical trials, including registration trials. The FDA or comparable foreign regulatory authorities may disagree with our trial design and our interpretation of data from preclinical studies and clinical trials. In addition, any of these regulatory authorities may change requirements for the approval of a product candidate even after reviewing and providing comments or advice on a protocol for a pivotal clinical trial that has the potential to result in approval by the FDA or comparable foreign regulatory authorities. In addition, any of these regulatory authorities may also approve a product candidate for fewer or more limited indications than we request or may grant approval contingent on the performance of costly post-marketing clinical trials. In addition, the FDA or other comparable foreign regulatory authorities may not approve the labeling claims that we believe would be necessary or desirable for the successful commercialization of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">Before obtaining marketing approvals for the commercial sale of any product candidate for a target indication, we must demonstrate with substantial evidence gathered in preclinical studies and adequate and well-controlled clinical trials, and, with respect to approval in the United States, to the satisfaction of the FDA and elsewhere to the satisfaction of other comparable foreign regulatory authorities, that the product candidate is safe and effective for use for that target indication. There is no assurance that the FDA or other comparable foreign regulatory authorities will consider our future clinical trials to be sufficient to serve as the basis for approval of one of our product candidates for any indication. The FDA and other comparable foreign regulatory authorities retain broad discretion in evaluating the results of our clinical trials and in determining whether the results demonstrate that a product candidate is safe and effective. If we are required to conduct additional clinical trials of a product candidate than we expect prior to its approval, we will need substantial additional funds and there is no assurance that the results of any such additional clinical trials will be sufficient for approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Hlk132637709"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Clinical drug development is a lengthy and expensive process, with an uncertain outcome. If clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs, experience delays in completing, or ultimately be unable to complete, the development of our product candidates or be unable to obtain marketing approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates. Clinical testing is expensive, difficult to design and implement, can take many years to complete and </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their drugs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">We do not know whether ongoing clinical trials will be completed on schedule or at all, or whether future clinical trials will begin on time, need to be redesigned, enroll patients on time or be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including delays related to:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining regulatory authorization to commence a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining institutional review board or ethics committee approval at each clinical trial site;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recruiting suitable patients to participate in a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of any outbreak or pandemic on patient screening, patient enrollment, and follow-up;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developing and validating any companion diagnostic to be used in the trial, to the extent we are required to do so;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patients failing to comply with the clinical trial protocol or dropping out of a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trial sites failing to comply with the clinical trial protocol or dropping out of a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">addressing any conflicts with new or existing laws or regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the need to add new clinical trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing sufficient quantities of product candidate for use in clinical trials and ensuring clinical trial material is provided to clinical sites in a timely manner; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining advice from regulatory authorities regarding the statistical analysis plan to be used to evaluate the clinical trial data or other trial design issues.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may receive feedback from regulatory authorities that requires us to modify the design of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon drug development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our third-party contractors, including our CROs, may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, our investigators, or any of the overseeing IRBs or ethics committees might decide to suspend or terminate clinical trials of our product candidates for various reasons, including non-compliance with regulatory requirements, a finding that our product candidates have undesirable side effects or other unexpected characteristics, or a finding that the participants are being exposed to unacceptable health risks;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of clinical trials of our product candidates may be greater than we anticipate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulators may revise the requirements for approving our product candidates, or such requirements may not be as we anticipate; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any future collaborators that conduct clinical trials may face any of the above issues and may conduct clinical trials in ways they view as advantageous to them but that are suboptimal for us.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are insufficiently positive to support marketing approval, or if there are safety concerns, we may:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incur unplanned costs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be delayed in obtaining marketing approval for our product candidates or not obtain marketing approval at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain marketing approval in some countries and not in others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain marketing approval for indications or patient populations that are narrower or more limited in scope than intended or desired;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain marketing approval subject to significant use or distribution restrictions or with labeling that includes significant safety warnings, including boxed warnings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be subject to additional post-marketing testing requirements; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">have the drug removed from the market after obtaining marketing approval.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Our drug development costs will also increase if we experience delays in testing or marketing approvals. We do not know whether clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Furthermore, we rely on third-party CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials, and while we have agreements governing their committed activities, we have limited influence over their actual performance. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring drugs to market before we do and impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman;">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial drugs or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable drugs. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other strategic arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are required to in the future and if we are unable to successfully develop companion diagnostic tests for our product candidates that require such tests, or experience significant delays in doing so, we may not realize the full commercial potential of these product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">We may be required by the FDA to develop, either by ourselves or with collaborators, companion diagnostic tests for our product candidates for certain indications. To be successful, we or our collaborators will need to address a number of scientific, technical, regulatory and logistical challenges. We have no prior experience with medical device or diagnostic test development. If we choose to develop and seek FDA approval for companion diagnostic tests on our own, we will require additional personnel. We may rely on third parties for the design, development and manufacture of companion diagnostic tests for our therapeutic product candidates that require such tests. If these parties are unable to successfully develop companion diagnostics for these therapeutic product candidates, or experience delays in doing so, we may be unable to enroll enough patients for our current and planned clinical trials, the development of these therapeutic product candidates may be adversely affected, these therapeutic product candidates may not obtain marketing approval, and we may not realize the full commercial potential of any of these therapeutics that obtain marketing approval. Any failure to successfully develop this companion diagnostic may cause or contribute to delayed enrollment of this trial, and may prevent us from initiating or completing further clinical trials to support marketing approval for our product candidates. As a result, our business, results of operations and financial condition could be materially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be successful in our efforts to identify or discover additional potential product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the research methodology used may not be successful in identifying potential product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be drugs that will receive marketing approval and/or achieve market acceptance; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential product candidates may not be safe or effective in treating their targeted diseases.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 12pt 0pt;">Research programs to identify new product candidates require substantial technical, financial and human resources. If we are unable to identify suitable compounds for preclinical and clinical development, our business would be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If any of our product candidates receives marketing approval and we, or others, later discover that the drug is less effective than previously believed or causes undesirable side effects that were not previously identified, our ability, or that of any future collaborators, to market the drug could be compromised.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">Clinical trials of our product candidates must be conducted in carefully defined subsets of patients who have agreed to enter into clinical trials. Consequently, it is possible that our clinical trials, or those of any future collaborator, may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. If one or more of our product candidates receives marketing approval and we, or others, discover that the drug is less effective than previously believed or causes undesirable side effects that were not previously identified, a number of potentially significant negative consequences could result, including:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may withdraw their approval of the drug or seize the drug;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">we, or any future collaborators, may be required to recall the drug, change the way the drug is administered or conduct additional clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">additional restrictions may be imposed on the marketing of, or the manufacturing processes for, the particular drug;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">we may be subject to fines, injunctions or the imposition of civil or criminal penalties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">we, or any future collaborators, may be required to create a Medication Guide outlining the risks of the previously unidentified side effects for distribution to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">we, or any future collaborators, could be sued and held liable for harm caused to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">the drug may become less competitive in the marketplace; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">our reputation may suffer.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any of these events could have a material and adverse effect on our operations and business and could adversely impact our stock price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Even if any of our product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors and others in the medical community necessary for commercial success.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">If any of our product candidates receive marketing approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare payors and others in the medical community. For example, current cancer treatments like chemotherapy and radiation therapy are well-established in the medical community, and doctors may continue to rely on these treatments. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant revenues from sales of drugs and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">the efficacy and safety of the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">the potential advantages of the product compared to alternative therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any side effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">whether the product is designated under physician and other provider treatment guidelines as a first-, second- or third-line therapy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">our ability, or the ability of any future collaborators, to offer the product for sale at competitive prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">the product&#8217;s convenience and ease of administration for patients and healthcare practitioners compared to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">the willingness of the target patient population to try, and of physicians to prescribe, the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">limitations or warnings, including distribution or use restrictions and safety information contained in the product&#8217;s approved labeling;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">the strength of sales, marketing and distribution support;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">changes in the standard of care for the targeted indications for the product; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">the availability of coverage by, and the amount of reimbursement from, government payors, managed care plans and other third-party payors.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">The pharmaceutical and biotechnology industries generally, and the cancer drug sector specifically, are highly competitive and characterized by rapidly advancing technologies, evolving understanding of disease etiology and a strong emphasis on proprietary drugs. We face competition with respect to ATRN-119, APR-1051 and our other product candidates, and will face competition with respect to any product candidates that we may seek to discover and develop or commercialize in the future, from major pharmaceutical, specialty pharmaceutical and biotechnology companies. There are a number of major pharmaceutical, specialty pharmaceutical and biotechnology companies that currently </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">market and sell drugs or are pursuing the development of drugs for the treatment of cancer. Potential competitors also include academic institutions and governmental agencies and public and private research institutions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">There are a large number of companies developing or marketing treatments for cancer, including the indications for which we may develop product candidates. Many of the companies that we compete or may compete against in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved drugs than we do. Small or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or that may be necessary for, our programs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize drugs that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any drugs that we may develop. Our competitors also may obtain FDA or other comparable foreign regulatory approval for their drugs more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. The key competitive factors affecting the success of all of our product candidates, if approved, are likely to be their efficacy, safety, convenience, price, the effectiveness of companion diagnostics in guiding the use of related therapeutics, the level of generic competition and the availability of reimbursement from government and other third-party payors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">The most common methods of treating patients with cancer are surgery, radiation and drug therapy. There are a variety of available drug therapies marketed for cancer. In many cases, these drugs are administered in combination to enhance efficacy. Some of the currently-approved drug therapies are branded and subject to patent protection and may be established as the standard of care for treatment of indications for which we may choose to seek regulatory approvals. Many of these approved drugs are well-established therapies and are widely accepted by physicians, patients and third-party payors, and, even if our product candidates were to be approved, there can be no assurance that our product candidates would displace existing treatments. In addition to currently marketed therapies, there are also a number of drugs in late-stage clinical development to treat cancer, including the indications for which we are developing product candidates. These clinical-stage product candidates may provide efficacy, safety, convenience and other benefits that are not provided by currently-marketed therapies. As a result, they may provide significant competition for any of our product candidates for which we obtain regulatory approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">We are developing ATRN-119, which is an orally bioavailable small molecule product candidate that targets Ataxia Telangiectasia and Rad3-related (&#8220;ATR&#8221;) protein within the DNA damage response pathway. We are aware of other product candidates that are in clinical development for the treatment of various cancers through similar mechanisms of action, including product candidates in clinical development being tested by Artios Pharma Ltd., AstraZeneca Plc, Merck KGaA, IMPACT Therapeutics, Inc., and Repare Therapeutics, Inc., among others. If ATRN-119 were to be approved, it will compete with currently marketed drugs or drugs that may be approved for marketing by the FDA or comparable foreign regulatory authorities in the future and such competition will not be limited to drugs with similar mechanisms of action. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">We are also developing APR-1051, which is an orally bioavailable small molecule inhibitor of WEE1, a key regulator of multiple phases of the cell cycle. We are aware of other product candidates that are in preclinical and clinical development for the treatment of various cancers through similar mechanisms of action, including product candidates developed by Debiopharm, IMPACT Therapeutics, Schrodinger and Zentalis Pharmaceuticals, among others. If APR-1051 were to be approved, it will compete with currently marketed drugs or drugs that may be approved for marketing by the FDA or comparable foreign regulatory authorities in the future and such competition will not be limited to drugs with similar mechanisms of action.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our business and operations would suffer in the event of IT system failures, cybersecurity attacks, data breaches, or vulnerabilities in our or our third-party vendors&#8217; information security program or defenses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">Our business relies upon information technology systems operated by us and by our third party service providers. These systems may fail or experience operational disruption, experience cybersecurity attacks, or be damaged by computer viruses and unauthorized access. In the ordinary course of business, we collect, store and transmit confidential information (including but not limited to intellectual property, proprietary business information and personal information). It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. We have developed, and continue to mature our policies and procedures to ensure the security and integrity of our information technology systems and confidential and proprietary information. If we do not continue to mature our cybersecurity defensive technological safeguards, policies and procedures or those safeguards, policies and procedures are insufficient to ensure the protection of our information technology systems and confidential and proprietary information, we may be vulnerable to security breaches or disruptions and system breakdowns or other damage or interruptions, and face legal and reputational risk. We also have outsourced elements of our operations to third parties, and as a result we manage a number of third-party vendors and other contractors and consultants who have access to or store our confidential information. While we endeavor to select providers with reasonable and industry standard information security programs, we are reliant on these third-party vendors&#8217; commitments regarding their information technology systems and cybersecurity programs. If our third-party vendors fail to protect their information technology systems and our confidential and proprietary information, we may be vulnerable to disruptions in service and unauthorized access to our confidential or proprietary information and we could incur liability and reputational damage and the further development and commercialization of our product candidates could be delayed. While we have not, to our knowledge, experienced any material IT system failures or cybersecurity attacks to date, we frequently must defend against and respond to cybersecurity incidents and attacks and cannot assure you that our data protection efforts and our investment in information technology will prevent significant breakdowns, data leakages, compromises of personal information or confidential commercial information, other operationally significant breaches in our systems or those of our third-party vendors and other contractors and consultants, or other cyber incidents that could have a material adverse effect upon our reputation, business, operations or financial condition. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs, business operations, a breach of sensitive personal information or a loss or corruption of critical data assets including trade secrets or other proprietary information. For example, the loss of clinical trial data from future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Such IT system failures, cybersecurity attacks or vulnerabilities to our or our third-party vendors&#8217; information security programs or defenses could result in legal liability, reputational damage, business interruption, and our competitive position could be harmed and the further development and commercialization of our products or any future products could be delayed or disrupted. Moreover, containing and remediating any IT system failure, cybersecurity attack or vulnerability may require significant investment of resources. Furthermore, significant security breaches or disruptions of our internal information technology systems or those of our third-party vendors and other contractors and consultants could result in the loss, misappropriation and/or unauthorized access, use, or disclosure of, or the prevention of access to, confidential information (including trade secrets or other intellectual property, proprietary business information and personal information), which could result in financial, legal, business and reputational harm to us.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If, in the future, we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates, we may not be successful in commercializing our product candidates if and when they are approved.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">We do not have a sales or marketing infrastructure and have no experience in the sale or marketing of pharmaceutical drugs. We are not currently a party to a strategic collaboration that provides us with access to a collaborator&#8217;s resources in selling or marketing drugs. To achieve commercial success for any approved drug for which sales and marketing is not the responsibility of any strategic collaborator that we may have in the future, we must either develop a sales and marketing organization or outsource these functions to other third parties. In the future, we may choose to build a sales and marketing infrastructure to market or co-promote some of our product candidates if and when they are approved, or enter into collaborations with respect to the sale and marketing of our product candidates.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">There are risks involved with both establishing our own sales and marketing capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time-consuming and could delay any commercial launch of a product candidate. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Factors that may inhibit our efforts to commercialize our product candidates on our own include:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">our inability to recruit and retain adequate numbers of effective sales and marketing personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">limitations or restrictions on the ability of sales personnel to appropriately market the product to physicians or other healthcare professionals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">the lack of complementary drugs to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">unforeseen costs and expenses associated with creating an independent sales and marketing organization; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">inability to obtain sufficient coverage and reimbursement from third-party payors and governmental agencies.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">If we enter into arrangements with third parties to perform sales and marketing services, our revenues from the sale of drugs or the profitability of these revenues to us are likely to be lower than if we were to market and sell any drugs that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market our product candidates or may be unable to do so on terms that are favorable to us. Third parties may also fail to devote the necessary resources and attention to sell and market our product candidates effectively and we may not have sufficient control or oversight over third parties to ensure they sell and market our product candidates in compliance with all applicable law. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If the FDA or comparable foreign regulatory authorities approve generic versions of any of our product candidates that receive marketing approval, or such authorities do not grant our product candidates appropriate periods of data or market exclusivity before approving generic versions of our product candidates, the sales of our product candidates could be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Once an NDA is approved, the drug covered thereby becomes a &#8220;reference-listed drug&#8221; in the FDA&#8217;s publication, &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations.&#8221; Manufacturers may seek marketing approval of generic versions of reference-listed drugs through submission of abbreviated new drug applications, or ANDAs, in the United States. In support of an ANDA, a generic manufacturer need not conduct clinical trials demonstrating safety and efficacy. Rather, the applicant generally must show that its drug is pharmaceutically equivalent to the reference listed drug, in that it has the same active ingredient(s), dosage form, strength, route of administration and conditions of use or labeling as the reference-listed drug, and that the generic version is bioequivalent to the reference-listed drug, meaning it is absorbed in the body at the same rate and to the same extent. Generic drugs may be significantly less costly to bring to market than the reference-listed drug and companies that produce generic drugs are generally able to offer them at lower prices. Thus, following the introduction of a generic drug, a significant percentage of the sales of any branded product or reference-listed drug is typically lost to the generic drug.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">The FDA may not approve an ANDA for a generic drug until any applicable period of non-patent exclusivity for the reference-listed drug has expired. The Federal Food, Drug, and Cosmetic Act, or FDCA, provides a period of five years of non-patent exclusivity for a new drug containing a new chemical entity, or NCE. During the exclusivity period, the FDA may not accept for review an ANDA or a 505(b)(2)&#160;NDA submitted by another company for another version of such product candidate where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2)&#160;NDA or supplement to an approved NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, for </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">new indications, dosages or strengths of an existing product candidate. This three-year exclusivity covers only the conditions associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for product candidates containing the original active agent for other conditions of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the nonclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. Manufacturers may seek to launch these generic drugs following the expiration of the marketing exclusivity period, even if we still have patent protection for our drug competition that our product candidates may face from generic versions of our product candidates could materially and adversely impact our future revenue, profitability and cash flows and substantially limit our ability to obtain a return on the investments we have made in those product candidates. Our future revenues, profitability and cash flows could also be materially and adversely affected and our ability to obtain a return on the investments we have made in those product candidates may be substantially limited if our product candidates, if and when approved, are not afforded the appropriate periods of non-patent exclusivity.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Even if we obtain regulatory approval of any product candidate, the approved product may be subject to post-approval studies and will remain subject to ongoing regulatory requirements. If we fail to comply, or if concerns are identified in subsequent studies, our approval could be withdrawn, and our product sales could be suspended.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">If we are successful at obtaining regulatory approval for ATRN-119 and/or APR-1051 or any of our other product candidates, regulatory agencies in the United States and other countries where a product will be sold may require extensive additional clinical trials or post-approval clinical trials that are expensive and time-consuming to conduct. These trials may reveal side effects or other harmful effects in patients that use our products after they are on the market, which may result in the limitation or withdrawal of our drugs from the market. Alternatively, we may not be able to conduct such additional trials, which might force us to abandon our efforts to develop or commercialize certain product candidates. Even if post-approval studies are not requested or required, after our products are approved and on the market, there might be safety issues that emerge over time that require a change in product labeling, additional post-market studies or clinical trials, imposition of distribution and use restrictions under a Risk Evaluation and Mitigation Strategy, or REMS, or withdrawal of the product from the market, which would cause our revenue to decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Additionally, any products that we may successfully develop will be subject to ongoing regulatory requirements after they are approved. These requirements will govern the manufacturing, packaging, marketing, distribution, and use of our products. If we fail to comply with such regulatory requirements, approval for our products may be withdrawn, and product sales may be suspended. We may not be able to regain compliance, or we may only be able to regain compliance after a lengthy delay, significant expense, lost revenues and damage to our reputation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Even if we are able to commercialize any product candidate, such product candidate may become subject to unfavorable pricing regulations, third-party coverage and reimbursement policies or healthcare reform initiatives, which could harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">The regulations that govern marketing approval, pricing, coverage and reimbursement for new drugs vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">Our ability to commercialize any products successfully also will depend in part on the extent to which reimbursement and coverage for these products and related treatments will be available from government authorities, private health insurers and other organizations, and if reimbursement and coverage is available, the level of reimbursement and coverage. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the healthcare industry in the United States and elsewhere is cost containment. Government authorities and third-party </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, the third-party payors who reimburse patients or healthcare providers, such as government and private insurance plans, are requiring that drug companies provide them with predetermined discounts from list prices, and are seeking to reduce the prices charged or the amounts reimbursed for medical products. We cannot be sure that coverage and reimbursement will be available for any drug that we commercialize and, if coverage and reimbursement are available, we cannot be sure as to the level of reimbursement. Reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">There may be significant delays in obtaining reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drug will be reimbursed in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs, may be incorporated into existing payments for other items or services and may reflect budgetary constraints or imperfections in Medicare data. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for new products that we develop and for which we obtain marketing approval could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any drugs that we may develop. Our insurance policies may be inadequate and may potentially expose us to unrecoverable risk.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">We face an inherent risk of product liability exposure related to the testing of our product candidates in clinical trials and will face an even greater risk if we commercially sell any drugs that we may develop. If we cannot successfully defend ourselves against claims that our product candidates or drugs caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for any product candidates or drugs that we may develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">injury to our reputation and significant negative media attention;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of clinical trial participants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">significant costs to defend the related litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to trial participants or patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">loss of revenue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">reduced resources of our management to pursue our business strategy; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">the inability to commercialize any drugs that we may develop.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">We currently hold clinical trial liability insurance coverage for up to $5.0 million, but that coverage may not be adequate to cover any and all liabilities that we may incur. We would need to increase our insurance coverage when we begin the commercialization of our product candidates, if ever. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Governments outside of the United States tend to impose strict price controls, which may adversely affect our revenues from the sales of our products, if any.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">In some countries, particularly member states of the EU, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, we, or our future collaborators, may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of any product candidate approved for marketing is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be materially harmed.</span></p><a id="_Hlk132639116"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">An epidemic or pandemic disease outbreak could disrupt our business operations as well as the business or operations of our single third-party manufacturer, our CROs, clinical data management organizations, medical institutions and clinical investigators, or other third parties with whom we conduct business which may have a material adverse effect on our business, results of operations, financial condition and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">An epidemic or pandemic disease outbreak could severely disrupt our operations or the operations of third parties that we depend on, including our single third-party contract manufacturer, our CROs, clinical data management organizations, medical institutions and clinical investigators, and have a material adverse effect on our business, results of operations, financial condition and prospects. In addition, supply chain disruptions due to an epidemic or pandemic disease outbreak could have a material adverse effect on the availability or cost of materials for the active pharmaceutical ingredients, or API for our product candidates. Quarantines, restrictions or bans in travel into and within the countries in which we operate, our manufacturer produces the API for our product candidates or where we conduct our clinical trials could impede, delay, limit or prevent the production or delivery or release of our product candidates to our trial sites, and trial investigators, patients or other critical staff could be restricted from traveling to our trial sites. In addition, some of our clinical sites could slow or cease patient recruitment, patient treatment and/or access to patient data. Additionally, we and our employees have taken steps to avoid or reduce infection, including limiting travel and implementing remote work arrangements. It is possible that remote work arrangements will not be as efficient as physical operations, and this could adversely affect our business, operations and internal controls. Any or all of these factors could impede, delay, limit or prevent completion of our ongoing clinical trials, or require changes to our ongoing clinical trials, and ultimately lead to the delay or denial of regulatory approval of our product candidates, which would materially adversely affect our business, results of operations, financial conditions and prospects.&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">While there is significant uncertainty relating to the potential effect of the coronavirus on our business and operations, infections may become more widespread and travel restrictions may worsen, including in the United States, Sweden and other countries where our trials are conducted or the API for our product candidates is manufactured, any of which could have a material adverse effect our business, results of operations, financial conditions and prospects. Additionally, disruptions at the at FDA, the EMA and other regulators, caused by global health concerns, including delays in inspections of clinical trial or manufacturing sites required as part of the drug application review process, could result in delays of reviews and approvals of our product candidate or our proposed clinical trials. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The reactivation of p53 is a novel and unproven therapeutic approach and our development of eprenetapopt may never lead to a marketable product.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">We believe that mutant p53 still has the potential to be an attractive target for novel cancer therapy due to the high incidence of p53 mutations across a range of cancer types and the universally inferior prognosis for cancer patients with mutated p53. However, to our knowledge, no one has advanced a product candidate with this mechanism of action into the market. The scientific evidence to support the feasibility of developing these product candidates is both preliminary </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">and limited. For instance, even though eprenetapopt has shown promising results in preclinical studies and early-stage clinical trials, we may not succeed in demonstrating safety and efficacy of eprenetapopt in larger-scale clinical trials. In December 2020, we announced that our pivotal Phase 3 trial failed to meet its predefined primary endpoint of complete remission (CR) rate. On August 4, 2021, the U.S. Food and Drug Administration (FDA) placed a partial clinical hold on the clinical trials of eprenetapopt in combination with azacitidine in our myeloid malignancy programs. On August 11, 2021, the FDA placed a clinical hold on our clinical trial evaluating eprenetapopt with acalabrutinib or with venetoclax and rituximab in lymphoid malignancies. In the first quarter of 2022, FDA notified us that it would continue the partial clinical hold on three ongoing clinical studies in our myeloid program. However, we received clearance from FDA to proceed under our existing IND with a new trial in R/R MDS and AML.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">Given these results, FDA feedback and the costs of continuing the p53 reactivator development programs, we have shifted our primary focus of our activities to the discovery and development of molecules targeting DDR pathways in oncology through synthetic lethality. Advancing eprenetapopt as a novel product to reactivate p53 creates significant challenges for us, including:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining marketing approval, as obtaining regulatory approval of a p53 reactivator from the FDA or comparable foreign regulatory authorities has never been done before;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">educating medical personnel regarding the potential efficacy and safety benefits, as well as the challenges, of incorporating our product candidates, if approved, into treatment regimens; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing the sale and marketing capabilities to gain market acceptance, if approved.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Risks related to our dependence on third parties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We rely on third parties to conduct our clinical trials and some aspects of our research and preclinical studies, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research and studies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">We currently rely on third parties, such as CROs, clinical data management organizations, medical institutions and clinical investigators, to conduct our clinical trials and expect to continue to rely upon third parties to conduct additional clinical trials. We currently rely and expect to continue to rely on third parties to conduct some aspects of our research and preclinical studies. Any of these third parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements, it would delay our drug development activities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our regulatory responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan, study protocols for the trial, statistical analysis plan and other study-specific documents (for example, monitoring and blinding plans). Moreover, the FDA requires us to comply with standards, commonly referred to as GCP,&#160;International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, or ICH, guidelines, and regulations regarding the informed consent process, safety reporting requirements, data collection guidelines, and other regulations for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. The EMA, also requires us to comply with similar standards. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP and other applicable regulations. In addition, our clinical trials must be conducted with product produced under current Good Manufacturing Practices, or cGMP, regulations. Our failure to comply with these regulations may require us to conduct new clinical trials, which would delay the marketing approval process. We also are required to register certain ongoing clinical trials and post the results of certain completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions<span style="font-family:'Times New Roman;">.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">We also expect to rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of such third parties could delay clinical development or marketing approval of our product candidates or commercialization of our product candidates, producing additional losses and depriving us of potential revenue from sales of drugs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Although we currently plan to retain all commercial rights to our product candidates, we may enter into strategic collaborations for the development, marketing and commercialization of our product candidates. If those collaborations are not successful, the development, marketing and/or commercialization of our product candidates that are the subject of such collaborations would be harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">As we further develop our product candidates, we may build a commercial infrastructure with the capability to directly market it to a variety of markets and geographies. Although we currently plan to retain all commercial rights to our product candidates, we may enter into strategic collaborations for the development, marketing and commercialization of our product candidates. Our likely collaborators for any collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. If we do enter into any such arrangements with any third parties, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development, marketing and/or commercialization of our product candidates. Our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements. In addition, any future collaborators may have the right to abandon research or development projects and terminate applicable agreements, including funding obligations, prior to or upon the expiration of the agreed upon terms.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Collaborations involving our product candidates would pose the following risks to us:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not perform their obligations as expected;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not pursue development, marketing and/or commercialization of our product candidates or may elect not to continue or renew development, marketing or commercialization programs based on clinical trial results, changes in the collaborator&#8217;s strategic focus or available funding or external factors such as an acquisition that diverts resources or creates competing priorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators could independently develop, or develop with third parties, drugs that compete directly or indirectly with our product candidates or product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a collaborator with marketing and distribution rights to one or more drugs may not commit sufficient resources to the marketing and distribution of such drug or drugs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not properly obtain, maintain, defend and enforce our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may infringe, misappropriate or otherwise violate the intellectual property rights of third parties, which may expose us to litigation and potential liability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may lose certain valuable rights under circumstances identified in any collaboration arrangement that we enter into, such as if we undergo a change of control;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development, marketing and/or commercialization of the applicable product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may learn about our discoveries, data, proprietary information, trade secrets, or compounds and use this knowledge to compete with us in the future; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and type of our collaborations could adversely affect our attractiveness to future collaborators or acquirers.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We are currently dependent on a single third party manufacturer for the manufacture of the active pharmaceutical ingredient for our product candidates. This reliance on a single third party increases the risk that we will not have sufficient quantities of our product candidates or drugs or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">We do not have any manufacturing facilities or personnel, and we currently have no plans to build our own clinical or commercial scale manufacturing capabilities. We currently contract with third parties for the manufacture of our product candidates for certain preclinical trials and clinical trial materials, including raw materials and consumables necessary for their manufacture, consistent with applicable cGMP requirements. We intend to continue to contract for these materials in the future, including commercial manufacture if our product candidates receive marketing approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">The API and drug product for our product candidates is currently manufactured by a single contract manufacturer. Although we may do so in the future, we do not currently have arrangements in place for redundant supply of the API and drug product for our product candidates. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Times New Roman;">We expect to rely on third-party manufacturers or third-party collaborators for the manufacture of our product candidates for commercial supply of any of our product candidates for which we or any of our future collaborators obtain marketing approval. We may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including</span>:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible failure of the third party to manufacture our product candidate according to our schedule, or at all, including if our third-party contractors give greater priority to the supply of other products over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreements between us and them;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible termination or nonrenewal of agreements by our third-party contractors at a time that is costly or inconvenient for us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible breach by the third-party contractors of our agreements with them;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the failure of third-party contractors to comply with applicable regulatory requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible failure of the third party to manufacture our product candidates according to our specifications;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible mislabeling of clinical supplies, potentially resulting in issues including the wrong dose amounts being supplied or active drug or placebo not being properly identified;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possibility of clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of drug supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the possible misappropriation of our proprietary information, including our trade secrets and know-how.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The facilities used by our contract manufacturers to manufacture our product candidates must be approved by the FDA or the EMA pursuant to inspections that will be conducted after we submit our NDA to the FDA or our MAA to the EMA. We do not have complete control over all aspects of the manufacturing process of, and are dependent on, our contract manufacturing partners for compliance with cGMP regulations for manufacturing both active drug substances and finished drug products. Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside of the United States. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or comparable foreign regulatory bodies, they will not be able to secure and/or maintain marketing approval for their manufacturing facilities. In addition, we do not have complete control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA, the EMA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain marketing approval for or market our product candidates, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates and harm our business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any drugs that we may develop may compete with other product candidates and drugs for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We do not currently have arrangements in place for redundant supply of the API of our product candidates. If our current contract manufacturer cannot perform as agreed, we may be required to replace that manufacturer. Although we believe that there are several potential alternative manufacturers who could manufacture our product candidates, we may incur added costs and delays in identifying and qualifying any such replacement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our current and anticipated future dependence upon others for the manufacture of our product candidates or drugs may adversely affect our future profit margins and our ability to commercialize any drugs that receive marketing approval on a timely and competitive basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks related to our intellectual property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we are unable to obtain and maintain intellectual property protection for our product candidates or for our technology, our competitors could develop and commercialize products or technology similar or identical to ours, and our ability to successfully commercialize any product candidates we may develop, and our technology may be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">Our commercial success will depend in large part on obtaining and maintaining patent, trademark and trade secret protection of our proprietary technologies and our product candidates, their respective components, formulations, methods used to manufacture them and methods of treatment, as well as successfully defending these patents against </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">third-party challenges. We seek to protect our proprietary position by filing patent applications in the United States and abroad relating to our product candidates as well as other technologies that are important to our business. Our ability to stop unauthorized third parties from making, using, selling, offering to sell or importing our product candidates is dependent upon the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">The chemical structure of eprenetapopt is in the public domain. Accordingly, we do not own or license any composition of matter patents claiming the compound of eprenetapopt and will not in the future own or license any composition of matter patents claiming the chemical structure of eprenetapopt as described in the public domain. Our patent portfolio for eprenetapopt currently consists of method-of-use and formulation patent claims, and dosing, manufacturing processes, crystalline solid form, and combination therapy patent application claims. Our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from using our technology or from developing competing products and technologies. Any failure to obtain or maintain patent protection with respect to eprenetapopt and our other product candidates could have a material adverse effect on our business, financial condition, results of operations and growth prospects. If it is later determined that our activities or product candidates infringe, misappropriate or otherwise violate the intellectual property of third parties we may be liable for damages, enhanced damages or subjected to an injunction, any of which could have a material adverse effect on our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">The patenting process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. In addition, we may not pursue or obtain patent protection in all relevant markets. During the course of business, we have decided not to pursue certain products or processes and have not pursued certain corresponding intellectual property. However, we may decide to pursue such products or processes again in the future. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">The patent position of pharmaceutical and biotechnology companies generally is highly uncertain and involves complex legal and factual questions for which many legal principles remain unresolved. In recent years patent rights have been the subject of significant litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued in the United States or in other jurisdictions which protect our technology or products or which effectively prevent others from commercializing competitive technologies and products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">Our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art, including our own previously filed patent applications and scientific publications, allow our inventions to be patentable over the prior art. We are aware of certain scientific publications by our inventors and other third parties that disclose subject matter, including the composition of eprenetapopt, relating to certain of our patents, that may be used by third parties to challenge the validity and enforceability of our patents and patent applications. If such third parties are successful, we could lose valuable patent rights. In the United States, an inventor&#8217;s own publication cannot be used as prior art to the inventor&#8217;s patent application on the same subject matter when published less than one year before the effective filing date of the patent application. Such a publication may be considered prior art in certain jurisdictions that do not provide such a grace period. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#160;months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. In addition, the U.S. Patent and Trademark Office, or USPTO, might require that the term of a patent issuing from a pending patent application be disclaimed and limited to the term of another patent that is commonly owned or names a common inventor. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors, and other third parties, certain of these parties have and others may in the future breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if our patent applications issue as patents, they may not issue in a form </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in the patent claims of our patents being narrowed, invalidated or held unenforceable, which could limit our ability to stop or prevent us from stopping others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. In addition, some of our owned patents and patent applications may in the future be co-owned with third parties. If we do not have exclusive control of the grant of licenses under any such third-party co-owners&#8217; interest in such patents or patent applications or we are otherwise unable to secure such exclusive rights, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our co-owned patents in order to enforce such patents against third parties, and such cooperation may not be provided to us.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Given the amount of time required for the development, testing and regulatory review of new product candidates, which may be extended due to epidemic or pandemic disease outbreaks, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours or otherwise provide us with a competitive advantage. Upon the expiration of our current patents, we may lose the right to exclude others from practicing these inventions based on patent exclusivity. The expiration of these patents could also have a similar material adverse effect on our business, results of operations, financial condition and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our proprietary position for eprenetapopt depends upon patents that consist of method-of-use and formulation patent claims, which may not prevent a competitor or other third party from using the same product candidate for another use or in another formulation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Composition-of-matter patent claims on the active pharmaceutical ingredient, or API, in pharmaceutical drug products are generally considered to be the favored form of intellectual property protection for drug products because such patents may provide protection without regard to any particular method of use or manufacture or formulation of the API used. The chemical structure of eprenetapopt is in the public domain. Accordingly, we do not own or license any composition of matter patents claiming the compound of eprenetapopt and will not in the future own or license any composition of matter patents claiming the chemical structure of eprenetapopt as described in the public domain.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">Method-of-use patent claims protect the use of a product for the specified method and dosing or formulation patent claims cover dosing regimens or formulations of the API. These types of patent claims do not prevent a competitor or other third party from marketing an identical API for an indication that is outside the scope of the method claims or from developing a different dosing regimen or formulation that is outside the scope of the dosing or formulation claims. Moreover, with respect to method-of-use patents, even if competitors or other third parties do not actively promote their product for our targeted indications or uses for which we may obtain patents, physicians may recommend that patients use these products off-label, or patients may do so themselves. Although off-label use may infringe or contribute to the infringement of method-of-use patents, the practice is common and such infringement is difficult to prevent or prosecute. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">In addition, there are numerous publications and other prior art that may be relevant to our patents and may be used to challenge the validity of such patents in litigation or other intellectual property-related proceedings. If such challenges are successful, our patents may be narrowed or found to be invalid and we may lose valuable intellectual property rights. Any of the foregoing could have a material adverse effect on our business, financial conditions and results of operations and prospects.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Issued patents covering our product candidates and other technologies could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">If we seek to enforce a patent covering our product candidates or other technologies against a third party, that third party could assert that such patent is invalid or unenforceable. In patent litigation in the United States, challenges to validity or enforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of patentable subject matter, lack of novelty, obviousness, inadequate written description, indefiniteness, or lack of enablement. Grounds for an unenforceability assertion could be an allegation that relevant information was withheld from or a misleading statement was made to the USPTO during prosecution.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">In addition, third parties may raise claims challenging the validity or enforceability of our patents before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include pre-issuance submission of prior art to the USPTO and re-examination, post-grant review, </span><i style="font-family:'Times New Roman;font-style:italic;">inter partes</i><span style="font-family:'Times New Roman;"> review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (</span><i style="font-family:'Times New Roman;font-style:italic;">e.g.</i><span style="font-family:'Times New Roman;">, opposition proceedings). Moreover, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention or in post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge our priority of invention or other features of patentability with respect to our patents and patent applications. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our patent rights, allow third parties to commercialize our product candidates or other technologies and compete directly with us, without payment to us.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">In the United States, an inventor&#8217;s own publication may not be effective prior art to the inventor&#8217;s patent application on the same subject matter when published less than one year before the effective filing date of the patent application. Such a publication might be considered prior art in certain jurisdictions that do not provide such a grace period. For those non-US jurisdictions, reliance on non-patent exclusivity may provide sufficient competitive protection to exclude others from commercializing generic versions of our products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. If we are unsuccessful in any such proceeding or other priority or inventorship dispute, we may be required to obtain and maintain licenses from third parties, including parties involved in any such interference proceedings or other priority or inventorship disputes. Such licenses may not be available on commercially reasonable terms or at all, or may be non-exclusive. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture, and commercialization of one or more of the product candidates we may develop. The loss of exclusivity or the narrowing of our patent claims could limit our ability to stop others from using or commercializing similar or identical technology and products. Any of the foregoing could have a material adverse effect on our business, results of operations, financial condition and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to other claims challenging the inventorship of our patents and other intellectual property.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">We may also be subject to claims that former employees, collaborators or other third parties have an interest in our patents, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates or other technologies. Litigation may be necessary to defend against these and other claims challenging inventorship of our patents, trade secrets or other intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates and other technologies. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we do not obtain patent term extension or data exclusivity for any product candidates we may develop, our business may be materially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent term extension of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar extensions as compensation for patent term lost during regulatory review processes are also available in certain foreign countries and territories, such as in Europe under a Supplementary Patent Certificate. However, we may not be granted an extension in the United States and/or foreign countries and territories because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is shorter than what we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations and growth prospects could be materially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may not be successful in obtaining, through acquisitions, in-licenses or otherwise, rights that may be necessary to our product candidates or other technologies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">The growth of our business may depend in part on our future ability to acquire or in-license any relevant third-party proprietary rights that we may identify as necessary or important to our business operations. For example, our programs may involve additional product candidates that may require the use of additional proprietary rights held by third parties. Our product candidates may also require specific formulations to work effectively and efficiently. These formulations may be covered by intellectual property rights held by others. We may develop products containing our compounds and pre-existing pharmaceutical compounds. These pharmaceutical compounds may be covered by intellectual property rights held by others. We may be required by the FDA or comparable foreign regulatory authorities to provide a companion diagnostic test or tests with our product candidates. These diagnostic test or tests may be covered by intellectual property rights held by others. We may be unable to acquire or in-license such third-party intellectual property rights. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, which would harm our business. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights, and may need to seek to develop alternative approaches that do not infringe, misappropriate or otherwise violate intellectual property rights which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license to such intellectual property rights, any such license may be non-exclusive, which may allow our competitors access to the same technologies licensed to us.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Additionally, we sometimes collaborate with academic institutions and clinical research organizations to accelerate our research or development under written agreements with these institutions and organizations. In certain cases, these institutions and organizations may own or jointly own with us inventions that are created under such collaborations and provide us with an option to negotiate a license to any of the institution&#8217;s rights in such inventions. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution or organization may offer the intellectual property rights to others, potentially blocking our ability to pursue our program and allowing third parties to compete with us.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">The licensing and acquisition of third-party intellectual property rights is a competitive practice, and companies that may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their larger size and cash resources or greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire. If we are unable to successfully obtain rights to third-party intellectual property that may be necessary, we may have to abandon development of such program and our business, results of operations, financial condition and prospects could suffer.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates and technology.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Recent or future patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. Assuming that other requirements for patentability are met, prior to March&#160;2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file&#160;a patent application was entitled to the patent regardless of whether another inventor had made the invention earlier. In March&#160;2013, under the Leahy-Smith America Invents Act, or America Invents Act, the United States moved from a &#8220;first-to-invent&#8221; to a &#8220;first-to-file&#8221; system. Under a &#8220;first-to-file&#8221; system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. A third party that files&#160;a patent application in the USPTO after March&#160;2013, but before us, could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we were the first to either (i)&#160;file any patent application related to our product candidates or other technologies or (ii)&#160;invent any of the inventions claimed in our patents or patent applications.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">The America Invents Act includes a number of other significant changes to U.S. patent law, including provisions that affect the way patent applications are prosecuted, redefine prior art and establish a new post-grant review system. These include allowing third party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO-administered post-grant proceedings, including post-grant review, </span><i style="font-family:'Times New Roman;font-style:italic;">inter partes</i><span style="font-family:'Times New Roman;"> review, and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party in a district court action. An adverse determination in any such proceeding could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights, all of which could have a material adverse effect on our business and financial condition. Accordingly, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time consuming and unsuccessful.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">Competitors may infringe our patents, or we may be required to defend against claims of infringement. In addition, our patents also may become involved in inventorship, priority, validity or unenforceability disputes. To counter or defend against such claims can be expensive and time consuming. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. For example, in an infringement </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">proceeding, a court may decide that a patent owned by us is invalid or unenforceable. There is also the risk that, even if the validity of these patents is upheld, the court will refuse to stop the third party on the ground that such third party&#8217;s activities do not infringe our owned patents, including finding that the other party&#8217;s use of our patented technology falls under the safe harbor to patent infringement under 35 U.S.C. &#167;&#160;271(e)(1). Even if resolved in our favor, these lawsuits are expensive and would consume time and other resources, including distracting our personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">We may not be able to detect infringement against our patents which may be more difficult for formulation patents. Even if we detect infringement by a third party of our patents, we may choose not to pursue litigation against or settlement with the third party. If we later sue such third party for patent infringement, the third party may have certain legal defenses available to it, which otherwise would not be available except for the delay between when the infringement was first detected and when the suit was brought. Such legal defenses may make it impossible for us to enforce our patents against such third party.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">If another party questions the patentability of any of our claims in our U.S. patents, the third party can request that the USPTO review the patent claims such as in an </span><i style="font-family:'Times New Roman;font-style:italic;">inter partes</i><span style="font-family:'Times New Roman;"> review, </span><i style="font-family:'Times New Roman;font-style:italic;">ex parte</i><span style="font-family:'Times New Roman;"> re-exam or post-grant review proceedings. These proceedings are expensive and may result in a loss of scope of some claims or a loss of the entire patent. In addition to potential USPTO review proceedings, we may become a party to patent opposition proceedings in the European Patent Office, or EPO, or similar proceedings in other foreign patent offices, where either our foreign patents are challenged. The costs of these opposition or similar proceedings could be substantial, and may result in a loss of scope of some claims or a loss of the entire patent. An unfavorable result at the USPTO, EPO or other patent office may result in the loss of our right to exclude others from practicing one or more of our inventions in the relevant country or jurisdiction, which could have a material adverse effect on our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we are sued for infringing, misappropriating or otherwise violating patents or other intellectual property rights of third parties, it will be costly and time consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">Our commercial success depends upon our ability to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries. We may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property rights alleging that our product candidates and/or proprietary technologies infringe, misappropriate or otherwise violate their intellectual property rights. We cannot guarantee that our product candidates and other technologies that we have developed, are developing or may develop in the future will not infringe existing or future patents owned by third parties. U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields relating to our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that others may assert our product candidates infringe the patent rights of others. Moreover, it is not always clear to industry participants, including us, which patents cover various types of drugs, products or their methods of use or manufacture. Thus, because of the large number of patents issued and patent applications filed in our fields, there may be a risk that third parties may allege they have patent rights encompassing our product candidates, technologies or methods. It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our product candidates or other technologies, could be found to be infringed by our product candidates or other technologies. In addition, </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">because some patent applications in the United States may be maintained in secrecy until the patents are issued, patent applications in the United States and many foreign jurisdictions are typically not published until 18&#160;months after filing, and publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications covering our product candidates or technology. If any such patent applications issue as patents, and if such patents have priority over our patent applications or patents, we may be required to obtain rights to such patents owned by third parties which may not be available on commercially reasonable terms or at all, or may only be available on a non-exclusive basis.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">If a third party claims that we infringe its intellectual property rights, we may face a number of issues even if we believe such claims are without merit, including, but not limited to:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">infringement and other intellectual property claims which, regardless of merit, may be expensive and time-consuming to litigate, may divert our management&#8217;s attention from our core business and may impact our reputation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial damages for infringement, which we may have to pay if a court decides that the product candidate or technology at issue infringes on or violates the third party&#8217;s rights, and, if the court finds that the infringement was willful, we could be ordered to pay treble damages and the patent owner&#8217;s attorneys&#8217; fees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a court prohibiting us from developing, manufacturing, marketing or selling our product candidates, including eprenetapopt, or from using our proprietary technologies, unless the third party licenses its patent rights to us, which it is not required to do;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if a license is available from a third party, we may have to pay substantial royalties, upfront fees and other amounts, and/or grant cross-licenses to intellectual property rights for our product candidates or such license is only available on a non-exclusive basis; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">redesigning our product candidates or processes so they do not infringe, which may not be possible or may require substantial monetary expenditures and time.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect on our business, results of operations, financial condition and prospects. The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition, results of operations or growth prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">We may choose to challenge the patentability of claims in a third party&#8217;s U.S. patent by requesting that the USPTO review the patent claims in an </span><i style="font-family:'Times New Roman;font-style:italic;">ex-parte</i><span style="font-family:'Times New Roman;"> re-exam, </span><i style="font-family:'Times New Roman;font-style:italic;">inter partes</i><span style="font-family:'Times New Roman;"> review or post-grant review proceedings. These proceedings are expensive and may consume our time or other resources. We may choose to challenge a third party&#8217;s patent in patent opposition proceedings in the EPO, or other foreign patent office. The costs of these opposition proceedings could be substantial, and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, EPO or other patent office then we may be exposed to litigation by a third party alleging that the patent may be infringed by our product candidates or proprietary technologies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to protect our intellectual property rights with patents throughout the world.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">Filing, prosecuting and defending patents on all of our product candidates throughout the world would be prohibitively expensive, and the laws of some foreign countries may not protect our rights to the same extent as the laws of the United States. Competitors may use our technology in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but where enforcement is not as strong as in the United States. These products may compete with our product candidates in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing. Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products against third parties in violation of our proprietary rights generally. The initiation of proceedings to enforce our intellectual property rights or proceedings by third parties to challenge the scope or validity of our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business and could put our patents at risk of being invalidated or interpreted narrowly.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations, and growth prospects may be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Obtaining and maintaining our patent protection depends upon compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent prosecution process and following the issuance of a patent. In some cases, an inadvertent failure to comply with such requirements can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance could result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case if our patent were in force, which would have a material adverse effect on our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to claims that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">As is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees, consultants or advisors or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their current or former employers. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. This type of litigation or proceeding could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other intellectual property related proceedings could adversely affect our ability to compete in the marketplace.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and growth prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure of trade secrets and other proprietary information.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our platform technology and discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect and we have limited control over the protection of trade secrets used by our collaborators and suppliers. Although we seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with parties who have access them, such as our employees, consultants, and outside scientific advisors, contractors and collaborators, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. Despite our efforts, any of these parties might breach the agreements and intentionally or inadvertently disclose our trade secret information and we may not be able to obtain adequate remedies for such breaches. In addition, competitors may otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Moreover, our competitors or other third parties may independently develop equivalent knowledge, methods and know-how.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Enforcing a claim that a third party illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, courts inside and outside the United States sometimes are less willing or unwilling to protect trade secrets. If we choose to go to court to stop a third party from using any of our trade secrets, we may incur substantial costs. These lawsuits may consume our time and other resources even if we are successful. If any of our trade secrets were determined to be lawfully obtained or independently developed by a competitor or other third party, we may not be able to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position, business, results of operations and prospects would be materially and adversely harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intellectual property rights do not necessarily address all potential threats.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may be able to make or use compounds that are similar to the pharmaceutical compounds used in our product candidates but that are not covered by the claims of our patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the APIs in our current product candidates will eventually become commercially available in generic drug products, and no patent protection may be available with regard to formulation or method of use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or our future licensors or collaborators, might not have been the first to file patent applications for these inventions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or our future licensors or collaborators, might not have been the first to make the inventions covered by our issued patents or pending patent applications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may independently develop similar or alternative technologies or duplicate any of our technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it is possible that our current or future pending or licensed patent applications will not result in issued patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it is possible that public disclosures or publications, including disclosures or publications made by us, could be used in an attempt to invalidate our patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors or other third parties;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our competitors or other third parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it is possible that others may circumvent our patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it is possible that there are unpublished applications or patent applications maintained in secrecy that may later issue with claims covering our products or technology similar to ours;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the laws of foreign countries may not protect our proprietary rights to the same extent as the laws of the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the claims of our issued patents or patent applications, if and when issued, may not cover our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our issued patents may not provide us with any competitive advantages, may be narrowed in scope, or be held invalid or unenforceable as a result of legal challenges by third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inventors of our patents or patent applications may become involved with competitors, develop products or processes which design around our patents, or become hostile to us or the patents or patent applications on which they are named as inventors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we have engaged in scientific collaborations in the past and will continue to do so in the future. Such collaborators may develop adjacent or competing products to ours that are outside the scope of our patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not develop additional proprietary technologies for which we can obtain patent protection;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may choose not to pursue patent protection in order to maintain certain trade secrets or know-how, and a third party may subsequently obtain a patent covering such intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it is possible that product candidates or diagnostic tests we develop may be covered by third parties&#8217; patents or other exclusive rights; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patents of others may have an adverse effect on our business.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If trademarks, brand names and trade names are not adequately protected or available, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may rely on trademarks, service marks, tradenames and brand names. We cannot assure you that our trademark applications will be approved. During trademark registration proceedings, we may receive rejections. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, any registered or unregistered trademarks or trade names that we currently have or may in the future acquire may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations and prospects.&#160;</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks related to regulatory and marketing approval and other legal compliance matters</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We have never obtained marketing approval for a product candidate and we may be unable to obtain, or may be delayed in obtaining, marketing approval for any of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">We have never obtained marketing approval for a product candidate. The time required to obtain approval by the FDA and comparable foreign regulatory authorities is unpredictable but typically takes many years following the commencement of preclinical studies and clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, extraneous factors, including an epidemic or pandemic disease outbreak, or other public health situations, could impact the timeline for FDA and comparable foreign regulatory authorities to review an application for one of our product candidates. It is possible that the FDA and comparable foreign regulatory authorities may refuse to accept for filing and substantive review any new drug applications, or NDAs, marketing authorization applications, or MAA, that we submit for our product candidates or may conclude after review of our data that our application is insufficient to obtain marketing approval of our product candidates. If the FDA, or comparable foreign regulatory authorities do not accept or approve our NDAs or MAAs for our product candidates, it may require that we conduct additional clinical, nonclinical or manufacturing validation studies and submit that data before it will reconsider our applications. Depending on the extent of these or any other regulatory authority-required studies, approval of any NDA, MAA or other application that we submit may be delayed by several years, or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA or comparable foreign regulatory authorities to approve our NDAs or our MAAs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">Any delay in obtaining, or an inability to obtain, marketing approvals would prevent us from commercializing our product candidates, generating revenues and achieving and sustaining profitability. If any of these outcomes occur, we may be forced to abandon our development efforts for our product candidates, which could significantly harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us, or any future collaborators, from obtaining approvals for the commercialization of some or all of our product candidates. As a result, we cannot predict when or if, and in which territories, we, or any future collaborators, will obtain marketing approval to commercialize a product candidate.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">The research, testing, manufacturing, labeling, approval, selling, marketing, promotion and distribution of drugs are subject to extensive regulation by the FDA and comparable foreign regulatory authorities, whose laws and regulations may differ from country to country. We, and any future collaborators, are not permitted to market our product candidates in the United States or in other countries until we or they receive approval of an NDA from the FDA or marketing approval from comparable foreign regulatory authorities. Our product candidates are in early stages of development and are subject to the risks of failure inherent in drug development. We have not submitted an application for or received marketing approval for any of our product candidates in the United States or in any other jurisdiction. We have limited experience in conducting and managing the clinical trials necessary to obtain marketing approvals, including FDA approval of an NDA.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">The process of obtaining marketing approvals, both in the United States and abroad, is a lengthy, expensive and uncertain process. It may take many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. The FDA or other comparable foreign regulatory authorities have substantial discretion and may determine that our product candidates are not safe and effective, only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Our product candidates could fail to receive marketing approval, or marketing approval for our product candidates could be limited or delayed, for many reasons, including the following:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA or other submission and applications or to obtain marketing approval in the United States or elsewhere;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may fail to approve any companion diagnostics that may be required in connection with approval of our therapeutic product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or the applicable foreign regulatory agency may fail to approve the formulation, labeling and/or the specifications for our product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in marketing approval policies during the development period, changes in or the enactment or promulgation of additional statutes, regulations or guidance or changes in regulatory review for each submitted drug application; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">This lengthy approval process as well as the unpredictability of clinical trial results may result in our failing to obtain marketing approval to market ATRN-119 and/or APR-1051, which would significantly harm our business, results of operations and prospects. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical studies, clinical trials or other studies and testing. In addition, varying interpretations of the data obtained from preclinical studies and clinical trials could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we, or any collaborators we may have in the future, ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved drug not commercially viable.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Any delay in obtaining or failure to obtain required approvals could materially adversely affect our ability or that of any collaborators we may have to generate revenue from the particular product candidate, which likely would result in significant harm to our financial position and adversely impact our stock price.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Failure to obtain marketing approval in foreign jurisdictions would prevent our product candidates from being marketed abroad. Any approval we are granted for our product candidates in the United States would not assure approval of our product candidates in foreign jurisdictions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">In order to market and sell our product candidates in the EU and many other jurisdictions, we, and any collaborators we may have in the future, must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The marketing approval process </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">outside of the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside of the United States, it is required that the drug be approved for reimbursement before the drug can be approved for sale in that country. We, and any collaborators we may have in the future, may not obtain approvals from regulatory authorities outside of the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside of the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">The U.K. having left the EU, the TCA and the Northern Ireland Protocol is likely to continue to affect European and worldwide economic conditions and could contribute to greater instability in the global financial markets. These effects could have an adverse effect on our business, investments, and future operations in Europe. There is a risk that trade between U.K. and EU businesses will be materially adversely affected, particularly in relation to highly regulated products such as pharmaceuticals and products of animal-origin, due to the additional regulatory burdens being imposed on exporters/importers which may affect the availability of these products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">The consequences for the economies of the U.K. and the EU member states as a result of the U.K.&#8217;s withdrawal from the EU are still largely unknown and unpredictable. Given the lack of comparable precedent, it is unclear what the broader macro-economic and financial implications the U.K. having left the EU will have.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We, or any future collaborators, may not be able to obtain or maintain orphan drug exclusivity for our product candidates and, even if we do, that exclusivity many not prevent the FDA or the European Commission from approving competing products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Regulatory authorities in some jurisdictions, including the United States and the EU, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. Eprenetapopt has received orphan drug designation from the FDA for use in the treatment of high-risk myelodysplastic syndromes, or MDS, and orphan drug designation from the European Commission for MDS, AML, and ovarian cancer. We may seek orphan drug designations for eprenetapopt for other indications or for other of our product candidates. There can be no assurances that we will be able to obtain such designations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In addition, the company that obtains the first FDA approval for a designated orphan drug for a rare disease receives marketing exclusivity for use of that drug for the designated condition for a period of seven years. Once a product receives orphan drug exclusivity, a second product that is considered to be the same drug for the same indication generally may be approved during the exclusivity period only if the second product is shown to be &#8220;clinically superior&#8221; to the original orphan drug in that it is more effective, safer or otherwise makes a &#8220;major contribution to patient care&#8221; or the holder of exclusive approval cannot assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">The European Commission can grant orphan drug product designation to products for which the sponsor can establish that it is intended for the diagnosis, prevention, or treatment of (1)&#160;a life-threatening or chronically debilitating condition affecting not more than five in 10,000 people in the European Union, or (2)&#160;a life threatening, seriously debilitating or serious and chronic condition in the European Union and that without incentives it is unlikely that sales of the drug in the European Union would generate a sufficient return to justify the necessary investment. In addition, it must be established that there is no other satisfactory method approved in the European Union of diagnosing, preventing or treating the condition, or if such a method exists, the proposed orphan drug will be of significant benefit to patients. Orphan drug designation is not a marketing authorization. It is a designation that provides a number of benefits, including fee reductions, regulatory assistance, and the possibility to apply for a centralized EU marketing authorization, as well as 10&#160;years of market exclusivity following a marketing authorization. During this market exclusivity period, neither the EMA nor the European Commission nor the EU member states can accept an application or grant a marketing authorization for a &#8216;similar medicinal product.&#8217; A &#8216;similar medicinal product&#8217; is defined as a medicinal product </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. The market exclusivity period for the authorized therapeutic indication may be reduced to six years if, at the end of the fifth year, it is established that the orphan designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. In addition, a competing similar medicinal product may in limited circumstances be authorized prior to the expiration of the market exclusivity period, including if it is shown to be safer, more effective or otherwise clinically superior to our product. Our product can lose orphan designation, and the related benefits, prior to us obtaining a marketing authorization if it is demonstrated that the orphan designation criteria are no longer met.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Even if we, or any future collaborators, obtain orphan drug designation for a product candidate, we, or they, may not be able to obtain or maintain orphan drug exclusivity for that product candidate. We may not be the first to obtain marketing approval of any product candidate for which we have obtained orphan drug designation for the orphan-designated indication due to the uncertainties associated with developing drug products. If this happens, marketing approval for our product candidate may be delayed due to the first-approved product&#8217;s orphan drug exclusivity, unless we demonstrate clinical superiority. We may not be able to demonstrate that our product is clinically superior to a first-approved product with orphan drug exclusivity, i.e.,&#160;that it provides greater safety or efficacy or a major contribution to patient care. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we, or any future collaborators, obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties may be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug with the same active moiety for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care or the manufacturer of the product with orphan exclusivity is unable to maintain sufficient product quantity. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">In the United States, Congress is also considering updates to the orphan drug provisions of the FDCA in response to a recent 11th Circuit decision. Any changes to the orphan drug provisions could change our opportunities for, or likelihood of success in obtaining, orphan drug exclusivity and could materially adversely affect our business, financial condition, results of operations, cash flows and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Even if we, or any collaborators we may have in the future, obtain marketing approvals for our product candidates, the terms of approvals and ongoing regulation of our product candidates could require substantial expenditure of resources and may limit how we, or they, manufacture and market our product candidates, which could materially impair our ability to generate revenue.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">Once marketing approval has been granted, an approved drug and its manufacturer and marketer are subject to ongoing review and extensive regulation. These requirements include submissions of safety and other post-marketing information and reports, user fee requirements, registration and listing requirements, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. We, and any collaborators we may have in the future, must also comply with requirements concerning advertising and promotion for any of our product candidates for which we or they obtain marketing approval. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the drug&#8217;s approved labeling. Thus, we, and any collaborators we may have in the future, may not be able to promote any drugs we develop for indications or uses for which they are not approved.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">The FDA or comparable foreign regulatory authorities may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a drug. For example, the approval may be subject to limitations on the indicated uses for which the drug may be marketed or to the conditions of approval, including the requirement to implement a REMS or comparable foreign equivalents, like the EU Risk Management Plan, or RMP, which could include requirements for a restricted distribution system. Manufacturers of approved drugs and those </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">manufacturers&#8217; facilities are also required to comply with extensive FDA or comparable foreign regulatory authorities requirements, including ensuring that quality control and manufacturing procedures conform to cGMPs, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation and reporting requirements. We, our contract manufacturers, our future collaborators and their contract manufacturers could be subject to periodic unannounced inspections by the FDA or comparable foreign regulatory authorities to monitor and ensure compliance with cGMPs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Accordingly, assuming we, or our future collaborators, receive marketing approval for one or more of our product candidates, we, and our future collaborators, and our and their contract manufacturers will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">If we, and our future collaborators, are not able to comply with post-approval regulatory requirements, regulatory agencies or enforcement authorities may:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issue warning letters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impose civil or criminal penalties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspend regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspend any of our ongoing clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refuse to approve pending applications or supplements to approved applications submitted by us or our collaborators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impose restrictions on our operations, including closing our or our collaborators&#8217; manufacturing facilities; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seize or detain products or require a recall.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our product candidates, if approved. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">The regulatory requirements and policies may change, and additional government regulations may be enacted for which we may also be required to comply. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or in other countries. If we or any future collaboration partner are not able to maintain regulatory compliance, we or such collaboration partner, as applicable, may face government enforcement action and our business will suffer. Moreover, our or our future collaborators&#8217; ability to market any future drugs could be limited, which could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The FDA&#8217;s and other comparable regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates, which would impact our ability to generate revenue.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. The policies of the FDA and of comparable foreign regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory licensure of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing licensure that we may have </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">obtained and we may not achieve or sustain profitability. If these actions impose constraints on FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Any of our product candidates for which we, or our future collaborators, obtain marketing approval in the future will be subject to substantial penalties if we, or they, fail to comply with regulatory requirements or if we, or they, experience unanticipated problems with our product candidates following approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Any of our product candidates for which we, or our future collaborators, obtain marketing approval in the future, will be subject to continual review by the FDA or comparable foreign regulatory authorities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">For example, in the United States, the FDA and other agencies, including the Department of Justice, or the DOJ, closely regulate and monitor the post-approval marketing and promotion of drugs to ensure that they are manufactured, marketed, and distributed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding off-label use and if we, or our future collaborators, do not market any of our product candidates for which we, or they, receive marketing approval for only their approved indications, we, or they, may be subject to warnings or enforcement action for off-label marketing. Violation of the FDCA and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription drugs may lead to investigations or allegations of violations of federal and state healthcare fraud and abuse laws and state consumer protection laws.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">In addition, later discovery of previously unknown adverse events or other problems with our product candidates or their manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">litigation involving patients taking our drug;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on such drugs, manufacturers or manufacturing processes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the labeling or marketing of a drug;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on drug distribution or use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements to conduct post-marketing studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">warning letters or untitled letters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of the drugs from the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to approve pending applications or supplements to approved applications that we submit;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recall of drugs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, restitution or disgorgement of profits or revenues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension or withdrawal of marketing approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">damage to relationships with any potential collaborators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on coverage by third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unfavorable press coverage and damage to our reputation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to permit the import or export of drugs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">drug seizure; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;"><span style="font-family:'Times New Roman;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Recently enacted and future legislation, and any change in existing government regulations and policies, may increase the difficulty and cost for us and our future collaborators to obtain marketing approval of and commercialize our product candidates and affect the prices we, or they, may obtain.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">In the United States and some foreign jurisdictions, there have been and continue to be a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability, or the ability of our future collaborators, to effectively sell any drugs for which we, or they, obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and additional downward pressure on the price that we, or our future collaborators, may receive for any approved drugs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">In the United States, the Congress and recent presidential administrations have enacted or are considering a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products, if approved, and to do so effectively. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and expanding access.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">In the United States, the pharmaceutical industry has been a particular focus of efforts to reform the healthcare system and has been significantly affected by major legislative initiatives, including the PPACA, which contains provisions that may potentially affect the profitability of our products, including, for example, increased rebates for products sold to Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part&#160;D beneficiaries and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs, and expansion of the entities eligible for discounts under the 340B pricing program. The framework of the PPACA continues to evolve as a result of executive, legislative, regulatory and administrative developments that have challenged the law and contribute to legal uncertainty that could affect the profitability of our products. See Part I, Item 1, &#8220;Government Regulation &#8211; U.S. Healthcare Reform&#8221; for further information.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">We expect that these and other healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and/or new payment methodologies, and place additional downward pressure on the price that we receive for any approved product and/or the level of reimbursement physicians receive for administering any approved product we might bring to market. Reductions in reimbursement levels and imposition of more rigorous coverage criteria or new payment methodologies may negatively impact the prices we receive or the frequency with which our products are prescribed or administered. Any coverage or reimbursement policies instituted by Medicare or other federal health care programs may result in similar policies from private payors. The implementation of cost containment measures or other healthcare reforms may affect our ability to generate revenue, attain or maintain profitability, or commercialize our product candidates. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Times New Roman;">The pricing of prescription pharmaceuticals is also subject to governmental control outside the United States. In countries outside of the United States, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidates to that of other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our ability to generate revenues and become profitable could be impaired.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Times New Roman;">Legislative and regulatory proposals have also been made to expand post-approval requirements and restrict sales and promotional activities for drug products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the United States Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us and any future collaborators to more stringent drug labeling and post-marketing testing and other requirements.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Times New Roman;">Regulatory proposals have been made to allow the importation of prescription drugs into the United States that are approved for marketing in Canada, and potentially other countries. If such proposal are implemented, and if any of our product candidates or other similar or equivalent drug products are approved in another ex-US jurisdiction, these regulatory proposals may impact the competition our product may face, if approved. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may seek a breakthrough therapy designation for one or more of our product candidates, but we might not receive such designation, and even if we do, such designation may not lead to a faster development or regulatory review or approval process.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">We may seek a breakthrough therapy designation for one or more of our product candidates. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs and biologics that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA may also be eligible for priority review if supported by clinical data at the time the NDA is submitted to the FDA, and parts of the NDA may be submitted and reviewed on a rolling basis.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe that one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. Even if we receive breakthrough therapy designation, the receipt of such designation for a product candidate may not result in a faster development or regulatory review or approval process compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. For example, in June 2022, FDA published a draft guidance document outlining considerations for the Agency in rescinding Breakthrough Therapy designation for products that no longer meet the requirements for that designation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">A fast track designation by the FDA for one of our product candidates may not actually lead to a faster development or regulatory review or approval process.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">If a drug is intended, whether alone or in combination with one or more other drugs, for the treatment of a serious or life-threatening condition and nonclinical or clinical data demonstrate the potential to address unmet medical need for this </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">condition, a drug sponsor may apply for FDA fast track designation. We may not experience a faster development or regulatory review or approval process for any product candidates, if any, for which we obtain fast track designation compared to conventional FDA procedures. In addition, the FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program. Fast track designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may seek priority review designation for one or more of our product candidates, but we might not receive such designation, and even if we do, such designation may not lead to a faster development or regulatory review or approval process.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">If the FDA determines that a product candidate offers a treatment for a serious condition and, if approved, the product would provide a significant improvement in safety or effectiveness, the FDA may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review an application is six months from the 60-day filing date, rather than the standard review period of ten months. We may request priority review for our product candidates. The FDA has broad discretion with respect to whether or not to grant priority review status to a product candidate, so even if we believe a particular product candidate is eligible for such designation or status, the FDA may decide not to grant it. Moreover, a priority review designation does not necessarily mean a faster development or </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">regulatory review or approval process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. Receiving priority review from the FDA does not guarantee approval within the six-month review cycle or at all.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our relationships with healthcare providers, physicians and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to penalties, including criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Although we do not currently have any products on the market, we are subject to a variety of regulatory requirements, including healthcare statutory and regulatory requirements and enforcement by the U.S. federal and state governments and the foreign governments of the countries in which we conduct our business. Even though we are not in a position to make patient referrals and do not bill Medicare, Medicaid, or other government or commercial third-party payors, our relationships with healthcare providers, physicians and third-party payors will subject us to healthcare statutory and regulatory requirements and enforcement by the U.S. federal government and the states and foreign governments in which we conduct our business. Our future arrangements with healthcare providers, physicians and third-party payors and patients may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our products for which we obtain marketing approval. See Part I, Item 1, &#8220;Government Regulation &#8211; Healthcare Law and Regulation&#8221; for more detail.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations, guidance, case law or other applicable law. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, individual imprisonment, exclusion from participation in federal healthcare programs, such as Medicare and Medicaid, disgorgement, reputational harm, additional oversight and reporting obligations pursuant to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with applicable laws and regulations, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to market our products, if approved, and adversely impact our financial results. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws and regulations, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, it may be costly to us in terms of money, time and resources, and they may be subject to criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our employees and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">We are exposed to the risk of our employees and consultants committing fraud or other misconduct, including intentional failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards we may establish, comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, incentive programs and other business arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">from a failure to be in compliance with such laws, standards or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Times New Roman;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Times New Roman;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of hazardous and flammable materials, including chemicals and biological materials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Times New Roman;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing and selling certain product candidates outside of the United States and require us to develop and implement costly compliance programs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">If we expand our operations outside of the United States, we must comply with numerous laws and regulations in each jurisdiction in which we plan to operate, such as the applicable anti-bribery, anti-corruption, anti-money laundering regulations. The creation and implementation of international business practices compliance programs is costly and such programs are difficult to enforce, particularly where reliance on third parties is required.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">The FCPA prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. The anti-bribery provisions of the FCPA are enforced primarily by the DOJ. The Securities and Exchange Commission, or SEC, is involved with enforcement of the books and records provisions of the FCPA.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">Violation of the FCPA can result in significant civil and criminal penalties. Indictment alone under the FCPA can lead to suspension of the right to do business with the U.S. government until the pending claims are resolved. Conviction of a violation of the FCPA can result in long-term disqualification as a government contractor. The termination of a government contract or relationship as a result of our failure to satisfy any of our obligations under laws governing international business practices would have a negative impact on our operations and harm our reputation and ability to </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">procure government contracts. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">We are also subject to other laws and regulations governing our international operations, including applicable import and export control regulations, economic sanctions on countries and persons administered or enforced by the U.S. government (including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury), anti-money laundering laws, customs requirements and currency exchange regulations, collectively referred to as the trade control laws. We can provide no assurance that we will be completely effective in ensuring our compliance with all applicable legal requirements, including trade control laws. If we are not in compliance with applicable trade control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, results of operations, financial condition and prospects. Likewise, any investigation of any potential violations of these trade control laws by U.S. or other authorities could also have an adverse impact on our reputation, our business, results of operations, financial condition and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain drugs and product candidates outside of the United States, which could limit our growth potential and increase our development costs. The failure to comply with laws governing international business practices may result in substantial penalties, including suspension or debarment from government contracting.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Security breaches, loss of data and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">In the ordinary course of our business, we collect and store sensitive data, including personally identifiable information, intellectual property and proprietary business information owned or controlled by ourselves and other parties. We manage and maintain our applications and data utilizing a combination of on-site systems, managed data centers and cloud-based data centers. We utilize external security and infrastructure vendors to manage our information technology systems and data centers. These applications and data encompass a wide variety of business-critical information, including research and development information, commercial information, and business and financial information. We face a number of risks relative to protecting this critical information, including loss of access or disruptions to our IT systems, inappropriate use or disclosure of protected information, inappropriate modification, and the risk of our being unable to adequately monitor, audit and modify our controls over our critical information. This risk extends to the third-party vendors and subcontractors we use to manage this sensitive data.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">The secure processing, storage, maintenance and transmission of this critical information are vital to our operations and business strategy. Although we take measures to protect sensitive data from unauthorized access, use or disclosure, including the development of policies and procedures to protect our information technology systems and confidential and proprietary information, there is no guarantee we can protect our data from data security incidents, and our information technology and infrastructure may be vulnerable to attacks by hackers or viruses or breached due to employee or vendor error, malfeasance or other malicious or inadvertent disruptions from internal or external threats. Any such breach or interruption could compromise our networks and the information stored there could be accessed by unauthorized parties, manipulated, publicly disclosed, lost or stolen. Any such access, breach or other loss of information could result in legal claims or proceedings, and liability under federal or state laws that protect the privacy of personal information, such as HIPAA, HITECH, and regulatory penalties. Notice of breaches must be made to affected individuals, the Secretary of the Department of Health and Human Services, and notice may need to be made to the media or other data protection regulators. Such incidents, and the publicity they may generate, could harm our reputation and our ability to compete. Unauthorized access, loss or dissemination could also damage our reputation or disrupt our operations, including our ability to conduct our analyses, process claims and appeals, conduct research and development activities, collect, process and prepare company financial information, provide information about our tests and other </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">patient and physician education and outreach efforts through our website, and manage the administrative aspects of our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Penalties for violations of these laws vary. For instance, penalties for failure to comply with a requirement of HIPAA and HITECH vary significantly and include civil monetary penalties of up to (as recently adjusted for inflation) $55,910 per violation, not to exceed approximately $1.68&#160;million per calendar year for each provision of HIPAA that is violated and, in certain circumstances, criminal penalties with fines up to $250,000 per violation and/or imprisonment. However, a single breach incident can result in multiple violations, which can lead to significant financial penalties. In addition, numerous breach incidents could lead to possible penalties in excess of $1.68&#160;million. A person who knowingly obtains or discloses individually identifiable health information in violation of HIPAA may face a criminal penalty of up to $50,000 and up to one-year imprisonment. The criminal penalties increase if the wrongful conduct involves false pretenses or the intent to sell, transfer or use identifiable health information for commercial advantage, personal gain or malicious harm.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Further, various states, such as California and Massachusetts, have implemented similar privacy laws and regulations, such as the California Confidentiality of Medical Information Act, that impose restrictive requirements regulating the use and disclosure of health information and other personally identifiable information. These laws and regulations are not necessarily preempted by HIPAA, particularly if a state affords greater protection to individuals than HIPAA. Where state laws are more protective, we have to comply with the stricter provisions. In addition to fines and penalties imposed upon violators, some of these state laws also afford private rights of action to individuals who believe their personal information has been misused. California&#8217;s patient privacy laws, for example, provide for penalties of up to $250,000 and permit injured parties to sue for damages. The interplay of federal and state laws may be subject to varying interpretations by courts and government agencies, creating complex compliance issues for us and data we receive, use and share, potentially exposing us to additional expense, adverse publicity and liability. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Further, as regulatory focus on privacy issues continues to increase and laws and regulations concerning the protection of personal information expand and become more complex, these potential risks to our business could intensify. Moreover, privacy and cybersecurity laws and regulations are evolving, and may continue to add additional compliance costs and legal risks. For example, the California legislature passed the CCPA, which came into effect January 1, 2020. The CCPA requires companies doing business in California to disclose information regarding the collection, use and sharing of a consumer&#8217;s personal data, and comply with certain qualified privacy rights requests, including rights to request deletion of or to stop the sale of their personal information. While the CCPA includes certain exemptions for data protected by HIPAA or in certain research contexts, the law covers a wide range of data we may process in other contexts. The CCPA also permits the imposition of civil penalties and expands existing state security laws by providing a private right of action for consumers in certain circumstances where consumer data is subject to a breach. Interpretations of the CCPA may continue to evolve with regulatory guidance and enforcement actions from the California Attorney General. The CPRA, which expands the CCPA, passed in November 2020. The CPRA will, among other things, impose additional data protection obligations on companies doing business in California, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It has also created a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. That rulemaking process is ongoing. Following the CPRA, Virginia, Colorado, Utah and Connecticut have enacted similar, but not completely consistent, comprehensive privacy legislation that will also go into effect in January and July 2023, respectively. Many other states are considering similar legislation in addition to the consideration of comprehensive privacy legislation at the federal level. If passed, such laws will require additional resources to ensure compliance, and may have potentially conflicting requirements that would make compliance challenging. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">Compliance with U.S. and international data protection laws and regulations could cause us to incur substantial costs or require us to change our business practices and compliance procedures in a manner adverse to our business. Moreover, complying with these various laws could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. We have policies and procedures in place, and have conducted an independent third-party audit, to support our compliance with all applicable data protection laws and regulations, and are continually improving our data protection program to address compliance risks and evolving requirements. Nevertheless, our efforts to comply with data protection laws and evaluate </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">as well as oversee our third party vendors&#8217; compliance with data protection laws and our contractual requirements may be insufficient to mitigate all data protection risks or compliance obligations, which could result in regulatory scrutiny, legal liability, reputational risk or operational disruption. Failure by us or by our third-party vendors to comply with U.S. and international data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity and could negatively affect our operating results and business. Claims that we or our third-party vendors have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we or our third-party vendor, as applicable, are not found liable, could be expensive and time consuming to defend and could result in adverse publicity that could harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Any clinical trial programs we conduct or research collaborations we enter into in the European Economic Area (&#8220;EEA&#8221;)/UK may subject us to the EU General Data Protection Regulation&#160;2016/679 (the &#8220;EU GDPR&#8221;) as implemented by countries within the EEA. In addition, where we conduct programs and collaborations in the UK we may be subject to the UK Data Protection Act 2018 and the UK General Data Protection Regulation, (together the &#8220;UK GDPR&#8221;).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">We are subject to the EU GDPR, which applies extra-territorially and implements stringent operational requirements on controllers (e.g.,&#160;sponsors) and processors (e.g.,&#160;CROs, laboratories) of personal data. For controllers this includes, for example, high standards for obtaining valid consent from individuals to process their personal data (where consent is the legal ground relied upon), the requirements to provide detailed disclosures to individuals, short timelines for personal data breach notifications to data protection authorities and data subjects, limitations on retention of personal data, additional considerations where processing health data and other &#8220;special categories of personal data&#8221; and specific obligations where third-party processors are engaged. The EU GDPR also prohibits the international transfer of personal data from the EEA to countries outside of the EEA unless made to a country deemed to have &#8220;adequate&#8221; data privacy laws by the European Commission or a data transfer mechanism has been put in place. Until recently, one such data transfer mechanism was the EU-US Privacy Shield. However, in July 2020 the Court of Justice of the European Union (&#8220;CJEU&#8221;) declared the Privacy Shield to be invalid for purposes of international transfers. The CJEU also imposed further restrictions on use of standard contractual clauses (SCCs) (i.e., an EU-style data transfer agreement) including, a requirement for companies to carry out a transfer privacy impact assessment, which among other things, assesses laws governing access to personal data in the recipient country and considers whether supplementary measures that provide privacy protections additional to those provided under SCCs will need to be implemented to ensure an essentially equivalent level of data protection to that afforded in the EEA. Moreover, new versions of the SCCs (new EU SCCs) have recently been published requiring additional compliance and implementation efforts. In turn, the findings of the CJEU will have significant implications for cross-border data flows.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">Further, the EU GDPR provides that EU Member States may establish their own laws and regulations further restricting the processing of genetic data, biometric data, health data and other personal data, which could limit our ability to use and share such personal data or could cause our costs to increase. The EU GDPR imposes onerous accountability obligations requiring controllers and processors to maintain a record of their data processing activities and policies and procedures to demonstrate compliance with the EU GDPR. The EU GDPR also grants certain privacy rights to individuals (e.g.,&#160;the right to access or erase their personal data). While we have established some data protection policies and have a maturing compliance program, additional resources will be needed to fully comply with the EU GDPR, including for evolving regulatory guidance. If our or our vendors&#8217; or service providers&#8217; privacy or data security measures fail to comply with the EU GDPR requirements, we may be subject to litigation, regulatory investigations, enforcement notices requiring us to stop or change the way we use personal data and/or fines of up to 20&#160;million Euros of the total worldwide annual turnover of the preceding financial year, whichever is higher, as well as compensation claims for financial or non-financial loss by affected individuals, negative publicity, reputational harm and a potential loss of business and goodwill. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">Relatedly, following the UK&#8217;s withdrawal from the EU (i.e., Brexit), the EU GDPR has been implemented in the United Kingdom (as the UK GDPR). The UK GDPR site alongside the UK Data Protection Act 2018 which implements certain derogations in the EU GDPR into UK law. The requirements of the UK GDPR are (at this time) largely aligned with those under the EU GDPR and as such, may lead to similar compliance and operational costs with potential fines for </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">non-compliance of up to &#163;17.5 million or 4% of annual worldwide turnover. As a result, we are potentially exposed to two parallel data protection regimes, each of which authorizes fines and the potential for divergent enforcement actions. It should also be noted that reliance on the new EU SCCs for transfers from the UK requires additional documentation in the form of a UK Addendum.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks related to employee matters and managing growth</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our future success depends on our ability to retain our President and Chief Executive Officer and our Senior Vice President and Chief Financial Officer and to attract, retain and motivate qualified personnel.*</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">We are highly dependent on Oren Gilad, Ph.D., our President and Chief Executive Officer and John P. Hamill, our Senior Vice President and Chief Financial Officer, as well as the other principal members of the scientific team. Our agreements with Dr. Gilad and Mr.&#160;Hamill do not prevent them from terminating their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees. However, the loss of the services of any of these persons could impede the achievement of our research, development and commercialization objectives.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We expect to expand our development and regulatory capabilities and potentially our sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">We expect to experience growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, clinical operations, regulatory affairs and, potentially, sales and marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The physical expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We will need to expand our organization, and may experience difficulties in managing this growth, which could disrupt operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-family:'Times New Roman;">Our future financial performance and our ability to commercialize our product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth. We expect to hire additional employees for our managerial, clinical, scientific and engineering, operational, manufacturing, sales and marketing teams. We may have operational difficulties in connection with identifying, hiring and integrating new personnel. Future growth would impose significant additional responsibilities on our management, including the need to identify, recruit, maintain, motivate and integrate additional employees, consultants and contractors. Also, our management may need to divert a disproportionate amount of our attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of our product candidates. </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-family:'Times New Roman;">If we are unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenues could be reduced, and we may not be able to implement our business strategy.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-family:'Times New Roman;">Many of the other pharmaceutical companies that we compete against for qualified personnel and consultants have greater financial and other resources, different risk profiles and a longer history in the industry than us. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates and consultants than what we have to offer. If we are unable to continue to attract and retain high-quality personnel and consultants, the rate and success at which we can select and develop our product candidates and our business will be limited.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our employees, independent contractors, principal investigators, consultants, commercial collaborators, service providers and other vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have an adverse effect on our results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">We are exposed to the risk that our employees and contractors, including principal investigators, consultants, commercial collaborators, service providers and other vendors may engage in fraudulent or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or other unauthorized activities that violate the laws and regulations of the FDA and other similar regulatory bodies, including those laws that require the reporting of true, complete and accurate information to such regulatory bodies, manufacturing standards, federal and state healthcare fraud and abuse and health regulatory laws and other similar foreign fraudulent misconduct laws, or laws that require the true, complete and accurate reporting of financial information or data. Misconduct by these parties may also involve the improper use or misrepresentation of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter third-party misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and financial results, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks related to tax matters</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We have significant deferred tax assets, which may become devalued if we do not generate sufficient future taxable income, applicable corporate tax rates are reduced or if we experience an ownership change.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Our total deferred tax assets as of December 31, 2023 were $49.4 million. Of that amount, $25.2 million relates to gross deferred tax assets in Aprea AB. Our anticipated activities are also expected to result in future significant net operating losses in the United States and Sweden resulting in additional deferred tax assets. Utilization of most deferred tax assets is dependent on generating sufficient future taxable income in the appropriate jurisdiction and/or entity. The company has provided a valuation allowance of $49.4 million on our deferred tax assets as of December 31, 2023, because, based on all available evidence, it is considered more likely than not that all the recorded deferred tax assets will not be realized in a future period. Additionally, most of our deferred tax assets are determined by reference to applicable corporate income tax rates in Sweden or the United States. Accordingly, in the event of a reduction of any such corporate income tax rates, the carrying value of certain of our deferred tax assets would decrease.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">Moreover, our ability to use our net operating losses and other deferred tax assets to offset future taxable income in Sweden and the United States may be significantly limited if we experience an ownership change. For Swedish income tax purposes, an ownership change will generally occur when one, or several shareholders together, acquire shares representing more than 50&#160;percent of the voting power over a five&#160;year period (under special provisions in Chapter 40 of the Swedish Income Tax Act; 1999:1229). Such an ownership change results in the forfeiture of tax losses carried forward exceeding 200&#160;percent of the cost of the change of control. In this calculation, capital contributions to the company prior to the ownership change and in the preceding two&#160;years should reduce the cost of the change of control. </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Due to potential ownership changes under the Swedish Income Tax Act, we may be limited in our ability to realize a tax benefit on our deferred tax assets, whether or not we attain profitability in future years.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">For U.S. federal income tax purposes, an ownership change will generally occur when the percentage of our stock (by value) owned by one or more &#8220;5&#160;percent shareholders&#8221; (as defined in the U.S. Internal Revenue Code of 1986, as amended) has increased by more than 50% over the lowest percentage owned by such shareholders at any time during the prior three years (calculated on a rolling basis). We anticipate that we will incur losses in the United States in the foreseeable future related to our research and development activities. Due to potential ownership changes under Section&#160;382 of the Code, we may be limited in our ability to realize a tax benefit from the use of our deferred tax assets, whether or not we attain profitability in future years. We believe the Merger likely resulted in an ownership change under Section 382 of the Code, and, accordingly, our net operating losses and other deferred tax assets are subject to limitations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">In addition, our ability to utilize any future net operating losses may be limited by Pub.&#160;L.&#160;115-97, commonly known as the Tax Cuts and Jobs Act of 2017 (&#8220;TCJA&#8221;). Under the TCJA, as amended by the CARES Act, the amount of our net operating losses incurred in taxable years beginning after December 31, 2020 that we are permitted to deduct in any taxable year is limited to 80% of our taxable income in such year, where taxable income is determined without regard to the net operating loss deduction itself, while allowing unused net operating losses to be carried forward indefinitely. Under the CARES Act, net operating losses arising in taxable years beginning before January 1, 2021 are not subject to the 80% limitation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">For these reasons, a material devaluation in our deferred tax assets due to insufficient taxable income, lower corporate income tax rates or ownership change would have an adverse effect on our results of operations and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may have taxable income as a result of the purging election made following the Holdco Reorganization</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">While not entirely clear, we intend to treat Aprea AB as having been a passive foreign investment company, or PFIC, for U.S. federal income tax purposes prior to the Holdco Reorganization and treat the Company as having succeeded to the tax basis and holding periods of those shareholders in Aprea AB that exchanged their shares for our common stock. Based on such treatment, and absent a purging election as described below, the stock of Aprea AB held by the Company would have retained its status as stock of a PFIC with respect to all periods prior to the Holdco Reorganization (the &#8220;PFIC Taint&#8221;) and therefore, absent a prior election by those shareholders to treat Aprea AB as a qualified electing fund, the Company, would have been subject to certain adverse U.S. federal income tax consequences with respect to distributions received on such stock and gain recognized on the disposition of such stock. In order to purge the PFIC Taint on the stock of Aprea AB, and avoid such adverse tax consequences, following the Holdco Reorganization we made a purging election in the form of a deemed dividend election under which, for U.S. federal income tax purposes, Aprea AB will be deemed to have made a distribution to the Company of all of its current and accumulated earnings and profits as determined for U.S. federal income tax purposes. Because Aprea AB did not have any accumulated or current year earnings and profits as of December 31, 2019, we do not expect the purging election to result in any incremental U.S. federal income taxes.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to current taxation on some of the income of our foreign subsidiaries even absent any cash distributions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Because we hold directly or indirectly all of the shares of our foreign subsidiaries, including Aprea AB, such subsidiaries are treated as controlled foreign corporations (&#8220;CFC&#8221;) for U.S. federal income tax purposes. For U.S. federal income tax purposes, the Company will therefore need to include in its taxable income each year Aprea AB&#8217;s &#8220;subpart&#160;F income,&#8221; and &#8220;global intangible low-taxed income&#8221;, if any, even if no distributions are made.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our foreign subsidiaries may directly become subject to U.S. federal income tax and be subject to a branch profits tax in the United States, which could reduce our after-tax returns and the value of our shares.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">We currently intend to conduct substantially all of our businesses and operations in a manner such that our foreign subsidiaries will not be treated as engaged in a trade or business in the United States and will not be subject to additional </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">U.S. income tax or branch profits tax. However, it is not entirely clear when a foreign subsidiary is treated as being engaged in a trade or business in the United States for U.S. federal income tax purposes and travel restrictions may further limit our ability to reduce the risk of our foreign subsidiaries being treated as engaged in a U.S. trade or business. Accordingly, we cannot assure you that the Internal Revenue Service (&#8220;IRS&#8221;) will not contend, perhaps successfully, that our foreign subsidiaries were engaged in a trade or business in the United States or are subject to more U.S. income tax than they currently incur. A foreign corporation deemed to be so engaged would be subject to U.S. federal income tax, as well as branch profits tax, on its income that is treated as effectively connected with the conduct of that trade or business unless the corporation is entitled to relief under an applicable tax treaty, which is determined on an annual basis.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The ongoing effects of the 2017 Tax Cuts and Jobs Act and GILTI could make our results difficult to predict.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Our effective tax rate may fluctuate in the future as a result of the TCJA, which included significant enacted changes in U.S. income tax law many aspects of which are not entirely clear and with respect to which some guidance has not yet been finalized. The enacted tax legislation included, among other new provisions, a reduction in the corporate tax rate, new limitations on the deductibility of net interest, the base erosion and anti-abuse minimum tax and new rules&#160;related to the global intangible low-taxed income of our foreign subsidiaries (&#8220;GILTI&#8221;). GILTI may require us to include in taxable income certain income of our foreign subsidiaries that are CFCs, though we may be eligible to claim foreign tax credits with respect to some of the taxes paid by such subsidiaries. While the U.S. tax authorities issued proposed and final regulations for GILTI, there are still certain aspects of the TCJA that remain unclear. We will continue to review the impact of GILTI and the other changes resulting from the TCJA as further guidance is issued. Any further guidance may result in changes to the interpretations and assumptions we made and actions we may take, which as a result may impact the amounts recorded with respect to international provisions of the TCJA, possibly materially.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Changes in U.S. federal income tax law and other jurisdictions could materially adversely affect an investment in our common shares.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">It is possible that tax laws in the United States and other jurisdictions will be changed. It remains difficult to predict whether or when there will be any tax law changes or further guidance by the authorities in the U.S. or elsewhere in the world that will have a material adverse effect on our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks related to our common stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our executive officers, directors and principal stockholders may have substantial influence over matters submitted to stockholders for approval. This may prevent new investors from influencing significant corporate decisions.*</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">As of September</span><span style="font-family:'Times New Roman;">&#160;</span><span style="font-family:'Times New Roman;">30,</span><span style="font-family:'Times New Roman;">&#160;</span><span style="font-family:'Times New Roman;">2024, our executive officers and directors and our stockholders which own more than 5% of our outstanding common stock beneficially owned shares representing approximately 25.9% of our common stock. As a result, if these stockholders were to choose to act together, they may have substantial influence over matters submitted to our stockholders for approval, as well as our management and affairs. This concentration of voting power could delay or prevent an acquisition of our company, or other significant corporate decisions, on terms that other stockholders may desire.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Provisions in our certificate of incorporation and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which common stockholders might otherwise receive a premium for our shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish a classified board of directors such that not all members of the board are elected at one time;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">allow the authorized number of our directors to be changed only by resolution of our board of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limit the manner in which stockholders can remove directors from the board;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limit who may call stockholder meetings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If securities analysts do not or do not continue to publish research or reports about our business or if they publish negative evaluations of our business, the price of our stock could decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">The trading market for our common stock is and will rely in part on the research and reports that industry or financial analysts publish about us or our business. If one or more of the analysts who currently cover our business downgrade their evaluations of our business, or in the event we obtain additional coverage and one or more of the new analysts issues an adverse evaluation of our business, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The price of our common stock has been and may continue to be volatile and fluctuate substantially.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Our stock price has been and is likely to continue to be volatile. The stock market in general and the market for pharmaceutical and biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, our stockholders may not be able to sell our common stock at or above the price they paid for it. The market price for our common stock may be influenced by many factors, including:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and results of clinical trials of any of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory actions with respect to our product candidates or our competitors&#8217; products and product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success of existing or new competitive products or technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishment or termination of collaborations for our product candidates or development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure or discontinuation of any of our development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">results of clinical trials of product candidates of our competitors;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory or legal developments in the United States and other countries;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the recruitment or departure of key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the level of expenses related to any of our product candidates or development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the results of our efforts to discover, develop, acquire or in-license additional product candidates or products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual or anticipated changes in estimates as to financial results or development timelines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcement or expectation of additional financing efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of our common stock by us, our insiders or other stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">variations in our financial results or those of companies that are perceived to be similar to us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in estimates or recommendations by securities analysts, if any, that cover our stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the structure of healthcare payment systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market conditions in the pharmaceutical and biotechnology sectors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general economic, industry and market conditions; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the other factors described in this &#8220;Risk Factors&#8221; section.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We could be subject to securities class action litigation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because pharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and our resources, which could harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company,&#8221; and the reduced disclosure requirements applicable to emerging growth companies or smaller reporting companies may make our common stock less attractive to investors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We may remain an emerging growth company for up to five years, which is December 31, 2024, or until such earlier time as we have more than $1.235 billion in annual revenue, the market value of our stock held by non-affiliates is more than $700 million or we issue more than $1 billion of non-convertible debt over a three-year period. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, or Section 404, not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements, being permitted to present only two years of audited financial statements and a correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure, reduced disclosure obligations regarding executive compensation and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Times New Roman;">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. An emerging growth company can therefore delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. However, we </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">are choosing to &#8220;opt out&#8221; of such extended transition period, and, as a result, we will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for public companies that are not emerging growth companies. The JOBS Act provides that our decision to opt out of the extended transition period for complying with new or revised accounting standards is irrevocable.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">We are also a &#8220;smaller reporting company,&#8221; as such term is defined in Rule&#160;12b-2 of the Exchange Act, meaning that the market value of our common stock held by non-affiliates is less than $700 million and our annual revenue is less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i)&#160;the market value of our common stock held by non-affiliates is less than $250 million or (ii)&#160;our annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our common stock held by non-affiliates is less than $700 million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form&#160;10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We continue to incur increased costs as a result of operating as a public company as we become subject to additional laws, regulations and listing exchange standards, and our management will continue to be required to devote substantial time to new compliance initiatives.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">As a public company, and particularly after we are no longer an &#8220;emerging growth company&#8221; or a &#8220;smaller reporting company,&#8221; we will incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act of 2002 and rules&#160;subsequently implemented by the SEC and Nasdaq have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules&#160;and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that these rules&#160;and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Pursuant to Section&#160;404, we are required to furnish a report by our management on our internal control over financial reporting, including an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section&#160;404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. There is a risk that neither we nor our independent registered public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section&#160;404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Accounting principles and related pronouncements, implementation guidelines and interpretations we apply to a wide range of matters that are relevant to our business, including, but not limited to, revenue recognition, leases and stock-based compensation, are complex and involve subjective assumptions, estimates and judgments by our management. Changes in accounting pronouncements or their interpretation or changes in underlying assumptions, estimates or judgments by our management could significantly change our reported or expected financial performance.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Because we do not anticipate paying any cash dividends on our common stock for the foreseeable future, capital appreciation, if any, of our common stock may be investors&#8217; sole source of gain.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">We have never declared or paid cash dividends on our common stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be investors&#8217; sole source of gain for the foreseeable future.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.*</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk127371401"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our certificate of incorporation designates the state courts in the State of Delaware or, if no state court located within the State of Delaware has jurisdiction, the federal court for the District of Delaware, as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could discourage lawsuits against the company and our directors, officers and employees.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">Our certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware) will be the sole and exclusive forum for any derivative action or proceeding brought on our behalf under Delaware law, any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or employees to our company or our stockholders, any action asserting a claim against us arising pursuant to any provision of the Delaware General Corporation Law or our certificate of incorporation or bylaws, any action asserting a claim against us governed by the internal affairs doctrine, or any other action asserting an &#8220;internal corporate claim,&#8221; as defined in Section&#160;115 of the Delaware General Corporation Law. These exclusive-forum provisions do not apply to claims under the Securities Act of 1933, as amended, or the Securities Act, or the Exchange Act. This exclusive forum provision may limit the ability of our stockholders to bring a claim in a judicial forum that such stockholders find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees. If a court were to find the exclusive-forum provision in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could harm our results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are required to meet the Nasdaq Stock Market, or Nasdaq, continued listing requirements and other Nasdaq rules, and if we fail to meet such rules and requirements,&#160;we may be subject to delisting. Delisting could negatively affect the price of our common stock, which could make it more difficult for us to sell securities in a future financing or for you to sell our common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman;">We are required to meet the continued listing requirements of Nasdaq and other Nasdaq rules, including those regarding director independence and independent committee requirements, minimum stockholders&#8217; equity, minimum share price and certain other corporate governance requirements. If we do not meet these continued listing requirements, our common stock could be delisted. Delisting would cause us to pursue eligibility for trading of these securities on other markets or exchanges, including the OTC BB or QB markets, or on the OTC &#8220;pink sheets.&#8221; In such case, our stockholders&#8217; ability to trade, or obtain quotations of the market value of our common stock would be severely limited because of lower trading volumes and transaction delays. These factors could contribute to lower prices and larger spreads in the bid and ask prices of our securities. There can be no assurance that our securities, if delisted from the Nasdaq Capital Market in the future, would be listed on a national securities exchange, a national quotation service, the OTC markets or the pink sheets. Delisting from Nasdaq, or even the issuance of a notice of potential delisting, would also result in negative publicity, make it more difficult for us to raise additional capital, cause us to lose eligibility to register the sale or resale of our shares on Form S-3 and the automatic exemption from registration under state securities laws for exchange-listed securities, adversely affect the market liquidity of our securities, decrease securities analysts&#8217; coverage of us or diminish investor, supplier and employee confidence.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_3b19a326_94b8_4cc5_8469_5c03d328ac62"></a><a id="Item2UnregisteredSalesofEquitySecurities"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Unregistered sales of equity securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">We had no sales of unregistered equity securities during the three and nine months ended September&#160;30,&#160;2024, other than pursuant to transactions previously disclosed in our Current Reports on Form 8-K.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of proceeds from registered securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On October 7, 2019, we completed our IPO, in which we sold 6,516,667 shares of common stock, $0.001 par value per share, which included the exercise in full by the underwriters of their option to purchase an additional 850,000 shares of common stock, at a price to the public of $15.00 per share.  The offer and sale of the shares in the IPO was registered under the Securities Act pursuant to registration statements on Form S-1 (File No. 333-233662), which was filed with the SEC on September 6, 2019 and amended subsequently and declared effective on October 2, 2019, and Form S-1MEF, which was filed and declared effective with the SEC on October 2, 2019.  The underwriters of the offering were J.P. Morgan Securities LLC, Morgan Stanley &amp; Co. LLC and RBC Capital Markets, LLC.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Our registration statements relating to the IPO registered common stock with a maximum aggregate offering price of up to $103,500,005.  We raised approximately $90.9 million in net proceeds after deducting underwriting discounts and commissions of $6.8 million but before deducting other offering expenses.  No offering expenses were paid directly or indirectly to any of our directors of officers (or their associates) or persons owning ten percent or more of any class of our equity securities or to any other affiliates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Through September&#160;30,&#160;<span style="white-space:pre-wrap;">2024, we have used approximately $84.6 million of the net proceeds from our IPO for matters described in our final IPO prospectus filed with the SEC on October 4, 2019, or our IPO prospectus.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Repurchases of equity securities by the issuer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_873894d9_6394_4f25_9f0f_6a502e484f89"></a><a id="Item3DefaultsUponSeniorSecurities_753349"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 3. Defaults Upon Senior Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_5f1f101a_08dc_444a_9838_f33d21fbee7a"></a><a id="Item4MineSafetyDisclosures_869418"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 4. Mine Safety Disclosures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_fc2eee2b_eccb_47c0_a35a_a0733cfdc01f"></a><a id="Item5OtherInformation_682434"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="-sec-ix-hidden:Hidden_crGT9flIcE6p7KBQXNYKVQ;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item</b></span> <span style="-sec-ix-hidden:Hidden_bgQIm2SdUki9zLB3cPayVA;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5</b></span>. <span style="-sec-ix-hidden:Hidden_iA1bmvAgEkabBTZ1yPfd7g;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Other</b></span> <span style="-sec-ix-hidden:Hidden_gT6Ck3ksFUm3M-K_GoMkjg;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Information</b></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_8ca5b8a0_3e87_4881_a88a_83c4f555f664"></a><a id="Item6Exhibits_309671"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 6.&#160; Exhibits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Exhibit&#160;Index</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:88.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:88.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.06%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:88.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description&#160;of&#160;Document</b></p></th></tr><tr><td style="vertical-align:top;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="apre-20240930xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Confidential Severance Agreement and General Release, effective as of October 9, 2024, by and between Aprea Therapeutics, Inc. and Nadeem Q. Mirza, M.D., M.P.H.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31.1</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="apre-20240930xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of the Registrant&#8217;s Chief Executive Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31.2</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="apre-20240930xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of the Registrant&#8217;s Chief Financial Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32.1*</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="apre-20240930xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of the Registrant&#8217;s Chief Executive Officer pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32.2*</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="apre-20240930xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of the Registrant&#8217;s Chief Financial Officer pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.INS</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</p></td></tr><tr><td style="vertical-align:top;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.SCH</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Schema With Embedded Linkbase Documents.</p></td></tr><tr><td style="vertical-align:top;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101).</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The certifications furnished in Exhibit&#160;32.1 and Exhibit&#160;32.2 hereto are deemed to accompany this Quarterly Report and will not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates it by reference.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">+</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Filed herewith</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_d7c95ffe_7bdf_4d02_9502_07744e444ab6"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:47.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November 7, 2024</p></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Aprea Therapeutics,&#160;Inc.</p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Oren Gilad</p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oren Gilad, Ph.D.</p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer (Principal Executive Officer)</p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November 7, 2024</p></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ John P. Hamill</p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">John P. Hamill</p></td></tr><tr><td style="vertical-align:top;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>apre-20240930xex10d1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 11/5/2024 12:12:53 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:8.82%;position:relative;"><div style="margin-top:9pt;min-height:63pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;text-indent:0pt;margin:0pt;">Exhibit 10.1</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">Confidential Severance Agreement And general Release</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;margin-top:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt;"><font style="display:inline-block;text-align:left;width:36pt;"></font><font style="font-size:11pt;">This Confidential Severance Agreement and General Release (&#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Agreement</font><font style="font-size:11pt;">&#8221;) is made by and between Nadeem Mirza, M.D., M.P.H. (&#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Employee</font><font style="font-size:11pt;">&#8221;) and Aprea Therapeutics, Inc., a Delaware corporation (&#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Company</font><font style="font-size:11pt;">&#8221;) (collectively, the &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Parties</font><font style="font-size:11pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt;"><font style="font-size:11pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt;"><font style="display:inline-block;text-align:left;width:36pt;"></font><font style="font-size:11pt;">WHEREAS, Employee was employed by Company pursuant to that certain Employment Agreement dated April 30, 2024 and effective May 1, 2024 (the &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Employment Agreement</font><font style="font-size:11pt;">&#8221;); &#160;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt;"><font style="font-size:11pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;">WHEREAS, the Parties wish for the Employee to step down from his position as an officer and executive of the Company effective October 9, 2024 (&#8220;<font style="font-style:italic;font-weight:bold;">Step-Down Date</font>&#8221;) and continue employment through a transition period until the Termination Date (as defined below); </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt;"><font style="font-size:11pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt;"><font style="display:inline-block;text-align:left;width:36pt;"></font><font style="font-size:11pt;">WHEREAS, Employee&#8217;s employment shall terminate on December 13, 2024 or, if earlier, the date Employee ceases providing services to the Company (the &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Termination Date</font><font style="font-size:11pt;">&#8221;); and </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt;"><font style="font-size:11pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt;">WHEREAS, Employee and Company wish to set forth the terms of Employee&#8217;s separation from Company and to resolve any and all claims or disputes claims arising or in any way related to Employee&#8217;s employment with or separation from Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt;"><font style="font-size:11pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt;"><font style="display:inline-block;text-align:left;width:36pt;"></font><font style="font-size:11pt;">NOW THEREFORE, in consideration of the promises made herein, the Parties hereby agree as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt;"><font style="font-size:11pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">1.</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination and Transition Period</u><font style="font-size:11pt;">.</font></div><div style="margin-top:12pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><font style="font-size:11pt;">Employee&#8217;s employment with Company will terminate effective as of the Termination Date. Notwithstanding anything in the Employment Agreement to the contrary, Employee hereby acknowledges and agrees that Employee will be paid (i) the earned but unpaid portion of Employee&#8217;s base salary through the Termination Date, and (ii) any unpaid expense or other reimbursements due to Employee pursuant to Company policy. &#160;Employee must submit all requests for reimbursement for Employee&#8217;s ordinary reasonable business-related expenses no later than 30 days after the Termination Date, accompanied by proper documentation, to Aprea Therapeutics, Inc., </font><font style="font-size:11pt;">Attention: &#160;John Hamill, CFO</font><font style="font-size:11pt;">. &#160;The payments discussed in this Section 1(a) are &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Accrued Benefits</font><font style="font-size:11pt;">&#8221; and shall be paid to Employee regardless of whether Employee executes this Agreement. &#160;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><font style="font-size:11pt;">As of the Termination Date, Employee hereby resigns and shall be deemed to have resigned from any and all positions and titles that Employee holds or may hold with respect to Company or any of its affiliates, and Company accepts such resignations. &#160;Employee agrees that Employee shall take any and all steps that may be necessary to effectuate Employee&#8217;s immediate resignation from any and all such positions. &#160;After the Termination Date, Employee is not to hold himself out as an employee, officer, executive, manager, agent, or authorized representative of Company, or to negotiate or enter into any agreements on behalf of Company or any of its affiliates, or to otherwise attempt to bind Company or any of its affiliates.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:0pt;margin:12pt 0pt 0pt 0pt;">From the Step-Down Date to and including the Termination Date (the &#8220;<font style="font-style:italic;font-weight:bold;">Transition Period</font>&#8221;), Employee agrees to cooperate fully with the Company and in good faith to provide all services that may be reasonably requested by the Company from time to time to ensure a smooth and orderly transition of Employee&#8217;s duties and responsibilities. &#160;From and after the Step-Down Date, Employee shall no longer be, nor hold out to be, an officer, executive, member, manager, representative, or agent of the Company or any of its affiliates, and shall no longer hold any title with the Company or any of its affiliates. &#160;During the Transition Period, Employee shall remain on payroll at Employee&#8217;s current base salary rate (as of the Step-Down Date), less all applicable deductions and withholdings, and be covered by the Company&#8217;s group medical and dental plans, subject to the provisions, requirements, conditions, and limitations of such plans, which may be amended from time to time. &#160;During the Transition Period, Employee shall continue to perform such job duties for the Company and to assist </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:8.82%;position:relative;"><div style="margin-top:9pt;min-height:63pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:12pt 0pt 0pt 0pt;"><font style="letter-spacing:-0.15pt;">Confidential Severance Agreement and General Release</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">October 8, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Page 2 of 9</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">in such transition-related duties as the Company may deem necessary and appropriate. &#160;For the avoidance of doubt, this is to confirm that for as long as Employee remains on the Company&#8217;s payroll (<i style="font-style:italic;">i.e.</i>, during the Transition Period), Employee shall continue to fully comply with, and be bound by, any and all policies and procedures in effect for the Company&#8217;s employees, including all requirements contained therein.</p><div style="margin-top:12pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">2.</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consideration</u><font style="font-size:11pt;">. &#160; In consideration for and conditioned on Employee&#8217;s entry into and non-revocation of this Agreement, Employee&#8217;s compliance with Employee&#8217;s obligations under this Agreement and Employee&#8217;s ongoing obligations under the Employment Agreement, the Company agrees to provide Employee with the following payments and benefits (collectively, the &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Separation Benefits</font><font style="font-size:11pt;">&#8221;):</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><font style="font-size:11pt;">Company shall make severance payments equivalent to Employee&#8217;s base salary at the rate in effect on the Termination Date, less applicable withholdings and deductions, for a period of seven (7) months following the Termination Date (such period, the &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Severance Period</font><font style="font-size:11pt;">&#8221;), which shall be paid to Employee in substantially equal installments during the Severance Period in accordance with Company&#8217;s payroll cycle; provided, however, that amounts that otherwise would be scheduled to be paid prior to the Effective Date (as defined below) shall accrue and shall be paid on the first administratively feasible payroll date following the Effective Date of this Agreement; and </font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;margin-left:0pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><font style="font-size:11pt;">Subject to Employee&#8217;s copayment of premium amounts at the applicable active employees&#8217; rate and Employee&#8217;s proper election to receive benefits under the Consolidated Omnibus Reconciliation Act of 1985 (&#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">COBRA</font><font style="font-size:11pt;">&#8221;) and/or any applicable state law COBRA, Company shall pay to Employee a monthly payment equal to the monthly employer contribution that Company would have made to provide health insurance to Employee if Employee had remained employed by Company until the earliest of (A) the seven (7) month anniversary of the Termination Date; (B) the date that Employee becomes eligible for group medical plan benefits under any other employer&#8217;s group medical plan; or (C) the cessation of Employee&#8217;s health continuation rights under COBRA; provided, however, that if Company determines that it cannot pay such amounts to the group health plan provider or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then Company shall convert such payments to payroll payments directly to Employee for the time period specified above. Such payments to Employee shall be subject to tax-related deductions and withholdings and paid on Company&#8217;s regular payroll dates. &#160;Should Employee wish to continue health benefits coverage through Company&#8217;s group insurance plans after the date on which Company&#8217;s payments cease (as described above), Employee will be responsible for paying the premium in full each month. &#160;Employee will receive a separate notice explaining Employee&#8217;s right to continuation and conversion of Employee&#8217;s health benefits under COBRA. </font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;margin-left:0pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:0pt;margin:0pt;">For the avoidance of doubt and notwithstanding anything in the Employment Agreement to the contrary, by Employee&#8217;s signature below, Employee acknowledges and agrees that (i) Employee&#8217;s termination is not a CIC Qualifying Termination, as such term is defined in the Employment Agreement, and (ii) except for the Separation Benefits, after the Termination Date, Employee will not be entitled to any other or further compensation, bonuses, fees, equity grants, remuneration, or benefits from Company. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt;"><font style="font-size:11pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">3.</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Treatment</u><font style="font-size:11pt;">.&#160; Employee understands and agrees that Company is neither providing tax nor legal advice, nor is Company making representations regarding tax obligations or consequences, if any, related to this Agreement.&#160; Employee further agrees that Employee will assume any such tax obligations or consequences that may arise from this Agreement, and that Employee shall not seek any indemnification from Company in this regard.&#160; Employee agrees that, in the event that any taxing body determines that additional taxes are due from Employee, Employee acknowledges and assumes all responsibility for the payment of any such taxes and agrees to indemnify, defend, and hold Company harmless from the payment of such taxes, and any failure to withhold.&#160; Employee further agrees to pay, on Company&#8217;s behalf, any interest or penalties imposed as a </font></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:8.82%;position:relative;"><div style="margin-top:9pt;min-height:63pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:12pt 0pt 0pt 0pt;"><font style="letter-spacing:-0.15pt;">Confidential Severance Agreement and General Release</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">October 8, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Page 3 of 9</p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="font-size:11pt;">consequence of such tax obligations, and to pay any judgments, penalties, taxes, costs, and attorneys&#8217; fees incurred by Company as a consequence of Employee&#8217;s failure to pay any taxes due.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">4.</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Return of Company Property</u><font style="font-size:11pt;">. &#160;No later than the Termination Date, Employee shall return to Company any and all Company property and information in Employee&#8217;s possession developed by Employee and/or obtained by Employee or on Employee&#8217;s behalf, directly or indirectly, pursuant to Employee&#8217;s employment with Company (including property and information stored on any of Employee&#8217;s personal devices and accounts) and otherwise comply with the obligations set forth in Section 5(b) of the Employment Agreement (</font><i style="font-size:11pt;font-style:italic;">Return of Property</i><font style="font-size:11pt;">). &#160;Employee agrees that, after the Termination Date, Employee will neither use nor possess Company property. &#160;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">5.</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General Release of Claims</u><font style="font-size:11pt;">. &#160;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt;"><font style="font-size:11pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">(a)</font><font style="font-size:11pt;">Employee agrees that the consideration set forth in Section 2 above represents adequate consideration for the Release of Claims set forth herein. &#160;</font><b style="font-size:11pt;font-weight:bold;">THIS IS A GENERAL RELEASE OF ALL CLAIMS. &#160;</b><font style="font-size:11pt;">As consideration for the Separation Benefits being provided to Employee, Employee, on Employee&#8217;s own behalf, and on behalf of Employee&#8217;s respective heirs, family members, executors, administrators, attorneys, representatives, and assigns, hereby fully and forever releases Company, its parents subsidiaries, and affiliates and its and their current and former legal representatives, officers, directors, fiduciaries, employees, investors, shareholders, insurers, agents, administrators, affiliates, divisions, subsidiaries, attorneys, underwriters, predecessor and successor corporations, and assigns, both in their individual and corporate capacities (collectively, the &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Releasees</font><font style="font-size:11pt;">&#8221;), of and from any and all claims, causes of action, obligations, demands, duties, obligations, agreements, promises, liabilities, damages, costs, and/or fees, whether known or unknown, suspected or unsuspected, arising out of or relating in any way to events, acts, conduct or omissions occurring prior to or on the date Employee signs this Agreement (collectively, the &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Released Claims</font><font style="font-size:11pt;">&#8221;). &#160;Without limiting the generality of the general released, the Released Claims include, without limitation: &#160;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;margin-left:0pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:72pt;text-indent:0pt;white-space:nowrap;">(i)</font><font style="font-size:11pt;">any and all claims relating to or arising from Employee&#8217;s employment or consulting relationships with Company and the termination of those relationships; </font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;margin-left:0pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:72pt;text-indent:0pt;white-space:nowrap;">(ii)</font><font style="font-size:11pt;">all claims related to Employee&#8217;s compensation or benefits from Company, including salary, expense reimbursements, fees, severance, or fringe benefits, discretionary or other bonuses, commissions, and other compensation of any kind;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;margin-left:0pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:72pt;text-indent:0pt;white-space:nowrap;">(iii)</font><font style="font-size:11pt;">any and all claims relating to, or arising from, any incentive compensation arrangements or plans (including the Annual Incentive Program, as such term is defined in the Employment Agreement) or Employee&#8217;s right to purchase, or the actual purchase of, shares of stock of Company; fraud; misrepresentation; breach of fiduciary duty; breach of duty under applicable state corporate law; and securities fraud under any state or federal law, other than Employee&#8217;s right to purchase vested option shares, if any, pursuant to the terms of a related restricted stock purchase agreement;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;margin-left:0pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:72pt;text-indent:0pt;white-space:nowrap;">(iv)</font><font style="font-size:11pt;">any and all claims under the law of any jurisdiction including without limitation wrongful discharge of employment; constructive discharge from employment; termination in violation of public policy; discrimination; breach of contract, both express and implied; breach of a covenant of good faith and fair dealing, both express and implied; promissory estoppel; negligent and intentional infliction of emotional distress; negligent and intentional misrepresentation; negligent and intentional interference with contract or prospective economic advantage; unfair business practices; defamation; libel; slander; </font></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:8.82%;position:relative;"><div style="margin-top:9pt;min-height:63pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:12pt 0pt 0pt 0pt;"><font style="letter-spacing:-0.15pt;">Confidential Severance Agreement and General Release</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">October 8, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Page 4 of 9</p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="font-size:11pt;">negligence; personal injury; assault; battery; invasion of privacy; false imprisonment; and conversion;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;margin-left:0pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:72pt;text-indent:0pt;white-space:nowrap;">(v)</font><font style="font-size:11pt;">any and all claims for violation of any federal, state or municipal statute, including without limitation all employment laws, including without limitation: &#160;the Age Discrimination in Employment Act; Title VII of the Civil Rights Act of 1964; the Civil Rights Act of 1866; the Civil Rights Act of 1871; the Fair Labor Standards Act; the Americans with Disabilities Act; the Older Workers&#8217; Benefits Protection Act; the Family and Medical Leave Act; the Equal Pay Act; the Rehabilitation Act of 1973; the Employee Retirement Income Security Act of 1974; the National Labor Relations Act (&#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">NLRA</font><font style="font-size:11pt;">&#8221;); the Genetic Information Nondiscrimination Act; the Fair Credit Reporting Act; the Worker Adjustment Retraining and Notification (&#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">WARN</font><font style="font-size:11pt;">&#8221;) Act and any state WARN statutes; Chapter 21 of the Texas Labor Code (Tex. Lab. Code Ann. &#167;&#167; 21.001 to 21.556); the Texas Anti-Retaliation Act (Tex. Labor Code Ann. &#167;&#167; 451.001 to 451.003); the Texas Whistleblower Act (Tex. Gov&#39;t Code Ann. &#167;&#167; 554.001 to 554.010); the Pennsylvania Human Relations Act; the Pennsylvania Whistleblower Law (each as amended, if applicable); and any and all other laws against discrimination or applicable to employment that may be the subject of a release under applicable law;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;margin-left:0pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:72pt;text-indent:0pt;white-space:nowrap;">(vi)</font><font style="font-size:11pt;">any and all claims for violation of the federal, or any state, constitution; </font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;margin-left:0pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:72pt;text-indent:0pt;white-space:nowrap;">(vii)</font><font style="font-size:11pt;">any and all claims arising out of any other laws and regulations relating to employment or employment discrimination;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;margin-left:0pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:72pt;text-indent:0pt;white-space:nowrap;">(viii)</font><font style="font-size:11pt;">any and all claims arising out of any personnel policies, contracts of employment, any other contracts, severance pay agreements, and covenants of good faith and fair dealing;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;margin-left:0pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:72pt;text-indent:0pt;white-space:nowrap;">(ix)</font><font style="font-size:11pt;">any claim for any loss, cost, damage, or expense arising out of any dispute over the non-withholding or other tax treatment of any of the proceeds received by Employee as a result of this Agreement; </font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;margin-left:0pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:72pt;text-indent:0pt;white-space:nowrap;">(x)</font><font style="font-size:11pt;">any claim or damage arising out of Employee&#8217;s employment with or separation from Company under any common law theory or any federal, state, or local statute or ordinance not specifically referred to above; and</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;margin-left:0pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;margin-right:36pt;min-width:72pt;text-indent:0pt;white-space:nowrap;">(xi)</font><font style="font-size:11pt;">any and all claims for attorneys&#8217; fees and costs.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><font style="margin-top:12pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">(b)</font><font style="font-size:11pt;">Employee understands and agrees that, to the fullest extent permitted by law, Employee is precluded from filing or pursuing any legal claim of any kind against any of the Releasees at any time in the future, in any federal, state or municipal court, administrative agency, or other tribunal, arising out of any of the claims that Employee has waived by virtue of this Agreement. &#160;Employee agrees not to file or pursue any such legal claims and, if Employee does pursue such legal claims, Employee waives any right to receive monetary recovery. &#160;Notwithstanding the broad scope of the general release, the following are not included in the Released Claims (the &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Excluded Claims</font><font style="font-size:11pt;">&#8221;): &#160;(i) any rights or claims for indemnification Employee may have pursuant to any written indemnification agreement with Company to which Employee is a party, the charter, bylaws, or operating agreements of Company, or under applicable law; &#160;(ii) any rights that, as a matter of law, whether by statute or otherwise, may not be waived, such as claims for workers&#8217; compensation benefits or unemployment insurance benefits; however, to the extent permitted by law, Employee waives any right or ability to be a class or collective action representative or to otherwise participate in any putative or certified class, collective or multi-party action or proceeding based on any Excluded Claims in which any of the Released Parties is a party; and (iii) any claims for breach of this Agreement. &#160;In addition, nothing in this Agreement </font></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:8.82%;position:relative;"><div style="margin-top:9pt;min-height:63pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:12pt 0pt 0pt 0pt;"><font style="letter-spacing:-0.15pt;">Confidential Severance Agreement and General Release</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">October 8, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Page 5 of 9</p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="font-size:11pt;">prevents Employee from filing a charge or complaint, reporting to, cooperating with, communicating with, or participating in any proceeding before the Securities and Exchange Commission, the Equal Employment Opportunity Commission, the Occupational Safety and Health Administration, the United States Department of Labor, the National Labor Relations Board, or other similar state or local agency (collectively, the &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Government Agencies</font><font style="font-size:11pt;">&#8221;), or from exercising any rights pursuant to Section 7 of the NLRA, or from taking any action protected under the whistleblower provisions of any federal securities law (collectively, the &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Protected Activities</font><font style="font-size:11pt;">&#8221;), none of which activities shall constitute a breach of the release, non-disparagement or confidentiality clauses of this Agreement; however, if Employee files any charge or complaint with a Government Agency or if a Government Agency pursues any claim on Employee&#8217;s behalf or if any third party pursues any claim on Employee&#8217;s behalf, Employee waives any right to monetary or other individualized relief (either individually, or as part of any collective or class action). &#160;Employee understands that in connection with such Protected Activity, Employee is permitted to disclose documents or other information as permitted by law, and without giving notice to, or receiving authorization from, Company. &#160;Notwithstanding the foregoing, Employee agrees to take all reasonable precautions to prevent any unauthorized use or disclosure of any information that may constitute Company confidential information under the Employment Agreement to any parties other than the Government Agencies. &#160;Employee further understand that &#8220;Protected Activity&#8221; does not include the disclosure of any Company attorney-client privileged communications, and that any such disclosure without the Company&#8217;s written consent shall constitute a material breach of this Agreement. &#160; &#160;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;margin-left:0pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-size:11pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">(c)</font><font style="font-size:11pt;">Nothing in this Agreement will affect the ability of Employee or Company to enforce rights or entitlements specifically provided for under this Agreement as set forth above, or any rights or claims that may arise after the date that Employee executes this Agreement. &#160;By Employee&#8217;s signature below, Employee represents that: (a)&#160;Employee has been paid or provided all wages, fees, vacation, bonuses, incentive compensation, expense reimbursements, or other amounts owed to Employee by Company, other than the Accrued Benefits and the Separation Benefits specifically promised in this Agreement; (b)&#160;Employee has not been denied any request for leave to which Employee was legally entitled; (c)&#160;Employee has not assigned or transferred, or purported to assign or transfer, to any person, entity, or individual whatsoever, any of the claims released in the foregoing general release and waiver; and (d) Employee has no known workplace injuries or occupational diseases for which Employee has not already filed a claim. &#160;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">6.</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ADEA Release</u><font style="font-size:11pt;">. &#160;In accordance with the Older Workers Benefit Protection Act of 1990, Employee hereby fully, finally, and completely releases the Releasees of and from any and all claims, charges, or causes of action arising on or before the Termination Date under the Age Discrimination in Employment Act and the Older Workers Benefit Protection Act (together, the &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">ADEA</font><font style="font-size:11pt;">&#8221;), which prohibit age discrimination in employment (the &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">ADEA Release</font><font style="font-size:11pt;">&#8221;), and hereby acknowledges and agrees that:</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">a)</font></font>the Agreement, which includes the ADEA Release, was negotiated at arms-length;</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:12pt;text-align:justify;"><font style="font-size:11pt;">b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:12pt;text-align:justify;"><font style="font-size:11pt;">the Agreement, which includes the ADEA Release, is worded in a manner that Employee fully understands;</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">c)</font></font>Employee specifically waives any rights or claims under the ADEA;</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:12pt;text-align:justify;"><font style="font-size:11pt;">d)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:12pt;text-align:justify;"><font style="font-size:11pt;">Employee knowingly and voluntarily agrees to all of the terms set forth in the Agreement, which includes the ADEA Release;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:12pt;text-align:justify;"><font style="font-size:11pt;">e)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:12pt;text-align:justify;"><font style="font-size:11pt;">Employee acknowledges and understands that any claims under the ADEA that may arise after the Termination Date are not waived;</font></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:8.82%;position:relative;"><div style="margin-top:9pt;min-height:63pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:12pt 0pt 0pt 0pt;"><font style="letter-spacing:-0.15pt;">Confidential Severance Agreement and General Release</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">October 8, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Page 6 of 9</p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">f)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">the rights and claims waived in this Agreement, which includes the ADEA Release, are in exchange for consideration over and above anything to which Employee is already undisputedly entitled;</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">g)</font></font>Employee has the right to consult with an attorney before signing this Agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">h)</font></font>Employee has twenty-one (21) days to consider whether to sign this Agreement; and</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:12pt;text-align:justify;"><font style="font-size:11pt;">i)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:12pt;text-align:justify;"><font style="font-size:11pt;">Employee has seven (7) days after signing this Agreement to revoke his acceptance to this Agreement, and this Agreement will not be effective, and Employee will not receive any of the Separation Benefits described herein, until that revocation period has expired, which shall be the eighth (8</font><sup style="font-size:8.25pt;vertical-align:top;">th</sup><font style="font-size:11pt;">) day after Employee signs the Agreement, assuming it is not revoked (such date, the &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Effective Date</font><font style="font-size:11pt;">&#8221;).</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">If Employee wishes to revoke Employee&#8217;s acceptance of this agreement, Employee must deliver written notice stating Employee&#8217;s intent to revoke by email to John Hamill, CFO, on or before 5:00 p.m. Eastern on the seventh (7th) day after the date on which Employee signs this Agreement. &#160;If the Agreement is revoked, Employee will not be entitled to the Separation Benefits under this Agreement. &#160;Nothing in this Agreement prevents or precludes Employee from challenging or seeking a determination in good faith of the validity of this waiver under the ADEA, nor does it impose any condition precedent, penalties, or costs for doing so, unless specifically authorized by federal law. &#160;The Parties agree that changes to this Agreement, whether material or immaterial, do not restart the running of the twenty-one (21) day review period</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">7.</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Disparagement</u><font style="font-size:11pt;">. Employee understands and agrees that Employee&#8217;s entitlement to the compensation and benefits due under this Agreement is conditioned upon Employee&#8217;s continued support of Company. &#160;Employee agrees to refrain from taking any action, and from making any statement (oral or written), that disparages or criticizes Company, its affiliates, parent companies, subsidiaries, and related entities, or its officers, directors, or employees, or that harms Company&#8217;s or any of Company&#8217;s affiliates&#8217;, parent companies&#8217;, subsidiaries&#8217;, and related entities&#8217;, or Company&#8217;s officers&#8217;, directors&#8217;, or employees&#8217; respective reputations, or that disrupts or impairs Company&#8217;s normal, ongoing business operations. &#160;This provision applies to all of Employee&#8217;s interactions with third parties, including without limitation any conversations or correspondence that Employee might have with organizations, governmental entities, and persons with whom Company engages in business, as well as with employees of Company. &#160;Employee understands that this provision does not apply on occasions when Employee is subpoenaed or ordered by a court or other governmental authority to testify or give evidence and must respond truthfully. &#160;Employee further agrees not to otherwise interfere with Company&#8217;s business operations, including, without limitation, Company&#8217;s efforts to market and sell its products and services.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">8.</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidentiality of this Agreement</u><font style="font-size:11pt;">. &#160;Employee agrees that Employee will not disclose the negotiation of, terms and conditions of, or amounts or benefits paid or provided under this Agreement to any third person(s), including, but not limited to, members of the media and Company employees, except that Employee may disclose the terms of this Agreement to </font><font style="font-size:11pt;">Employee&#8217;s </font><font style="font-size:11pt;">significant other, attorneys, accountants, or tax advisors (and conditioned on such persons agreeing to maintain the same confidentiality). &#160;Nothing in this Agreement prohibits or restricts Employee from disclosing the underlying facts or circumstances giving rise to any claim of sexual harassment or sexual assault, exercising protected rights to the extent that such rights cannot be waived by agreement or complying with any applicable law, regulation, or valid order of a court of competent jurisdiction or an authorized government agency, provided that the disclosure does not exceed the extent of disclosure required by such law, regulation, or order. &#160;Employee agrees that Employee shall be separately responsible and liable for Employee&#8217;s own disclosure prohibited by this Section and its subparts, including disclosures made by Employee&#8217;s respective representatives. &#160;Employee further agrees both to immediately notify Company upon receipt of any court order, subpoena, or any legal discovery device that seeks or might require the disclosure or production of the existence or terms of this Agreement, and to furnish, within three (3) </font></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:8.82%;position:relative;"><div style="margin-top:9pt;min-height:63pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:12pt 0pt 0pt 0pt;"><font style="letter-spacing:-0.15pt;">Confidential Severance Agreement and General Release</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">October 8, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Page 7 of 9</p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="font-size:11pt;">business days of its receipt, a copy of such subpoena or legal discovery device to Company. &#160;It shall not be a breach of this Section or its subparts for Employee to respond, if asked, that any dispute regarding Employee&#8217;s employment or termination of employment with Company has been resolved. &#160;The Parties acknowledge that Employee&#8217;s agreement to keep the terms and conditions of this Agreement confidential is a material factor on which Company relied in entering into this Agreement. &#160;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">9.</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Cooperation</u><font style="font-size:11pt;">. &#160;Employee agrees not to act in any manner that might damage the business of Company. &#160;Employee agrees not to counsel or assist any attorneys or their clients or any Company employees or service providers in the presentation or prosecution of any disputes, differences, grievances, claims, charges, or complaints by any third party against Company or any Releasee, unless under a subpoena or other court order to do so. &#160;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">10.</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Obligations Under Section 5 of the Employment Agreement</u><font style="font-size:11pt;">. &#160;Employee agrees and acknowledges that Employee remains bound by each of the terms of Section 5 of the Employment Agreement, which provisions are incorporated by reference for all purposes, and which survive the termination of Employee&#8217;s employment. &#160;By signing this Agreement, Employee represents and warrants that Employee has complied with all such obligations and will comply with all such obligations. &#160;Employee further acknowledges and agrees that (i) the restrictions set forth in Section 5 of the Employment Agreement are no broader than necessary to protect Company&#8217;s legitimate business interests, which cannot be adequately protected through an alternative restrictive covenant, (ii) Employee&#8217;s obligations under Section 5 of the Employment Agreement are supported by good and valuable consideration and/or such other mutually-agreed upon consideration as required by applicable law, (iii) the geographic restrictions set forth in Section 5 of the Employment Agreement are reasonable and aligned with the geographic area in which Employee provided services to Company or in which Employee had a material presence or influence within Company; and (iv) the non-competition covenant set forth in Section 5 of the Employment Agreement does not relate to the practice of medicine and shall not interfere with Employee&#8217;s ability to practice medicine and therefore is not subject to Section 15.50 of the Texas Business and Commerce Code, as amended.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">11.</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transition of Matters</u><font style="font-size:11pt;">. &#160;The Parties agree that certain matters in which Employee has been involved during Employee&#8217;s employment may necessitate Employee&#8217;s cooperation with Company in the future. &#160;Accordingly, during the time that Employee is receiving Separation Benefits under this Agreement, to the extent reasonably requested by Company, Employee agrees to cooperate in connection with matters arising out of Employee&#8217;s service to Company; provided that, Company will make reasonable efforts to minimize disruption of Employee&#8217;s other activities. &#160;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">12.</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Admissibility; No Admission of Liability</u><font style="font-size:11pt;">. &#160;Employee agrees that this Agreement shall not be admissible as evidence in any future proceeding of any kind, except in court on a claim of breach of this Agreement. &#160;The Parties understand and acknowledge that this Agreement constitutes a compromise and settlement of disputed claims. &#160;No action taken by the Parties hereto, or either of them, either previously or in connection with this Agreement shall be deemed or construed to be:</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><font style="font-size:11pt;">an admission of the truth or falsity of any claims heretofore made; or </font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><font style="font-size:11pt;">an acknowledgment or admission by either Party of any fault or liability whatsoever to the other Party or to any third party.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">13.</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Knowledge of Wrongdoing</u><font style="font-size:11pt;">. &#160;Employee represents that Employee has no knowledge of any wrongdoing involving improper or false claims against a federal or state governmental agency, or any other wrongdoing that involves Employee or other present or former Company employees, officers, directors or other service providers.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:8.82%;position:relative;"><div style="margin-top:9pt;min-height:63pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:12pt 0pt 0pt 0pt;"><font style="letter-spacing:-0.15pt;">Confidential Severance Agreement and General Release</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">October 8, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Page 8 of 9</p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">14.</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Contingent Obligation</u><font style="font-size:11pt;">. &#160;Company&#8217;s continuing obligations under this Agreement are contingent upon Employee&#8217;s compliance with all terms and conditions provided for herein (including Section 5 of the Employment Agreement which is incorporated as if fully set forth herein). &#160;In the event that Employee breaches any of the obligations under this Agreement, Employee agrees that Company may cease making any payments due under this Agreement (other than the Accrued Benefits and $500, which the Parties agree constitutes adequate consideration for the general release of claims), and recover all payments already made under this Agreement, in addition to all other available legal remedies. </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:12pt;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">15.</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fees and Costs</u><font style="font-size:11pt;white-space:pre-wrap;">.  The Parties shall each bear their own costs, accountant or tax advisor fees, attorneys&#8217; fees, and other fees incurred in connection with the execution of this Agreement.  </font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">16.</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Choice of Law; Venue</u><font style="font-size:11pt;">. &#160;This Agreement will be interpreted and enforced in accordance with the law of the State of Texas; if Texas&#8217;s conflict of law rules would apply another state&#8217;s laws, the Parties agree that Texas law shall still govern. &#160;Employee further agrees that all disputes arising under this Agreement shall be subject to the exclusive jurisdiction of the federal and local courts of the Commonwealth of Pennsylvania and Employee consents to the exclusive jurisdiction of and venue in those courts. &#160;</font>THE PARTIES TO THIS AGREEMENT HEREBY WAIVE THEIR RIGHT TO A TRIAL BY JURY WITH RESPECT TO DISPUTES ARISING UNDER THIS AGREEMENT AND THE RELATED AGREEMENTS AND CONSENT TO A BENCH TRIAL WITH THE APPROPRIATE JUDGE ACTING AS THE FINDER OF FACT.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">17.</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Representations</u><font style="font-size:11pt;">. &#160;The Parties represent that they each have had the opportunity to consult with an attorney, at their own expense, and have carefully read and understand the scope and effect of the provisions of this Agreement. &#160;Neither Party has relied upon any representations or statements made by the other Party hereto which are not specifically set forth in this Agreement.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">18.</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</u><font style="font-size:11pt;">. &#160;In the event that any provision in this Agreement becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable, or void, this Agreement shall continue in full force and effect without said provision so long as the remaining provisions remain intelligible and continue to reflect the original intent of the Parties.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">19.</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</u><font style="font-size:11pt;">. &#160;</font><font style="font-size:11pt;">Employee acknowledges that this Agreement constitutes a full and accurate embodiment of the understanding between Employee and Company, and that it supersedes any prior agreements or understandings made by the Parties, except any confidentiality, non-disclosure, non-solicitation, trade secret, assignment of inventions, and other intellectual property provisions to which Employee&#8217;s employment was subject, which will remain in effect subsequent to the execution of this Agreement, including, without limitation, those set forth in Section 5 of the Employment Agreement (together with any other provisions of the Employment Agreement that are necessary or desirable to enforce Section 5 of the Employment Agreement). &#160;The terms of this Agreement may not be modified, except by mutual consent of the Parties. &#160;Any and all modifications must be reduced to writing and signed by the Parties to be effective.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">20.</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u><font style="font-size:11pt;">.&#160; This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">21.</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Good Faith Compliance</u><font style="font-size:11pt;">.&#160; The Parties agree to cooperate in good faith and to do all things necessary to effectuate this Agreement.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-size:11pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">22.</font><u style="font-size:11pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Voluntary Execution of Agreement</u><font style="font-size:11pt;">. &#160;This Agreement is executed voluntarily and without any duress or undue influence on the part or behalf of the Parties hereto, with the full intent of releasing all claims. &#160;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:0pt;margin:0pt;"><font style="font-size:11pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;text-indent:0pt;margin:0pt;">[<i style="font-style:italic;">Signature page to follow</i>.]</p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:0pt;text-indent:0pt;margin:0pt;"><font style="font-size:0pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:8.82%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:8.82%;position:relative;"><div style="margin-top:9pt;min-height:63pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;text-indent:0pt;margin:0pt;">Exhibit 10.1</p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="font-size:11pt;">IN WITNESS WHEREOF, the Parties have executed this Confidential Severance Agreement and General Release on the respective dates set forth below.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt;"><font style="display:inline-block;text-align:left;width:21.6pt;"></font><font style="display:inline-block;width:194.4pt;"></font><font style="font-size:11pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt;"><font style="display:inline-block;text-align:left;width:21.6pt;"></font><font style="display:inline-block;width:194.4pt;"></font><font style="font-size:11pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt;"><font style="font-size:11pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:0pt;margin:0pt;">Dated: &#160;__<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10/9/2024</u>______________<font style="display:inline-block;width:48.57pt;"></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u>/s/ Oren Gilad</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt;"><font style="display:inline-block;width:21.6pt;"></font><font style="display:inline-block;width:194.4pt;"></font><font style="font-size:11pt;">APREA THERAPEUTICS, INC.</font><font style="font-size:11pt;"><br></font><font style="display:inline-block;width:21.6pt;"></font><font style="display:inline-block;width:194.4pt;"></font><font style="font-size:11pt;">Oren Gilad, Ph.D.</font><font style="font-size:11pt;"><br></font><font style="display:inline-block;width:21.6pt;"></font><font style="display:inline-block;width:194.4pt;"></font><font style="font-size:11pt;">Its: Chief Executive Officer</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt;"><font style="font-size:11pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt;"><font style="font-size:11pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt;"><font style="font-size:11pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:0pt;margin:0pt;">Dated: &#160;__<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10/8/2024</u>______________<font style="display:inline-block;width:48.57pt;"></font>By <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:20.41pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u>/s/ Nadeem Mirza</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt;"><font style="display:inline-block;text-align:left;width:21.6pt;"></font><font style="display:inline-block;width:194.4pt;"></font><font style="font-size:11pt;"> &#160; &#160; &#160;Nadeem Mirza, M.D., M.P.H.</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;text-indent:0pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:8.82%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>apre-20240930xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 11/5/2024 12:12:53 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Exhibit&#160;31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION OF PERIODIC REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PURSUANT TO SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">I, Oren Gilad, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:15.1pt;text-indent:-15.1pt;margin:0pt 0pt 10pt 0pt;">1.&#160;&#160;&#160;I have reviewed this quarterly report on Form&#160;10-Q of Aprea Therapeutics,&#160;Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:15.1pt;text-indent:-15.1pt;margin:0pt 0pt 10pt 0pt;">2.&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:15.1pt;text-indent:-15.1pt;margin:0pt 0pt 10pt 0pt;">3.&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:15.1pt;text-indent:-15.1pt;margin:0pt 0pt 10pt 0pt;">4.&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.6pt;text-indent:-21.6pt;margin:0pt 0pt 10pt 15.1pt;">a)&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.6pt;text-indent:-21.6pt;margin:0pt 0pt 10pt 15.1pt;">b)&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.6pt;text-indent:-21.6pt;margin:0pt 0pt 10pt 15.1pt;">c)&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.6pt;text-indent:-21.6pt;margin:0pt 0pt 10pt 15.1pt;">d)&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:15.1pt;text-indent:-15.1pt;margin:0pt 0pt 10pt 0pt;">5.&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.6pt;text-indent:-21.6pt;margin:0pt 0pt 10pt 15.1pt;">a)&#160;&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.6pt;text-indent:-21.6pt;margin:0pt 0pt 0pt 15.1pt;">b)&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Date: November 7, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:48.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Oren Gilad</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oren Gilad</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>apre-20240930xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 11/5/2024 12:12:53 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Exhibit&#160;31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION OF PERIODIC REPORT PURSUANT TO SECTION&#160;302 OF THE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">I, John P. Hamill, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:15.1pt;text-indent:-15.1pt;margin:0pt 0pt 10pt 0pt;">1.&#160;&#160;&#160;I have reviewed this quarterly report on Form&#160;10-Q of Aprea Therapeutics,&#160;Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:15.1pt;text-indent:-15.1pt;margin:0pt 0pt 10pt 0pt;">2.&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:15.1pt;text-indent:-15.1pt;margin:0pt 0pt 10pt 0pt;">3.&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:15.1pt;text-indent:-15.1pt;margin:0pt 0pt 10pt 0pt;">4.&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.6pt;text-indent:-21.6pt;margin:0pt 0pt 10pt 15.1pt;">a)&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:15.1pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:21.6pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.6pt;text-indent:-21.6pt;margin:0pt 0pt 10pt 15.1pt;">c)&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.6pt;text-indent:-21.6pt;margin:0pt 0pt 10pt 15.1pt;">d)&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:15.1pt;text-indent:-15.1pt;margin:0pt 0pt 10pt 0pt;">5.&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.6pt;text-indent:-21.6pt;margin:0pt 0pt 10pt 15.1pt;">a)&#160;&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.6pt;text-indent:-21.6pt;margin:0pt 0pt 0pt 15.1pt;">b)&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Date: November 7, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:48.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ John P. Hamill</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">John P. Hamill</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>apre-20240930xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 11/5/2024 12:12:52 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Exhibit&#160;32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">STATEMENT OF CHIEF EXECUTIVE OFFICER OF</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">APREA THERAPEUTICS,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PURSUANT TO 18 U.S.C. SECTION&#160;1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 10pt 0pt;">In connection with the quarterly report of Aprea Therapeutics,&#160;Inc. (the &#8220;Company&#8221;) on Form&#160;10-Q for the period ended September 30, 2024 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;),&#160;I, Oren Gilad, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;">1)&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934, as amended; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Date: November 7, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:48.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Oren Gilad</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oren Gilad</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>apre-20240930xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 11/5/2024 12:13:03 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Exhibit&#160;32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">STATEMENT OF CHIEF ACCOUNTING OFFICER OF</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">APREA THERAPEUTICS,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PURSUANT TO 18 U.S.C. SECTION&#160;1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:23.75pt;margin:0pt 0pt 10pt 0pt;">In connection with the quarterly report of Aprea Therapeutics,&#160;Inc. (the &#8220;Company&#8221;) on Form&#160;10-Q for the period ended September 30, 2024 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;),&#160;I, John P. Hamill, Chief Accounting Officer of the Company, certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;">1)&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934, as amended; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Date: November 7, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:48.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ John P. Hamill</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">John P. Hamill</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>apre-20240930.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/5/2024 12:13:12 PM-->
<!--Modified on: 11/5/2024 12:13:12 PM-->
<xsd:schema targetNamespace="http://aprea.com/20240930" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:apre="http://aprea.com/20240930" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:attributeFormDefault="unqualified" xmlns:srt="http://fasb.org/srt/2024" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://aprea.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
        <link:definition>995200100 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>995200200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>995200400 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsCalc2" id="StatementCondensedConsolidatedStatementsOfCashFlowsCalc2">
        <link:definition>00405 - Statement - Condensed Consolidated Statements of Cash Flows (Calc2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureAccruedExpensesDetails" id="DisclosureAccruedExpensesDetails">
        <link:definition>99940401 - Disclosure - Accrued expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>995200090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" id="StatementCondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>995200105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" id="StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity">
        <link:definition>995200300 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>99930203 - Disclosure - Summary of significant accounting policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureAccruedExpensesTables" id="DisclosureAccruedExpensesTables">
        <link:definition>99930403 - Disclosure - Accrued expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails" id="DisclosureNatureOfBusinessAndBasisOfPresentationDetails">
        <link:definition>99940101 - Disclosure - Nature of business and basis of presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails">
        <link:definition>99940202 - Disclosure - Summary of significant accounting policies - Potentially dilutive securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureLeasesSummaryDetails" id="DisclosureLeasesSummaryDetails">
        <link:definition>99940301 - Disclosure - Leases - Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureStockholdersEquityDetails" id="DisclosureStockholdersEquityDetails">
        <link:definition>99940501 - Disclosure - Stockholders' equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureIncomeTaxesNarrativeDetails" id="DisclosureIncomeTaxesNarrativeDetails">
        <link:definition>99940601 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation" id="DisclosureNatureOfBusinessAndBasisOfPresentation">
        <link:definition>995210101 - Disclosure - Nature of business and basis of presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>995210201 - Disclosure - Summary of significant accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>995210301 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureAccruedExpenses" id="DisclosureAccruedExpenses">
        <link:definition>995210401 - Disclosure - Accrued expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>995210501 - Disclosure - Stockholders' equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>995210601 - Disclosure - Income taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>995210701 - Disclosure - Commitments and contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>99920202 - Disclosure - Summary of significant accounting policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails">
        <link:definition>99940201 - Disclosure - Summary of significant accounting policies - Restricted cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aprea.com/role/DisclosureCommitmentsAndContingenciesDetails" id="DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>99940701 - Disclosure - Commitments and contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="apre-20240930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="apre-20240930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="apre-20240930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="apre-20240930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="https://xbrl.org/2023/calculation-1.1" schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd-sub/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" />
  <xsd:element id="apre_ConvertiblePreferredStockSeriesaMember" name="ConvertiblePreferredStockSeriesaMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="apre_LeaseDisclosureTextBlock" name="LeaseDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="apre_TemporaryEquityPolicyTextBlock" name="TemporaryEquityPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="apre_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock" name="UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="apre_CommonStockNumberOfVotingRightsPerShare" name="CommonStockNumberOfVotingRightsPerShare" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="apre_ResearchAndDevelopmentRelatedLiabilitiesCurrent" name="ResearchAndDevelopmentRelatedLiabilitiesCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" name="AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="apre_LesseeOperatingLeaseNumberOfOperatingLeases" name="LesseeOperatingLeaseNumberOfOperatingLeases" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="apre_LesseeOperatingLeaseAnnualBaseRent" name="LesseeOperatingLeaseAnnualBaseRent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="apre_ScheduleOfEarningsPerShareBasicAndDilutedTable" name="ScheduleOfEarningsPerShareBasicAndDilutedTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="apre_ScheduleOfEarningsPerShareBasicAndDilutedLineItems" name="ScheduleOfEarningsPerShareBasicAndDilutedLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract" name="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="apre_PercentageOfOutstandingShares" name="PercentageOfOutstandingShares" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="apre_CommonStockTextBlock" name="CommonStockTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="apre_StockSharesAuthorized" name="StockSharesAuthorized" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="apre_ShelfRegistrationStatementAbstract" name="ShelfRegistrationStatementAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="apre_UniversalShelfRegistrationMaximumAmountToBeIssued" name="UniversalShelfRegistrationMaximumAmountToBeIssued" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="apre_AtMarketOfferingProgramMaximumAmountToBeIssued" name="AtMarketOfferingProgramMaximumAmountToBeIssued" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element name="AtMarketOfferingCommissionPayableAsPercentageOfGrossProceedsFromSaleOfCommonStock" id="apre_AtMarketOfferingCommissionPayableAsPercentageOfGrossProceedsFromSaleOfCommonStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AtMarketOfferingMember" id="apre_AtMarketOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShelfRegistrationStatementMember" id="apre_ShelfRegistrationStatementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShelfRegistrationStatement2024Member" id="apre_ShelfRegistrationStatement2024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement" id="apre_AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="HCWainrightCoLlcMember" id="apre_HCWainrightCoLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AtMarket2024OfferingMember" id="apre_AtMarket2024OfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PreFundedWarrantsMember" id="apre_PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PreFundedWarrantsExercisePrice7.29PerShareMember" id="apre_PreFundedWarrantsExercisePrice7.29PerShareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PreFundedWarrantsExercisePrice9.1125PerShareMember" id="apre_PreFundedWarrantsExercisePrice9.1125PerShareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SecuritiesPurchaseAgreementMember" id="apre_SecuritiesPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CertainPurchasersMember" id="apre_CertainPurchasersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise" id="apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AtEventOfElectionOfHolderMember" id="apre_AtEventOfElectionOfHolderMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="StockIssuanceAnniversaryPeriod" id="apre_StockIssuanceAnniversaryPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119" id="apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="SharesIssuedVolumeWeightedAveragePricePerShare" id="apre_SharesIssuedVolumeWeightedAveragePricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="NumberOfConsecutiveTradingDays" id="apre_NumberOfConsecutiveTradingDays" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PrivatePlacementAbstract" id="apre_PrivatePlacementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LesseeOperatingLeaseAnnualBaseRentObligationAfterCurrentYear" id="apre_LesseeOperatingLeaseAnnualBaseRentObligationAfterCurrentYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>apre-20240930_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/5/2024 12:13:12 PM-->
<!--Modified on: 11/5/2024 12:13:12 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef xlink:type="simple" xlink:href="apre-20240930.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://aprea.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <link:roleRef xlink:type="simple" xlink:href="apre-20240930.xsd#StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://aprea.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <link:roleRef xlink:type="simple" xlink:href="apre-20240930.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <link:roleRef xlink:type="simple" xlink:href="apre-20240930.xsd#StatementCondensedConsolidatedStatementsOfCashFlowsCalc2" roleURI="http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsCalc2" />
  <link:roleRef xlink:type="simple" xlink:href="apre-20240930.xsd#DisclosureAccruedExpensesDetails" roleURI="http://aprea.com/role/DisclosureAccruedExpensesDetails" />
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" />
  <link:calculationLink xlink:role="http://aprea.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - Condensed Consolidated Balance Sheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638664055918267014" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638664055918267014" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638664055918277039" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638664055918267014" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638664055918277039" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638664055918277039" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638664055918267014" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638664055918277039" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638664055918277039" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638664055918277039" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638664055918277039" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent_638664055918277039" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638664055918277039" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_638664055918277039" order="4" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638664055918277039" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent_638664055918277039" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638664055918277039" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638664055918277039" xlink:to="us-gaap_AccountsPayableCurrent_638664055918277039" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:label="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_638664055918287016" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638664055918277039" xlink:to="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_638664055918287016" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent_638664055918287016" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638664055918277039" xlink:to="us-gaap_DeferredRevenueCurrent_638664055918287016" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638664055918287016" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_638664055918287016" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638664055918287016" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638664055918287016" order="3" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638664055918287016" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638664055918287016" order="4" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638664055918287016" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638664055918287016" xlink:to="us-gaap_CommonStockValue_638664055918287016" order="1" use="optional" weight="1" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638664055918287016" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638664055918287016" xlink:to="us-gaap_AdditionalPaidInCapital_638664055918287016" order="2" use="optional" weight="1" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638664055918287016" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638664055918287016" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638664055918287016" order="3" use="optional" weight="1" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638664055918297011" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638664055918287016" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638664055918297011" order="4" use="optional" weight="1" priority="3" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://aprea.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="995200200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638664055918297011" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_638664055918297011" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638664055918297011" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638664055918297011" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638664055918297011" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_638664055918297011" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_638664055918297011" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_638664055918297011" order="1" use="optional" weight="1" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638664055918297011" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_638664055918297011" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638664055918297011" order="2" use="optional" weight="1" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638664055918297011" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638664055918297011" xlink:to="us-gaap_OperatingIncomeLoss_638664055918297011" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_638664055918307017" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638664055918297011" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_638664055918307017" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638664055918307017" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638664055918297011" xlink:to="us-gaap_OperatingExpenses_638664055918307017" order="2" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638664055918307017" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638664055918307017" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638664055918307017" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638664055918307017" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638664055918307017" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638664055918307017" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638664055918307017" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638664055918307017" order="2" use="optional" weight="1" priority="2" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - Condensed Consolidated Statements of Cash Flows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638664055918307017" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638664055918307017" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638664055918307017" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638664055918307017" xlink:to="us-gaap_ProfitLoss_638664055918307017" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638664055918317027" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638664055918307017" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638664055918317027" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_638664055918317027" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638664055918307017" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_638664055918317027" order="3" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638664055918317027" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638664055918307017" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638664055918317027" order="4" use="optional" weight="-1" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638664055918317027" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638664055918307017" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638664055918317027" order="5" use="optional" weight="-1" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638664055918317027" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638664055918307017" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638664055918317027" order="6" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638664055918317027" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638664055918307017" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638664055918317027" order="7" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_638664055918317027" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638664055918307017" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_638664055918317027" order="8" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638664055918317027" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638664055918317027" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638664055918327013" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638664055918317027" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638664055918327013" order="1" use="optional" weight="-1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638664055918327013" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638664055918327013" order="3" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638664055918327013" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638664055918327013" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638664055918327013" order="1" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638664055918327013" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638664055918327013" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638664055918327013" order="2" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsCalc2" xlink:type="extended" xlink:title="00405 - Statement - Condensed Consolidated Statements of Cash Flows (Calc2)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638664055918327013" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638664055918327013" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash_638664055918327013" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCash_638664055918327013" order="2" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://aprea.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - Accrued expenses (Details)">
    <link:loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:label="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638664055918337018" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638664055918337018" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638664055918337018" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638664055918337018" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_ResearchAndDevelopmentRelatedLiabilitiesCurrent" xlink:label="apre_ResearchAndDevelopmentRelatedLiabilitiesCurrent_638664055918337018" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:to="apre_ResearchAndDevelopmentRelatedLiabilitiesCurrent_638664055918337018" order="3" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638664055918337018" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638664055918337018" order="4" use="optional" weight="1" priority="2" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>apre-20240930_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/5/2024 12:13:12 PM-->
<!--Modified on: 11/5/2024 12:13:12 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="apre-20240930.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://aprea.com/role/StatementCondensedConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20240930.xsd#StatementCondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://aprea.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20240930.xsd#StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" roleURI="http://aprea.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20240930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails" roleURI="http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20240930.xsd#DisclosureStockholdersEquityDetails" roleURI="http://aprea.com/role/DisclosureStockholdersEquityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://aprea.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="apre-20240930.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:role="http://aprea.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis_1" xlink:title="srt_ConsolidatedEntitiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_1" xlink:title="srt_ConsolidatedEntitiesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidatedEntitiesAxis_1" xlink:to="srt_ConsolidatedEntitiesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidatedEntitiesAxis_1 To srt_ConsolidatedEntitiesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_1" xlink:title="srt_RestatementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_1" xlink:title="srt_RestatementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RestatementAxis_1" xlink:to="srt_RestatementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RestatementAxis_1 To srt_RestatementDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityNameAxis_1 To us-gaap_IncomeTaxAuthorityNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_1" xlink:title="us-gaap_RelatedPartyTransactionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1" xlink:title="us-gaap_RelatedPartyTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionAxis_1" xlink:to="us-gaap_RelatedPartyTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionAxis_1 To us-gaap_RelatedPartyTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" xlink:title="us-gaap_BusinessAcquisitionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain" xlink:title="us-gaap_BusinessAcquisitionAcquireeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BusinessAcquisitionAxis_1 To us-gaap_BusinessAcquisitionAcquireeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis_1" xlink:title="us-gaap_AssetAcquisitionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_1" xlink:title="us-gaap_AssetAcquisitionDomain_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://aprea.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - Condensed Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638664055918347027" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_638664055918347027" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_ConvertiblePreferredStockSeriesaMember" xlink:label="apre_ConvertiblePreferredStockSeriesaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="apre_ConvertiblePreferredStockSeriesaMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:label="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_CommonStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aprea.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="995200105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638664055918397033" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_638664055918397033" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_ConvertiblePreferredStockSeriesaMember" xlink:label="apre_ConvertiblePreferredStockSeriesaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="apre_ConvertiblePreferredStockSeriesaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aprea.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" xlink:type="extended" xlink:title="995200300 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638664055918417036" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_638664055918417036" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638664055918427018" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_638664055918427018" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_ConvertiblePreferredStockSeriesaMember" xlink:label="apre_ConvertiblePreferredStockSeriesaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="apre_ConvertiblePreferredStockSeriesaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638664055918427018" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638664055918427018" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_AtMarketOfferingMember" xlink:label="apre_AtMarketOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="apre_AtMarketOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails" xlink:type="extended" xlink:title="99940202 - Disclosure - Summary of significant accounting policies - Potentially dilutive securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_ScheduleOfEarningsPerShareBasicAndDilutedTable" xlink:label="apre_ScheduleOfEarningsPerShareBasicAndDilutedTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="apre_ScheduleOfEarningsPerShareBasicAndDilutedTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638664055918467042" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638664055918467042" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="apre_ScheduleOfEarningsPerShareBasicAndDilutedTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638664055918477029" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638664055918477029" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="apre_ScheduleOfEarningsPerShareBasicAndDilutedTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638664055918477029" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638664055918477029" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_PreFundedWarrantsMember" xlink:label="apre_PreFundedWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="apre_PreFundedWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_PreFundedWarrantsExercisePrice7.29PerShareMember" xlink:label="apre_PreFundedWarrantsExercisePrice7.29PerShareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="apre_PreFundedWarrantsMember" xlink:to="apre_PreFundedWarrantsExercisePrice7.29PerShareMember" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_ScheduleOfEarningsPerShareBasicAndDilutedLineItems" xlink:label="apre_ScheduleOfEarningsPerShareBasicAndDilutedLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="apre_ScheduleOfEarningsPerShareBasicAndDilutedLineItems" xlink:to="apre_ScheduleOfEarningsPerShareBasicAndDilutedTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract" xlink:label="apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="apre_ScheduleOfEarningsPerShareBasicAndDilutedLineItems" xlink:to="apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://aprea.com/role/DisclosureStockholdersEquityDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - Stockholders' equity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638664055918497043" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638664055918497043" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_ShelfRegistrationStatementMember" xlink:label="apre_ShelfRegistrationStatementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="apre_ShelfRegistrationStatementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_AtMarketOfferingMember" xlink:label="apre_AtMarketOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="apre_ShelfRegistrationStatementMember" xlink:to="apre_AtMarketOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_ShelfRegistrationStatement2024Member" xlink:label="apre_ShelfRegistrationStatement2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="apre_ShelfRegistrationStatement2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_AtMarket2024OfferingMember" xlink:label="apre_AtMarket2024OfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="apre_ShelfRegistrationStatement2024Member" xlink:to="apre_AtMarket2024OfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638664055918507019" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638664055918507019" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_HCWainrightCoLlcMember" xlink:label="apre_HCWainrightCoLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="apre_HCWainrightCoLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_CertainPurchasersMember" xlink:label="apre_CertainPurchasersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="apre_CertainPurchasersMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638664055918507019" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_638664055918507019" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_ConvertiblePreferredStockSeriesaMember" xlink:label="apre_ConvertiblePreferredStockSeriesaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="apre_ConvertiblePreferredStockSeriesaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638664055918517022" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638664055918517022" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_SecuritiesPurchaseAgreementMember" xlink:label="apre_SecuritiesPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="apre_SecuritiesPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638664055918527016" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638664055918527016" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_PreFundedWarrantsMember" xlink:label="apre_PreFundedWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="apre_PreFundedWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_PreFundedWarrantsExercisePrice7.29PerShareMember" xlink:label="apre_PreFundedWarrantsExercisePrice7.29PerShareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="apre_PreFundedWarrantsMember" xlink:to="apre_PreFundedWarrantsExercisePrice7.29PerShareMember" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_PreFundedWarrantsExercisePrice9.1125PerShareMember" xlink:label="apre_PreFundedWarrantsExercisePrice9.1125PerShareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="apre_PreFundedWarrantsMember" xlink:to="apre_PreFundedWarrantsExercisePrice9.1125PerShareMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638664055918657060" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_638664055918657060" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_AtEventOfElectionOfHolderMember" xlink:label="apre_AtEventOfElectionOfHolderMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="apre_AtEventOfElectionOfHolderMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_StockSharesAuthorized" xlink:label="apre_StockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="apre_StockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_AtMarketOfferingCommissionPayableAsPercentageOfGrossProceedsFromSaleOfCommonStock" xlink:label="apre_AtMarketOfferingCommissionPayableAsPercentageOfGrossProceedsFromSaleOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="apre_AtMarketOfferingCommissionPayableAsPercentageOfGrossProceedsFromSaleOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_CommonStockNumberOfVotingRightsPerShare" xlink:label="apre_CommonStockNumberOfVotingRightsPerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="apre_CommonStockNumberOfVotingRightsPerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_ShelfRegistrationStatementAbstract" xlink:label="apre_ShelfRegistrationStatementAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="apre_ShelfRegistrationStatementAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_UniversalShelfRegistrationMaximumAmountToBeIssued" xlink:label="apre_UniversalShelfRegistrationMaximumAmountToBeIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="apre_ShelfRegistrationStatementAbstract" xlink:to="apre_UniversalShelfRegistrationMaximumAmountToBeIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_AtMarketOfferingProgramMaximumAmountToBeIssued" xlink:label="apre_AtMarketOfferingProgramMaximumAmountToBeIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="apre_ShelfRegistrationStatementAbstract" xlink:to="apre_AtMarketOfferingProgramMaximumAmountToBeIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement" xlink:label="apre_AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="apre_ShelfRegistrationStatementAbstract" xlink:to="apre_AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="apre_ShelfRegistrationStatementAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="apre_ShelfRegistrationStatementAbstract" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="apre_ShelfRegistrationStatementAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="apre_ShelfRegistrationStatementAbstract" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="apre_ShelfRegistrationStatementAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_PrivatePlacementAbstract" xlink:label="apre_PrivatePlacementAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="apre_PrivatePlacementAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="apre_PrivatePlacementAbstract" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="apre_PrivatePlacementAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="apre_PrivatePlacementAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_StockIssuanceAnniversaryPeriod" xlink:label="apre_StockIssuanceAnniversaryPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="apre_PrivatePlacementAbstract" xlink:to="apre_StockIssuanceAnniversaryPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119" xlink:label="apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="apre_PrivatePlacementAbstract" xlink:to="apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_SharesIssuedVolumeWeightedAveragePricePerShare" xlink:label="apre_SharesIssuedVolumeWeightedAveragePricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="apre_PrivatePlacementAbstract" xlink:to="apre_SharesIssuedVolumeWeightedAveragePricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_NumberOfConsecutiveTradingDays" xlink:label="apre_NumberOfConsecutiveTradingDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="apre_PrivatePlacementAbstract" xlink:to="apre_NumberOfConsecutiveTradingDays" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_PercentageOfOutstandingShares" xlink:label="apre_PercentageOfOutstandingShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="apre_PrivatePlacementAbstract" xlink:to="apre_PercentageOfOutstandingShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="apre_PrivatePlacementAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise" xlink:label="apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="apre_PrivatePlacementAbstract" xlink:to="apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="apre_PrivatePlacementAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>apre-20240930_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/5/2024 12:13:12 PM-->
<!--Modified on: 11/5/2024 12:13:12 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Quarterly Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Consolidated Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock (as converted)</label>
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_ConvertiblePreferredStockSeriesaMember" xlink:label="apre_ConvertiblePreferredStockSeriesaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_ConvertiblePreferredStockSeriesaMember" xlink:to="apre_ConvertiblePreferredStockSeriesaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_ConvertiblePreferredStockSeriesaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock that may be exchanged into common shares or other types of securities at the owner's option. Each share of Series A Preferred may be converted at any time, at the option of the holder, into a share of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_ConvertiblePreferredStockSeriesaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_ConvertiblePreferredStockSeriesaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other noncurrent assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:label="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:to="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Also includes obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities and Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Revenue, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred grant revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 7)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Carrying Amount, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary equity, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary equity, beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A convertible preferred stock, $0.001 par value, 40,000,000 shares authorized; 56,227 shares issued and outstanding at September 30, 2024 and December 31, 2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.001 par value, 400,000,000 shares authorized, 5,434,903 and 3,736,673 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity, beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary equity, ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary equity, beginning balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Consolidated Statements of Operations and Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueNotFromContractWithCustomer" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Including Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense (Excluding Acquired in Process Cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense):</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Income (Expense), Nonoperating, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transaction Gain (Loss), before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency (gain) loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency (loss) gain</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive (loss):</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency translation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share attributable to common stockholders, basic (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share attributable to common stockholders, diluted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common shares outstanding, basic (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common shares outstanding, diluted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Condensed Convertible Preferred Stock and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AOCI Attributable to Parent [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_AtMarketOfferingMember" xlink:label="apre_AtMarketOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_AtMarketOfferingMember" xlink:to="apre_AtMarketOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_AtMarketOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to ATM offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_AtMarketOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At Market Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_AtMarketOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ATM offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Temporary Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Temporary Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity, ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity, beginning balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock, net (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Restricted Stock Award, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of restricted stock units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of restricted stock units (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Consolidated Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Benefit and Share-based Payment Arrangement, Noncash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockbased compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred grant revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from investing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in cash and cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of exchange rate changes on cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash-end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash-beginning of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of business and basis of presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of business and basis of presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of significant accounting policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of significant accounting policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_LeaseDisclosureTextBlock" xlink:label="apre_LeaseDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_LeaseDisclosureTextBlock" xlink:to="apre_LeaseDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_LeaseDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure of information about leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_LeaseDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_LeaseDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_CommonStockTextBlock" xlink:label="apre_CommonStockTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_CommonStockTextBlock" xlink:to="apre_CommonStockTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_CommonStockTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_CommonStockTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="apre_CommonStockTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidation, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principles of consolidation</label>
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock" xlink:label="apre_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock" xlink:to="apre_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for unaudited interim condensed consolidated financial statements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unaudited Interim Condensed Consolidated Financial Statements [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unaudited interim consolidated financial statements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency and currency translation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of financial instruments</label>
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_TemporaryEquityPolicyTextBlock" xlink:label="apre_TemporaryEquityPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_TemporaryEquityPolicyTextBlock" xlink:to="apre_TemporaryEquityPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_TemporaryEquityPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for temporary equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_TemporaryEquityPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_TemporaryEquityPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting for leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recently issued accounting pronouncements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of potentially dilutive securities excluded from calculation of diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance or Sale of Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from sale of common stock in a private placement</label>
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_ScheduleOfEarningsPerShareBasicAndDilutedTable" xlink:label="apre_ScheduleOfEarningsPerShareBasicAndDilutedTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_ScheduleOfEarningsPerShareBasicAndDilutedTable" xlink:to="apre_ScheduleOfEarningsPerShareBasicAndDilutedTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_ScheduleOfEarningsPerShareBasicAndDilutedTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The table contains disclosure pertaining to an entity's basic and diluted earnings per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_ScheduleOfEarningsPerShareBasicAndDilutedTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic and Diluted [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to purchase common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units (RSUs) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested restricted stock units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2024 Private Placement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_PreFundedWarrantsMember" xlink:label="apre_PreFundedWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_PreFundedWarrantsMember" xlink:to="apre_PreFundedWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_PreFundedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to pre-funded warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_PreFundedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-funded Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_PreFundedWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-funded Warrants</label>
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_PreFundedWarrantsExercisePrice7.29PerShareMember" xlink:label="apre_PreFundedWarrantsExercisePrice7.29PerShareMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_PreFundedWarrantsExercisePrice7.29PerShareMember" xlink:to="apre_PreFundedWarrantsExercisePrice7.29PerShareMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_PreFundedWarrantsExercisePrice7.29PerShareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Pre-funded warrants exercise price of 7.29 per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_PreFundedWarrantsExercisePrice7.29PerShareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-funded Warrants Exercise Price 7.29 Per Share [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_PreFundedWarrantsExercisePrice7.29PerShareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche A Warrants (Pre-funded Warrants Exercise Price 7.29 Per Share)</label>
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_ScheduleOfEarningsPerShareBasicAndDilutedLineItems" xlink:label="apre_ScheduleOfEarningsPerShareBasicAndDilutedLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_ScheduleOfEarningsPerShareBasicAndDilutedLineItems" xlink:to="apre_ScheduleOfEarningsPerShareBasicAndDilutedLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_ScheduleOfEarningsPerShareBasicAndDilutedLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_ScheduleOfEarningsPerShareBasicAndDilutedLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic and Diluted [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_ScheduleOfEarningsPerShareBasicAndDilutedLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share</label>
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract" xlink:label="apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract" xlink:to="apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potentially dilutive securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to purchase of shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total shares of common stock equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_LesseeOperatingLeaseNumberOfOperatingLeases" xlink:label="apre_LesseeOperatingLeaseNumberOfOperatingLeases" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_LesseeOperatingLeaseNumberOfOperatingLeases" xlink:to="apre_LesseeOperatingLeaseNumberOfOperatingLeases_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_LesseeOperatingLeaseNumberOfOperatingLeases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of operating leases held by the Company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_LesseeOperatingLeaseNumberOfOperatingLeases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Number of Operating Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_LesseeOperatingLeaseNumberOfOperatingLeases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rent expense</label>
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_LesseeOperatingLeaseAnnualBaseRent" xlink:label="apre_LesseeOperatingLeaseAnnualBaseRent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_LesseeOperatingLeaseAnnualBaseRent" xlink:to="apre_LesseeOperatingLeaseAnnualBaseRent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_LesseeOperatingLeaseAnnualBaseRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of base rent due annually.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_LesseeOperatingLeaseAnnualBaseRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Annual Base Rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_LesseeOperatingLeaseAnnualBaseRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual base rent</label>
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_LesseeOperatingLeaseAnnualBaseRentObligationAfterCurrentYear" xlink:label="apre_LesseeOperatingLeaseAnnualBaseRentObligationAfterCurrentYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_LesseeOperatingLeaseAnnualBaseRentObligationAfterCurrentYear" xlink:to="apre_LesseeOperatingLeaseAnnualBaseRentObligationAfterCurrentYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_LesseeOperatingLeaseAnnualBaseRentObligationAfterCurrentYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of base rent obligations after current year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_LesseeOperatingLeaseAnnualBaseRentObligationAfterCurrentYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Annual Base Rent Obligation After Current Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_LesseeOperatingLeaseAnnualBaseRentObligationAfterCurrentYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease obligations after current year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Professional fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation, severance and benefits</label>
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_ResearchAndDevelopmentRelatedLiabilitiesCurrent" xlink:label="apre_ResearchAndDevelopmentRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_ResearchAndDevelopmentRelatedLiabilitiesCurrent" xlink:to="apre_ResearchAndDevelopmentRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_ResearchAndDevelopmentRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to research and development costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_ResearchAndDevelopmentRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_ResearchAndDevelopmentRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</label>
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_ShelfRegistrationStatementMember" xlink:label="apre_ShelfRegistrationStatementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_ShelfRegistrationStatementMember" xlink:to="apre_ShelfRegistrationStatementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_ShelfRegistrationStatementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to a Shelf Registration Statement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_ShelfRegistrationStatementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shelf Registration Statement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_ShelfRegistrationStatementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2020 Shelf Registration Statement</label>
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_ShelfRegistrationStatement2024Member" xlink:label="apre_ShelfRegistrationStatement2024Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_ShelfRegistrationStatement2024Member" xlink:to="apre_ShelfRegistrationStatement2024Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_ShelfRegistrationStatement2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to a 2024 Shelf Registration Statement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_ShelfRegistrationStatement2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shelf Registration Statement 2024 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_ShelfRegistrationStatement2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024 Shelf Registration Statement</label>
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_AtMarket2024OfferingMember" xlink:label="apre_AtMarket2024OfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_AtMarket2024OfferingMember" xlink:to="apre_AtMarket2024OfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_AtMarket2024OfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to the 2024 ATM offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_AtMarket2024OfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At Market 2024 Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_AtMarket2024OfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024 ATM offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_HCWainrightCoLlcMember" xlink:label="apre_HCWainrightCoLlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_HCWainrightCoLlcMember" xlink:to="apre_HCWainrightCoLlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_HCWainrightCoLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to H.C Wainright &amp; Co, LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_HCWainrightCoLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">HC Wainright Co Llc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_HCWainrightCoLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">HCW</label>
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_CertainPurchasersMember" xlink:label="apre_CertainPurchasersMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_CertainPurchasersMember" xlink:to="apre_CertainPurchasersMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_CertainPurchasersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to certain purchaser with whom company entered into securities purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_CertainPurchasersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Certain Purchasers [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_CertainPurchasersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchasers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_SecuritiesPurchaseAgreementMember" xlink:label="apre_SecuritiesPurchaseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_SecuritiesPurchaseAgreementMember" xlink:to="apre_SecuritiesPurchaseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the securities purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Securities Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Securities purchase agreement</label>
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_PreFundedWarrantsExercisePrice9.1125PerShareMember" xlink:label="apre_PreFundedWarrantsExercisePrice9.1125PerShareMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_PreFundedWarrantsExercisePrice9.1125PerShareMember" xlink:to="apre_PreFundedWarrantsExercisePrice9.1125PerShareMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_PreFundedWarrantsExercisePrice9.1125PerShareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Pre-funded warrants exercise price of 9.1125  per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_PreFundedWarrantsExercisePrice9.1125PerShareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-funded Warrants Exercise Price 9.1125 Per Share [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_PreFundedWarrantsExercisePrice9.1125PerShareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche B Warrants (Pre-funded Warrants Exercise Price 9.1125 Per Share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Domain]</label>
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_AtEventOfElectionOfHolderMember" xlink:label="apre_AtEventOfElectionOfHolderMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_AtEventOfElectionOfHolderMember" xlink:to="apre_AtEventOfElectionOfHolderMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_AtEventOfElectionOfHolderMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents scenario or event of election of holder.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_AtEventOfElectionOfHolderMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At Event of Election of Holder [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_AtEventOfElectionOfHolderMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At the election of holder</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary, Sale of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock</label>
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_StockSharesAuthorized" xlink:label="apre_StockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_StockSharesAuthorized" xlink:to="apre_StockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_StockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The maximum number of shares permitted to be issued by an entity's charter and bylaws.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_StockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_StockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Convertible, Shares Issuable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock issuable upon conversion (in shares)</label>
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_AtMarketOfferingCommissionPayableAsPercentageOfGrossProceedsFromSaleOfCommonStock" xlink:label="apre_AtMarketOfferingCommissionPayableAsPercentageOfGrossProceedsFromSaleOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_AtMarketOfferingCommissionPayableAsPercentageOfGrossProceedsFromSaleOfCommonStock" xlink:to="apre_AtMarketOfferingCommissionPayableAsPercentageOfGrossProceedsFromSaleOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_AtMarketOfferingCommissionPayableAsPercentageOfGrossProceedsFromSaleOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the commission payable as a percentage of gross proceeds from sale of common stock under the at-the market offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_AtMarketOfferingCommissionPayableAsPercentageOfGrossProceedsFromSaleOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At the Market Offering, Commission Payable As A Percentage Of Gross Proceeds From Sale Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_AtMarketOfferingCommissionPayableAsPercentageOfGrossProceedsFromSaleOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commission payable as a percentage of gross proceeds from sale of common stock under ATM offering</label>
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_CommonStockNumberOfVotingRightsPerShare" xlink:label="apre_CommonStockNumberOfVotingRightsPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_CommonStockNumberOfVotingRightsPerShare" xlink:to="apre_CommonStockNumberOfVotingRightsPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_CommonStockNumberOfVotingRightsPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of voting rights per share of common stock owned.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_CommonStockNumberOfVotingRightsPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Number of Voting Rights Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_CommonStockNumberOfVotingRightsPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of voting rights per common share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock based compensation expense</label>
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_ShelfRegistrationStatementAbstract" xlink:label="apre_ShelfRegistrationStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_ShelfRegistrationStatementAbstract" xlink:to="apre_ShelfRegistrationStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_ShelfRegistrationStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_ShelfRegistrationStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shelf Registration Statement Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_ShelfRegistrationStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shelf Registration Statement</label>
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_UniversalShelfRegistrationMaximumAmountToBeIssued" xlink:label="apre_UniversalShelfRegistrationMaximumAmountToBeIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_UniversalShelfRegistrationMaximumAmountToBeIssued" xlink:to="apre_UniversalShelfRegistrationMaximumAmountToBeIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_UniversalShelfRegistrationMaximumAmountToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of common stock, preferred stock, warrants, rights and debt securities and units that can be issued under a universal shelf registration statement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_UniversalShelfRegistrationMaximumAmountToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Universal Shelf Registration Maximum Amount To Be Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_UniversalShelfRegistrationMaximumAmountToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount to be issued under universal shelf registration statement</label>
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_AtMarketOfferingProgramMaximumAmountToBeIssued" xlink:label="apre_AtMarketOfferingProgramMaximumAmountToBeIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_AtMarketOfferingProgramMaximumAmountToBeIssued" xlink:to="apre_AtMarketOfferingProgramMaximumAmountToBeIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_AtMarketOfferingProgramMaximumAmountToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of common stock to be issued under an at-the-market offering program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_AtMarketOfferingProgramMaximumAmountToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At The Market Offering Program Maximum Amount To Be Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_AtMarketOfferingProgramMaximumAmountToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount to be issued under at-the-market offering program</label>
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement" xlink:label="apre_AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement" xlink:to="apre_AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of common stock to be issued under a supplemental at-the-market offering program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At The Market Offering Program Maximum Amount To Be Issued, Supplement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount to be issued under at-the-market offering program, supplement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issue price per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Consideration Received on Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common shares</label>
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_PrivatePlacementAbstract" xlink:label="apre_PrivatePlacementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_PrivatePlacementAbstract" xlink:to="apre_PrivatePlacementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_PrivatePlacementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_PrivatePlacementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_PrivatePlacementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2024 Private Placement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering price per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock with an exercise price</label>
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_StockIssuanceAnniversaryPeriod" xlink:label="apre_StockIssuanceAnniversaryPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_StockIssuanceAnniversaryPeriod" xlink:to="apre_StockIssuanceAnniversaryPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_StockIssuanceAnniversaryPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of anniversary of issuance of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_StockIssuanceAnniversaryPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issuance Anniversary Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_StockIssuanceAnniversaryPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock issuance anniversary period</label>
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119" xlink:label="apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119" xlink:to="apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of days after the Company announces the recommended Phase 2 dose for ATRN-119.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Days after Company Announces Recommended Phase 2 Dose for ATRN 119</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of days after announcement of Phase 2 dose for ATRN-119</label>
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_SharesIssuedVolumeWeightedAveragePricePerShare" xlink:label="apre_SharesIssuedVolumeWeightedAveragePricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_SharesIssuedVolumeWeightedAveragePricePerShare" xlink:to="apre_SharesIssuedVolumeWeightedAveragePricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_SharesIssuedVolumeWeightedAveragePricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Volume weighted average price per share of common stock after announcement of recommended Phase 2 dose for ATRN-119.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_SharesIssuedVolumeWeightedAveragePricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Volume Weighted Average Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_SharesIssuedVolumeWeightedAveragePricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Volume weighted average price</label>
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_NumberOfConsecutiveTradingDays" xlink:label="apre_NumberOfConsecutiveTradingDays" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_NumberOfConsecutiveTradingDays" xlink:to="apre_NumberOfConsecutiveTradingDays_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_NumberOfConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of consecutive trading days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_NumberOfConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Consecutive Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_NumberOfConsecutiveTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of consecutive trading days</label>
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_PercentageOfOutstandingShares" xlink:label="apre_PercentageOfOutstandingShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_PercentageOfOutstandingShares" xlink:to="apre_PercentageOfOutstandingShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_PercentageOfOutstandingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of outstanding shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_PercentageOfOutstandingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Outstanding Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_PercentageOfOutstandingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of outstanding shares</label>
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise" xlink:label="apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise" xlink:to="apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The expected gross proceeds from potential future warrant cash exercises.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected Gross Proceeds from Potential Future Warrant Cash Exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected gross proceeds from potential future warrants cash exercise</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant exercises</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability for Uncertainty in Income Taxes, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Uncertain tax positions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualProvision" xlink:label="us-gaap_LossContingencyAccrualProvision" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualProvision" xlink:to="us-gaap_LossContingencyAccrualProvision_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyAccrualProvision_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingency Accrual, Provision</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingencyAccrualProvision_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for contingent losses</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>apre-20240930_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/5/2024 12:13:12 PM-->
<!--Modified on: 11/5/2024 12:13:12 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="apre-20240930.xsd#DocumentDocumentAndEntityInformation" roleURI="http://aprea.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20240930.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://aprea.com/role/StatementCondensedConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20240930.xsd#StatementCondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://aprea.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20240930.xsd#StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://aprea.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20240930.xsd#StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" roleURI="http://aprea.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20240930.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20240930.xsd#DisclosureNatureOfBusinessAndBasisOfPresentation" roleURI="http://aprea.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20240930.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20240930.xsd#DisclosureLeases" roleURI="http://aprea.com/role/DisclosureLeases" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20240930.xsd#DisclosureAccruedExpenses" roleURI="http://aprea.com/role/DisclosureAccruedExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20240930.xsd#DisclosureStockholdersEquity" roleURI="http://aprea.com/role/DisclosureStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20240930.xsd#DisclosureIncomeTaxes" roleURI="http://aprea.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20240930.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://aprea.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20240930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20240930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20240930.xsd#DisclosureAccruedExpensesTables" roleURI="http://aprea.com/role/DisclosureAccruedExpensesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20240930.xsd#DisclosureNatureOfBusinessAndBasisOfPresentationDetails" roleURI="http://aprea.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20240930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails" roleURI="http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20240930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails" roleURI="http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20240930.xsd#DisclosureLeasesSummaryDetails" roleURI="http://aprea.com/role/DisclosureLeasesSummaryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20240930.xsd#DisclosureAccruedExpensesDetails" roleURI="http://aprea.com/role/DisclosureAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20240930.xsd#DisclosureStockholdersEquityDetails" roleURI="http://aprea.com/role/DisclosureStockholdersEquityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20240930.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://aprea.com/role/DisclosureIncomeTaxesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="apre-20240930.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://aprea.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <presentationLink xlink:role="http://aprea.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="995200090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638664055918757050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638664055918757050" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_638664055918757050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_638664055918757050" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638664055918757050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638664055918757050" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638664055918757050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_638664055918757050" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638664055918757050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638664055918757050" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638664055918757050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638664055918757050" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638664055918757050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638664055918757050" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638664055918757050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638664055918757050" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638664055918757050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638664055918757050" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638664055918757050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638664055918757050" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638664055918757050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638664055918757050" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638664055918757050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638664055918757050" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638664055918767028" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638664055918767028" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638664055918767028" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638664055918767028" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638664055918767028" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638664055918767028" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638664055918767028" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638664055918767028" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638664055918767028" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638664055918767028" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638664055918767028" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638664055918767028" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638664055918767028" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638664055918767028" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638664055918767028" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_638664055918767028" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638664055918767028" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_638664055918767028" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638664055918777017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638664055918777017" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_638664055918777017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_638664055918777017" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638664055918777017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_638664055918777017" order="24" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638664055918777017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638664055918777017" order="25" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638664055918777017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638664055918777017" order="26" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638664055918777017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638664055918777017" order="27" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638664055918777017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638664055918777017" order="28" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638664055918777017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638664055918777017" order="29" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638664055918787023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638664055918787023" order="30" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - Condensed Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638664055918787023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_638664055918787023" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638664055918787023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638664055918787023" xlink:to="us-gaap_StatementClassOfStockAxis_638664055918787023" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638664055918787023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638664055918787023" xlink:to="us-gaap_ClassOfStockDomain_638664055918787023" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember_638664055918787023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638664055918787023" xlink:to="us-gaap_ConvertiblePreferredStockMember_638664055918787023" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_ConvertiblePreferredStockSeriesaMember" xlink:label="apre_ConvertiblePreferredStockSeriesaMember_638664055918787023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConvertiblePreferredStockMember_638664055918787023" xlink:to="apre_ConvertiblePreferredStockSeriesaMember_638664055918787023" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638664055918797036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638664055918787023" xlink:to="us-gaap_StatementLineItems_638664055918797036" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638664055918797036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638664055918797036" xlink:to="us-gaap_AssetsAbstract_638664055918797036" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638664055918797036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638664055918797036" xlink:to="us-gaap_AssetsCurrentAbstract_638664055918797036" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638664055918797036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638664055918797036" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638664055918797036" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638664055918797036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638664055918797036" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638664055918797036" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638664055918797036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638664055918797036" xlink:to="us-gaap_AssetsCurrent_638664055918797036" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638664055918797036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638664055918797036" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638664055918797036" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638664055918797036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638664055918797036" xlink:to="us-gaap_RestrictedCashNoncurrent_638664055918797036" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638664055918797036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638664055918797036" xlink:to="us-gaap_OtherAssetsNoncurrent_638664055918797036" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638664055918797036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638664055918797036" xlink:to="us-gaap_Assets_638664055918797036" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638664055918807025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638664055918797036" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638664055918807025" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638664055918807025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638664055918807025" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638664055918807025" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638664055918807025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638664055918807025" xlink:to="us-gaap_AccountsPayableCurrent_638664055918807025" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:label="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_638664055918807025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638664055918807025" xlink:to="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_638664055918807025" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent_638664055918807025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638664055918807025" xlink:to="us-gaap_DeferredRevenueCurrent_638664055918807025" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638664055918807025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638664055918807025" xlink:to="us-gaap_LiabilitiesCurrent_638664055918807025" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638664055918807025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638664055918807025" xlink:to="us-gaap_CommitmentsAndContingencies_638664055918807025" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract_638664055918807025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638664055918807025" xlink:to="us-gaap_TemporaryEquityAbstract_638664055918807025" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638664055918807025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityAbstract_638664055918807025" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638664055918807025" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638664055918817021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638664055918807025" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638664055918817021" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638664055918817021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638664055918817021" xlink:to="us-gaap_CommonStockValue_638664055918817021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638664055918817021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638664055918817021" xlink:to="us-gaap_AdditionalPaidInCapital_638664055918817021" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638664055918817021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638664055918817021" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638664055918817021" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638664055918817021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638664055918817021" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638664055918817021" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638664055918817021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638664055918817021" xlink:to="us-gaap_StockholdersEquity_638664055918817021" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638664055918817021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638664055918807025" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638664055918817021" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="995200105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638664055918827019" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_638664055918827019" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638664055918827019" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638664055918827019" xlink:to="us-gaap_StatementClassOfStockAxis_638664055918827019" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638664055918827019" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638664055918827019" xlink:to="us-gaap_ClassOfStockDomain_638664055918827019" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_ConvertiblePreferredStockSeriesaMember" xlink:label="apre_ConvertiblePreferredStockSeriesaMember_638664055918827019" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638664055918827019" xlink:to="apre_ConvertiblePreferredStockSeriesaMember_638664055918827019" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638664055918827019" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638664055918827019" xlink:to="us-gaap_StatementLineItems_638664055918827019" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_638664055918827019" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638664055918827019" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_638664055918827019" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_638664055918827019" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638664055918827019" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_638664055918827019" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued_638664055918827019" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638664055918827019" xlink:to="us-gaap_TemporaryEquitySharesIssued_638664055918827019" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_638664055918827019" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638664055918827019" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_638664055918827019" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638664055918837025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638664055918827019" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638664055918837025" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638664055918837025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638664055918827019" xlink:to="us-gaap_CommonStockSharesAuthorized_638664055918837025" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638664055918837025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638664055918827019" xlink:to="us-gaap_CommonStockSharesIssued_638664055918837025" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638664055918837025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638664055918827019" xlink:to="us-gaap_CommonStockSharesOutstanding_638664055918837025" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="995200200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_638664055918837025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_638664055918837025" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638664055918837025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_638664055918837025" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638664055918837025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638664055918837025" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638664055918837025" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638664055918837025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638664055918837025" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638664055918837025" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638664055918837025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638664055918837025" xlink:to="us-gaap_OperatingExpenses_638664055918837025" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638664055918847037" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_638664055918847037" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_638664055918847037" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_638664055918847037" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_638664055918847037" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638664055918847037" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_638664055918847037" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638664055918847037" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638664055918847037" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638664055918847037" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638664055918847037" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638664055918847037" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638664055918847037" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638664055918847037" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_638664055918847037" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_638664055918847037" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_638664055918847037" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638664055918847037" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_638664055918847037" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638664055918847037" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_638664055918847037" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_638664055918847037" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638664055918847037" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic_638664055918847037" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638664055918857024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_638664055918857024" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638664055918857024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638664055918857024" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638664055918857024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638664055918857024" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity" xlink:type="extended" xlink:title="995200300 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638664055918857024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638664055918857024" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638664055918857024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638664055918857024" xlink:to="us-gaap_StatementClassOfStockAxis_638664055918857024" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_ConvertiblePreferredStockSeriesaMember" xlink:label="apre_ConvertiblePreferredStockSeriesaMember_638664055918857024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638664055918857024" xlink:to="apre_ConvertiblePreferredStockSeriesaMember_638664055918857024" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638664055918857024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638664055918857024" xlink:to="us-gaap_ClassOfStockDomain_638664055918857024" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638664055918857024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638664055918857024" xlink:to="us-gaap_StatementEquityComponentsAxis_638664055918857024" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_638664055918857024" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638664055918857024" xlink:to="us-gaap_PreferredStockMember_638664055918857024" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638664055918867022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638664055918857024" xlink:to="us-gaap_CommonStockMember_638664055918867022" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638664055918867022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638664055918857024" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638664055918867022" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638664055918867022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638664055918857024" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638664055918867022" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638664055918867022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638664055918857024" xlink:to="us-gaap_RetainedEarningsMember_638664055918867022" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638664055918867022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638664055918857024" xlink:to="us-gaap_EquityComponentDomain_638664055918867022" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638664055918867022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638664055918857024" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638664055918867022" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_AtMarketOfferingMember" xlink:label="apre_AtMarketOfferingMember_638664055918867022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638664055918867022" xlink:to="apre_AtMarketOfferingMember_638664055918867022" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638664055918867022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638664055918867022" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638664055918867022" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638664055918867022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638664055918857024" xlink:to="us-gaap_StatementLineItems_638664055918867022" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638664055918867022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638664055918867022" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638664055918867022" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_638664055918877017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638664055918867022" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_638664055918877017" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638664055918877017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638664055918867022" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638664055918877017" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_6386640559188770171" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638664055918867022" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_6386640559188770171" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_6386640559188770171" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638664055918867022" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_6386640559188770171" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638664055918877017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638664055918867022" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638664055918877017" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638664055918877017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638664055918877017" xlink:to="us-gaap_StockholdersEquity_638664055918877017" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638664055918877017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638664055918877017" xlink:to="us-gaap_SharesOutstanding_638664055918877017" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638664055918877017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638664055918877017" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638664055918877017" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638664055918877017" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_638664055918877017" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638664055918877017" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_638664055918887035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638664055918877017" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_638664055918887035" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_638664055918887035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638664055918877017" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_638664055918887035" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_638664055918887035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638664055918877017" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_638664055918887035" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638664055918887035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638664055918877017" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638664055918887035" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638664055918887035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638664055918877017" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638664055918887035" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638664055918887035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638664055918877017" xlink:to="us-gaap_NetIncomeLoss_638664055918887035" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638664055918887035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638664055918877017" xlink:to="us-gaap_StockholdersEquity_638664055918887035" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638664055918897028" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638664055918877017" xlink:to="us-gaap_SharesOutstanding_638664055918897028" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - Condensed Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638664055918897028" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638664055918897028" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638664055918897028" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638664055918897028" xlink:to="us-gaap_ProfitLoss_638664055918897028" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638664055918897028" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638664055918897028" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638664055918897028" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638664055918897028" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638664055918897028" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638664055918897028" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_638664055918897028" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638664055918897028" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_638664055918897028" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638664055918897028" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638664055918897028" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638664055918897028" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638664055918897028" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638664055918897028" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638664055918897028" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638664055918907035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638664055918897028" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638664055918907035" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638664055918907035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638664055918897028" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638664055918907035" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638664055918907035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638664055918897028" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638664055918907035" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_638664055918907035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638664055918897028" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_638664055918907035" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638664055918907035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638664055918897028" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638664055918907035" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638664055918907035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638664055918907035" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638664055918907035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638664055918907035" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638664055918907035" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638664055918907035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638664055918907035" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638664055918907035" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638664055918907035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638664055918907035" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638664055918907035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638664055918907035" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638664055918907035" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638664055918917026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638664055918907035" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638664055918917026" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638664055918917026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638664055918907035" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638664055918917026" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_638664055918917026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_638664055918917026" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638664055918917026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638664055918917026" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638664055918917026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638664055918917026" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6386640559189170261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6386640559189170261" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638664055918917026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638664055918917026" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638664055918917026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638664055918917026" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638664055918917026" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash_638664055918927019" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638664055918917026" xlink:to="us-gaap_RestrictedCash_638664055918927019" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638664055918927019" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638664055918917026" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638664055918927019" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation" xlink:type="extended" xlink:title="995210101 - Disclosure - Nature of business and basis of presentation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638664055918927019" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638664055918927019" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="995210201 - Disclosure - Summary of significant accounting policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638664055918927019" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638664055918927019" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureLeases" xlink:type="extended" xlink:title="995210301 - Disclosure - Leases" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_LeaseDisclosureTextBlock" xlink:label="apre_LeaseDisclosureTextBlock_638664055918937027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="apre_LeaseDisclosureTextBlock_638664055918937027" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureAccruedExpenses" xlink:type="extended" xlink:title="995210401 - Disclosure - Accrued expenses" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638664055918937027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638664055918937027" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="995210501 - Disclosure - Stockholders' equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_CommonStockTextBlock" xlink:label="apre_CommonStockTextBlock_638664055918937027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="apre_CommonStockTextBlock_638664055918937027" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="995210601 - Disclosure - Income taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638664055918937027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638664055918937027" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="995210701 - Disclosure - Commitments and contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638664055918947022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638664055918947022" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="99920202 - Disclosure - Summary of significant accounting policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock_638664055918947022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock_638664055918947022" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock" xlink:label="apre_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock_638664055918947022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="apre_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock_638664055918947022" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638664055918947022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638664055918947022" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_638664055918947022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_638664055918947022" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_638664055918947022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_638664055918947022" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_638664055918947022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_638664055918947022" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_TemporaryEquityPolicyTextBlock" xlink:label="apre_TemporaryEquityPolicyTextBlock_638664055918947022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="apre_TemporaryEquityPolicyTextBlock_638664055918947022" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_638664055918947022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_638664055918947022" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638664055918947022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638664055918947022" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_638664055918957026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_638664055918957026" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638664055918957026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638664055918957026" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638664055918957026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638664055918957026" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638664055918957026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638664055918957026" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="99930203 - Disclosure - Summary of significant accounting policies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638664055918957026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638664055918957026" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureAccruedExpensesTables" xlink:type="extended" xlink:title="99930403 - Disclosure - Accrued expenses (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638664055918957026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638664055918957026" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails" xlink:type="extended" xlink:title="99940101 - Disclosure - Nature of business and basis of presentation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638664055918967026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638664055918967026" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_638664055918967026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_638664055918967026" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails" xlink:type="extended" xlink:title="99940201 - Disclosure - Summary of significant accounting policies - Restricted cash (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash_638664055918967026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_RestrictedCash_638664055918967026" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails" xlink:type="extended" xlink:title="99940202 - Disclosure - Summary of significant accounting policies - Potentially dilutive securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_ScheduleOfEarningsPerShareBasicAndDilutedTable" xlink:label="apre_ScheduleOfEarningsPerShareBasicAndDilutedTable_638664055918967026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="apre_ScheduleOfEarningsPerShareBasicAndDilutedTable_638664055918967026" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638664055918967026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_ScheduleOfEarningsPerShareBasicAndDilutedTable_638664055918967026" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638664055918967026" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638664055918967026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638664055918967026" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638664055918967026" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember_638664055918967026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638664055918967026" xlink:to="us-gaap_ConvertiblePreferredStockMember_638664055918967026" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638664055918967026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638664055918967026" xlink:to="us-gaap_EmployeeStockOptionMember_638664055918967026" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_638664055918977029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638664055918967026" xlink:to="us-gaap_WarrantMember_638664055918977029" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638664055918977029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638664055918967026" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638664055918977029" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638664055918977029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_ScheduleOfEarningsPerShareBasicAndDilutedTable_638664055918967026" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638664055918977029" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638664055918977029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638664055918977029" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638664055918977029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_638664055918977029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638664055918977029" xlink:to="us-gaap_PrivatePlacementMember_638664055918977029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638664055918977029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_ScheduleOfEarningsPerShareBasicAndDilutedTable_638664055918967026" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638664055918977029" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638664055918977029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638664055918977029" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638664055918977029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_PreFundedWarrantsMember" xlink:label="apre_PreFundedWarrantsMember_638664055918977029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638664055918977029" xlink:to="apre_PreFundedWarrantsMember_638664055918977029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_PreFundedWarrantsExercisePrice7.29PerShareMember" xlink:label="apre_PreFundedWarrantsExercisePrice7.29PerShareMember_638664055918977029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_PreFundedWarrantsMember_638664055918977029" xlink:to="apre_PreFundedWarrantsExercisePrice7.29PerShareMember_638664055918977029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_ScheduleOfEarningsPerShareBasicAndDilutedLineItems" xlink:label="apre_ScheduleOfEarningsPerShareBasicAndDilutedLineItems_638664055918977029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_ScheduleOfEarningsPerShareBasicAndDilutedTable_638664055918967026" xlink:to="apre_ScheduleOfEarningsPerShareBasicAndDilutedLineItems_638664055918977029" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract" xlink:label="apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract_638664055918977029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_ScheduleOfEarningsPerShareBasicAndDilutedLineItems_638664055918977029" xlink:to="apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract_638664055918977029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638664055918987032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract_638664055918977029" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638664055918987032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638664055918987032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract_638664055918977029" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638664055918987032" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureLeasesSummaryDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - Leases - Summary (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_LesseeOperatingLeaseNumberOfOperatingLeases" xlink:label="apre_LesseeOperatingLeaseNumberOfOperatingLeases_638664055918987032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="apre_LesseeOperatingLeaseNumberOfOperatingLeases_638664055918987032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense_638664055918987032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseExpense_638664055918987032" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_LesseeOperatingLeaseAnnualBaseRent" xlink:label="apre_LesseeOperatingLeaseAnnualBaseRent_638664055918987032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="apre_LesseeOperatingLeaseAnnualBaseRent_638664055918987032" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_LesseeOperatingLeaseAnnualBaseRentObligationAfterCurrentYear" xlink:label="apre_LesseeOperatingLeaseAnnualBaseRentObligationAfterCurrentYear_638664055918987032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="apre_LesseeOperatingLeaseAnnualBaseRentObligationAfterCurrentYear_638664055918987032" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - Accrued expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638664055918987032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638664055918987032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638664055918987032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638664055918987032" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_ResearchAndDevelopmentRelatedLiabilitiesCurrent" xlink:label="apre_ResearchAndDevelopmentRelatedLiabilitiesCurrent_638664055918997020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="apre_ResearchAndDevelopmentRelatedLiabilitiesCurrent_638664055918997020" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638664055918997020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638664055918997020" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:label="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_638664055918997020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_638664055918997020" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureStockholdersEquityDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - Stockholders' equity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638664055918997020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638664055918997020" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638664055918997020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638664055918997020" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638664055918997020" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638664055918997020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638664055918997020" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638664055918997020" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_638664055918997020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638664055918997020" xlink:to="us-gaap_PrivatePlacementMember_638664055918997020" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_ShelfRegistrationStatementMember" xlink:label="apre_ShelfRegistrationStatementMember_638664055918997020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638664055918997020" xlink:to="apre_ShelfRegistrationStatementMember_638664055918997020" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_AtMarketOfferingMember" xlink:label="apre_AtMarketOfferingMember_638664055918997020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_ShelfRegistrationStatementMember_638664055918997020" xlink:to="apre_AtMarketOfferingMember_638664055918997020" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_ShelfRegistrationStatement2024Member" xlink:label="apre_ShelfRegistrationStatement2024Member_638664055918997020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638664055918997020" xlink:to="apre_ShelfRegistrationStatement2024Member_638664055918997020" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_AtMarket2024OfferingMember" xlink:label="apre_AtMarket2024OfferingMember_638664055919007022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_ShelfRegistrationStatement2024Member_638664055918997020" xlink:to="apre_AtMarket2024OfferingMember_638664055919007022" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638664055919007022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638664055918997020" xlink:to="srt_CounterpartyNameAxis_638664055919007022" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638664055919007022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638664055919007022" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638664055919007022" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_HCWainrightCoLlcMember" xlink:label="apre_HCWainrightCoLlcMember_638664055919007022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638664055919007022" xlink:to="apre_HCWainrightCoLlcMember_638664055919007022" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_CertainPurchasersMember" xlink:label="apre_CertainPurchasersMember_638664055919007022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638664055919007022" xlink:to="apre_CertainPurchasersMember_638664055919007022" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638664055919007022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638664055918997020" xlink:to="us-gaap_StatementClassOfStockAxis_638664055919007022" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638664055919007022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638664055919007022" xlink:to="us-gaap_ClassOfStockDomain_638664055919007022" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638664055919007022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638664055919007022" xlink:to="us-gaap_CommonStockMember_638664055919007022" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_ConvertiblePreferredStockSeriesaMember" xlink:label="apre_ConvertiblePreferredStockSeriesaMember_638664055919007022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638664055919007022" xlink:to="apre_ConvertiblePreferredStockSeriesaMember_638664055919007022" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638664055919007022" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638664055918997020" xlink:to="us-gaap_TypeOfArrangementAxis_638664055919007022" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638664055919017019" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638664055919007022" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638664055919017019" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_SecuritiesPurchaseAgreementMember" xlink:label="apre_SecuritiesPurchaseAgreementMember_638664055919017019" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638664055919017019" xlink:to="apre_SecuritiesPurchaseAgreementMember_638664055919017019" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638664055919017019" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638664055918997020" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638664055919017019" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638664055919017019" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638664055919017019" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638664055919017019" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_PreFundedWarrantsMember" xlink:label="apre_PreFundedWarrantsMember_638664055919017019" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638664055919017019" xlink:to="apre_PreFundedWarrantsMember_638664055919017019" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_PreFundedWarrantsExercisePrice7.29PerShareMember" xlink:label="apre_PreFundedWarrantsExercisePrice7.29PerShareMember_638664055919017019" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_PreFundedWarrantsMember_638664055919017019" xlink:to="apre_PreFundedWarrantsExercisePrice7.29PerShareMember_638664055919017019" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_PreFundedWarrantsExercisePrice9.1125PerShareMember" xlink:label="apre_PreFundedWarrantsExercisePrice9.1125PerShareMember_638664055919017019" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_PreFundedWarrantsMember_638664055919017019" xlink:to="apre_PreFundedWarrantsExercisePrice9.1125PerShareMember_638664055919017019" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638664055919017019" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638664055918997020" xlink:to="srt_StatementScenarioAxis_638664055919017019" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638664055919017019" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638664055919017019" xlink:to="srt_ScenarioUnspecifiedDomain_638664055919017019" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_AtEventOfElectionOfHolderMember" xlink:label="apre_AtEventOfElectionOfHolderMember_638664055919027020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638664055919017019" xlink:to="apre_AtEventOfElectionOfHolderMember_638664055919027020" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_638664055919027020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638664055918997020" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_638664055919027020" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_StockSharesAuthorized" xlink:label="apre_StockSharesAuthorized_638664055919027020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638664055919027020" xlink:to="apre_StockSharesAuthorized_638664055919027020" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638664055919027020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638664055919027020" xlink:to="us-gaap_CommonStockSharesAuthorized_638664055919027020" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638664055919027020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638664055919027020" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638664055919027020" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638664055919027020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638664055919027020" xlink:to="us-gaap_PreferredStockSharesAuthorized_638664055919027020" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638664055919027020" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638664055919027020" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638664055919027020" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_638664055919037026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638664055919027020" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_638664055919037026" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_638664055919037026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638664055919027020" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_638664055919037026" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_AtMarketOfferingCommissionPayableAsPercentageOfGrossProceedsFromSaleOfCommonStock" xlink:label="apre_AtMarketOfferingCommissionPayableAsPercentageOfGrossProceedsFromSaleOfCommonStock_638664055919037026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638664055919027020" xlink:to="apre_AtMarketOfferingCommissionPayableAsPercentageOfGrossProceedsFromSaleOfCommonStock_638664055919037026" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_CommonStockNumberOfVotingRightsPerShare" xlink:label="apre_CommonStockNumberOfVotingRightsPerShare_638664055919037026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638664055919027020" xlink:to="apre_CommonStockNumberOfVotingRightsPerShare_638664055919037026" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638664055919037026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638664055919027020" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638664055919037026" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_ShelfRegistrationStatementAbstract" xlink:label="apre_ShelfRegistrationStatementAbstract_638664055919037026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638664055919027020" xlink:to="apre_ShelfRegistrationStatementAbstract_638664055919037026" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_UniversalShelfRegistrationMaximumAmountToBeIssued" xlink:label="apre_UniversalShelfRegistrationMaximumAmountToBeIssued_638664055919037026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_ShelfRegistrationStatementAbstract_638664055919037026" xlink:to="apre_UniversalShelfRegistrationMaximumAmountToBeIssued_638664055919037026" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_AtMarketOfferingProgramMaximumAmountToBeIssued" xlink:label="apre_AtMarketOfferingProgramMaximumAmountToBeIssued_638664055919047030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_ShelfRegistrationStatementAbstract_638664055919037026" xlink:to="apre_AtMarketOfferingProgramMaximumAmountToBeIssued_638664055919047030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement" xlink:label="apre_AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement_638664055919047030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_ShelfRegistrationStatementAbstract_638664055919037026" xlink:to="apre_AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement_638664055919047030" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638664055919047030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_ShelfRegistrationStatementAbstract_638664055919037026" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638664055919047030" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare_638664055919047030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_ShelfRegistrationStatementAbstract_638664055919037026" xlink:to="us-gaap_SaleOfStockPricePerShare_638664055919047030" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638664055919047030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_ShelfRegistrationStatementAbstract_638664055919037026" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638664055919047030" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638664055919047030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_ShelfRegistrationStatementAbstract_638664055919037026" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638664055919047030" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638664055919057025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_ShelfRegistrationStatementAbstract_638664055919037026" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638664055919057025" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_PrivatePlacementAbstract" xlink:label="apre_PrivatePlacementAbstract_638664055919057025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638664055919027020" xlink:to="apre_PrivatePlacementAbstract_638664055919057025" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638664055919057025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_PrivatePlacementAbstract_638664055919057025" xlink:to="us-gaap_SharesIssuedPricePerShare_638664055919057025" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638664055919057025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_PrivatePlacementAbstract_638664055919057025" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638664055919057025" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638664055919057025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_PrivatePlacementAbstract_638664055919057025" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638664055919057025" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_StockIssuanceAnniversaryPeriod" xlink:label="apre_StockIssuanceAnniversaryPeriod_638664055919067021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_PrivatePlacementAbstract_638664055919057025" xlink:to="apre_StockIssuanceAnniversaryPeriod_638664055919067021" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119" xlink:label="apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119_638664055919067021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_PrivatePlacementAbstract_638664055919057025" xlink:to="apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119_638664055919067021" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_SharesIssuedVolumeWeightedAveragePricePerShare" xlink:label="apre_SharesIssuedVolumeWeightedAveragePricePerShare_638664055919067021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_PrivatePlacementAbstract_638664055919057025" xlink:to="apre_SharesIssuedVolumeWeightedAveragePricePerShare_638664055919067021" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_NumberOfConsecutiveTradingDays" xlink:label="apre_NumberOfConsecutiveTradingDays_638664055919067021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_PrivatePlacementAbstract_638664055919057025" xlink:to="apre_NumberOfConsecutiveTradingDays_638664055919067021" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_PercentageOfOutstandingShares" xlink:label="apre_PercentageOfOutstandingShares_638664055919067021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_PrivatePlacementAbstract_638664055919057025" xlink:to="apre_PercentageOfOutstandingShares_638664055919067021" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_638664055919067021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_PrivatePlacementAbstract_638664055919057025" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_638664055919067021" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="apre-20240930.xsd#apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise" xlink:label="apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise_638664055919077028" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_PrivatePlacementAbstract_638664055919057025" xlink:to="apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise_638664055919077028" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638664055919077028" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="apre_PrivatePlacementAbstract_638664055919057025" xlink:to="us-gaap_ProceedsFromWarrantExercises_638664055919077028" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - Income Taxes - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638664055919077028" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638664055919077028" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_638664055919087037" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_638664055919087037" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://aprea.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="99940701 - Disclosure - Commitments and contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualProvision" xlink:label="us-gaap_LossContingencyAccrualProvision_638664055919087037" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingencyAccrualProvision_638664055919087037" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended" xlink:title="995445 - Disclosure - Insider Trading Arrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46326898655728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Nov. 07, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Aprea Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-2246769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3805 Old Easton Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Doylestown<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">18902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">463-9385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">APRE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,434,903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001781983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46326899066368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 26,249,625<span></span>
</td>
<td class="nump">$ 21,606,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">234,195<span></span>
</td>
<td class="nump">914,275<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">26,483,820<span></span>
</td>
<td class="nump">22,521,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">86,950<span></span>
</td>
<td class="nump">88,362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">41,537<span></span>
</td>
<td class="nump">40,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">281,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">26,893,969<span></span>
</td>
<td class="nump">22,650,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,153,880<span></span>
</td>
<td class="nump">1,670,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">2,482,008<span></span>
</td>
<td class="nump">2,186,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">528,974<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,635,888<span></span>
</td>
<td class="nump">4,385,605<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 400,000,000 shares authorized, 5,434,903 and 3,736,673 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively</a></td>
<td class="nump">5,435<span></span>
</td>
<td class="nump">3,736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">350,693,403<span></span>
</td>
<td class="nump">335,644,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(10,604,747)<span></span>
</td>
<td class="num">(10,611,273)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(318,147,073)<span></span>
</td>
<td class="num">(308,083,161)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">21,947,018<span></span>
</td>
<td class="nump">16,953,506<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">26,893,969<span></span>
</td>
<td class="nump">22,650,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=apre_ConvertiblePreferredStockSeriesaMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Convertible preferred stock:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Series A convertible preferred stock, $0.001 par value, 40,000,000 shares authorized; 56,227 shares issued and outstanding at September 30, 2024 and December 31, 2023</a></td>
<td class="nump">$ 1,311,063<span></span>
</td>
<td class="nump">$ 1,311,063<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Also includes obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=apre_ConvertiblePreferredStockSeriesaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=apre_ConvertiblePreferredStockSeriesaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46326898428832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">5,434,903<span></span>
</td>
<td class="nump">3,736,673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">5,434,903<span></span>
</td>
<td class="nump">3,736,673<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=apre_ConvertiblePreferredStockSeriesaMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="nump">40,000,000<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="nump">56,227<span></span>
</td>
<td class="nump">56,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="nump">56,227<span></span>
</td>
<td class="nump">56,227<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=apre_ConvertiblePreferredStockSeriesaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=apre_ConvertiblePreferredStockSeriesaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46326899027424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Grant revenue</a></td>
<td class="nump">$ 354,621<span></span>
</td>
<td class="nump">$ 319,468<span></span>
</td>
<td class="nump">$ 1,296,764<span></span>
</td>
<td class="nump">$ 569,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">2,846,399<span></span>
</td>
<td class="nump">2,122,603<span></span>
</td>
<td class="nump">7,004,451<span></span>
</td>
<td class="nump">5,581,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,605,238<span></span>
</td>
<td class="nump">1,719,715<span></span>
</td>
<td class="nump">5,385,923<span></span>
</td>
<td class="nump">6,784,388<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">4,451,637<span></span>
</td>
<td class="nump">3,842,318<span></span>
</td>
<td class="nump">12,390,374<span></span>
</td>
<td class="nump">12,366,190<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(4,097,016)<span></span>
</td>
<td class="num">(3,522,850)<span></span>
</td>
<td class="num">(11,093,610)<span></span>
</td>
<td class="num">(11,797,034)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income, net</a></td>
<td class="nump">348,741<span></span>
</td>
<td class="nump">321,215<span></span>
</td>
<td class="nump">1,014,518<span></span>
</td>
<td class="nump">913,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency (loss) gain</a></td>
<td class="num">(35,494)<span></span>
</td>
<td class="num">(2,880)<span></span>
</td>
<td class="nump">15,180<span></span>
</td>
<td class="nump">39,686<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">313,247<span></span>
</td>
<td class="nump">318,335<span></span>
</td>
<td class="nump">1,029,698<span></span>
</td>
<td class="nump">953,532<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,783,769)<span></span>
</td>
<td class="num">(3,204,515)<span></span>
</td>
<td class="num">(10,063,912)<span></span>
</td>
<td class="num">(10,843,502)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">23,557<span></span>
</td>
<td class="num">(1,002)<span></span>
</td>
<td class="nump">6,526<span></span>
</td>
<td class="num">(12,466)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (3,760,212)<span></span>
</td>
<td class="num">$ (3,205,517)<span></span>
</td>
<td class="num">$ (10,057,386)<span></span>
</td>
<td class="num">$ (10,855,968)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders, basic (in dollars per share)</a></td>
<td class="num">$ (0.64)<span></span>
</td>
<td class="num">$ (0.86)<span></span>
</td>
<td class="num">$ (1.88)<span></span>
</td>
<td class="num">$ (3.03)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders, diluted (in dollars per share)</a></td>
<td class="num">$ (0.64)<span></span>
</td>
<td class="num">$ (0.86)<span></span>
</td>
<td class="num">$ (1.88)<span></span>
</td>
<td class="num">$ (3.03)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic (in shares)</a></td>
<td class="nump">5,939,755<span></span>
</td>
<td class="nump">3,735,176<span></span>
</td>
<td class="nump">5,360,579<span></span>
</td>
<td class="nump">3,577,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">5,939,755<span></span>
</td>
<td class="nump">3,735,176<span></span>
</td>
<td class="nump">5,360,579<span></span>
</td>
<td class="nump">3,577,482<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46326889942112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th">
<div>Series A Convertible Preferred Stock </div>
<div>Preferred Stock</div>
</th>
<th class="th"><div>Series A Convertible Preferred Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>At Market Offering [Member]</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Additional Paid-in capital </div>
<div>At Market Offering [Member]</div>
</th>
<th class="th"><div>Additional Paid-in capital</div></th>
<th class="th"><div>Accumulated other comprehensive loss</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>At Market Offering [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">56,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 1,311,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">56,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 1,311,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, beginning balance at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 330,060,836<span></span>
</td>
<td class="num">$ (10,623,408)<span></span>
</td>
<td class="num">$ (293,796,405)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,643,678<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,655,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 1,050<span></span>
</td>
<td class="nump">$ 268,099<span></span>
</td>
<td class="nump">4,870,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 268,125<span></span>
</td>
<td class="nump">4,871,865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,302<span></span>
</td>
<td class="nump">1,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,956<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,379,890)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,379,890)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, ending balance at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">335,215,994<span></span>
</td>
<td class="num">(10,561,452)<span></span>
</td>
<td class="num">(298,176,295)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,481,978<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,731,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">56,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 1,311,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, ending balance (in shares) at Sep. 30, 2023</a></td>
<td class="nump">56,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, ending balance at Sep. 30, 2023</a></td>
<td class="nump">$ 1,311,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, beginning balance at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330,060,836<span></span>
</td>
<td class="num">(10,623,408)<span></span>
</td>
<td class="num">(293,796,405)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,643,678<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,655,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,466)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,843,502)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, ending balance at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">335,561,343<span></span>
</td>
<td class="num">(10,635,874)<span></span>
</td>
<td class="num">(304,639,907)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,289,298<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,736,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, beginning balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">56,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, beginning balance at Mar. 31, 2023</a></td>
<td class="nump">$ 1,311,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="nump">56,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, ending balance at Jun. 30, 2023</a></td>
<td class="nump">$ 1,311,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, beginning balance at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">335,215,994<span></span>
</td>
<td class="num">(10,561,452)<span></span>
</td>
<td class="num">(298,176,295)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,481,978<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, beginning balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,731,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269,323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73,420)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73,420)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,259,097)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,259,097)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, ending balance at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">335,485,317<span></span>
</td>
<td class="num">(10,634,872)<span></span>
</td>
<td class="num">(301,435,392)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,418,784<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,731,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, ending balance (in shares) at Sep. 30, 2023</a></td>
<td class="nump">56,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, ending balance at Sep. 30, 2023</a></td>
<td class="nump">$ 1,311,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,002)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,002)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,204,515)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,204,515)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, ending balance at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">335,561,343<span></span>
</td>
<td class="num">(10,635,874)<span></span>
</td>
<td class="num">(304,639,907)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,289,298<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,736,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">56,227<span></span>
</td>
<td class="nump">56,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 1,311,063<span></span>
</td>
<td class="nump">$ 1,311,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="nump">56,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, ending balance at Mar. 31, 2024</a></td>
<td class="nump">$ 1,311,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, beginning balance at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">335,644,204<span></span>
</td>
<td class="num">(10,611,273)<span></span>
</td>
<td class="num">(308,083,161)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,953,506<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,736,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,708,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,709,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,687,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,083)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,083)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,810,091)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,810,091)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, ending balance at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,438,045<span></span>
</td>
<td class="num">(10,626,356)<span></span>
</td>
<td class="num">(310,893,252)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,923,867<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,430,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">56,227<span></span>
</td>
<td class="nump">56,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 1,311,063<span></span>
</td>
<td class="nump">$ 1,311,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, ending balance (in shares) at Sep. 30, 2024</a></td>
<td class="nump">56,227<span></span>
</td>
<td class="nump">56,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, ending balance at Sep. 30, 2024</a></td>
<td class="nump">$ 1,311,063<span></span>
</td>
<td class="nump">$ 1,311,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, beginning balance at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">335,644,204<span></span>
</td>
<td class="num">(10,611,273)<span></span>
</td>
<td class="num">(308,083,161)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,953,506<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,736,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,063,912)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, ending balance at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,693,403<span></span>
</td>
<td class="num">(10,604,747)<span></span>
</td>
<td class="num">(318,147,073)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,947,018<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,434,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, beginning balance (in shares) at Mar. 31, 2024</a></td>
<td class="nump">56,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, beginning balance at Mar. 31, 2024</a></td>
<td class="nump">$ 1,311,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, ending balance (in shares) at Jun. 30, 2024</a></td>
<td class="nump">56,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, ending balance at Jun. 30, 2024</a></td>
<td class="nump">$ 1,311,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, beginning balance at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,438,045<span></span>
</td>
<td class="num">(10,626,356)<span></span>
</td>
<td class="num">(310,893,252)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,923,867<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, beginning balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,430,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,060)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,060)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,948)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,948)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,470,052)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,470,052)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, ending balance at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,545,473<span></span>
</td>
<td class="num">(10,628,304)<span></span>
</td>
<td class="num">(314,363,304)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,559,295<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,430,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, ending balance (in shares) at Sep. 30, 2024</a></td>
<td class="nump">56,227<span></span>
</td>
<td class="nump">56,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, ending balance at Sep. 30, 2024</a></td>
<td class="nump">$ 1,311,063<span></span>
</td>
<td class="nump">$ 1,311,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,155)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,155)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,783,769)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,783,769)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity, ending balance at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,693,403<span></span>
</td>
<td class="num">$ (10,604,747)<span></span>
</td>
<td class="num">$ (318,147,073)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,947,018<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,434,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46326899003280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10,063,912)<span></span>
</td>
<td class="num">$ (10,843,502)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,890<span></span>
</td>
<td class="nump">2,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash', window );">Stockbased compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">363,408<span></span>
</td>
<td class="nump">361,598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency (gain) loss</a></td>
<td class="nump">$ 35,494<span></span>
</td>
<td class="nump">$ 2,880<span></span>
</td>
<td class="num">(15,180)<span></span>
</td>
<td class="num">(39,686)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">398,531<span></span>
</td>
<td class="nump">1,077,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(515,964)<span></span>
</td>
<td class="nump">21,873<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">299,387<span></span>
</td>
<td class="nump">982,563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(528,974)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,045,814)<span></span>
</td>
<td class="num">(8,437,950)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,478)<span></span>
</td>
<td class="num">(85,943)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,478)<span></span>
</td>
<td class="num">(85,943)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,999,598<span></span>
</td>
<td class="nump">5,788,918<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Common stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,312,108)<span></span>
</td>
<td class="num">(648,928)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,687,490<span></span>
</td>
<td class="nump">5,139,990<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Change in cash and cash equivalents and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,626,198<span></span>
</td>
<td class="num">(3,383,903)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,427<span></span>
</td>
<td class="num">(8,782)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash-beginning of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,647,537<span></span>
</td>
<td class="nump">28,786,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash-end of period</a></td>
<td class="nump">26,291,162<span></span>
</td>
<td class="nump">25,393,962<span></span>
</td>
<td class="nump">26,291,162<span></span>
</td>
<td class="nump">25,393,962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">26,249,625<span></span>
</td>
<td class="nump">25,353,513<span></span>
</td>
<td class="nump">26,249,625<span></span>
</td>
<td class="nump">25,353,513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">41,537<span></span>
</td>
<td class="nump">40,449<span></span>
</td>
<td class="nump">41,537<span></span>
</td>
<td class="nump">40,449<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 26,291,162<span></span>
</td>
<td class="nump">$ 25,393,962<span></span>
</td>
<td class="nump">$ 26,291,162<span></span>
</td>
<td class="nump">$ 25,393,962<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense (reversal of expense) for employee benefits and share-based payment arrangement. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46326897641600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of business and basis of presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of business and basis of presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of business and basis of presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Nature of business and basis of presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Nature of business</b><span style="white-space:pre-wrap;">&#8212;Aprea Therapeutics, Inc. (the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company began principal operations in 2006 and is headquartered in Doylestown, Pennsylvania.  Prior to the acquisition of Atrin Pharmaceuticals Inc. (&#8220;Atrin&#8221;) in May 2022, the Company was engaged in the clinical development of cancer therapeutics that reactivate the mutant p53 tumor suppressor protein. In December 2020, the Company announced that its pivotal Phase 3 myelodysplastic syndromes trial failed to meet its predefined primary endpoint of complete remission (CR) rate. Given these results, FDA feedback and the costs of continuing the APR-246 development program, the Company shifted focus of its activities to the assets acquired in the May 2022 acquisition of Atrin. The Company&#8217;s two clinical programs are a novel oral macrocyclic ATR inhibitor, ATRN-119, and our next-generation oral inhibitor of the WEE1 kinase, APR-1051. Both programs are the cornerstones of our pipeline of synthetic lethality-based cancer therapeutics and were internally discovered, developed, and evaluated by our dedicated team of chemists, scientists, and clinicians.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Basis of presentation and management plans</b>&#8212;The accompanying financial statements are prepared in conformity with accounting principles generally accepted in the United States (&#8220;U.S.&#160;GAAP&#8221;). The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Since its inception, the Company has devoted substantially all of its efforts to business planning, clinical operations, research and development, recruiting management, technical staff, raising capital and has financed its operations through the issuance of convertible preferred stock and common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks common to companies in the biopharmaceutical industry. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be maintained, that any therapeutic products developed will obtain required regulatory approval or that any approved or consumer products will be commercially viable. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will generate significant product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company believes that the September&#160;30,&#160;2024 cash balance of approximately $26.2 million will be sufficient to fund the Company&#8217;s operating expenses and capital expenditure requirements through at least twelve months from the date of issuance of these condensed consolidated financial statements. In the event that additional funds are not available thereafter, management would expect to significantly reduce expenditures to conserve cash, which would involve scaling back or curtailing new development activity.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46326902738528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Summary of significant accounting policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company's complete listing of significant accounting policies are described in Note 2 to the Company's audited consolidated financial statements as of December&#160;31,&#160;2023 included in its annual report on Form 10-K filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Principles of consolidation</b>&#8212;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries Aprea Therapeutics AB, which was incorporated in May 2009, Aprea US,&#160;Inc., which was incorporated in June&#160;2016 and ATR Pharmaceuticals LLC which was incorporated in May 2022. Management has concluded it has a single reporting segment for purposes of reporting financial condition and results of operations. All intercompany transactions and balances have been eliminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Unaudited interim consolidated financial statements</b>&#8212;The accompanying unaudited interim condensed consolidated financial statements have been prepared by the Company in accordance with U.S. GAAP for interim information and pursuant to the rules and regulations of the SEC for reporting on Form 10-Q. Accordingly, certain information and footnote disclosure normally included in financial statements prepared in accordance with U.S. GAAP have been </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">condensed or omitted pursuant to such rules and regulations. These unaudited condensed interim financial statements should be read in conjunction with the audited financial statements and related notes included in the Company&#8217;s annual report on Form 10-K for the year ended December&#160;31,&#160;2023 filed with the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The unaudited interim consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements, and in management&#8217;s opinion, include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of the financial information for the interim periods have been made. The results of operations for the three and nine months ended September&#160;30,&#160;2024 are not necessarily indicative of the results to be expected for the full fiscal year or any future period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of estimates</b>&#8212;The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses as of and during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates. Significant items subject to such estimates and assumptions, are used for, but not limited to, include stock-based compensation and accounting for research and development costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Foreign currency and currency translation</b>&#8212;The functional currency for Aprea Therapeutics AB is the Swedish Krona. Assets and liabilities of Aprea Therapeutics AB are translated into United States dollars at the exchange rate in effect on the balance sheet date. Operating expenses are translated at the average exchange rate in effect during the period. Unrealized translation gains and losses are recorded as a cumulative translation adjustment, which is included in the consolidated statements of stockholders&#8217; equity as a component of accumulated other comprehensive loss. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other income, net in the condensed consolidated statements of operations and comprehensive loss as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cash and cash equivalents&#8212; </b>The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Restricted cash&#8212; </b>The Company has restricted cash of $41,537 and $40,717 at September&#160;30,&#160;2024 and December&#160;31,&#160;2023, respectively, that is securing the Company&#8217;s credit card program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Fair value of financial instruments</b>&#8212;The accounting standard for fair value measurements provides a framework for measuring fair value and requires expanded disclosures regarding fair value measurements. Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic 820, Fair Value Measurement (&#8220;ASC 820&#8221;), establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The hierarchy defines three levels of valuation inputs, of which the first two are considered observable and the last is considered unobservable:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;1 inputs: Quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;2 inputs: Inputs other than quoted prices included within Level&#160;1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;3 inputs: Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use in pricing the asset or liability.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial instruments consist of cash, cash equivalents, restricted cash, accounts payable and accrued expenses. The carrying amount of accounts payable and accrued expenses is considered a reasonable estimate of fair value due to the short-term maturity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Series A Convertible Preferred Stock</b>&#8212;The Company classifies the Series A Preferred Stock as temporary equity outside of stockholders&#8217; equity on the accompanying condensed consolidated balance sheets&#160;due to certain events that are not within the Company's control.&#160;The Series A Preferred Stock was recorded at fair value upon the acquisition of Atrin in May 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Accounting for leases</b>&#8212;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified asset(s), if any, and the Company&#8217;s control over the use of the identified asset(s), if applicable. Operating lease liabilities and their corresponding right of use assets are recorded based on the present value of future lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;">The Company has elected not to separate lease and non-lease components as a single component. Operating leases are recognized on the balance sheet as right of use (ROU) lease assets, lease liabilities current and lease liabilities non-current. Fixed rents are included in the calculation of the lease balances while variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis. The Company has also elected the short-term lease exemption for all leases with an original term of less than 12&#160;months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Research and development costs</b>&#8212;Research and development costs are charged to expense as incurred. Research and development expenses incurred in performing research and development activities, include salaries and benefits, materials and supplies, preclinical expenses, stock-based compensation expense, depreciation of equipment, contract services, and other outside expenses. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development. Deposits made by the Company with certain service providers that are to be applied to future payments due under the service agreements or returned to the Company if not utilized are recorded in the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Revenue recognition</b>&#8212; The Company&#8217;s revenue is primarily generated through grants from government and non-government organizations. Grant revenue is recognized during the period that the reimbursable research and development services occur, as qualifying expenses are incurred or conditions of the grants are met. Grant revenue received in advance is recorded as deferred grant revenue and recognized as revenue once the conditions for revenue recognition are met. Associated expenses are recognized when incurred as research and development expenses. The Company concluded that payments received under these grants represent conditional, nonreciprocal contributions, as described in ASC&#160;<i style="font-style:italic;">958,</i><i style="font-style:italic;">&#160;</i>Not-for-Profit Entities, and that the grants are&#160;<i style="font-style:italic;">not</i>&#160;within the scope of ASC&#160;<i style="font-style:italic;">606,</i>&#160;Revenue from Contracts with Customers, as the organizations providing the grants do&#160;<i style="font-style:italic;">not</i>&#160;meet the definition of a customer. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stock-based compensation</b>&#8212;The Company measures stock options and other stock-based awards granted to employees and directors based on their fair value on the date of the grant and recognize compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective award. The Company applies the straight-line method of expense recognition to all awards with only service based vesting conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For stock-based awards granted to non-employees, compensation expense is recognized over the period during which services are rendered by such non-employees until completed in accordance with ASC 718. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company estimates the fair value of each stock option grant on the date of grant using the Black Scholes option pricing model, which uses as inputs the fair value of the Company&#8217;s common stock and assumptions the Company makes for the volatility of its common stock, the expected term of its stock options, the risk-free interest rate for a period that approximates the expected term of its stock options and its expected dividend yield. The Company elects to account for forfeitures when they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company also awards restricted stock units (&#8220;RSUs&#8221;) to employees and directors. RSUs are generally subject to forfeiture if employment terminates prior to the completion of the vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Net loss per share</b>&#8212;The Company has reported losses since inception and has computed basic net loss per share attributable to common stockholders by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company computes diluted net loss per common share after giving consideration to all potentially dilutive common shares, including options to purchase common stock, outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential common shares have been anti-dilutive and basic and diluted loss per share have been the same. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Included within weighted average common shares outstanding for the three and nine months ended September&#160;30,&#160;2024 are 507,076 common shares issuable upon the exercise of certain warrants, which are exercisable at any time for nominal consideration, and as such, the shares are considered outstanding for the purpose of calculating basic and diluted net loss per share attributable to common stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine months ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:67.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Convertible preferred stock (as converted)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 28,112</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 28,112</p></td></tr><tr><td style="vertical-align:top;width:67.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 734,131</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 582,641</p></td></tr><tr><td style="vertical-align:top;width:67.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,194,788</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:67.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 36,442</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 23,870</p></td></tr><tr><td style="vertical-align:top;width:67.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total shares of common stock equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,993,473</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 634,623</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently issued accounting pronouncements&#8212;<span style="font-weight:normal;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies that the Company adopts as of the specified effective date. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 will improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses on an interim and annual basis. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods after December 15, 2024, with early adoption permitted. The adoption of this standard is not expected to have a material impact on the Company&#8217;s condensed financial statements at adoption date.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46326902686784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_LeaseDisclosureTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3. Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is party to one operating lease for office and laboratory space. The Company&#8217;s finance leases are immaterial both individually and in the aggregate. The Company has elected to apply the short-term lease exception to all leases of one&#160;year or less. Rent expense for each of the three months ended September&#160;30,&#160;2024 and 2023 was $19,998. Rent expense for each of the nine months ended September&#160;30,&#160;2024 and 2023 was $59,993, which is included in operating expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company has an annual operating lease for office and laboratory space in Doylestown, Pennsylvania which was amended in October 2024 and is currently set to expire on October 31, 2025. Rent expense under this lease is $110,000 annually and the Company has applied the short-term exception to this lease. The Company has <span style="-sec-ix-hidden:Hidden_dXY0fqi6LUqjrBt7mcO_tw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no</span></span> lease obligations beyond October 2025.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_LeaseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of information about leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_LeaseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46326897674768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued expenses<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">4. Accrued expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Accrued expenses consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:72.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Professional&#160;fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 168,225</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 138,601</p></td></tr><tr><td style="vertical-align:top;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Compensation, severance&#160;and&#160;benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 673,322</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,016,960</p></td></tr><tr><td style="vertical-align:top;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research&#160;and&#160;development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,582,173</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 856,575</p></td></tr><tr><td style="vertical-align:top;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 58,288</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 174,126</p></td></tr><tr><td style="vertical-align:top;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total&#160;accrued&#160;expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,482,008</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,186,262</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46326902778992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_CommonStockTextBlock', window );">Stockholders' equity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">5. Stockholders&#8217; equity </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The total number of shares of all classes of capital stock that the Company is authorized to issue is 440,000,000 shares, consisting of 400,000,000 shares of common stock, par value $0.001 per share and 40,000,000 shares of preferred stock, par value $0.001 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Series A Preferred Stock</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of September&#160;30,&#160;2024, a total of 56,227 shares of Series A Preferred Stock remained outstanding, which are convertible into 28,112 shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;font-weight:normal;">Common Stock</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The holders of common stock are entitled to one<span style="white-space:pre-wrap;"> vote for each share of common stock.  In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, after the payment or provision for payment of all debts and liabilities of the Company, the holders of common stock shall be entitled to share in the remaining assets of the Company available for distribution, if any.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Shelf Registration Statement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On November 12, 2020, the Company filed a universal shelf registration statement with the SEC for the issuance of common stock, preferred stock, warrants, rights, debt securities and units up to an aggregate of $350.0 million (the &#8220;2020 Shelf Registration Statement&#8221;). On November 30, 2020, the 2020 Shelf Registration Statement was declared effective by the SEC and on November 30, 2023, the 2020 Shelf Registration Statement expired. The 2020 Shelf Registration Statement included an at-the-market offering program with SVB Leerink LLC (the &#8220;SVB ATM Program&#8221;) and the Company filed a Prospectus Supplement dated September 2, 2022, for the sale of up to $14,744,728 of shares of the Company&#8217;s common stock pursuant to its ATM offering program. The Company agreed to pay a commission of 3% </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">of the gross proceeds of any common stock sold in connection with the SVB ATM Program. During the nine months ended September&#160;30,&#160;2023, the Company issued and sold 26,302 shares of common stock under the ATM offering program resulting in net proceeds to the Company of approximately $0.3 million after deducting approximately $8,000 in issuance costs. The SVB ATM Program has terminated and is no longer effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In February 2023, the Company issued and sold 1,050,000 shares of common stock at a public offering price of $5.25 per share pursuant to the 2020 Shelf Registration Statement resulting in net proceeds to the Company of approximately $4.9 million, after deducting underwriting discounts and offering expenses of approximately $0.6 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On January 26, 2024, the Company filed a new shelf registration statement (the &#8220;2024 Shelf Registration Statement&#8221;) with the SEC for issuance of common stock, preferred stock, warrants, rights, debt securities and units up to an aggregate of $150 million, including a prospectus for the sale of $1<span style="white-space:pre-wrap;"> million of shares of our common stock under the ATM Agreement, as defined below, which was declared effective on February 2, 2024.  The Company subsequently filed a prospectus supplement to the 2024 Shelf Registration Statement for the sale of up to </span>$2<span style="white-space:pre-wrap;"> million of shares of common stock pursuant to the ATM Agreement.  On January 26, 2024, the Company entered into an At the Market Offering Agreement (the &#8220;ATM Agreement&#8221;) with H.C. Wainwright &amp; Co., LLC (&#8220;HCW&#8221;).  Pursuant to the ATM Agreement and the prospectus supplement filed in connection therewith, the Company was able, from time to time, in its sole discretion, to issue and sell through HCW, acting as sales agent and/or principal, up to </span>$2<span style="white-space:pre-wrap;"> million of shares of common stock.  The Company did not make any sales under the ATM Agreement and in March 2024, the Company terminated the ATM Agreement with HCW.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">March 2024 Private Placement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On March 11, 2024, the Company entered into a securities purchase agreement with certain purchasers (the &#8220;Purchasers&#8221;) pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement offering exempt from registration under the Securities Act of 1933, as amended, or the Securities Act, and the Purchasers agreed to purchase from the Company (i) 1,687,712 shares of the Company&#8217;s common stock at a purchase price of $7.29 per share (the &#8220;Shares&#8221;), (ii) pre-funded common stock purchase warrants at a purchase price of $7.289 to purchase an aggregate of up to 507,076 shares of the Company&#8217;s common stock at an exercise price of $0.001 per share (the &#8220;Pre-Funded Shares&#8221;), (iii) tranche A common stock purchase warrants to purchase up to 1,097,394 shares of the Company&#8217;s common stock at an exercise price of $7.29 per share (the &#8220;Tranche A Warrants&#8221;), and (iv) tranche B common stock purchase warrants to purchase up to 1,097,394 shares of the Company&#8217;s common stock at an exercise price of $9.1125 per share (the &#8220;Tranche B Warrants&#8221;). The Tranche A Warrants will be exercisable until the earlier of (i) the three-year anniversary of issuance and (ii) 30 days after the Company announces the recommended Phase 2 dose for ATRN-119, and, following such announcement, the daily volume weighted average price of the Company&#8217;s common stock equals or exceeds $14.58 for 30 consecutive trading days. The Tranche B Warrants will be exercisable until the earlier of (i) the five-year anniversary of issuance and (ii) 30 days after the Company announces the recommended Phase 2 dose for APR-1051 and, following such announcement, the daily volume weighted average price of the Company&#8217;s common stock equals or exceeds $18.225 for 30 consecutive trading days. To the extent that the exercise of a Tranche A Warrant or Tranche B Warrant would result in the holder beneficially owning greater than 4.99% (or, at the election of the holder, greater than 9.99%) of the Company&#8217;s outstanding common stock immediately following such exercise, the holder will instead receive pre-funded warrants in substantially the same form as the pre-funded warrants issued at closing. The aggregate upfront gross proceeds from the issuance of common stock and pre-funded common stock purchase warrants totaled approximately $16.0 million, before deducting placement agent fees and offering costs of approximately $1.3 million. The gross proceeds from potential future warrant cash exercises are expected to be up to approximately $18.0 million, before deducting placement agent fees. In April 2024, we registered on Form S-3 the resale of the Shares, the Pre-Funded Shares and the shares underlying the Tranche A Warrants and Tranche B Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company evaluated the terms of the warrants issued and determined that they should be classified as equity instruments within additional paid-in capital. As of September&#160;30,&#160;2024, none of the pre-funded warrants, Tranche A Warrants or Tranche B Warrants have been exercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Stock-Based Compensation Expense</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company recorded stock-based compensation expense of $149,090 and $76,031 for the three months ended September&#160;30,&#160;2024 and 2023, respectively. The Company recorded stock-based compensation expense of $363,408 and $361,598 for the nine months ended September&#160;30,&#160;2024 and 2023, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_CommonStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_CommonStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46326902641840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">6. Income Taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has no income tax expense due to operating losses incurred for the three and nine months ended September&#160;30,&#160;2024 and 2023. The Company has provided a valuation allowance for the full amount of the net deferred tax assets as, based on all available evidence, it is considered more likely than not that all the recorded deferred tax assets will not be realized in a future period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Realization of the future tax benefits is dependent on may factors, including the Company&#8217;s ability to generate taxable income within the net operating loss carryforward period.  Under the provisions of the U.S. Internal Revenue Code and Sweden tax law, certain substantial changes in the Company&#8217;s ownership, including a sale of the Company or significant changes in ownership due to sales of equity, may have limited, or may limit in the future, the amount of net operating loss carryforwards that could be used annually to offset future taxable income.  For U.S. and Swedish income tax purposes, the Company has not completed a study to assess whether a change of control has occurred or whether there have been changes of control since the Company&#8217;s formation due to the complexity and cost associated with such study and because there could be additional changes of control in the future.  As a result, the Company is not able to estimate the effect of the change in control, if any, on the Company&#8217;s ability to utilize U.S. or Swedish net operating losses or other tax attribute carryforwards in the future.  For Swedish income tax purposes, the Company&#8217;s net operating losses may be subject to limitations in accordance with the country&#8217;s group contribution restriction laws.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company files tax returns in Sweden, the United States, Massachusetts and Pennsylvania. Income tax returns prior to 2020 in the United States and Massachusetts are no longer subject to examination and income tax returns prior to 2017 are no longer subject to examination in Sweden. The Company is not currently under examination by the IRS or any other jurisdictions for any tax years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As tax law is complex and often subject to varied interpretations, it is uncertain whether some of the Company&#8217;s tax positions will be sustained upon examination. Tax liabilities associated with uncertain tax positions represent unrecognized tax benefits, which arise when the estimated benefit recorded in the Company&#8217;s financial statements differs from the amounts taken or expected to be taken in a tax return because of the uncertainties described above. Substantially all of these unrecognized tax benefits, if recognized, would benefit the Company&#8217;s effective income tax rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of September&#160;30,&#160;2024 and December&#160;31,&#160;2023, the Company had approximately $0.1 million of liabilities related to uncertain tax positions. As the Company&#8217;s uncertain tax positions can be offset by available net operating losses, the Company did not recognize interest and penalties for 2024 and 2023.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46326902664640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">7. Commitments and contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company records a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. As of September&#160;30,&#160;2024, the Company has not recorded a provision for any contingent losses.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46326897898944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (3,783,769)<span></span>
</td>
<td class="num">$ (3,470,052)<span></span>
</td>
<td class="num">$ (2,810,091)<span></span>
</td>
<td class="num">$ (3,204,515)<span></span>
</td>
<td class="num">$ (3,259,097)<span></span>
</td>
<td class="num">$ (4,379,890)<span></span>
</td>
<td class="num">$ (10,063,912)<span></span>
</td>
<td class="num">$ (10,843,502)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46326903667648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46326899089456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Principles of consolidation</b>&#8212;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries Aprea Therapeutics AB, which was incorporated in May 2009, Aprea US,&#160;Inc., which was incorporated in June&#160;2016 and ATR Pharmaceuticals LLC which was incorporated in May 2022. Management has concluded it has a single reporting segment for purposes of reporting financial condition and results of operations. All intercompany transactions and balances have been eliminated.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock', window );">Unaudited interim consolidated financial statements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Unaudited interim consolidated financial statements</b>&#8212;The accompanying unaudited interim condensed consolidated financial statements have been prepared by the Company in accordance with U.S. GAAP for interim information and pursuant to the rules and regulations of the SEC for reporting on Form 10-Q. Accordingly, certain information and footnote disclosure normally included in financial statements prepared in accordance with U.S. GAAP have been </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">condensed or omitted pursuant to such rules and regulations. These unaudited condensed interim financial statements should be read in conjunction with the audited financial statements and related notes included in the Company&#8217;s annual report on Form 10-K for the year ended December&#160;31,&#160;2023 filed with the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The unaudited interim consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements, and in management&#8217;s opinion, include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of the financial information for the interim periods have been made. The results of operations for the three and nine months ended September&#160;30,&#160;2024 are not necessarily indicative of the results to be expected for the full fiscal year or any future period.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of estimates</b>&#8212;The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses as of and during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates. Significant items subject to such estimates and assumptions, are used for, but not limited to, include stock-based compensation and accounting for research and development costs.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign currency and currency translation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Foreign currency and currency translation</b>&#8212;The functional currency for Aprea Therapeutics AB is the Swedish Krona. Assets and liabilities of Aprea Therapeutics AB are translated into United States dollars at the exchange rate in effect on the balance sheet date. Operating expenses are translated at the average exchange rate in effect during the period. Unrealized translation gains and losses are recorded as a cumulative translation adjustment, which is included in the consolidated statements of stockholders&#8217; equity as a component of accumulated other comprehensive loss. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other income, net in the condensed consolidated statements of operations and comprehensive loss as incurred.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and cash equivalents and restricted cash</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cash and cash equivalents&#8212; </b>The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Restricted cash&#8212; </b>The Company has restricted cash of $41,537 and $40,717 at September&#160;30,&#160;2024 and December&#160;31,&#160;2023, respectively, that is securing the Company&#8217;s credit card program.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value of financial instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Fair value of financial instruments</b>&#8212;The accounting standard for fair value measurements provides a framework for measuring fair value and requires expanded disclosures regarding fair value measurements. Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic 820, Fair Value Measurement (&#8220;ASC 820&#8221;), establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The hierarchy defines three levels of valuation inputs, of which the first two are considered observable and the last is considered unobservable:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;1 inputs: Quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;2 inputs: Inputs other than quoted prices included within Level&#160;1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;3 inputs: Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use in pricing the asset or liability.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s financial instruments consist of cash, cash equivalents, restricted cash, accounts payable and accrued expenses. The carrying amount of accounts payable and accrued expenses is considered a reasonable estimate of fair value due to the short-term maturity.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_TemporaryEquityPolicyTextBlock', window );">Series A Convertible Preferred Stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Series A Convertible Preferred Stock</b>&#8212;The Company classifies the Series A Preferred Stock as temporary equity outside of stockholders&#8217; equity on the accompanying condensed consolidated balance sheets&#160;due to certain events that are not within the Company's control.&#160;The Series A Preferred Stock was recorded at fair value upon the acquisition of Atrin in May 2022.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Accounting for leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Accounting for leases</b>&#8212;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified asset(s), if any, and the Company&#8217;s control over the use of the identified asset(s), if applicable. Operating lease liabilities and their corresponding right of use assets are recorded based on the present value of future lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;">The Company has elected not to separate lease and non-lease components as a single component. Operating leases are recognized on the balance sheet as right of use (ROU) lease assets, lease liabilities current and lease liabilities non-current. Fixed rents are included in the calculation of the lease balances while variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis. The Company has also elected the short-term lease exemption for all leases with an original term of less than 12&#160;months.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Research and development costs</b>&#8212;Research and development costs are charged to expense as incurred. Research and development expenses incurred in performing research and development activities, include salaries and benefits, materials and supplies, preclinical expenses, stock-based compensation expense, depreciation of equipment, contract services, and other outside expenses. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development. Deposits made by the Company with certain service providers that are to be applied to future payments due under the service agreements or returned to the Company if not utilized are recorded in the consolidated balance sheets.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Revenue recognition</b>&#8212; The Company&#8217;s revenue is primarily generated through grants from government and non-government organizations. Grant revenue is recognized during the period that the reimbursable research and development services occur, as qualifying expenses are incurred or conditions of the grants are met. Grant revenue received in advance is recorded as deferred grant revenue and recognized as revenue once the conditions for revenue recognition are met. Associated expenses are recognized when incurred as research and development expenses. The Company concluded that payments received under these grants represent conditional, nonreciprocal contributions, as described in ASC&#160;<i style="font-style:italic;">958,</i><i style="font-style:italic;">&#160;</i>Not-for-Profit Entities, and that the grants are&#160;<i style="font-style:italic;">not</i>&#160;within the scope of ASC&#160;<i style="font-style:italic;">606,</i>&#160;Revenue from Contracts with Customers, as the organizations providing the grants do&#160;<i style="font-style:italic;">not</i>&#160;meet the definition of a customer. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stock-based compensation</b>&#8212;The Company measures stock options and other stock-based awards granted to employees and directors based on their fair value on the date of the grant and recognize compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective award. The Company applies the straight-line method of expense recognition to all awards with only service based vesting conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For stock-based awards granted to non-employees, compensation expense is recognized over the period during which services are rendered by such non-employees until completed in accordance with ASC 718. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company estimates the fair value of each stock option grant on the date of grant using the Black Scholes option pricing model, which uses as inputs the fair value of the Company&#8217;s common stock and assumptions the Company makes for the volatility of its common stock, the expected term of its stock options, the risk-free interest rate for a period that approximates the expected term of its stock options and its expected dividend yield. The Company elects to account for forfeitures when they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company also awards restricted stock units (&#8220;RSUs&#8221;) to employees and directors. RSUs are generally subject to forfeiture if employment terminates prior to the completion of the vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse.<span style="font-size:12pt;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Net loss per share</b>&#8212;The Company has reported losses since inception and has computed basic net loss per share attributable to common stockholders by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company computes diluted net loss per common share after giving consideration to all potentially dilutive common shares, including options to purchase common stock, outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential common shares have been anti-dilutive and basic and diluted loss per share have been the same. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Included within weighted average common shares outstanding for the three and nine months ended September&#160;30,&#160;2024 are 507,076 common shares issuable upon the exercise of certain warrants, which are exercisable at any time for nominal consideration, and as such, the shares are considered outstanding for the purpose of calculating basic and diluted net loss per share attributable to common stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine months ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:67.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Convertible preferred stock (as converted)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 28,112</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 28,112</p></td></tr><tr><td style="vertical-align:top;width:67.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 734,131</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 582,641</p></td></tr><tr><td style="vertical-align:top;width:67.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,194,788</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:67.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 36,442</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 23,870</p></td></tr><tr><td style="vertical-align:top;width:67.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total shares of common stock equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,993,473</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 634,623</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued accounting pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently issued accounting pronouncements&#8212;<span style="font-weight:normal;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies that the Company adopts as of the specified effective date. </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_TemporaryEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_TemporaryEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for unaudited interim condensed consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46326897873408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potentially dilutive securities excluded from calculation of diluted net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine months ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:67.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Convertible preferred stock (as converted)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 28,112</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 28,112</p></td></tr><tr><td style="vertical-align:top;width:67.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 734,131</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 582,641</p></td></tr><tr><td style="vertical-align:top;width:67.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,194,788</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:67.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 36,442</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 23,870</p></td></tr><tr><td style="vertical-align:top;width:67.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total shares of common stock equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,993,473</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 634,623</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46326902659632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:72.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:top;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Professional&#160;fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 168,225</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 138,601</p></td></tr><tr><td style="vertical-align:top;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Compensation, severance&#160;and&#160;benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 673,322</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,016,960</p></td></tr><tr><td style="vertical-align:top;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research&#160;and&#160;development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,582,173</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 856,575</p></td></tr><tr><td style="vertical-align:top;width:72.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 58,288</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 174,126</p></td></tr><tr><td style="vertical-align:top;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total&#160;accrued&#160;expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,482,008</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,186,262</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46326902705888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Nature of business and basis of presentation (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of business and basis of presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash balance</a></td>
<td class="nump">$ 26,249,625<span></span>
</td>
<td class="nump">$ 21,606,820<span></span>
</td>
<td class="nump">$ 25,353,513<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46326902725792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of significant accounting policies - Restricted cash (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of significant accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 41,537<span></span>
</td>
<td class="nump">$ 40,717<span></span>
</td>
<td class="nump">$ 40,449<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46326898919776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Potentially dilutive securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract', window );"><strong>Potentially dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares of common stock equivalents</a></td>
<td class="nump">2,993,473<span></span>
</td>
<td class="nump">634,623<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">March 2024 Private Placement | Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract', window );"><strong>Potentially dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase of shares</a></td>
<td class="nump">507,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock (as converted)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract', window );"><strong>Potentially dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares of common stock equivalents</a></td>
<td class="nump">28,112<span></span>
</td>
<td class="nump">28,112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract', window );"><strong>Potentially dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares of common stock equivalents</a></td>
<td class="nump">734,131<span></span>
</td>
<td class="nump">582,641<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract', window );"><strong>Potentially dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares of common stock equivalents</a></td>
<td class="nump">2,194,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract', window );"><strong>Potentially dilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares of common stock equivalents</a></td>
<td class="nump">36,442<span></span>
</td>
<td class="nump">23,870<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=apre_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=apre_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46326899075424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>lease</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>lease</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_LesseeOperatingLeaseNumberOfOperatingLeases', window );">Number of operating leases | lease</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="nump">$ 19,998<span></span>
</td>
<td class="nump">$ 19,998<span></span>
</td>
<td class="nump">$ 59,993<span></span>
</td>
<td class="nump">$ 59,993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_LesseeOperatingLeaseAnnualBaseRent', window );">Annual base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_LesseeOperatingLeaseAnnualBaseRentObligationAfterCurrentYear', window );">Lease obligations after current year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_LesseeOperatingLeaseAnnualBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of base rent due annually.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_LesseeOperatingLeaseAnnualBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_LesseeOperatingLeaseAnnualBaseRentObligationAfterCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of base rent obligations after current year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_LesseeOperatingLeaseAnnualBaseRentObligationAfterCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_LesseeOperatingLeaseNumberOfOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of operating leases held by the Company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_LesseeOperatingLeaseNumberOfOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46327004304560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">$ 168,225<span></span>
</td>
<td class="nump">$ 138,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation, severance and benefits</a></td>
<td class="nump">673,322<span></span>
</td>
<td class="nump">1,016,960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_ResearchAndDevelopmentRelatedLiabilitiesCurrent', window );">Research and development</a></td>
<td class="nump">1,582,173<span></span>
</td>
<td class="nump">856,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">58,288<span></span>
</td>
<td class="nump">174,126<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 2,482,008<span></span>
</td>
<td class="nump">$ 2,186,262<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Also includes obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_ResearchAndDevelopmentRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to research and development costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_ResearchAndDevelopmentRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46326887947696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 11, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 12, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 26, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_StockSharesAuthorized', window );">Stock, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Common stock issuable upon conversion (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_CommonStockNumberOfVotingRightsPerShare', window );">Number of voting rights per common share | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,090<span></span>
</td>
<td class="nump">$ 76,031<span></span>
</td>
<td class="nump">$ 363,408<span></span>
</td>
<td class="nump">$ 361,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_ShelfRegistrationStatementAbstract', window );"><strong>Shelf Registration Statement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,999,598<span></span>
</td>
<td class="nump">5,788,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Common stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,312,108<span></span>
</td>
<td class="nump">$ 648,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_PrivatePlacementAbstract', window );"><strong>March 2024 Private Placement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=apre_ConvertiblePreferredStockSeriesaMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,227<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">March 2024 Private Placement | Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_PrivatePlacementAbstract', window );"><strong>March 2024 Private Placement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase of shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">507,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">507,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">March 2024 Private Placement | Purchasers | Securities purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_ShelfRegistrationStatementAbstract', window );"><strong>Shelf Registration Statement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued | shares</a></td>
<td class="nump">1,687,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Common stock issuance costs</a></td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_PrivatePlacementAbstract', window );"><strong>March 2024 Private Placement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share | $ / shares</a></td>
<td class="nump">$ 7.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock with an exercise price | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_PercentageOfOutstandingShares', window );">Percentage of outstanding shares</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from sale of common stock in a private placement</a></td>
<td class="nump">$ 16,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise', window );">Expected gross proceeds from potential future warrants cash exercise</a></td>
<td class="nump">$ 18,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">March 2024 Private Placement | Purchasers | Securities purchase agreement | At the election of holder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_PrivatePlacementAbstract', window );"><strong>March 2024 Private Placement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_PercentageOfOutstandingShares', window );">Percentage of outstanding shares</a></td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">March 2024 Private Placement | Purchasers | Securities purchase agreement | Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_PrivatePlacementAbstract', window );"><strong>March 2024 Private Placement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share | $ / shares</a></td>
<td class="nump">$ 7.289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase of shares | shares</a></td>
<td class="nump">507,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">March 2024 Private Placement | Purchasers | Securities purchase agreement | Tranche A Warrants (Pre-funded Warrants Exercise Price 7.29 Per Share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_PrivatePlacementAbstract', window );"><strong>March 2024 Private Placement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase of shares | shares</a></td>
<td class="nump">1,097,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock with an exercise price | $ / shares</a></td>
<td class="nump">$ 7.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_StockIssuanceAnniversaryPeriod', window );">Stock issuance anniversary period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119', window );">Number of days after announcement of Phase 2 dose for ATRN-119</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_SharesIssuedVolumeWeightedAveragePricePerShare', window );">Volume weighted average price | $ / shares</a></td>
<td class="nump">$ 14.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_NumberOfConsecutiveTradingDays', window );">Number of consecutive trading days</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">March 2024 Private Placement | Purchasers | Securities purchase agreement | Tranche B Warrants (Pre-funded Warrants Exercise Price 9.1125 Per Share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_PrivatePlacementAbstract', window );"><strong>March 2024 Private Placement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock with an exercise price | $ / shares</a></td>
<td class="nump">$ 9.1125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_StockIssuanceAnniversaryPeriod', window );">Stock issuance anniversary period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119', window );">Number of days after announcement of Phase 2 dose for ATRN-119</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_SharesIssuedVolumeWeightedAveragePricePerShare', window );">Volume weighted average price | $ / shares</a></td>
<td class="nump">$ 18.225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=apre_ShelfRegistrationStatementMember', window );">2020 Shelf Registration Statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_ShelfRegistrationStatementAbstract', window );"><strong>Shelf Registration Statement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_UniversalShelfRegistrationMaximumAmountToBeIssued', window );">Maximum amount to be issued under universal shelf registration statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=apre_ShelfRegistrationStatementMember', window );">2020 Shelf Registration Statement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_ShelfRegistrationStatementAbstract', window );"><strong>Shelf Registration Statement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Issue price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Common stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=apre_AtMarketOfferingMember', window );">ATM offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_AtMarketOfferingCommissionPayableAsPercentageOfGrossProceedsFromSaleOfCommonStock', window );">Commission payable as a percentage of gross proceeds from sale of common stock under ATM offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_ShelfRegistrationStatementAbstract', window );"><strong>Shelf Registration Statement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_AtMarketOfferingProgramMaximumAmountToBeIssued', window );">Maximum amount to be issued under at-the-market offering program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,744,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from issuance of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Common stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=apre_ShelfRegistrationStatement2024Member', window );">2024 Shelf Registration Statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_ShelfRegistrationStatementAbstract', window );"><strong>Shelf Registration Statement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_UniversalShelfRegistrationMaximumAmountToBeIssued', window );">Maximum amount to be issued under universal shelf registration statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_AtMarketOfferingProgramMaximumAmountToBeIssued', window );">Maximum amount to be issued under at-the-market offering program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement', window );">Maximum amount to be issued under at-the-market offering program, supplement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=apre_AtMarket2024OfferingMember', window );">2024 ATM offering | HCW</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_ShelfRegistrationStatementAbstract', window );"><strong>Shelf Registration Statement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_apre_AtMarketOfferingProgramMaximumAmountToBeIssued', window );">Maximum amount to be issued under at-the-market offering program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_AtMarketOfferingCommissionPayableAsPercentageOfGrossProceedsFromSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the commission payable as a percentage of gross proceeds from sale of common stock under the at-the market offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_AtMarketOfferingCommissionPayableAsPercentageOfGrossProceedsFromSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_AtMarketOfferingProgramMaximumAmountToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of common stock to be issued under an at-the-market offering program</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_AtMarketOfferingProgramMaximumAmountToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of common stock to be issued under a supplemental at-the-market offering program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_CommonStockNumberOfVotingRightsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of voting rights per share of common stock owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_CommonStockNumberOfVotingRightsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected gross proceeds from potential future warrant cash exercises.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_NumberOfConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of consecutive trading days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_NumberOfConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of days after the Company announces the recommended Phase 2 dose for ATRN-119.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_PercentageOfOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of outstanding shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_PercentageOfOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_PrivatePlacementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_PrivatePlacementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_SharesIssuedVolumeWeightedAveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Volume weighted average price per share of common stock after announcement of recommended Phase 2 dose for ATRN-119.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_SharesIssuedVolumeWeightedAveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_ShelfRegistrationStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_ShelfRegistrationStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_StockIssuanceAnniversaryPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of anniversary of issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_StockIssuanceAnniversaryPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_StockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_StockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apre_UniversalShelfRegistrationMaximumAmountToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of common stock, preferred stock, warrants, rights and debt securities and units that can be issued under a universal shelf registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apre_UniversalShelfRegistrationMaximumAmountToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apre_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=apre_ConvertiblePreferredStockSeriesaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=apre_ConvertiblePreferredStockSeriesaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=apre_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=apre_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=apre_CertainPurchasersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=apre_CertainPurchasersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=apre_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=apre_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=apre_AtEventOfElectionOfHolderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=apre_AtEventOfElectionOfHolderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=apre_PreFundedWarrantsExercisePrice7.29PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=apre_PreFundedWarrantsExercisePrice7.29PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=apre_PreFundedWarrantsExercisePrice9.1125PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=apre_PreFundedWarrantsExercisePrice9.1125PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=apre_ShelfRegistrationStatementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=apre_ShelfRegistrationStatementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=apre_AtMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=apre_AtMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=apre_ShelfRegistrationStatement2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=apre_ShelfRegistrationStatement2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=apre_AtMarket2024OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=apre_AtMarket2024OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=apre_HCWainrightCoLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=apre_HCWainrightCoLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46326897662912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent', window );">Uncertain tax positions</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46326902733088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Provision for contingent losses</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>39
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M4B+*/ZXY\[G4!\#W2R'484/_0+F8/_D74$L#!!0    ( &U$9UFDQ%P&GP4
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M"*6SS:(4O@47"9)"4RBE5J$=,2[1&1=S6DC6H$RF:JA'ZW/1.R^4$=SG8@"
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MX\, =/<$=!.K:G_M4L?0)>Z');V:J%T ?<^5LIN)VV!XAY?_ %!+ P04
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M"11YH234<#!OK?1KRA&@'C&; P9A\)C%96I1T 4FZW3],]:(N4A2\?5$A.#
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MCZ_I9=LD,TV[G>U#9S)QL_M,2Y#%AB)5DK+C?OT>D)(LIXZ[+XTE$> YP %
M]G)GW8,OB8)XK+3Q5Z,RA/K==.JSDBKI)[8F@R^%=94,>'2;J:\=R3P:57JZ
MF,U>3RNIS.CZ,KZ[==>7M@E:&;IUPC=5)=W^AK3=78WFH^[%G=J4@5],KR]K
MN:$5A?OZUN%IVGO)547&*VN$H^)J]&'^[N:"U\<%_RC:^<%OP4S6UC[PPY?\
M:C1C0*0I"^Q!XL^6/I+6[ @P?K0^1_V6;#C\W7G_'+F#RUIZ^FCUORH/Y=7H
M[4CD5,A&ASN[^YM:/J_87V:UC_^*75H[7XY$UOA@J]88""IETE_YV,9A8/!V
M]HS!HC581-QIHXCRDPSR^M+9G7"\&M[X1Z0:K0%.&4[**CA\5; +UU],9BL2
M03Z2OYP&>.3WTZRUODG6BV>L_Q1?K0FE%W^9G/)C^RF0]' 6'9R;Q5F'*ZHG
M8CD;B\5L<7'&W[*GMXS^EN?I?7N.7K*^.&W-!?'.US*CJQ$4[\EM:73]\L7\
M]>S]&6P7/;:+<]Y_B^V\]>N)&#H0+U^\7<R6[\6WDL1'6]72[$4IO3!6J#['
M@AY1S9Y$WN#9"M2VDT&9C=#6>WC!TL8YR@7*702X"J4C$M+DP@" J%*ZB=,M
MD*Q U9I<G[&X$#^6DU]PU,YN%5M)L96ZD:DF-9J"-!GU^Q6-UD)6MC%!V"*^
M,FA-J#.*N)B$!-3@\6<<"S(7R9.06ZFT7&L2Q%O![5BH()07F447R8D=5-:1
MT.J!]![>I4&  O\(T07OYRBSCI&>VG2GL(I-UKQ0:O43WQ7V!_+0P#4BJFP^
M$7?Q8Z+9$FE7L+<U&2H4_ %<3C7'DPD;E/9>%&A5UH$=LJ&;G-,3#M'D1,_?
MO ?_M=(J[#F/&[A#(J/O&( VY3L52H#KHGB<;I%)Y_8(_$ZZO,=]#R@I%3%C
MW'Q]1^!^LF+5!7)&:C#<DFD85YX4LMH1:$1^6N[&(B,7,!;0\-<^2!,4C#*$
M?!.%=I*3W8&(+U4])"^%E^#4@NA$!<%XM3&J4!E\#QWW3CJ9LWDD03\:1&P<
MHUS*+0NA4H'R,7OCE_&Y Y?R-8Z_#Y+\32!]$E-F&YVS2!H6J#2F@;QBKFQ1
M0$D#,0P2-A$8-2G,74"5+X<%7#>NMJC4\5$L4J'SKE6M*<0J\Z')XX:L7(#<
ME003AR\I5,P%=1$<9@[;VZPM?2#HUO(_E"*U)J2V"_+ U"LNWU.Y3"<&UG^;
M!EZ4$#ZR;IEA9GU@@#93DF&S8*&7K&SA\YHU91)1;,'T@95YKMC[0%0#6$<I
MG(@/*!?4J\>L/HZ<2H&+.0!$\D%5L9"PAHH"9X=.=VW4X+C= Q(M !!RLJ?%
M/"C0)BAN%2FU"'"7V5_%Q#2<L"G\W'="<&K= -*QRIX0_#QP^CNY] !/[LYE
M@/"B:+\S>X"/11$S&;>5&??'V+5CNE):41WNX'GC;%.G0#'X=(+S>$AG,;0'
M/SDYL@K%I<K0'8%9VC$UEL3AWG#!BA4 ,:VO$(_,2N@C\$B 7&[)&+_76VF4
M[&?DT&&-1N>8%P;5K(OCD=OHYXEG2 ^C5%MHP V#0X\2Q[)VG)E\&/P3&\[?
M_#]//>GC0=JJ-1:J">@G3>S60\OU/O+Y<K=B'<5&&;7TO7'*YRG^L3;C-X:Y
M)^E\+)&V<Z>)&>LT4K)%(#-$NI5.Q;&'28"#4:N-;M@VIFO\71OQ')'C]MTK
M):K4>I5PQ?$:U>?9 S9I:I :$)SP>0>23,6E.%E/VL=A_V/?CN(A#EV\,3SC
M,3M^ML.]&\=C0%9H/N"'A@/X21Q=5\B[A8<SPC-SK !:D_' \ZPHW&*@H5RA
MH3A\=+8:#!6.P0-VLBX>SS+>!T%>4_L^GBX.>NK[81O0GFX,1DX^0\GQ!%C;
M+1K#ZC!\H1<^XR0[3^?"@,YV^(:HM$TWD3]%./5*7+"."@#4H["PY3.'Q4^4
MM6_G\>WRZ6 #D1HGD<>8 ##X8S:9XR*D=7NP&BK!D99M])X109+Y"?S/B09G
M"\Y$.[117(=#YJGN>8P^5WFLUSZ4J62(9Y[A(Q>&5P3.Y7A\?CYUOY@.KGD5
MN4V\S/K4>].-KW_;WY<_I&OB87FZ;'^5;J- 3U,!T]GDS:N1<.D"FQZ"K>.E
M<6T#KJ#Q9XD[/SE>@.^%M:%[X WZ_T6X_@]02P,$%     @ ;41G61U%H 9S
M @  S@4  !D   !X;"]W;W)K<VAE971S+W-H965T,3,N>&ULG53;;MLP#/T5
MP@/V5-BNDU[6)0::;L/V4"!H=WF6;286JHLG,4WS]Z-DQ\VV-L#V8HO2.8>'
MLLG9UKH'WR(2/&EE_#QIB;JK+/-UBUKXU'9H^&1EG1;$H5MGOG,HFDC2*BOR
M_#S30IJDG,6]I2MG=D-*&EPZ\!NMA=LM4-GM/#E-]AMW<MU2V,C*62?6>(_T
MK5LZCK)1I9$:C9?6@,/5/+D^O5I, SX"ODO<^H,UA$HJ:Q]"\*69)WDPA IK
M"@J"7X]X@TH%(;;Q<]!,QI2!>+C>JW^*M7,ME?!X8]4/V5 [3RX3:' E-HKN
M[/8S#O6<!;W:*A^?L.VQ$\Y8;SQ9/9 YUM+T;_$TW,,!X3)_A5 ,A"+Z[A-%
MEQ\$B7+F[!9<0+-:6,12(YO-21,^RCTY/I7,H_+&:BV);YD\"-- ;0U)LT93
M2_2SC#A% &;U(+?HY8I7Y-[!+0NT'CZ:!IO?^1E;&_T5>W^+XJC@/78I3/(3
M*/)B>D1O,M8[B7J3_ZDW?:G@7F_ZLE[HF2O?B1KG"3>%1_>(2?GVS>EY_OZ(
MV^GH=GI,_=^_SG&YBQ2.*L+7%@.B$V;''5=;US *.F<?9>Q"'@+/# )EO6?6
MMD4#DD!ZJ"RU 5^)2B%0*XCY2HI**DD[: 5#,*!-O7$.F^B!.*O0=L.*=A6C
M( RU, QF'\);PWH[0$^2&Q&;%*Y]P/+?0:@K=.,O<A+Y^QI"/F-IJ"6D^Z.8
M /JKH/2E+Y<=])A&MXZ3A$T&VWV[C;OCL+KN>_09WD^Z6^'6TGA0N&)JGEZ<
M)>#ZZ=$'9+O8L7R;W/]QV?+ 11< ?+ZREO9!2#".\/(74$L#!!0    ( &U$
M9UEUQ'9>Z0(  %8+   9    >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;*V6
M:V_:,!2&_XJ535,GK8US(X1!I%*NTSJAHFZ?TW" J$F<V0;:?S_;"2D@%T4=
M7XCMO,_K<Y)#?+H[0I_9&H"CERS-6<]8<UYT3)/%:\@B=D,*R,6=):%9Q,64
MKDQ64(@6"LI2T\:X9691DAMA5ZW-:-@E&YXF.<PH8ILLB^AK'U*RZQF6L5]X
M2%9K+A?,L%M$*Y@#?RQF5,S,VF619)"SA.2(PK)GW%J=J2OU2O [@1T[&".9
MR1,ASW(R7?0,+ ."%&(N'2)QV<(=I*DT$F'\K3R->DL)'H[W[B.5N\CE*6)P
M1](_R8*O>T;;0 M81IN4/Y#=!*I\/.D7DY2I7[0KM2XV4+QAG&05+"+(DKR\
M1B_5<S@ A(\>L"O /@7<=P"G IRF@%L!;E/ JP"O*="J@%93P*\ O^E3:E=
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M+AH&-5R+QA>H%(C[2T+X?B(WJ%OI\!]02P,$%     @ ;41G60!ZCZM# @
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M-0.01X]11W#<+)RO^PDQ$_<K33E=+:A!P"/K55*ZDUPZF%S75 /<<[)N/$G
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M 9XO+  K71"#[B<;5_\#4$L#!!0    ( &U$9UDN!M<8.P,  ( '   9
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M(INE5T>4EY/R\AC[>D-56O42O?1..R2U3,HO4 G9^_L.%GEOA/,)Q$<N>TH
MU$:WP)GDO62A-@@< +2GJ!%(;2UT2+7;,(//N7Q<U%V#4&M)!>]#Y_RU(1W.
MTJ)Q#3C:_I56US '#:/%+:+Z0;HG^&WY1,!9;Q&<!J$"C2=HJ5WTLJ)=H%2+
MOR81)T(!UVU+O%1]_![P<R\>F"2Y Z$]O827+Q9Y6ES][_^_%"EHAV) 7PQ
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M/>4*,:@-ZB\^FE8BAV8S3+3H7/GMA#;%[(:-Z<\@;8#9KX70IXFMZ*GCY_\
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MA6U9"3EU;6+!'( 6']Y-Y_'7"V[3T6UZB5ZLC3[PT!&N(5^](A':6K#G[/;
M>0#Z'CT4<18=3CU$)_='@JE#EUA'WROLK](X.S;B;7__7M/[+KYGIN;*$@$[
M)XTGGVXH,7UG] 'J-MS&K49WM\.P<3\3,#[!K>^TQF/@-QA_3\5?4$L#!!0
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M5+T']]Y'X?H]%6[^/QS] 5!+ P04    " !M1&=9EXJ[',     3 @  "P
M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=
MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'
MTD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[P
MS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T
M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( &U$9UE+AEET] (
M !T2   /    >&PO=V]R:V)O;VLN>&ULQ9A;;]L@%(#_"O++NH?-L9ND%S65
MNF:72%47+55?)X*/&U0,&>#>?OT.]JR1M3K:"\J3;<#XXX#YCGWV:.S]VIA[
M]M0H[6;9QOOM:9X[L8&&NX]F"QIK:F,;[O'2WN5N:X%7;@/@&Y67H]$T;[C4
MV?G9T-?2YO&%\2"\-!H+0\&MA$?WMSY<L@?IY%HJZ9]G67>N(&.-U+*1+U#-
MLE'&W,8\?C-6OACMN5H):Y2:945?<0O62_&J>!4@;_C:=26>KW]P!)EETQ%V
M6$OK?->BZY\CXP-@X_ZJ]>:+5![LG'OX:DV[E?HN=(.CR*-A='$8CGT03^W_
MA-'4M10P-Z)M0/L^CA94 -1N([<N8YHW,,N&)HSKBGW6'H/$%KKO"MN&D>*C
M%U4_:H^X40SMJ<0*NZ@Z\'20ET97H!U4#,^<4;)"CHI]XHIK 2R"+ G(<H^0
M/\L(\I" /-P+Y"K@X*T1Y)B '.\1<B>2$P)RLD_(PPAR2D!.TT)><]]:8*9F
MZ]9)#<YU[_F:.^FP-((\(B"/TD*NVJ;A]CE0.GFG)=[&PX8DA&EQ0XH@CPG(
MX[205\ =N(CEA& Y2<MR(81M<:W!TS:LP)BJ&%&[]"CQ1'HC[C=&56#=.P:_
M6I1)S$8:)+%"%EJ8!M#23[OQHH11)#=&TT@?&O6OI<#D _, T$+N0E+"*!(;
M8\F?V8-C2[#=[<&W<^F$,@YWEAB2$D:1V!@+[22N.G9C>8419!?6<@QD%]J8
MD?)%D5@8Y#:W8[6",D:16!DT9NRU@G)&D5@:_^Z![ "3:P7N?0Q(^:)(+ Q2
MO;O33:FD2.P2>KK'<6I-J:5,K182<Q)C4I8I$UNFSQ+8!S;P'LS!<ZEVEF5)
M?J0D=L[K]^8M0DHX96+AO)5%O$U)&:=,;IPNG[@)^03.]S5'XX1/_#^D,28E
MG3+Y5PJ18K"#&).23ME))Q]^1U10XXY67>,C')8+KL32LG#H<ZKQ).QI=:O4
M)99]UU>&5\/?C>'/S/EO4$L#!!0    ( &U$9UG_Y+WC0@$  $40   :
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MZWZ0S#X!4$L! A0#%     @ ;41G60=!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !M1&=9ZV7UYN\
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M=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ ;41G6<EOFOSO @
M3PH  !@              ("!_1,  'AL+W=O<FMS:&5E=',O<VAE970S+GAM
M;%!+ 0(4 Q0    ( &U$9UFE3FDN!08  %$;   8              " @2(7
M  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " !M1&=9]20"
M5> 5  #P1 $ &               @(%='0  >&PO=V]R:W-H965T<R]S:&5E
M=#4N>&UL4$L! A0#%     @ ;41G69]3&;T!!P  WRD  !@
M ("!<S,  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( &U$
M9UD=B2 1T 8  *0/   8              " @:HZ  !X;"]W;W)K<VAE971S
M+W-H965T-RYX;6Q02P$"% ,4    " !M1&=9-)+E)X@+  !$'@  &
M        @(&P00  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%
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M+GAM;%!+ 0(4 Q0    ( &U$9UD=1: &<P(  ,X%   9              "
M@2UE  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ ;41G
M677$=E[I @  5@L  !D              ("!UV<  'AL+W=O<FMS:&5E=',O
M<VAE970Q-"YX;6Q02P$"% ,4    " !M1&=9 'J/JT,"  "*!@  &0
M        @('W:@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0
M   ( &U$9UE#C";W*@L  +XA   9              " @7%M  !X;"]W;W)K
M<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ ;41G62X&UQ@[ P  @ <
M !D              ("!TG@  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q0
M2P$"% ,4    " !M1&=9<0B^UJ<"   [!@  &0              @(%$?
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( &U$9UG)]O'3
M- (  /T%   9              " @2)_  !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&UL4$L! A0#%     @ ;41G6=,H27,R @  !08  !D
M ("!C8$  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " !M
M1&=99=F/X 4$  #9$P  &0              @('V@P  >&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( &U$9UG1KB=(^ (  ,<+   9
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M970R-BYX;6Q02P$"% ,4    " !M1&=9'O!!%T(#  !,%   #0
M    @ '<I   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( &U$9UF7BKL<P
M !,"   +              "  4FH  !?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M &U$9UE+AEET] (  !T2   /              "  3*I  !X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " !M1&=9_^2]XT(!  !%$   &@
M@ %3K   >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !M
M1&=9JAT0L'8!   H$0  $P              @ '-K0  6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     (@ B "4)  !TKP     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>108</ContextCount>
  <ElementCount>157</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>23</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="apre-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995200090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="apre-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995200100 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="apre-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995200105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="apre-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995200200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="apre-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995200300 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="apre-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995200400 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="apre-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995210101 - Disclosure - Nature of business and basis of presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation</Role>
      <ShortName>Nature of business and basis of presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="apre-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995210201 - Disclosure - Summary of significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="apre-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995210301 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="apre-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995210401 - Disclosure - Accrued expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="apre-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995210501 - Disclosure - Stockholders' equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="apre-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995210601 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="apre-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995210701 - Disclosure - Commitments and contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="apre-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="apre-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="apre-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>99920202 - Disclosure - Summary of significant accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of significant accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="apre-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>99930203 - Disclosure - Summary of significant accounting policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of significant accounting policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="apre-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>99930403 - Disclosure - Accrued expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aprea.com/role/DisclosureAccruedExpenses</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="apre-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>99940101 - Disclosure - Nature of business and basis of presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails</Role>
      <ShortName>Nature of business and basis of presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aprea.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="apre-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>99940201 - Disclosure - Summary of significant accounting policies - Restricted cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails</Role>
      <ShortName>Summary of significant accounting policies - Restricted cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="apre-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>99940202 - Disclosure - Summary of significant accounting policies - Potentially dilutive securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails</Role>
      <ShortName>Summary of significant accounting policies - Potentially dilutive securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="apre-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>99940301 - Disclosure - Leases - Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureLeasesSummaryDetails</Role>
      <ShortName>Leases - Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="apre-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>99940401 - Disclosure - Accrued expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureAccruedExpensesDetails</Role>
      <ShortName>Accrued expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aprea.com/role/DisclosureAccruedExpensesTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="apre-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>99940501 - Disclosure - Stockholders' equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureStockholdersEquityDetails</Role>
      <ShortName>Stockholders' equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aprea.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="apre-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>99940601 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureIncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="apre-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>99940701 - Disclosure - Commitments and contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aprea.com/role/DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aprea.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>apre-20240930.xsd</File>
    <File>apre-20240930_cal.xml</File>
    <File>apre-20240930_def.xml</File>
    <File>apre-20240930_lab.xml</File>
    <File>apre-20240930_pre.xml</File>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="apre-20240930x10q.htm">apre-20240930x10q.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="354">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>46
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "apre-20240930x10q.htm": {
   "nsprefix": "apre",
   "nsuri": "http://aprea.com/20240930",
   "dts": {
    "schema": {
     "local": [
      "apre-20240930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "apre-20240930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "apre-20240930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "apre-20240930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "apre-20240930_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "apre-20240930x10q.htm"
     ]
    }
   },
   "keyStandard": 136,
   "keyCustom": 21,
   "axisStandard": 8,
   "axisCustom": 0,
   "memberStandard": 10,
   "memberCustom": 12,
   "hidden": {
    "total": 16,
    "http://xbrl.sec.gov/dei/2024": 5,
    "http://fasb.org/us-gaap/2024": 6,
    "http://xbrl.sec.gov/ecd/2024": 4,
    "http://aprea.com/20240930": 1
   },
   "contextCount": 108,
   "entityCount": 1,
   "segmentCount": 23,
   "elementCount": 336,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 354,
    "http://xbrl.sec.gov/dei/2024": 30,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://aprea.com/role/DocumentDocumentAndEntityInformation",
     "longName": "995200090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheets",
     "longName": "995200100 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "995200105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "995200200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g",
      "name": "us-gaap:RevenueNotFromContractWithCustomer",
      "unitRef": "Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g",
      "name": "us-gaap:RevenueNotFromContractWithCustomer",
      "unitRef": "Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity",
     "longName": "995200300 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity",
     "shortName": "Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8CsMqAUtn0GBba1hxVBFiQ",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "unitRef": "Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_sqNgwBmbiUi7e68XTiWaJg",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "unitRef": "Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
     "longName": "995200400 - Statement - Condensed Consolidated Statements of Cash Flows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://aprea.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation",
     "longName": "995210101 - Disclosure - Nature of business and basis of presentation",
     "shortName": "Nature of business and basis of presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "995210201 - Disclosure - Summary of significant accounting policies",
     "shortName": "Summary of significant accounting policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://aprea.com/role/DisclosureLeases",
     "longName": "995210301 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA",
      "name": "apre:LeaseDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA",
      "name": "apre:LeaseDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://aprea.com/role/DisclosureAccruedExpenses",
     "longName": "995210401 - Disclosure - Accrued expenses",
     "shortName": "Accrued expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://aprea.com/role/DisclosureStockholdersEquity",
     "longName": "995210501 - Disclosure - Stockholders' equity",
     "shortName": "Stockholders' equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA",
      "name": "apre:CommonStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA",
      "name": "apre:CommonStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://aprea.com/role/DisclosureIncomeTaxes",
     "longName": "995210601 - Disclosure - Income taxes",
     "shortName": "Income taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://aprea.com/role/DisclosureCommitmentsAndContingencies",
     "longName": "995210701 - Disclosure - Commitments and contingencies",
     "shortName": "Commitments and contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R15": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R16": {
     "role": "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "99920202 - Disclosure - Summary of significant accounting policies (Policies)",
     "shortName": "Summary of significant accounting policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "longName": "99930203 - Disclosure - Summary of significant accounting policies (Tables)",
     "shortName": "Summary of significant accounting policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://aprea.com/role/DisclosureAccruedExpensesTables",
     "longName": "99930403 - Disclosure - Accrued expenses (Tables)",
     "shortName": "Accrued expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://aprea.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails",
     "longName": "99940101 - Disclosure - Nature of business and basis of presentation (Details)",
     "shortName": "Nature of business and basis of presentation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "19",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R20": {
     "role": "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails",
     "longName": "99940201 - Disclosure - Summary of significant accounting policies - Restricted cash (Details)",
     "shortName": "Summary of significant accounting policies - Restricted cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "20",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ",
      "name": "us-gaap:RestrictedCash",
      "unitRef": "Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R21": {
     "role": "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails",
     "longName": "99940202 - Disclosure - Summary of significant accounting policies - Potentially dilutive securities (Details)",
     "shortName": "Summary of significant accounting policies - Potentially dilutive securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://aprea.com/role/DisclosureLeasesSummaryDetails",
     "longName": "99940301 - Disclosure - Leases - Summary (Details)",
     "shortName": "Leases - Summary (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ",
      "name": "apre:LesseeOperatingLeaseNumberOfOperatingLeases",
      "unitRef": "Unit_Standard_lease_uug6S_kQsEij919rCVEEeQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "apre:LeaseDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:OperatingLeaseExpense",
       "p",
       "apre:LeaseDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "unique": true
     }
    },
    "R23": {
     "role": "http://aprea.com/role/DisclosureAccruedExpensesDetails",
     "longName": "99940401 - Disclosure - Accrued expenses (Details)",
     "shortName": "Accrued expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ",
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "unitRef": "Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ",
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "unitRef": "Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://aprea.com/role/DisclosureStockholdersEquityDetails",
     "longName": "99940501 - Disclosure - Stockholders' equity (Details)",
     "shortName": "Stockholders' equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ",
      "name": "apre:StockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "apre:CommonStockTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA",
      "name": "apre:CommonStockNumberOfVotingRightsPerShare",
      "unitRef": "Unit_Standard_Vote_xLAtZ3mDNEadoQnTSpr_cQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "apre:CommonStockTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "unique": true
     }
    },
    "R25": {
     "role": "http://aprea.com/role/DisclosureIncomeTaxesNarrativeDetails",
     "longName": "99940601 - Disclosure - Income Taxes - Narrative (Details)",
     "shortName": "Income Taxes - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "us-gaap:IncomeTaxExpenseBenefit",
       "us-gaap:IncomeTaxExpenseBenefit",
       "us-gaap:IncomeTaxExpenseBenefit",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "us-gaap:IncomeTaxExpenseBenefit",
       "us-gaap:IncomeTaxExpenseBenefit",
       "us-gaap:IncomeTaxExpenseBenefit",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://aprea.com/role/DisclosureCommitmentsAndContingenciesDetails",
     "longName": "99940701 - Disclosure - Commitments and contingencies (Details)",
     "shortName": "Commitments and contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA",
      "name": "us-gaap:LossContingencyAccrualProvision",
      "unitRef": "Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA",
      "name": "us-gaap:LossContingencyAccrualProvision",
      "unitRef": "Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "apre-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of significant accounting policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureAccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued expenses",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r31",
      "r508"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r376"
     ]
    },
    "apre_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aprea.com/20240930",
     "localname": "AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/DisclosureAccruedExpensesDetails",
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Also includes obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities and Employee-related Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r41",
      "r79",
      "r267",
      "r282",
      "r283"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive loss",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r8",
      "r12",
      "r230",
      "r233",
      "r254",
      "r278",
      "r279",
      "r483",
      "r484",
      "r485",
      "r491",
      "r492",
      "r493",
      "r495"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r376",
      "r519"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r491",
      "r492",
      "r493",
      "r495",
      "r510",
      "r520"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r161"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "negatedLabel": "Issuance costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r52"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r396",
      "r406",
      "r416",
      "r448"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r399",
      "r409",
      "r419",
      "r451"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r400",
      "r410",
      "r420",
      "r444",
      "r452",
      "r456",
      "r464"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r197"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "apre_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aprea.com/20240930",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Abstract]",
        "terseLabel": "Potentially dilutive securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Total shares of common stock equivalents",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r60",
      "r75",
      "r94",
      "r124",
      "r128",
      "r131",
      "r132",
      "r134",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r223",
      "r227",
      "r238",
      "r263",
      "r325",
      "r371",
      "r372",
      "r376",
      "r387",
      "r506",
      "r507",
      "r514"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r80",
      "r94",
      "r134",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r223",
      "r227",
      "r238",
      "r376",
      "r506",
      "r507",
      "r514"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "apre_AtEventOfElectionOfHolderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20240930",
     "localname": "AtEventOfElectionOfHolderMember",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents scenario or event of election of holder.",
        "label": "At Event of Election of Holder [Member]",
        "terseLabel": "At the election of holder"
       }
      }
     },
     "auth_ref": []
    },
    "apre_AtMarket2024OfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20240930",
     "localname": "AtMarket2024OfferingMember",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to the 2024 ATM offering.",
        "label": "At Market 2024 Offering [Member]",
        "terseLabel": "2024 ATM offering"
       }
      }
     },
     "auth_ref": []
    },
    "apre_AtMarketOfferingCommissionPayableAsPercentageOfGrossProceedsFromSaleOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aprea.com/20240930",
     "localname": "AtMarketOfferingCommissionPayableAsPercentageOfGrossProceedsFromSaleOfCommonStock",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the commission payable as a percentage of gross proceeds from sale of common stock under the at-the market offering.",
        "label": "At the Market Offering, Commission Payable As A Percentage Of Gross Proceeds From Sale Of Common Stock",
        "terseLabel": "Commission payable as a percentage of gross proceeds from sale of common stock under ATM offering"
       }
      }
     },
     "auth_ref": []
    },
    "apre_AtMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20240930",
     "localname": "AtMarketOfferingMember",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to ATM offering.",
        "label": "At Market Offering [Member]",
        "terseLabel": "ATM offering"
       }
      }
     },
     "auth_ref": []
    },
    "apre_AtMarketOfferingProgramMaximumAmountToBeIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aprea.com/20240930",
     "localname": "AtMarketOfferingProgramMaximumAmountToBeIssued",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of common stock to be issued under an at-the-market offering program",
        "label": "At The Market Offering Program Maximum Amount To Be Issued",
        "terseLabel": "Maximum amount to be issued under at-the-market offering program"
       }
      }
     },
     "auth_ref": []
    },
    "apre_AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aprea.com/20240930",
     "localname": "AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of common stock to be issued under a supplemental at-the-market offering program.",
        "label": "At The Market Offering Program Maximum Amount To Be Issued, Supplement",
        "terseLabel": "Maximum amount to be issued under at-the-market offering program, supplement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r456"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r456"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails",
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash balance",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r73",
      "r363"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and cash equivalents and restricted cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r54"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash-end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash-beginning of year",
        "totalLabel": "Total cash, cash equivalents and restricted cash",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r46",
      "r92"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Change in cash and cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r46"
     ]
    },
    "apre_CertainPurchasersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20240930",
     "localname": "CertainPurchasersMember",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to certain purchaser with whom company entered into securities purchase agreement.",
        "label": "Certain Purchasers [Member]",
        "terseLabel": "Purchasers"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r76",
      "r77",
      "r78",
      "r94",
      "r115",
      "r116",
      "r118",
      "r120",
      "r126",
      "r127",
      "r134",
      "r140",
      "r142",
      "r143",
      "r144",
      "r147",
      "r148",
      "r150",
      "r151",
      "r154",
      "r155",
      "r156",
      "r238",
      "r287",
      "r288",
      "r289",
      "r290",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r313",
      "r334",
      "r352",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r475",
      "r489",
      "r496"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Common stock with an exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants to purchase of shares",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 7)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r56",
      "r264",
      "r312"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r138",
      "r139",
      "r360",
      "r503",
      "r504"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r378",
      "r379",
      "r381",
      "r382",
      "r383",
      "r384",
      "r491",
      "r492",
      "r495",
      "r510",
      "r518",
      "r520"
     ]
    },
    "apre_CommonStockNumberOfVotingRightsPerShare": {
     "xbrltype": "integerItemType",
     "nsuri": "http://aprea.com/20240930",
     "localname": "CommonStockNumberOfVotingRightsPerShare",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of voting rights per share of common stock owned.",
        "label": "Common Stock, Number of Voting Rights Per Share",
        "terseLabel": "Number of voting rights per common share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r313"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r35",
      "r313",
      "r331",
      "r520",
      "r521"
     ]
    },
    "apre_CommonStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aprea.com/20240930",
     "localname": "CommonStockTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to common stock.",
        "label": "Common Stock [Text Block]",
        "verboseLabel": "Stockholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.001 par value, 400,000,000 shares authorized, 5,434,903 and 3,736,673 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r265",
      "r376"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r82",
      "r84",
      "r88",
      "r258",
      "r274",
      "r275"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r367"
     ]
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails",
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible preferred stock (as converted)",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r151",
      "r154",
      "r381",
      "r382",
      "r383",
      "r384"
     ]
    },
    "apre_ConvertiblePreferredStockSeriesaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20240930",
     "localname": "ConvertiblePreferredStockSeriesaMember",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option. Each share of Series A Preferred may be converted at any time, at the option of the holder, into a share of common stock.",
        "label": "Series A Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97",
      "r149",
      "r153",
      "r255",
      "r256",
      "r262",
      "r364",
      "r366"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueCurrent",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue, Current",
        "terseLabel": "Deferred grant revenue",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r124",
      "r129",
      "r132",
      "r371",
      "r372"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share attributable to common stockholders, basic (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r113",
      "r115",
      "r118",
      "r119",
      "r120",
      "r123",
      "r217",
      "r220",
      "r236",
      "r237",
      "r259",
      "r276",
      "r369"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share attributable to common stockholders, diluted (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r115",
      "r118",
      "r119",
      "r120",
      "r123",
      "r217",
      "r220",
      "r236",
      "r237",
      "r259",
      "r276",
      "r369"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net loss per share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r122"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeBenefitsAndShareBasedCompensationNoncash",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit and Share-based Payment Arrangement, Noncash",
        "terseLabel": "Stockbased compensation",
        "documentation": "Amount of noncash expense (reversal of expense) for employee benefits and share-based payment arrangement. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation, severance and benefits",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r69",
      "r85",
      "r86",
      "r87",
      "r98",
      "r99",
      "r100",
      "r102",
      "r107",
      "r109",
      "r111",
      "r125",
      "r135",
      "r136",
      "r137",
      "r158",
      "r207",
      "r208",
      "r214",
      "r215",
      "r216",
      "r218",
      "r219",
      "r220",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r254",
      "r273",
      "r278",
      "r279",
      "r280",
      "r294",
      "r352"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r396",
      "r406",
      "r416",
      "r448"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r393",
      "r403",
      "r413",
      "r445"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "apre_ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aprea.com/20240930",
     "localname": "ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expected gross proceeds from potential future warrant cash exercises.",
        "label": "Expected Gross Proceeds from Potential Future Warrant Cash Exercise",
        "terseLabel": "Expected gross proceeds from potential future warrants cash exercise"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair value of financial instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedLabel": "Foreign currency (gain) loss",
        "terseLabel": "Foreign currency (loss) gain",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r243",
      "r349"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign currency and currency translation",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r400",
      "r410",
      "r420",
      "r452"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r400",
      "r410",
      "r420",
      "r452"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r400",
      "r410",
      "r420",
      "r452"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r400",
      "r410",
      "r420",
      "r452"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r400",
      "r410",
      "r420",
      "r452"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r336"
     ]
    },
    "apre_HCWainrightCoLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20240930",
     "localname": "HCWainrightCoLlcMember",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to H.C Wainright &amp; Co, LLC.",
        "label": "HC Wainright Co Llc [Member]",
        "terseLabel": "HCW"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Operations and Comprehensive Loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r199",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r209",
      "r211",
      "r212",
      "r213",
      "r292",
      "r373"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r67",
      "r110",
      "r111",
      "r124",
      "r130",
      "r132",
      "r200",
      "r201",
      "r210",
      "r277",
      "r373"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred grant revenue",
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Temporary Equity",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r400",
      "r410",
      "r420",
      "r444",
      "r452",
      "r456",
      "r464"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r392",
      "r468"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r392",
      "r468"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r392",
      "r468"
     ]
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Income (Expense), Nonoperating, Net",
        "verboseLabel": "Interest income, net",
        "documentation": "Amount of interest income (expense) classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r486",
      "r498"
     ]
    },
    "apre_LeaseDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aprea.com/20240930",
     "localname": "LeaseDisclosureTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of information about leases.",
        "label": "Lease Disclosure [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Accounting for leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r252"
     ]
    },
    "apre_LesseeOperatingLeaseAnnualBaseRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aprea.com/20240930",
     "localname": "LesseeOperatingLeaseAnnualBaseRent",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/DisclosureLeasesSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of base rent due annually.",
        "label": "Lessee, Operating Lease, Annual Base Rent",
        "terseLabel": "Annual base rent"
       }
      }
     },
     "auth_ref": []
    },
    "apre_LesseeOperatingLeaseAnnualBaseRentObligationAfterCurrentYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aprea.com/20240930",
     "localname": "LesseeOperatingLeaseAnnualBaseRentObligationAfterCurrentYear",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/DisclosureLeasesSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of base rent obligations after current year.",
        "label": "Lessee, Operating Lease, Annual Base Rent Obligation After Current Year",
        "terseLabel": "Lease obligations after current year"
       }
      }
     },
     "auth_ref": []
    },
    "apre_LesseeOperatingLeaseNumberOfOperatingLeases": {
     "xbrltype": "integerItemType",
     "nsuri": "http://aprea.com/20240930",
     "localname": "LesseeOperatingLeaseNumberOfOperatingLeases",
     "presentation": [
      "http://aprea.com/role/DisclosureLeasesSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of operating leases held by the Company.",
        "label": "Lessee, Operating Lease, Number of Operating Leases",
        "terseLabel": "Number of operating leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r57",
      "r269",
      "r376",
      "r490",
      "r502",
      "r511"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r72",
      "r94",
      "r134",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r224",
      "r227",
      "r228",
      "r238",
      "r376",
      "r506",
      "r514",
      "r515"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForUncertainTaxPositionsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilityForUncertainTaxPositionsNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability for Uncertainty in Income Taxes, Noncurrent",
        "terseLabel": "Uncertain tax positions",
        "documentation": "Amount recognized for uncertainty in income taxes classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyAccrualProvision": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyAccrualProvision",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency Accrual, Provision",
        "terseLabel": "Provision for contingent losses",
        "documentation": "Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47",
      "r48"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity",
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r48",
      "r58",
      "r70",
      "r81",
      "r83",
      "r87",
      "r94",
      "r101",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r110",
      "r111",
      "r117",
      "r134",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r217",
      "r220",
      "r237",
      "r238",
      "r272",
      "r333",
      "r350",
      "r351",
      "r385",
      "r506"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently issued accounting pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r400",
      "r410",
      "r420",
      "r444",
      "r452"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "auth_ref": []
    },
    "apre_NumberOfConsecutiveTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aprea.com/20240930",
     "localname": "NumberOfConsecutiveTradingDays",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of consecutive trading days.",
        "label": "Number of Consecutive Trading Days",
        "terseLabel": "Number of consecutive trading days"
       }
      }
     },
     "auth_ref": []
    },
    "apre_NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aprea.com/20240930",
     "localname": "NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of days after the Company announces the recommended Phase 2 dose for ATRN-119.",
        "label": "Number of Days after Company Announces Recommended Phase 2 Dose for ATRN 119",
        "terseLabel": "Number of days after announcement of Phase 2 dose for ATRN-119"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r370",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/DisclosureLeasesSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Expense",
        "terseLabel": "Rent expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of business and basis of presentation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Nature of business and basis of presentation",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r53",
      "r284",
      "r285"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other noncurrent assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity",
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r273"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive (loss):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Total other income",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r398",
      "r408",
      "r418",
      "r450"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r401",
      "r411",
      "r421",
      "r453"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r401",
      "r411",
      "r421",
      "r453"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Common stock issuance costs",
        "verboseLabel": "Common stock issuance costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "apre_PercentageOfOutstandingShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://aprea.com/20240930",
     "localname": "PercentageOfOutstandingShares",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of outstanding shares.",
        "label": "Percentage of Outstanding Shares",
        "terseLabel": "Percentage of outstanding shares"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "apre_PreFundedWarrantsExercisePrice7.29PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20240930",
     "localname": "PreFundedWarrantsExercisePrice7.29PerShareMember",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Pre-funded warrants exercise price of 7.29 per share.",
        "label": "Pre-funded Warrants Exercise Price 7.29 Per Share [Member]",
        "terseLabel": "Tranche A Warrants (Pre-funded Warrants Exercise Price 7.29 Per Share)"
       }
      }
     },
     "auth_ref": []
    },
    "apre_PreFundedWarrantsExercisePrice9.1125PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20240930",
     "localname": "PreFundedWarrantsExercisePrice9.1125PerShareMember",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Pre-funded warrants exercise price of 9.1125  per share.",
        "label": "Pre-funded Warrants Exercise Price 9.1125 Per Share [Member]",
        "terseLabel": "Tranche B Warrants (Pre-funded Warrants Exercise Price 9.1125 Per Share)"
       }
      }
     },
     "auth_ref": []
    },
    "apre_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20240930",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to pre-funded warrants.",
        "label": "Pre-funded Warrants [Member]",
        "terseLabel": "Pre-funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockConvertibleSharesIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockConvertibleSharesIssuable",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Convertible, Shares Issuable",
        "terseLabel": "Common stock issuable upon conversion (in shares)",
        "documentation": "Number of common shares issuable upon conversion of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r378",
      "r381",
      "r382",
      "r383",
      "r384",
      "r518",
      "r520"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r150"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r313"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "apre_PrivatePlacementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aprea.com/20240930",
     "localname": "PrivatePlacementAbstract",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Private Placement [Abstract]",
        "terseLabel": "March 2024 Private Placement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "terseLabel": "March 2024 Private Placement",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Proceeds from issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationDetails",
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Proceeds from sale of common stock in a private placement",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r287"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Warrant exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r81",
      "r83",
      "r90",
      "r94",
      "r101",
      "r107",
      "r110",
      "r111",
      "r134",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r217",
      "r220",
      "r222",
      "r225",
      "r226",
      "r237",
      "r238",
      "r260",
      "r271",
      "r293",
      "r333",
      "r350",
      "r351",
      "r374",
      "r375",
      "r386",
      "r485",
      "r506"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r253",
      "r261",
      "r270",
      "r376"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r393",
      "r403",
      "r413",
      "r445"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97",
      "r149",
      "r153",
      "r255",
      "r256",
      "r262",
      "r365",
      "r366"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development",
        "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r198"
     ]
    },
    "apre_ResearchAndDevelopmentRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aprea.com/20240930",
     "localname": "ResearchAndDevelopmentRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to research and development costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Research and Development Related Liabilities, Current",
        "terseLabel": "Research and development"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r394",
      "r404",
      "r414",
      "r446"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r395",
      "r405",
      "r415",
      "r447"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r402",
      "r412",
      "r422",
      "r454"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails",
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r488",
      "r516",
      "r517"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r480",
      "r488"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Unvested restricted stock units",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r52",
      "r268",
      "r281",
      "r283",
      "r291",
      "r314",
      "r376"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r98",
      "r99",
      "r100",
      "r102",
      "r107",
      "r109",
      "r111",
      "r135",
      "r136",
      "r137",
      "r207",
      "r208",
      "r214",
      "r215",
      "r216",
      "r218",
      "r219",
      "r220",
      "r229",
      "r231",
      "r232",
      "r234",
      "r235",
      "r250",
      "r251",
      "r278",
      "r280",
      "r294",
      "r520"
     ]
    },
    "us-gaap_RevenueNotFromContractWithCustomer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueNotFromContractWithCustomer",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Grant revenue",
        "documentation": "Amount of revenue that is not accounted for under Topic 606."
       }
      }
     },
     "auth_ref": [
      "r478"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r362",
      "r368"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Proceeds from issuance of common shares",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails",
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Issue price per share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r112",
      "r159",
      "r476",
      "r494"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureAccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of potentially dilutive securities excluded from calculation of diluted net loss per share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "apre_ScheduleOfEarningsPerShareBasicAndDilutedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aprea.com/20240930",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedLineItems",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Line Items]",
        "terseLabel": "Net loss per share"
       }
      }
     },
     "auth_ref": []
    },
    "apre_ScheduleOfEarningsPerShareBasicAndDilutedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aprea.com/20240930",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTable",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The table contains disclosure pertaining to an entity's basic and diluted earnings per share.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "apre_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20240930",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the securities purchase agreement.",
        "label": "Securities Purchase Agreement [Member]",
        "terseLabel": "Securities purchase agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-based compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r165",
      "r184",
      "r185",
      "r186",
      "r187",
      "r190",
      "r192",
      "r193",
      "r194",
      "r195"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Offering price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "apre_SharesIssuedVolumeWeightedAveragePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://aprea.com/20240930",
     "localname": "SharesIssuedVolumeWeightedAveragePricePerShare",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Volume weighted average price per share of common stock after announcement of recommended Phase 2 dose for ATRN-119.",
        "label": "Shares Issued, Volume Weighted Average Price Per Share",
        "terseLabel": "Volume weighted average price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Equity, ending balance (in shares)",
        "periodStartLabel": "Equity, beginning balance (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "apre_ShelfRegistrationStatement2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20240930",
     "localname": "ShelfRegistrationStatement2024Member",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to a 2024 Shelf Registration Statement.",
        "label": "Shelf Registration Statement 2024 [Member]",
        "terseLabel": "2024 Shelf Registration Statement"
       }
      }
     },
     "auth_ref": []
    },
    "apre_ShelfRegistrationStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://aprea.com/20240930",
     "localname": "ShelfRegistrationStatementAbstract",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Shelf Registration Statement Abstract",
        "terseLabel": "Shelf Registration Statement"
       }
      }
     },
     "auth_ref": []
    },
    "apre_ShelfRegistrationStatementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://aprea.com/20240930",
     "localname": "ShelfRegistrationStatementMember",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to a Shelf Registration Statement.",
        "label": "Shelf Registration Statement [Member]",
        "terseLabel": "2020 Shelf Registration Statement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of significant accounting policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r93"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r76",
      "r77",
      "r78",
      "r94",
      "r115",
      "r116",
      "r118",
      "r120",
      "r126",
      "r127",
      "r134",
      "r140",
      "r142",
      "r143",
      "r144",
      "r147",
      "r148",
      "r150",
      "r151",
      "r154",
      "r155",
      "r156",
      "r238",
      "r287",
      "r288",
      "r289",
      "r290",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r313",
      "r334",
      "r352",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r475",
      "r489",
      "r496"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r35",
      "r38",
      "r39",
      "r69",
      "r85",
      "r86",
      "r87",
      "r98",
      "r99",
      "r100",
      "r102",
      "r107",
      "r109",
      "r111",
      "r125",
      "r135",
      "r136",
      "r137",
      "r158",
      "r207",
      "r208",
      "r214",
      "r215",
      "r216",
      "r218",
      "r219",
      "r220",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r254",
      "r273",
      "r278",
      "r279",
      "r280",
      "r294",
      "r352"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r125",
      "r251",
      "r257",
      "r286",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r352",
      "r380"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Cash Flows"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Balance Sheets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Condensed Convertible Preferred Stock and Stockholders' Equity"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r112",
      "r159",
      "r476",
      "r477",
      "r494"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r125",
      "r133",
      "r251",
      "r257",
      "r286",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r332",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r352",
      "r380"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r397",
      "r407",
      "r417",
      "r449"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "apre_StockIssuanceAnniversaryPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://aprea.com/20240930",
     "localname": "StockIssuanceAnniversaryPeriod",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of anniversary of issuance of common stock.",
        "label": "Stock Issuance Anniversary Period",
        "terseLabel": "Stock issuance anniversary period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Shares issued",
        "verboseLabel": "Issuance of common stock, net (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r34",
      "r35",
      "r52",
      "r287",
      "r352",
      "r356"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted stock units (in shares)",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r52"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issuance of common stock, net",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r34",
      "r35",
      "r52",
      "r294",
      "r352",
      "r356",
      "r386"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted stock units",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r34",
      "r35",
      "r52"
     ]
    },
    "apre_StockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://aprea.com/20240930",
     "localname": "StockSharesAuthorized",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Stock Shares Authorized",
        "terseLabel": "Stock, shares authorized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Equity, ending balance",
        "periodStartLabel": "Equity, beginning balance",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r38",
      "r39",
      "r50",
      "r315",
      "r331",
      "r353",
      "r354",
      "r376",
      "r387",
      "r490",
      "r502",
      "r511",
      "r520"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails",
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Common stock",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_TemporaryEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityAbstract",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity [Abstract]",
        "terseLabel": "Convertible preferred stock:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Temporary equity, ending balance",
        "periodStartLabel": "Temporary equity, beginning balance",
        "verboseLabel": "Series A convertible preferred stock, $0.001 par value, 40,000,000 shares authorized; 56,227 shares issued and outstanding at September 30, 2024 and December 31, 2023",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r142",
      "r143",
      "r144",
      "r147",
      "r148",
      "r196",
      "r266"
     ]
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Convertible preferred stock, par value (in dollars per share)",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r22"
     ]
    },
    "apre_TemporaryEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aprea.com/20240930",
     "localname": "TemporaryEquityPolicyTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for temporary equity.",
        "label": "Temporary Equity [Policy Text Block]",
        "terseLabel": "Series A Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Authorized",
        "terseLabel": "Convertible preferred stock, shares authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Issued",
        "verboseLabel": "Convertible preferred stock, shares issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails",
      "http://aprea.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Temporary equity, ending balance (in shares)",
        "periodStartLabel": "Temporary equity, beginning balance (in shares)",
        "terseLabel": "Convertible preferred stock, shares outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://aprea.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "apre_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://aprea.com/20240930",
     "localname": "UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for unaudited interim condensed consolidated financial statements.",
        "label": "Unaudited Interim Condensed Consolidated Financial Statements [Policy Text Block]",
        "terseLabel": "Unaudited interim consolidated financial statements"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "apre_UniversalShelfRegistrationMaximumAmountToBeIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://aprea.com/20240930",
     "localname": "UniversalShelfRegistrationMaximumAmountToBeIssued",
     "crdr": "credit",
     "presentation": [
      "http://aprea.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of common stock, preferred stock, warrants, rights and debt securities and units that can be issued under a universal shelf registration statement.",
        "label": "Universal Shelf Registration Maximum Amount To Be Issued",
        "terseLabel": "Maximum amount to be issued under universal shelf registration statement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r63",
      "r64",
      "r65",
      "r66"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://aprea.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "terseLabel": "Warrants to purchase common stock",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r378",
      "r381",
      "r382",
      "r383",
      "r384"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding, diluted (in shares)",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r120"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://aprea.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding, basic (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r120"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r478": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r484": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r485": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r486": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r488": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r489": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r492": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r493": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r494": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r495": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r496": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r497": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r499": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r500": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r501": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r502": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r503": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r504": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r505": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r507": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r508": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r512": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r514": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r515": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r516": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r519": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r521": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>47
<FILENAME>0001558370-24-014767-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-24-014767-xbrl.zip
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M3!*(KD\>.M'$BUV$@>WI7B'63JTY3&>\,->]"W(=W\I%738KST<XF$70LDL
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M\S8A1F16A6:"7'OP'I "P5O!=4:$[3+A<SRV;>YCY_QEKK009U@BXN:[)%]
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MC1-.HYNI?L+G4@A?O<%4U8"DW@[(Z%)#&FWHQ/25QQB_T5I3S8T?&V-'J#K
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M2Q<\!I8LCLG$)#M/Q8*=9<@M$NK.4(3'4^8DV8&I98T4F7.&9249=1:EZ^W
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MT.,8V-=Z.Z,41Q?->_W"WM9^A%EGY^*SH^/S_.UKT>[:.GHDQ,2HY$QHD;5
MD7&'^$6RT73G6CK?A5H3[YHWVQBB\_VKL@W<]98%))=[-UMUCU.T39E'8VT!
M)XM&V+]\2WAKLH'.&N,E<S[L72SS]]E*T&JP8%-KWR_ZAAU*&QO9M T<XZG;
M2NGFTG82.?*Z^W[KM&A(#;50]_ECE80WZW2PT^&HD@Y6.NT=I_6VGM;5X&+"
M#<W:XBN.9\3['#[A*,:X,.%TL:P*YV+*4^,;?<1^K:7V6?,M4+Y?C $QI[5?
MC-EIA>+\;/@&T"VQ;2[&K*#N%V-^J,48V03,# >/MWCJ\QB.5[P^K4,^)Z8O
M R#5:8>CUO2X]N?:B28M#$VHU2/MK,V;R^YBXL5R /+)&C7S(K8639W_8F[N
M(FFX)E\UJXK9BP UW]E&-"YTM.S3II-E'WZ[Y -K3!>(QDMN.((!BURL]YRP
MML<I<NB=$W6+%PEU9VS4/YY2O+H%KZR9,-"U+-OOX$1GD3DG%H!^3*)*D?KI
M\&PXZG_UO7'RA"!;Z(_^=?DK>QKE4]:7Y$O@ROLBF62/_=!.)K?NBV2 VKA2
M %-^Z\IDI2E5)#E(17L<3]1K9RDB&,<WO\8K9V2!<-M3EOL+:_87UK1Y80V0
MWKPA4AKOP_\LUS?N=&>-0O?])4&[S1_^*)<$W;.Z;Q['/$%CFOJSHI^7R';?
MQTNVZ;7=QTOP]YN_LM$F&H?>-Z;#YIO"9)_Z]D;K6F!$!DKC+>69V.+[\W%:
M[I%'9\-C.$=&M,6S$',;RPSKU*;)]D!1L<:@+P0@\-C15C>K#7J4$,+WU[G'
M3'(D;=O]Y'X3VGX3&IQ-:*?\TKFW8/JR5C:AY1CWF]#VF]#VF] ZI>C\:#0Z
M/JU+DKB6OC/_FZ%)C*WS!=CUC.6=BUF0ZA-)3H-$KOOH37)N?)M)#1+LW7.U
M>OSW,%I@UW_TL2=='%?(]I^UH#2Z=:O+$;S.EB_%)F]/SX9OA[W'7_79$*)J
M)0_N^HGI>/-X'6 WV_CTKW13D"H93E.DYTP$K545LN T2. =G/9%=\FQIE#G
M6\WMT(@WYC31]T#9>IXMRJ2WZ8P3!H?Z_\7;-VRJ! $L1YE3J0("9UMN8:52
M0XQ1"0B9V-;.ID0$DJH)HC<T[62SB\KRF%]/F;PD@.,_:U$G1P:'PJWE:3.'
MTQ4"</>:/7$Z4% YL_0\T\( KDFKR^'K\[]"WDAF@.F];?+=\<:E =Q&5I=-
M!3HX=&Y=1&]ZO;2^&(![O>P)U,-JC#G#/92\=_8C/FDP04MN/&-^H@@;HL9H
MRB"EMV=.*'$Q]B)^!DF&M-"GBX?@C3\$P%U?EN.*%AJA;>,H/"P_P>@7PN_>
MRLXJDG2D=D4[G7T9-L*D,38XK]UQD-:+O?Q$M/)=E-<O_$_I7:"&A3NELK%Y
M&U-T;3N;?&.LZOP^DU*=\M+0)(P!K+8)^1[Z+)Z*^/VM6\I\12_^/)EG1VS=
MDPN<W2$LXF>'2OI>@#8WQ#5=.Z#L.K!A7>F4HKD%=;8U]+TBO0-OMA!AD7:7
M+!;93'A]^HIU]3@CV@V11;!P8I3";>Q720HBO1$[&Q1]P\_I3_)]EF:%>YPR
MW8%;6W2 R-ST\FFBBV;232[>XU1I'<*D>.!05!Q<IE-%H:L<REN4ZW%NM 9I
M!L#@L%>PL$L2LM@:9TAOL8M9,.;=A(4=!GJO,ZFCQSG29ES1!"0<AB=HF6X=
M62F?6^0EB:0'<ZN+]#A%6L<KE9C:CDBWSQ-4C<7ELIT.Z6HOLFO P/&0S3('
M]HRB#+E\WX-NG9V5WFAR&'"XV=\\($D;-^?Y![I*0 BEE F__G&M_\C&!O1U
M]3VJK\V\'F+K4]3%#G@<KB;]Z#(;C4JS A4E^AZ.FY!B!*3MIL_=_@HMH_%C
MC"E?HT#ADJE"$J92Q,)9-E!)KU28\*W"QU<DPI\('<<T'(W.1>34K[/OP;DQ
M??6AMK_\L^G4?R%!,L>_8N[7V!LS4T-3K IP=JJA[T&ZN>]9 NO*%_EPDO7"
M_((6-H3D^1K<O%2>)BO1]\C:VH]D0%H?CA4R) IY,IF%",=DZ@)]#XF-&UZ#
M TZD)YQ$H]F0,\MRLIE6W"K88]:/=0QG@J=M=^')"RY[3U:2B28D9NK[*/B4
MQ G%JUCR$D6S/,H4.5.MZOI,]+'SM5HP87KB2M5<3>G\H;)(G_D]M=RO"F6'
M6]$^#+(6\[.+Q'[Z'U!+ P04    " !M1&=9-V_,+2X[  #-CP, %0   &%P
M<F4M,C R-# Y,S!?;&%B+GAM;-U];7/<.)+F]XVX_X#KN[BQ(TJV94_/K'MG
M9J,LRSV*LRV=+'?OGN-B@B)1*NZPR!J0):OFUQ\2X O((DCP%<G^,--R%9"9
M3U9F(O&6^-._/^T"\DA9[$?AGW\X?_'J!T)#-_+\\.'//QR2S=F__O#O?_EO
M__*G_WYV]A_O;C\2+W(/.QHFQ&742:A'OOO)EMQ%^[T3DD^4,3\(R#OF>P^4
MD/-7+_[UQ:L7;W\D9V=_$33>.3'O$X5$$'O]XCS[XB(E%X4_D?/SES^^?/WJ
M]>_)^>N?SM_\=/Z:W'S*&G[BLFW\UI:!'_[])_B_>\Z1<)!A_--3[/_YAVV2
M[']Z^?+[]^\OOK]Y$;$'WO_5^<O_^/3QB[NE.^?,#^/$"5WZ ^'M?XK%AQ\C
MUTF$AI3N3_<LR B\>9GSTK: ?YUES<[@H[/SUV=OSE\\Q=X/J8CPM0&3K/G3
M2?L4T_G;MV]?BF_SIIR0E^1M5;H_OI1?_O"7?R'D3RP*Z"W=$-'[I^2XIW_^
M(?9W^P"XBL^VC&[JA0P8>PG]7X;T 7Y.0/D64)[_ 5#^C_3CC\X]#7X@T/+K
M[946[]L2K;230&.DHI<"CC0$Z/N1_U5"19\2&GK4RW !MP;*0ABA4B ,I".W
M1"\ *XG8J9KB3.$Q=5\\1(\O/>H+LX4_SN /H1W^C[]=1-P9U_=QPAPWR2@)
M\?_\0]WWW;0!0@.M-2M+[C WX\7_;-%#VN*E&W$OV2=G0?K#B.X;%NWJ)97L
MHIHO_Q;<=_]A,R@E'(S&T8&YM-,OJHJOTW0N(F\!D9&&9U^_=)#Y+^^SN.F$
M'KD,$S\YDJMP$[&=""Q_DF),:%B9  K3.^>^<&H%>4-3O.;6AB^S/%T[G$;8
M*NU@>U0HDV^"]O^S8HP\.M.KA.YB,RVHS1=EE"<X&PPS;[L8XSR5>%P#!?I$
M,*A:Z2A($YX(TX]6X=H>'^XXQ0;PZ=?X74[%474Q^ ZW2Y4D'&Q30&T^"_H_
M!X=Q1PJ.MW0?L;HD5M\2OUUIT%5-K-(,M[7IA!UL>#EA(BG/9X0WE/F1=QEZ
M[_G<L0%ZM1U^ ZQ%5C6_4B/<QE<OZF#3DV3Y4.H1(#SC ,J<,/9AT&Z-?S5-
M\=N?#M_)(%MIA]L*M=(.'WQSRK,%09D_?O #^OFPNZ>L!G=-$[RFI\.3F5SU
M>YRFII6RKXFETP2@2"3)N4SKEC[XL# 6)I^=7=WPJFF&W<3J<97-K-P&LZEI
M)!UH;@55 F3G,KFKT(T8#Y]B.OPEX4/Z170($W:\B#R]!;;UPFZ01JC+]MG8
M!;.YF@D^T'I+3%9$L"$1(RDK KSF,ND[Y^G*XRF"O_'E]F++:*UOC]V,6Y"6
M#5C3&+/IMHD\T&@Y>5*F/_-XO_8\KK0X_0^L>IYK=5'?%KN%-B L6V=-0\R6
MV23N0*M,::ZR/XA8G+\.9XN?*=\+_N<UNXN^AVU:*+5<B$6>HJNUQZ+9 JRQ
M1MBQ;!%(PW@.Q&>V0Y%+7+,;%CWZH:O/2;7-%V*1&IRU9EEINP#;U$D\EH'F
M&6?&868KO8GBQ G^K[]OG#=I&B_$0FLQUMIGJ>4"K+->WK%L4U(GG/Q,\R"(
MUFM&'8TM5K[&:WUU./*C;LIW."VL5L*^-B4&8* VDPG!T=S@9AN%^K7NFB9X
M34F')S.GZO<X34HK95^S$@2)H#C;W/<+=0^,F_/YZ_L[/ZD]*EG3!*]IZ?!D
MIE7]'J=I::7L:UJ""HDVY/SUL_OG)*,_O7W=,0?N67PY[NZC.J35[_%:5BV2
MS*Q*7^*TJ7H1>QN4I$8DN?GBU.63N^424\V>G*897JMJPE6-66H;G#;6*&E?
M4\N(DHSJK'MR%P?&:)C(8PW@/WQN>Z@[P-W2'*\)FN L3RSKV^(T22.)!TXN
M4^HD)T\D_?GVC1,*-WC\1_K>29Q4G(9-2$US[#;:C+.Z15S7%K.-MD@\>%,X
MIPZ'!9W,:.<\J<4NG(0^1.RHU4&U%7:+K$5U>F0K;X+9_NH%'>'@%B,9U;F,
M[<O."8)WA]@/::P?JZNML!M;+:JRL96:8#:V>D$'&IL@2C*J<QG;Y8ZR!S[H
M_\RB[\GV(MKMG5 ?X72ML1M?(\JR$=8VQ6R,S0(/-,J,.)'424I^-NM\*@YG
MR_L">C74-45OEUI\%:,\:8?:(O72#C7')_6TOJ0]V["\I4'0%B KC;#;7QVF
MRIBLM,!L<[5R#AV1@>;<(8^SV\'IVLC]^Y>MPQ5U?4B@W@TL6.I7")H[83=#
M$\R519R&'IC-U$CNH0LZ@@<13%9$LB$*G]DLF4_0F1-<A1Y]^M]4'S-/VZ&W
MUWID%1,M-T)ME1I1AQJB)$L$7<()SW!>1:X+??!CUPG^DSI,?\&XH2E>^VO#
MEY]IT;3#:86MTO8^ZY*N;4O*!$A;N'!<X/K /VFJGW/:$J\IMJ"KWC:N-,-I
MB&W"#KYKK!JB(#VW%<HYDYD=EMLNQ1)K$-;;HM)P"=98)^Y8]IC68IC)(M><
MM2> !4[=G*;Z/5[+JT6265OI2YP65B]B7ZO*J1$@-]2.-DY\+[@<XK,'Q]E+
M8Z)!$F>?%%:5?O W<78?)+C>?/!#)W1][C>17"[2U.SLV!6G+?;!#V;:I1\^
M"^XE?>]4,N*SF!"*(_._XBCP/5$.^9T30"UB6"NBR>#8.<CFZZJ%:ALMQ(Y/
M*H36MUB ;8Y3%30G-U8IT$$6=Q$X<7R]$2M-ZR>_FE&:M%^('>J0UIIDM?$"
MK%,K<N]P"03AS+8@2;X!42O&JB)['^T<OWH)N;$A;O/48U/M\K057H-LD'4L
M2Y1D[=AB%#Y2EO@\<-]PBI0QZ@FI/M&:FU'FO9!;J1GJDLDV=T%LOX:"#\A"
M,_HD9Y!9MN0Q;]UE&\#W.?!8 '_FQ,25WU/O>0_'=CA%X:VOWKYY)3P6/M%C
M^D*93V.GUFN[]<3IN3W0@_=VZ&;7@[,W<D2EGOZ_WV"COJD8<K)U$K)SCN2>
M$IK>%_&('R81MV^QJ1O+W=R(D2C94D9 !V)PB^4]$RX<X33X=R3Z'E+V._[E
M'E"^()>.NY7]Q6 H@)"U$D52QKDG 2$G/)+$W]%53E50 PKPKVT4>)2MI(A.
M03V3%E"]F"(>U<7@.7^Y7'WH C(V+5B=H'[4O%G1V!!G3&['5CL7_8CWA0H#
M64=8)OFH?9!B%E-<QS%-XI:UYY-&N$VP'I-J?N46>$U/(V?O#1!!CGS+"-I)
MQ2<!9<]WTC,<1BYTVG8)GJ1!>.I0E8;8_4HG[C!+7.4W5E'XV=@@,W".H/Z3
ME64J)]ZN0P_^<_F/@__H!%R@>)U<.(P=_?#A%R<XZ#::3/OB]LM.&B@M7)ET
MQ.NWW<3O;>*<O'A&2_RA,!*SS(P7$<SL+&;-JP87_J %HRDP\^G9?80&];W<
M-;<1W/CT=._XWN73'G;S.=YK6$@IQ7*-?LQZX@YL'="K8<V@&]Z@UD7X 2MY
MP(.D3(1;"S:DDK18B6=S:H!*)K%0@5RD=$LIC?69A$DZA]Z16UUV(<XYKA'.
MX6Q1X@3&TX+AI<J '0(/NF'1GK+D>,-Q)#R"0(:PAQ6VSU0_7C9VP>U?)GC+
M(Z2^/5[O,Y*Z_X@@B:^(("\?SLT8K AG86DPG &S $L+L.$)V%F\]I;&"?/=
MA(JL_C,W^\8AL*$Y;F]MPZEZJJXM7B]ME;BOM1:$Q52<^V1.VXIKS@$4)MLV
M7%%)N5O]4-<6MQ,V(E0]L+8A7O=K%K>O299GAY8=;TJ(84[0^@2P,6-'[U]E
M#*=S/;P>5)%OU)W(.2=U(\WF[+G!1]^Y]P-Q3(QGON)\CCS"%4,6G!Q;-ED[
M=,?M2EWUH#J;:5^\[M@90>\W(0I&^>R/SXTL[]M:@Z^R^EVJ#,M1P.QP16.'
MQ7BZP3$+?>M%>//89Q$4TFA.74P(-T,8%"RLG+]8NRX\=AS?.$>XX]FR;:%K
MC-LOFS&6DMO:EGC]L47>WLEO2I:D=.WN*$X-<B_ICG>7AU-F!^J5Q_[+W3Z(
MCI3>T@ N\Y^&E@KZ891P.N0(VLGO_O0C@_PNT$!0O:>*6TK<["C4(QR]X4ED
MG%V\20_0D!C*3A!/O%BZ(=%]X#\((#'QY:J+QYNSZ/"PE9>+1$O(15,'(QNX
M2E3736FT(K"GX?@AB"+N(L7<104]N.\3PW,AW ^/O#,)^=\,K@OQ+W):40BW
MBL0@?>#S7X7?"JXR.2[_"0Z! /$(EYK\G102A/N^]=TM)_48^2Y7P=9YI"2,
M$G+DN.\I#0FC+O4?@0MO[ >!^/:>\L]#GFA3[P59!W$$P@0'#RY+*6B9_/D
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M13)F1.%&@%U>!_->\!Q](_JMU$=('\23QLC4XF9J>?; >3ROJWXY3_9C%SS
M?DY !586%" OTZ9_NCE?6R?<<= ,<VG%H;$'WFAG*/>PI+YQ9F-G36):V.F"
MH#*CL;(X09/61<!J&]Q^68NHM,"@-K#K=:TV6"]K[]4#FEBK#FU2&KOV11Q9
M6;3MP-=HU'$;]\A:/!F=AI-&/HR-"'#8>&=8T7ZE??!*2F5[S0^74LN%\&52
M;&5UL$DM^HG".O3$OP*Q6;'V_NL0BU>U6Y[>F(S9<F/A<!V;AL;^G)89*4?
M.V'@;%PL@=,MBH2D$-'Z&R)(-7ZRSI 4["Q=/:UJJ"4V-O? '> ,T%;NG>J:
MXPTU)D(/N()IEF+-]YA!ZX1O2GW(%0<<CP5E[Z9DI6?>.;'O:G2B:XO;>QL1
MJGY;VQ"OQS:+V_LEBNR)G[Q(THH(RE:&XVDP9LLO10DDXE0BCZO<&D_KVZ_(
M/7!'5$.IJIWW?G!(M"59]*V7Y;\5E$T>G#9=C@]7!1[3BU/:*/QX+)Q]/=F3
M_!'Y\J\\O]]RD=:/E#D/]/,!W@J^WIS4PV@:G[O2P.WWO32B1H-.!/#&B'XP
M^GI4QHVD[(CD!RGZ:2E=FZF!';6<.:E:LK!R4D]&31/J"\S:C"=IX#6M%]6=
MRB)C2IM6#***CL3BXDHKD)DBB\UTQ99J3**+FKI8C"]Y12(><D]>&VO9)#;M
MBSN6=-) ^1E3@XYXXT8W\0<4PM*5ORK5R,IKG-_D-<Z%5&*3H>[%5*O.(D6
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MC<9AKQN%A7O'N+,LU3U*#%&-EI854XH;=L*&<E96G!@ZM@>)QB[80T([WG(
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MR3R"%?DQ$4C&-;;%%?M"AXJ(=7.V/51,':R!(BNYU?BPF&OFIF^QF1@"%][
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MR?"N9-:G=_MN6CZ]'4!^6 )[ 9_(6+J=SR%S@=5L)W0CNNSB3 -IJ7+()L9
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MA]E[]E<K@#>3^3-:V&B.3!H8%M[2H/F#B;#,Q%&?@-D[WC=[T3>HA7-W7S'
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M]9MG*9#1Y5_63;*\LMU1N#R,ML,\)$;SV+9]8-'4/$]P;U87K-4=558!U'9
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M_?/_1:.$<I=NE@G9D)PQT&U",H%H YF8*_;HAF@;DXFH$Q5@FHJF$6E3D8?
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M?I23,V<0EJ3;*"!N@T&-QW3!;0Z<8B?JE@=9LJ"6[L27&#0U,8%(M$? %"?
ML17)BA!%7;K^6N_)7_Q"E&P\=+2]9*Z&3(@684V A/;>94+1"<6V"&F$+;F_
MSU>>^%M$29JF28Y."!P39P169#BA+_7A'UKJ,Q+-)D$\Z6\1>6^T)>'Q(6]U
M'QQFQ$_)4DT"[.".[L\%6B"?EDRZ[:Y,BOD2.1W=-T<SDD_,6J@D];1D=!DU
MP#"]&*BEI=J(YY:R7C.&0FRW3O.^5N%R_%VBDRDMZ5FA0Y>&A8; [984V&:*
MK3(/#;65&*0ZDJ)K#34%2P:MVWBS,!!<WK82%%J:.+' 3?!A<QX0?7TYAK8
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M8:>4[R9S) G:"@,'.6-P/CV ?'#8$^$OL-CA8Q#H^A3D@=,!>D$TW;T.\!"
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M#4F;=D)YJ)7(GNOD.9"8)>]F0Q1O&6>X"!??0QH?/EO*4]0"4E191#W-Z::
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M@M -&]9O&Q EHB,K:+,(3KZ,[H3$G[!:C?>0!HHNZI*"O3I^+@SK^H@]?YZ
MZX(0Z;]?*]!D91;\A7^"NB0-B";B^Y'?X(JK4<,^UY/D_YR$=[=GA&8W%$UO
MV+&G7?]?FWU?VT%1R= ,\R80/QN#&GD'H6@LB88@VC>!J$;% 6SW1M3FHFOY
M@XPGKYE LMVL)!B#E5[RFHG]#['Q&5%CAY1C<1'=()@O^*(:&-@W_FO!;UAH
MK7XT+!Q+=F.B^]&4&4"U;]6+YP6J_S<T=<TA:,"O_L!8ZCH>.]%,/='_F?6\
M_",2(Q,)P_^T:YF]Z'SQ1%H;"1O"&! 9)%LA[ZS *FX"]B!4,6FCD(SKWOJD
M7?^X/2<[I/8>0HDJ_85*$/^7H/&;?S^9A">SN5[85G.)?GJF^F!:1"RQA81$
M2=*  X*8 )3 4C'XJ2\FA7XB%HM3"9KK]^-7'B$^10C^T]]JQ9^I/EQUT+;Y
M!'(,T1X!J 4 !RH+5H0HZA*4=/U/E-,'NYA9">C,IH!>I2BR$,QJ$S@"-#F>
MK;H5.$&4<03BIPUH%99 O&)T?W6"E>CO51=]("'U(Y%,<$)2&L@"RT#[HC^0
MDT*2DN-,7!*Y/C/P@>2_P= 237$@*<23+"VP\;@D)&01" .*8DB&8^E^0MYZ
M YU.:0M]KBZTIJ0H\4-W81?ZL6A#@-K/TY(9J?O02+ACI=-[+#46VH2$5)C#
MDHFG)9>U<2K?Z)4MOE8<U%+V?-ZJ#E("O5MGT^Z0B\RXVU.GBI5K)5+V[';<
M@"5C3TNFZ^FATQR;+5Y)TLMHC,\GX^DY++G3NDR-FK8D5LE.:]9.%UJCKJU+
MJ'6*>EHTV^J/ZO5!O<=/J>HP4^=*=YG[AL (Y-.2M")',TRTV%%K:<9B[ ;3
MS3!#6')G2,Y#,M65JPK5X;K3:H.,N\8RANK<&9(5*X)!F5=3G9X3CU7OEG0Q
MVT-U[@R)<NZTUF(RY#MY[?8./!2;9EU/P9*[0Y*2X*XKF.P=J91GG5%REB&;
MU93 [@Z)*M/5GM+-I-2\/G3O\UFZP]S/A=ANR7LZ\4!W>V*.K_7ZMC5O==V*
M/!2XW9(=GM2+;7J2(]W;64.?L,5X-9\2XKLE\XK=M>?WC66GEV\7Q]DNX$;3
MH9#8+5G)5ZK-:C?;5&M:O3!R.V9QE)M#@WNG9+20T.X$P2%)=_BXS C37#;G
MI 2*W"V:DXM]<'?+F2IH.!6GU^43%7((Z;E;=''75[-+XW[*3V_=?JM/)Z)5
M=/\0O5M4K\EYL1%?=DBZU:93T])$DLNPUCV 2E>&66<2JU*=4O4N9C^6]78B
MG4)%=Q U?Z33#>.A)O/C8H5OR'?1_@#,4=$=2$6765EX'$3[G;PHM.*<U-29
M BZZ@ZE'K=P6F5YCH-9<Y?&^VBT]\$8#%=T%54$T8\5,CV^0;IEK)G@'-""O
MH@OD=\9ES$JYR:+2RJO3?&=4O4]433*!KVW>*:KRTUG/%+M+7F$G4=WL:*/%
M?(CNK-LI2AJM3J]6Y>IJ9K@H#:J%>2VKX8M@=HI*O0PT>._N:JI;K$]X]@X
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M'^"1=QN+Q]M)KHZ*]:5[]77]1,_& <R?\'5UZ&]S@*H&F\!*F[4[_DIS 2,
M/7E!&OS,@_^T>O*!I*, ,'E/+@&>36!(GN0#_U7Y0/ _L<RT0V1[>$DGK=QB
M_M_OVAEB_$#-.TU$9-\;!',Y^P,PT#?DP!)Z%)A_.&>S<6S (D]\6>TIQB(]
M^O<6I21B_OW3=88-+CK%-.5^EXV2$9BNMM)LS]AK@ FNA"74=6^^%W1[ !9X
M3AP8.GXZT38S<O![A@"WM_Q95F2& N^;!,FE(_O?"PG^*0.EP*;U:5;WY6#P
MNIDG5SK[2^@\&"TT'[ ;)[#]@ERN<@8!2:9$@8_^TA!0Q*/_?00@_R2*S08
M 2[G2"DP&ZC*UO"+DQ*06T8X78$*S B6XUU0*3PI%YQ\(07F@H6V-%3C@FJA
MD(SP.RD@=SS\WPA\4]N/5_-<H)2JP!*B[8*80L!OE'>3L0 D /5,H)X)U#.!
M>B8 K:">"3 &R-,&]4Q .(!PW+V(X?WFC4\K' ^4\0*DXUJ=<(!T/"MG .D
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M\Z?Z[GM,D,K#=X.RB^?Z[GM,NLC#=P,^?Z[OOL>XHCQ\-^#SY_KN@N-Y4:K
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M=[_+K)IBC%,'-8YW&6N3/RK<8QQ.,40$\,8])NX WB@&;]RCX77^J'"/H3Y
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MM.W%0> SRC%]\LJQXK/Q3ALY@P$,W)Q.M<ZT90I\:+8-GBQ;5#_!  1^!0$
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M@S?NT>XZ?U2XQTP?("'%X T@(?>:&E0,"0'&)Q"1N\U: ")2$.8 (G*O>3I
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M<YO<-7I=3=I )E1SM.;Z8*9F31+PNF:PZ]E%#0#.O5)BP70KP/AWI\(]RB4
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M^]/XL6CFQ5Q[4M&D\V3K:= M+JAZSX!ZCR03R4A._"X,<GQU;_?F-GXV8QU
MG^^Q'3][ID>LS]]=?KRYJ\38T&!S+#:0$/&QK U  S>7%YV[N]AZ4KF]&[?G
M2Q0?M#$-R(]3<YJ3[#C86;K/GNE7E1W/%_%;IL^5<KRYOA!KRUMC/.@J:_/N
M]WI@O21'U,1E>6:6Q9$4'=J3AXOAU6U?'U$YDOCCWT1*C*1SB4CR8$CDV Y6
MG,3) <7)WH,5GSW3#PYJ_*8,>?4AQNG51<\8%%8/8FTTN"_=U%,E0_[E:&BH
M/-D;(KD!KNF<G]>[G6GC 0BD'VLESZE]@R<18R!7Q&0DD]SU89YZ6IT$R[L=
M1_SLF7XIP;(GIR*3KQLIY\G)=XC4RR_/2SVYM'Y?ZV:O%"FLVH52^[)1Z,2'
MX\N"<Y6/]>^9F8.)%;%L));,1,3,+CPYB9&3&/D)^.2#S9U"M#57C6ZF+!;-
M9+%3CU4E8WE85X>Z7-;[JK%*2_%Y1WVR;K-=3:2A!'J,,Q;)H0B(/=?Q^^5D
MBY=(X_ '/(\AP^@GG",X>&>I8YCDQYSY_/1)?D07J4\GUP.WB3J&2?X,N7/@
MCE'',,F?L)$_H@;\P9M''<,D3]3Z329Y\#Y2QS#)'W30XYM/\N --HYADB=R
M_2Z3/'C/HF.8Y(E<O\LDOY)TI8[)_Z')U$<SL'<_SJ$0W29FT&>-_X_%/:=U
MBQ!!5A1C"F/ 3'-!-VQXF6T(CBX[ ]CG 3JE8<06^XN>>,0 N#!4=5E75%F#
M0?,8EW6V.8V!:LTT>8VN8?+/V^:DJ3J)C@FZW/]^;5Q&?$-<9J NW/_"?]QG
M*1J1323S,7^A%WC 9W-.%L7_'.3LS>9FQ9-^=(%O5F9[Z/\K.'8_>!)5#,TP
M_W8C)(%)\06-4]8<D6C?)/(D*@_AO7_+VE)>6WR26:]BU=]>B 770,C^1^#_
MXAKL+.!47D4#R\3Y/ZJ1H0W?G"52_G<TG.)]:5@T.^MODV"9R07!IV\\E^Z&
M;<S^CL?.: @*/O+I)-'G>J#]V6*=A+\;_U<6QB8&:OZK72N&TB3^#;1O3F6-
M/7;)QLN_^N/?-DH?P1@*18S[ /]X)"H'R?19 J5+&X5E]$?+E];_<G-/=I::
M_0AB7OD3KQ#^CQ"G=_ZUM0E;N^G+=V\O\:L]CW>W1:;!I5XVDTFE!O%X+SE(
M)'O)83S3ZV?D7"^>2\M]>9C)]6.I/]A"'%XJXKCZ&V_A.]4WM '\F)\!GPCM
M,0%51QS0B%9$J.H*2+O^1PGNEX98](1T,2BDO?0#BY*9;(V%LF8LK0\<^;;*
M>78:?W9<M?.7-T1.,4DEEA.S8K(WB"7%7C*>B/7DW"#;BR?D5#HABT!@24XQ
MLAO E*6+ZT+V:563[JJ-=:72J8V=;![/LV]?62U7+YYZR<I4K%B59N-^7+J<
M-!N]^.Z5R>IYLUBOY+-BNC/4+U9/L<0@F8<K4]M7-BL:N;];+MIB\;:O]=79
ML-X;YGN)GKA]Y3"M/-5TY^%IDL[>2C-C$N\IE7PON7OE4V\Z:L8-TIQ4TM?&
ME9%*)F*K)5RY,TYS^?B@FK'H=4<^+XKWW?/&]:36@"MWQGE>GCTX&4F_FL1K
MMC:>7&6KYW>C7BKD[7KSH>6TVVK'4<\;#^U2UBPI^5YZ]\I^*6]G[B?7U4GE
MO'!1;T\32JJ\[&5VKWPLY K)9O.Q+%Y6SN?92NYA<JXN>]G=*QOIYL-]29&7
MDUKV<CGLMY/C^N.RE]N],J%<1Z^6ZWE?FL[U1=7(S=;+U+(7$W<O751+G=5%
ML:5TTNU4/F^JU\7;;*,7B^U>*G:Z_=2=5NUW*M'[].#V/OND7,%3X[N77B5G
MYXU,OS>5XKWAL#I.U4BC!9>&[/U\;<WO<T^/Q4XZ=R.19+UW52B-\-+T]J7W
M"5-M2\E+19KJUFW\41E.U]=P:0B=M*Q9M2K=7B7$M3AJ9T=12U=N85HAFWJ?
MD8?5VVAS(L:STBQ?ORBU;ZOPU)!=-1ZM;O.BE9"D8N.ALNKK@XO1 J85LJVQ
M:**[ZE=FK8YZD=&F1FTUM!T80,B^]MKB=&A7UII("DI)E M/YZLY/#5D8]NU
M^U@Y=Y5+=FH/VG0^F';B#[EE+QZRL4H%Q>%P]-B)/S5,=1V-J4N@ZGC(QL:D
M=+&S[%8?I'1BWB:QN=1+%X#Y0S8VE[H9ZHOU(#%9I[JMJQ19BE8#N#]D8^/]
MSBBEE!^N.]/)0[(GY[,-YQ8&$+);ZFK^*/8N6UUQG:CF-;O<&HY$F%;(;HFI
MRL7#5"TF)]%Z+T,JZ[O>*M' 2W<D0/-V2%*9Q8Q,U-Z<+*++@69?T$MW1,#5
M?-(QI&[VL7.9O9Y=7URWIYU;F%;(QO;6\)3FO#B6XM/U/"Z1^NRQ#Y>&;&QA
M>)^.UQN#T41VJNW;^5QYC-XO\=*=L0XK)%]*7B4,46Y<*J)N.4\7!?K4G;%&
M#4M)6A,C.RD6^XO19-IHM+LPK1!RN;R*-Y]:\F-9JF0TNRGEZZOKY A3:G8O
MO4D_@!2,ER7GUBC-$A<Y[3&VI-DWVY>F[9PTJ4^FUV+4UOOD*15;UL;T4G>L
MU*ST@#E+80)0KLDSB_SM_A%4HHAH.9I%N*8P/+B!\63'-C8!'OUF Y3M8K)=
MN\4VW8'Q%\:86GY%-91T]BP7?\[ #X#%P,,->. 04(=KD;F?H^@Z^)O9($M8
MI!>M .]WN0\0Q[')/V@0',HT>XW)&?LUD_/WW"SQLWCB$W>!F\0;8-_;D!^U
M$;&SY&>RPVDCO(V(G66?#2B?=N(DFW[61IQDT[%LQ$DVO>].O#ZE_'6@]>-F
MG84?=YQ>'Q*9>TDL?ZTU  L*O_Q_?Z3^^-7UR)YE$Y]:T3/[FP[?&U4GPC5\
M/[8$21^@KW=/<4C/D7KBGF/EGNS.$CRW]6Q;=_^[N=%!/HG_*I_$$F=?FTU8
M9=3^EZ""SY&A/YHV$F\5CCO.L$\_H_IL5! #?H@:+6%H&E/!F!$LZJR/!#RH
MMP P2*R_WY4]/GLYWJW^'[.?/GLZGY"HQLR5HRM#NZGHO@FU?D8>XHFLCXFL
M?R]_\6VJZN.VV$M<P[R/?]ZU8^YGH[ /Y-(/G>1[5'%XT=7U$1QUN$88L=!&
M&&31>I@5KV5ITFK:>K+Y:.8;@_ROUF6HF\90M5_J@B&E5QVE/5C+$^>B7[&-
M19Q49<SM2= "3V(Z$<G%X@>IS'+BOQ/_?2[_)8+\E^A-LIU.IUM;]Z7YS##S
MK45JD5L>F/^:V4M],5GGI$FM2>[CJG-S'VUA%AXKL)9-)B(I\5G^^VJ6YK9&
MSP\>'<MFF:6V(9@$=DQ1-2+H7-7CM_BW@B:H@XFIJK[/_CRA^2^-YM_/YOYN
M(/U$T%^2H$_FZ4\Q3[/T!24R P6F4I0A #H1Y*D!8WVB7YPP\]%BYO=6/)_(
M:T+B+'70<H(?:L4&&0K^U@C^D=<'^0!?A;56N"[&C'%\+HGIS+@;S8R&R8R)
MQTO0K$U'LCGQ$+703]SY;2;Y\]CXH,;P+[+QJA55IM>IIM)II9^RS4(O=YGI
MCH"-P3J.1\1T^K?JA1ZK7<R@!*VK2@D[!P-CA^:G,Z);[XLE?B!"/@K+X'N;
MNM\+A$C3F6:L"2D0G0Q5VP+!1=O#%9 MBP&NO#%T]%*%2#+Y%I;RNM?K3^3.
M^%$OIYW9-#/J91"0)-+8G>6YVL<G'O^2/'ZR_K\AE'D'83"YO%GHU^OL2G1D
M\KB8D,=XLX9'VM,H#&*15.[W"J$?D4.D;)@$AB0HCFD275D+?XYD5?_K%,,_
M;HOK&_E#OGP@G[-0D7-0VY1!P-!I5("5,,!8(/ PTI97(;(FKDG%S,2JFYW+
MDCTK#$N)AWP+BV*@)R05B65W/2&GX/[Q,N9/=(5\^52 W^-@.5WK99;=L=F1
M:^G4Y#+?7Y=[R,&(%G*1=';7"_(MT@,8@"B.97T$S]J,^5L6L2T:8-%4F;+
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MSH9335"G. F59I^P*^E2T 7'M*CU#'U)-(F8UA0;8&JM9[?3N><MZL;;W'Z
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M)#.OZ@;S&_W)&BNSV-5?[R8GCVP%?N44P_M(S(]?AP S4,=;<&$29ZGMI3E
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M?C]E3\3+PD5Z?+E*QV+ST:M+S_WJ[+?D9CH5RURKB5Q2:L5OR]51(GF52WS
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M+@TE89R=D$LRPUL?[EHQ6FO> ; ?@FYB\@I%)6V]2+5THV5+OVA=NZ.J_E#
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MA$D)? _;NSD12J:VCZYRFEE@3)R>1]%'_"J;4K# ZL'*/Z_FH"Q)*1+-FM3
M*,N7/^%KP-- )%1?:IU40A\/TGQ#3]B*N/5<G; T8"M3P?I3Q[R$*84E6>8L
M$H9OL7<M941Z*6SMT'@7=D5%-K$-(WW;DHW37R.=H5T?/@H*97L\](?P \LS
MJH+R=>E+JAR@(/; ?A8"]H//ZCCOE(1'DP[+P_2!H<XQ$,V@0^,L$N@_T!3E
MK8.BNX97757V2>52"$9(%6A5J 0"+ C$!+%G%]>^5:$J<,7 W+PHJ3F%*1BG
MY)XLL$6>/<0OI1-53T:RH].E1>#Q>OZ_BBPW=*[GEK+>B(ABP*T-5E[*SJZ
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M75)_[^2N_1C4WS\]-;\CZN\](^H?N;W18-=QM!.[]@=3_P,,VV/N\Z.>@:I
MHEX_A>C724JO4XH&'RHML+VV[1AI@1TG?_8=I#O%:SW(K1[P#F\M]3MZ^NI
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M^5ERPL0=#-I \O,&1=BY!7S"G/! <W?D=B>3MASVJ<>A^14?@KP-/1\A]#P
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MLAE0I?4''\/N)X.??A)G(JKR],'3'Z W!Y.1>[';N4,MU[1<\ZRY9NR>3X;
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MA#_@I^9PV_+]&U 1L'Z0]CZ>*84"BQF00#8O2ANC?>&#\\*+2N=J(J QAFZ
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M($H&V*XN/[T?B(<WTC0O]6)6^[]Y<R,:0E+&@_#\?Q6$MX.-[G$2GY'!-%O
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MR]6A_I8K,=+F2:U]BIT?WC5\@TS2(%UF[%AX4;X@QTB9Q]]649)B43B.5:?
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M^HI$:K+Y$AET<L=3%H/)IYWG9_".,R7-%%*R2%WE(:IK_#5-T%C*P?[^7*S
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M'IO'*PYO8GI"UE*_I9:Y7BQSV5ZA2'\J@G__X6<B6/A?QT/$*]VKQ0A8L_+
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M''Z6RTV<:SLAB@E<^B/U-36]*MZ2ICHE9=%2Z^&H]9VI.-0%7]RVKC+R3:7
M&[DA_%H-Z0D0L)IE2.,&7"J!/$.,GF*I$E8:@$37HTF2WREX?C,2L.YQBPA6
M'25R)L.[-0=8I0-6)&&S9X4"'_C<*-K"&#BSR9,4%44M9SBS--<Y+8H^HB<S
M=Q6BC(3I@S1%-RGD:.<M6Z *?W'C:DY1%9@:OV=SK2T/OTP>_L4+(QD/T4Q
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M-6^)TDF+.$\AI^9V,<<P:<R+YI<]+IKQ-)L:>FU30]O4\'R:&DX;:+ 44PS
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M902+#"G\2_2U!__7'W4G@](P0OY+]_R\.YX,]SB(L"'+TS1A^LF,%_F_+X"
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M"]68MKIXI($E8YN@;JG\;7M_U8"FCF"O"41Q";>9,UO=@J+&: _D#IQE\.3
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MI#C/VL-1S*ANKO-*ZES<4/KRY?=^,[YT)5!8=[P/_=*8KLGJD1%Z#:T4\0&
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M\W2A1$W^%D+#$F!-RXLD^L6X$B>D^"ZXXM7J2_W0JL[A+R4Q,AU3E8B?SHE
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M0D DC*5*?RO_\_9>\L-$"O_G@A1>D,*_'Z3P^T]-;XMEI\$?0N8GYQP2@-M
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M-5"#Q[[CTXX,AW@K7?,;\CA<?,T'0O+PS"*@1=QR$^<-\ZA^2WY;,-RAJR?
M_A3GFXRZ\[4B]IL&[#?<<FR[VB>AQZ;8N >$$/C:KX&T&6]O#4Z"T0&0LF)'
MBG-B #TU;>G*(]03S:\<]^>VV!0Y84KU%,Q$)(6ZP_XOSS1-0DO+?<?@!V7
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M*<*LZ-/VW E&N.2V"<4\7S: DY%&>_=C$\)0<AK4I<:%)UMWNEMQZ8&Y S*
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M$51IJ4ZBC J# N9)4_:2QB4*]+ND-,J3;5)3"=*B?3-I5&&P[<'.A'PC^71
MD DF$*^D!2><ZW;B:R924*V24Z4CN@LU_F/A]N$=I"4GKCZRHPCCH%$N@AN&
M*!>%F:_+&VBA'GN<9C4@3$R($$5.W SML0G%<6(ZN$/MSP4 ;<)!3"=W9.P,
M=;F$.+;>^<,&I;&%%?:1&B(*RBBO[P;#X@+!!I(;%->,K1K8HN7C.O8=<&$=
MRB:Q-[$MVJ :L=+X6TY?805 Z,FCU3]U$B"J)8/#?;'/QVF?/;4 ?/CK*FD
M*B,&VFIYV]:; IA$'BG0>=^<0C46.D)+_I8:UL+>^'@M+(GN9";3(.T"D2,'
M?*/I^?'D\#Q3S_L2E-2DZ1=HU0%W%ALW=R\33&TU+1ID@@&P^FBQU+^+XS\2
MR$ 3+41!G :'WT8?;TS.4-8G5)OS2A)<A8 ,29W&#!N!_(Z^<'GCTH'KRUVG
M>Y=5[M;J4E*AM>V_,: 7K>?F8(;/=H02U!_JN2Q@;AJ8=Q1)Y]^W[A@Z$6E@
M4NZAO.ND,WSW1PZI3WE67)LN&[,?V<U5=4T-9!SMEY9V)OYKO%X1[GJ^ZX-P
M,_!(H,:-S)S1G* /G4OON6B=ROPTP/W>H[=IJ4(S[9N86@%PK8-^T]@6N"1D
M1LW>IIOY_@?&;^\CO]U<GC1@ J<)K$(@&)=GZ[$-+HEH$NX6X#!S._GJUPUP
MK],7-JD6>;E"N$6 A H]/Q^3;,K>QZV D3!U#=^:'F+J;>9ZV^H0+_Q0Q-Y$
M=5RFNEE:UV_#)\7D$:M_>F,MVI3(@UNR" *$(L*M55B<8.-"1M X2I#\=9Z4
M1:N3K$)/H)U6OQ=" YGI^@3BJ(0&V@7^BF[Y0G%6<!EF3G?U];_[0K74OO;_
MT7,=X4IO]UT@@G.BD JBE?&6L-Q!UC(G7\:,(_?K0X&Z 3;E>NV/9([!*[^H
M6"]QL0)X])ODF5_;-B!+_E5A"N95QTP@SP,3/^]R_#3A)/7A#N:-_$WH3CRB
MP?MB@$#<NH._+;C3*/9@20FD#8$[YV5.7Y(_L#QKU44Z8NZ$M_OZQ%Z%F$3P
M7MXZ4@2"_UFGGR-T@L/ZK<SZR<OC:OX<%"J=_. P+XQ^_+4W,3H6_]!^E'G/
MU%+423%5%F0-LI7_!-V40I  QSA4P5<$?U035#&4O6?RXRK_<LXUI(%1T&NO
MB_K"BZ;7.K@<S9\"\TCYNJV;==3O6-=;PO3%]X> ;LZ [O"7* -T5ZMOY5&$
MDHQ#H10E"OHT[GH@!F06O#H6Q?)J_FD5 VDY'153>IW<FR*L:"$:9@7QKP.]
M$P>?+/-%X5?O;7[G X#Z%!ES.M[8NGV2NY#16V"B/VZH$X\IF5UZ,M!AJ(1.
M>D*@DCCUDOXS=.>C&"R:/[+6]N8/B77FM<0.&CAJ6"#.@=MJR=/[^+@K2H73
M:(#'YS6M5U573X3IRA[52L0PO6ZT3]U/QZ(A1"N>R6W) %;?U+4_'[X*6^?+
MNCTX<L[/:$K07_.;K[Y\ED5D46Z>9$>[_>QR;A1<>*X\.E2+H<7?DJPVG!Z%
MYR):]\\OO[Y:?=4W:FOV>GS[+ 1E86'!CH7;D1OW5]8EQ@/\Z>,__6']T1\^
M^>B__9>GGWW\-_I[N/].QD#SRE ,5O+8\G?J/71P<-R!/:'1G3KAV#_E$%K0
M9 R8;CA!,$<4ZYR5 ?^MB&#FB0B$2JN_^YT)-')>V=,I>)3P4L"?^%_V@1=_
M(Y]%\I0G?0#ZDANJ?.ST @1*X\]75/Y.Q1;9:H/O2D"E0O) L1]O%I'^%*;A
MCU5G["$>TR-S0(2237T3A+9'*=XR_WL$E2&LV;'5Z%')3>'B.AS1@M$BSK+
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MO'^8'?3/E@[ZTD'__730'])\4 (6V_M\WQ&#.,K*K7-OA/6OTRC/ND=]3:J
M[XHRNMQ$S5A+44G!E&/5=5/G6Y%;C&B@J<PW>CY1OK.>.8AY4?6DZ:3H;BL
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M*WWYVZ1 OBJ4E\+87KN2J?*L0PP@,%'W:K6[AQ2[IN0/MF?/:!K>T@2#A6,
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MJDI,":V)]T76B '-9/BXX3EV*(9CN0X^4Z=Z,-%[3(U4$H3 (\$AH ;UU'.
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MP:,D@U(3?UWF()A20F(N@+#7;O-_!8M#CZKK@Z]V3_@U*<ZYE+[W7L5IC5=
M"7"7[_<X>NQZ">3@MM@SFY;O\0R/8I\>W1)>,Z=L"W<S/&#*[,-L2CM&Q0"T
M,%7#45RF'P5.H4Z/0"02L$QJ$M^#=F]?1J@AZ9N$Z=%4IK\P(C7ZLG"7SW^;
MS2:G!02P/AIO-\+.5E"OZ@;IG%TDCXR7L[J&<NO$Q(_B1M;45,%1@:0=,0J8
M"/[,.//+5B<<(G4(;>D\XD+32,F%+1?\_K&FRQ/;UQYV8:R'1#,;S*=RX(*5
M EQ?J/:T(7BGHQTGP!TB.VX)YN%A EQ.CDM:@X=RPS3ZF'R)Z].\T6 ]3.X_
MMQX03,7'T6C*DCB;XO_TM)"C$IRX#['G1M=%*=,O. @;B'AU$"%[0^?6%&VV
M^G6Y#O^_":MDEY?[ 1$K_([$@9$XKRK6KB6)UAN;,TF,3)BP=V. GNIR3+IF
MDM4SJB:O0-4)XN34%1E7?M_HA-+TS/ARLPD;9JY3LQ(BC?5M-H1'>_Y0WE%"
M)4[]..9'^_>9KXNQN1I0K+IQDK)NXD ]>1_S;U,O&IT#,N<@/JBT2NS.45DQ
M\ ;'K,>4IP&60-,C,C62,?.96<XA<0I&:<:G*(-.T%OZZH04$^5^2A[,_$1:
M(9NHK7[4?NH;$OUOI9:)'&;J99TF(Z6UT[<IB,1\W)ET\*K(0[3JV9X2+!CQ
MU^.8PS,4$0I!MQ^"8Z^)I;DY9OS3NFZ:_J"]8N$7*)>&YT _/BW+H:E:$=&A
ME=K'_,GIIIE T4P5]\M6ER=VA+!L29:X<4I*##E"S2!S>7H:2 A7$-D+$TA5
M U^U;(TY]2E!J= 9].*'*\N\MS ]0 HZG$SM4@&"C3G"GJ U#/_2J@:0YL+^
M#?X5_H"@A A(CG_?Y3LBH]Z$ 5EW7"*A^_%/(-L!6Z048FI0L]"I1IS:+&+
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M6'CDU/&[@A,AZO38=;4W'VC"1/0'Y84AG,XV#_P(-^YDI7>\9*5R(7D$EH4
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M$<9=P\+@ ,@XT(-D]CGM!.<L'R$:8PM"1SKG(J#;JQ7+X76$1L/+OKLGX6@
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MFCDB!SBF;K00!]!QN)^T-Z?;3))5HBVE\,#/GZ4P>?)9S.AV-34&W]?-;@.
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MP Y^J;J:>PNN*$5$KW.$8SLI=RFY^5?%45:NEBE2'4PGW6!4LTY;T%1/7+D
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M>;@JG*X5>.459DE9SLAK+0LTOOCY24RGUP4+T^LE=)J[YE?_74],D\OMA![
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M<&2'50SEYJC["TY0>:.V4$W!J#<2D)&C,)^&6JYWWI^GZL+*=(]DVKFCL\5
M0)Z=E]*W<S]_&&>KTH)(?:!Y.N!= *SM%4'@O4?C!I[ *P2WR]5)F#.T#(0=
ML3T7OE9O&&V^\DS2<2 Z1:77A%^>N1-CC".I90*QPJ<Z.;QDB3 *9#H12L8\
MP5@*&V^'::;)[?"\6$DC8L@"LX: 7UZ>90PR!5E#>*"*&Q_%!BS*<B*6(29[
M8Y]8F[U;-_JOM;16A>$N?HF1V 3?]]:\YT!.L'C-1UNU\9ZP)+3<B4*TTM]I
MLHZ97KX3C@';%;)D<-@!L2PL!U)]EY'5]044LEWDYFGU,$V6O#[:_L"B R(=
M[]=-+T%"H!KNH_3[G,"/$8DCC.: V\AA1>*L!@S&)*L*(&AEQ"U4XA%D@,LU
MED_+5H1@1GHEXZMM>C(CQ45JIZQM>'0/D3#9(6W<ZKFARV)'O*.RZ?A:]BFV
M@&CRV/K8I>6'H2HW>"GW[BE>>O"PC$VN&>9=;K3P9BL,N-PE4K<!MG<)L$PH
M-@#.HLT%[&B @:.]P^AQ,P)KT]K/ ,Q!JS8F2;3(@KVQ6@T1X/0N 2"6*X8!
M"SA#2B;D!D,5!,I3>B2%QKKAX>P84/K/_I2P&BU]%QBN"])1R2F2W%D[]$MV
MIK!>2XOJTV=IVFV;E=IFI:^G6>DQ';' IT525*;H8]=$*RI O!0W D &\)BR
M48]VP.9T?"-VQLS9KG.YA6ZU.((<W>'B44'M=-4HCLK>B4Q^[-4BO-<7^/&;
M[ ^U&Q-E*IX8:*K$%[]U4P,?E6@_\C3#0\K]4GW?X+ .W)#7B=T(.Y7VNN%3
MG?/[QRI5A$C;'TQW!C+#;\Z9/E.O32=8J'!)-(UAN?$([(/[;3P),XYK_20L
MWI1_X*[=T'=NB*O<,$=F1<GQPY30Y%)%IX8"0I-PFC!AAAJH7;@Q"'4!3JA*
MT(=]GKR@.;J];Q_L>E& YXF\X@XGH0[.=WO+)P%;%,Y+II3%!R,P@(PIL)E3
M=55XHKYV7QZ2. V3U*#U;8Y$=H,CB(5#_#I-+UC[;OY"&:KAP/8/M_#Q^H#K
M+):[0%>?>;F4[24)R$<ZH>MI>*MM/6_CWLYO9"><<K6-6KAS:1 6PV-?>*1]
ME(%R5Y*29815I5$.TAA+_L#'@+0(DO@+S^9=<)QM"@5?7O+,"9@ 8#N$!["I
M%B<.-F/*V%5*U*VQ2!VC$6W:0BR]I\'<"%.L\.3O9D-PJ^E?"326WLF ?9DL
M]<#0;VICYM<WPR_798#6R^*)0G0$0=)9*RXI) O1EFT3-!BFV]K&BR-(XNSF
MW+!WN^/Z/;9+VS2Y$6D'D+O%Z+?18TC8O:/O18WW^?+8*"%.:A^C(.T$HJD%
MEHQ4LN (I UV'KTYP%O^"(LX_#<I('U9!AL3*GJSJJC%PI9K#JA+W.W#*%&%
M"L:U!0'6L(NX^@T1AXWZ9?IPVK&6[I[ _O$Y*XPO16 LWOL[ULZTZ3:E95HJ
M;\N&WJ8-%[!2Z(OQ]J40V(8-'%C& KK.F7!"_+1:1V0$E1WJ%VKMKW^R>9%-
MI^*MF)/#V!N&RBAO3:D+/51(5!25@1J%>],+RDFH\Q"6&XTY]888=_+R$9M,
MX#K_-JXG_(C$&%:1L]1P9IBR(T!T+[04<*=>#/UM!H9;KSA\Z*/U^3]4>5&%
M%*;W*"0PU<#JQ;4"LRI?$F$M1_"9 <<1RVS)K10EB+ 1<4HKN77RK&W<+07(
MZE[J1'R0K9\F#?T\KD0?Y59PGEN"3W2B3:*"+^%M[:@MR&*X8;<YH(-OG>"B
M;4<HS>YT2?;HH;_KD_87HGFB3KU]CB?8^K+C3Z6"T_)<2)1 /A8I9T["$TN)
MD2%J)JB=+*J,@F* ?'5=F3"I5P@4\6:G?3\':[6$E4!K@85=Y"@Z2Z$D+6;]
MF1AR!S 2,PJG'L.01.FWT'<A84@2HS\'GEIHTD(0OL :&*T#@'$'B:A6:8C1
MA+ H,-:O+S3S0+%C+19AA"W>UY@&\P%Z@5=$N;7 O(BYER>>VBLQ:;*"YA2M
M#/7,8]\N9'*AJ"<  31';6MY]!:?54N4 G9"9>22K!5;BBDQ'!#92I%-O@C&
M)=WI* P(.;[MQV+0)L<3:4C%0D1XS>?D,_!S\NL+OQ%7.8\!(@ANRF9!!U,S
MR\.%LM&BZVQ2Q^B'3C!+;]OZ1N.RJ'JYD4,NH>VH(;SQDYYTR-8+1:(= @,$
MX:-ERYD66K+B$H4S!HF/XTVGOT=KHIR<M!9L/>Q5REA @IV@I<U!6NU8<25E
M>U+I"<%^8E-YD.OU+L5I<1(QH98)+1@Y'I>PJDLK[=PYV)N0IC#!&K(/8\,Z
M^H=$TXZ$BZB'.B;< HT[)TMV;X'MBT>%H9&=*1\2[0FW@Z^EB,LYC_\T2T_-
M49 $3?M%*P:T<=JM]=5_5_&) :#U#74W.+"-'Z$[R^YT<DU-DM<F#C%F[?V5
MWHTYQ44WC$9??\E@>!LX1PL(--&YE4KG8(NIV';_>E$,AWJA^_3397MMNJQ-
ME[7ILEL-S+VR='O,?&;A*J &A=P8R/WKTXV> 3"BE,I:"V#/N,P0J@,*I7!%
M9U6)-3H"NPV.&%0Y<U4QMV$VA<,-T0I7FPAE09%!\PKZIW ?E&.WT;2;)+6(
MNA6.=5BV'N9D19 3Y^K5IO(CPTGFUBU2_4>:&K<*90!*0<&/=KMO!?2$B'GX
M_(A'! ?VI,8?UA *@Q2;(5+AMV'%9GB2*S;7($X@>NCA5IRX8/DV'^K1$-U$
M:,6GWD9J+]DOCR]^?R0H$7[0;%EA]2\DK*&V;2..!,(N"6F$1^,D!PTZHYA6
MMDO)UV9:N+K_\30V?1@D\7\^._XE_=P?[ _W^Z->_QE9M<>D#KYD>2]9P2S"
M@':)&Q,.D%)(C* CIBX=,1]6[HF.GV)RWRX;<*!5E?9^U\9F51#R@-%/.^8<
M"0FUQJ:<=<WVZ'8?!+@AR8I' .)^M;RXF)-6<$((B1-9T?$5OCRWF+$(%@MW
M&NK;+$=EMLS<Z_6).<+3HQ,%6+\5FJ/^KO*D@+)3HX=G*L8^57J0J+?7>MOG
M":4G+'MOR"/-F&Q0G6O5+-'D:D$U)9Q7+B]6+)V13>-A+$6!SU5XE=P<I+<A
M05?=^ U&B/Y6(<LEI HKI/GE_BX8G$DU<E;0L)AW)*A-0U'Z%)I=J#:M=T-J
MQ$M%VRM2,J3$9Q1_!/\ 6(^AH8[JO%"H5,J= 50E&Z88IRJ-=)&X'J"8PIEC
M#CY(?F':#M;D_3GOE>;;XDQ1F3:Z5)OW12P[X>H-\L*X$E?N$I!0_7S(%V+0
M(Y(PA-TAIGN1';FIFH?IC((3]B-3H+U&>:='0,B6XYC0)9DL8(!P8@8&9%#$
MLT0KU020@.,*HFAGM.E<^HJ&'0.1"MDP$B^2G>8RLIHM>^F09+]6$+!-L-IO
MY21OX%[#"+XM^;>A([I,+@TE_/8#K%.5F_AI.)N%28[Q92T)2]4)>%TIC;G^
M;)/.=D*PDB/%UV[H'/-BK?W^[K8S8AN 6/YV2/X<LG4Y/4K,$(=1L(SAKK(]
MMYRL[D^&0RKN66!IH7$(_$O-C]T".8X2US>$76LP!QAII#2#'^GU7%"HZ<C=
M)</$S=^5WL/@!-&#T<1P5:9S+[9 S,)3/5?HOKL0VT+JSM)TU5X0VP0#=RP3
MM>+6S5-57,,J0:%8R$KG#%()=/"*N:YSPY)*W=.ENX#J8?0ASC:;80.@@EZE
MB,XT'+QGA<C%6ESKX!).4PE0D46)<4 P%96>2KT=3RV.#'>&JVLW=0^[Z*^F
MC^@>POHWAS P-:=NRG2A%(DREVD<H?/]#IU9W"'T<YL:LY5.?J^PJ8[@!V$9
M )72)-P!#DT:_$84/[R$<POV41U2(V>F!<>IPH+,0D'9J]?R5UZ8I3I!2X75
M.C.J2;B$L]I?U0U%";8"@7Q_JS]P+W-,P()@ D^[_N\BJS;R!C_:Q,]ELG'%
MVNOIY47?) 6VY("Z=&REH:GIL%G&2''FQ:8=B5:O5'X%:"=8:+=\H;6+JSPE
M-@(7 L6SN6:.?;$H$)C9YF. <%PT% .Y+Y.Z6#9(,C?%5;/363_:&G .$F=H
MNK/2?.8$*4CVT/'0&C5-3H1Q'GT\;FPS%/:.>&;R69*YQ#P.)Y#\Y5#!^T\'
MP:M7<,F?K^0&W/K<6 "_9[]@E2P_ZXG4WUYTQ14X7-)NCL)"K1-JRVJ(I01?
M6@^<?!&NZ_EWE4EZD!V'*ZN:SPR^"40:8=-+^D] +?1=J78=[3R=9FFU8'V#
MS0;L_V##F>E%%C0;CA5!!CJ9@G$H,WX>2A#7?$+(0'_O2GNOL3D23Q/*XX?%
M9[E8_ ,/I -,)O2^3;&D$/)X.0<M.1%N+\=3@DB+;27E37;  <5WAL(=CP<<
M(S=3Q7>#RQ<0^V#HZ301D([[>[,V^LK\5'],Q\B$(UNH:AW9<.09!RM&!,3P
M5-'XH,)&2O>@][5D36UJ0ZRVEX_ 9@F;NQ>5ST$BVNU7:?(\3'S@=0['=KP]
MEX*6<G<<AJ"I]H'.3B'Y)'HT86JQ SB>157<P='.T!3JAY4^3^OA1K;.G>:&
M'LN.#_FU%#AQE@8<-?P&6:,=7DQ71+B.P3> O)/21&NDV'55G1MCQ36$#:"6
MLG\1S9([1"OF? '-6LQ-5+I#C>B)RCU'T2F2^ J2Q?MMLKA-%G\]R6+.(PRG
M_4DX'.P=3T;3\?$HBG:/QZ.]R?%NU!O&P\$XC/8&G%^@.PY+M1C\M;3E8!CJ
MSV9OT.FR!^U;34JLG6@N\7RGWAO=FUSL/6VX=Q!][]E/\$7!H!L$[E<%)H-!
M'^:&$$#'_46.Q@<*B6F!F=ZF8W^-[_4&;;#7R05VU/K##&Y],]:W'N:-8\P9
MR-@K]XO6/L1MET/D'%R.)8"D:2>QG&MO!KM*C]2J1"@A.E0.>WRZ9% A])&Q
M!<Z-[CG>8>%B9'!; <6\P(@>4**:F[>LW1_O_'8'Y[SKB /))8=J"]?1( FY
M"XG84@ V[+_WR^"]=KTA^;8/H$_]28?"\=+]"!-^^.%]!R/S>'8_PQ!V'.QU
M=OM[G;V]?2>?Z)_UO],:M->'GAX^4ZP4.VNF])FJ5"5XI?((W$1(IU<0,*?(
M*GIGD!7@I"%5ZG%[-9W4M'M64 &Z]3#'N[V.=@(VC@XRF38-[60]]97?]7?U
MT.UXM8*"9NM,>WCD9HG[B4ZII"SQ7WJR@C.LBC7KOC%LZHJ_YY Z#8O6J^T'
MS]]"P?X?63<8#H<[@^%P;V_P0N827CJC6FU!:H)FH&QIMZ->,UQC.BA1G#;P
M.HJH7H,+2&R5;V;%9"!B I?*R-Z]>;L^C W/JH^N]F">ZH9%I^G'TSH<XG[M
M?L#&G9-PZ<[K[[\?=,R/RW )_53_#!>K'[6#T87?$A[1JX/: 4Y[Y/J7#Q<H
MVK1!,>C9+!KD7=A4&8B>(W:U8A:HQM$'DW,,RX0G)Q -*IU)-4$[@HC[KM\;
M=G9[L(=V]9K\EZ(S7$SE]^=8\*H%YKM)KSLQ[=1X/"RM!J0.OACR]3A0LZH4
MA"JP'E?ZPA:+I"@D'O'=7G=L'@O%QE,!JI%GD1DQPY=&/#W6/[+U'Y/,8#T4
M!;_2"V(%,__RV>E,(!Y_(*'XYZ90V,2VBQ>8GL/F-'WQ&?7YJR450A"5#QZ+
MN:2)($J%O6S-PF:Y&0BEBTSS^+V*YB?NIMADR;<17;+V A)8-<C.>-3=LTW\
MM,D]^4$+RB8(3^)2K.[!'DNY?XJ7Z9L!?+6L-JE#43@CT62<T_%OUG+TH,Z$
M]F[8KC4[E2;O""U3^;T(Q1_9$H()MA!JO#\<3T;QY'AO.!D=CV:#W>/)K#<[
MW@MW>P,U&H]FX\G: 6;X6LU"2.+\M<J61VJ99+E5W\?[N\/A:/)0!Q@\C@PA
MD$9##&", 0W2,3+W--NE _OHS?ONK#_K]_KA<6\<1\>CT2@\GHR'X^/9<!@/
M^K.I4OOAVKR/WFD__2B<J?+BM>G4+8['>Y-1?_R@$S[2=AS.$#2XP!G=0T_T
M+!HHI0;38Q5%T^/1?M0[#H>[X7'8VQ\.HUD<]?JSM8G>?0^:^] "/![OC0>C
MX>C!3N6NKM[1&F0G.=^ADJ(??L$_CJ/\YT^367H8O=E;[?_VZL___N/__?:O
M/]=/]'<#;\]Y4I@[.LNCV@VV&/?TY,_#Q> H_NMS,OF?WU\-HP_AQ;]>WO.X
M=YU!=[<9=?*R/UV<OCQY\SF<OOKT__L7'V;Q_LD]CQJ%])K3??)I[^#S\'/Q
M]J_%\-W.;\<_9^\^_WW? W<VEC/\!],4]U)3>@-.A*<9Z!^W@?XVT/] @7YG
MDOO][BY]]QV%_L=1N#L=A[WCH1KO'X_&X_YQ.!Z'Q^-A-)KM[N[.]O9&:X[%
MWIOSN=[Z97$\[$WV]F^W]^"Z3MM>ETZ"@0SJ-M7AVF V*A$:$8^!1G2XC-7Y
M/=;[PX63[0NVK\'81&, !<!R"=(=T?;QM@2DN?W]@#_Q)'9=8-<U?IG+P&0C
MT$>7\TL2"<[:P(OJ]$MD7_A%D^YX_ ]W1FN$2LYV<T8 6?!9FIW)O,J_,=+P
M VGX,SV35VI6A\/*7!I.BRRMROI&=>WG]^7\%N=@T.WM/8TYN+_]T]]^_]S=
MPHS'W=YNNS*WMS)(+8;_W9?^^.)Y&:]-R^:<MK$[)@-]OXKBCOWS2\5BW&2E
MMY63^]VU3WJ:[FH+L>,A#6>K<TCJ)G$@)ZI'L\7^P-;0.]UAF^8"*Q)686Z]
MK4<P'^3C;OK_'<T3[[$'%IJKMN!ET_8:$T8KVS"5S>C/UPP#YL^<W7:&^K/.
M*IJM[LLF76&KMU8G\26?\P"&YXZ_R"[0/5F(V_F>QR=Y5VR[?J_;;P7L_@4L
M]&+U>HT 0_<'11ZIQ_C\3V@G^/'*U]%E/S[C2%\(J7S(X?<FP]ZY.N_WXGYW
M7BYN@?;XRECA 1>O8T/"$32;8,_"2X& P8H1:6_]J!!CKN.C$@+3&"?Z)T)G
M.*4"IZDJSX &]B5TD&!+2+A"&M:B$QPNHRX#*,?Z7<&?D)O,_R?L!.^ZK[OP
M_P_=7[IKH<LGN7-;*_+H-_DW8T6&_=:*? M69-B_1RMBFMV=^K*/7$SI\%D>
MS!,U"]X8]HWW#'*^V@0</NP9GI_-R/U?HY&X4<+C">WH._B^1V1 ;OYU3TYJ
MM3D9/#7A^QK$[0',R>!QFA/+A-R:D]:<M.;D:9N30;?_'T]-^KX&>;MW>S+X
M"HXGD]Y>:T]:>_(4]O>W:T\&K3WY-NS)TS^?M/:DM2=/9']_H_:DW^MW#_\X
M>FKR]Q5(W.$26->"_W[U\??@< ED"Y$*I*8HV&%H:/ZY(4LT(./A:@6\\H(=
M BL;4@K[=5B& >)]"+8B0 ;C>\KPA!@-H3,_CGU\?W= \K[N$Q;M5B$_Y>WQ
M+2ODHX-?GIK\?042AXKO4WB>+;/%1?#FO 1>:P!QB.9J$0;_!6 @;T1O_IXL
M/P,?I='81:LJGXBHMJKRJU&5HZ<F>U^!M!T@O?,'P!9N]CJ?$\H"TF,7GE=)
M4&*6(Z(49:N,LDTL1@.B>8?"62+-PH$VD"_JNO9[;(WU6N)N_L%NB[C36.?T
MUN,_G9[O;G^B%E<V<&\#1V": \\;'H>O[NXI(\R[W9[!(5AF2V46"M&K@U[0
M^['6C[I="[&!-GAVE4* #8KBZ !Y+3.$\>*/']^M4'K$5[4E>O938Z3TP48#
MZ(21&VHK@EF5 R:W)^*<VA]T^UA.7/_I(  D>H!Z0U [M2#R!Z"H)O:D$AAQ
M_JS"O 3.:08[Q4<AF10<'J?F3B8*0+PS80@ N+15E6L!) 0QGRYH;")Z%E',
MI>1A2I^13^FCSH';3_ &<;\[Q'ZYB34& **&$Y0BGZCA>2@ )7YZH2^=Z<\G
M</)&'?"-B?C_?50B_A9Q\T! 0==O6*';&8X/JF&ZO!)D(/EAI[_>''<#0_Q8
M_($G"<DS:2%Y6DB>S;+Z1+'WX_UHLCN;J>/]:3P['L6]P?%D5_^OM[\_&BF
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M*'+K?L-$))A#A)@_6(OP7.\"6=#\3051N!X='9&&\8%H""?R^C09XG1+$#9
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MS'>-%U92=@J= /D$0\!D^,Z\FV3ICD+1)'D)3HRWEZZ\[13UHX_7S%#G,:)
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MS//=4I;HR*O[U2A1?CW&LX"#K.CTEC98_V1TVE%@.S$6#T74Y(#S/7(=Z\;
M!QD\MH!65Y"B%:1H!2E:08K4\]N#%*WDWW(^RD5R8_2PQ-\-9T$@$%;OR0G(
MTDW0_YWHQA)&'\HW=%D9H-5(RJR[OBN434D.(NHW8YN_]T/#Q6E?9Y*,&?N!
MD)6M^+UMQ?-YMB)&52SQX-Y)+7V!]606+V!\O1AN8B!'(UYV2VWB5SLUOG*G
M+F&0LPW$B:T]WEY7,>@Q9M/P9-J\!_B.XH+MJ":E9*ZL_-LS.Y*')3Z^V7H:
M$X#A0F=J[870%UM!_>>>$[8N\B]P)[+Y*-+3BA0^2G3IZT+?A6M('HXFU$:"
MB G"^#:[-\(U)C/,"U?WA?A!H$5%,M2Q="_#AE!5DK)QAX.5U*8I+&\>TXSU
MUVE"X7667(Q7DCI5=#[':NVEV>BRGG;7\>7@,>J_;7+/IR2<7VW"38L:7>)J
MRV)W>@XU'"?4ZY[@+Q7*5EX:W(-8K3%,BQ*XOT?BFMDB,H*OUXKH 0CYGE"]
MD2 PTL.13W/EF%U:0MT==(U'Z@:[%KHM<@EW-59)TRD")"PN3O"4"/K&;>P\
MFTM?>V\?@K(T"9&&<_7/?)RI#[A ::#VWWT.FK'89SM;6VHZF S405@"+66F
MF16=:B3D%]78IS4+.,JSMN+6U_'*!K1'3;)$2A0J['1>E?,MZI[)@>L[NWV8
M*@]*.@?T99,6"*>D1:EM9C!$>*9U=B[)OZ76##>'S6E5:_<*U@B7N0"2BFV?
MK$04ZZ+E/0JHK2S!,?%@3J9YJ040G'$2&@U.QT0A7B-Q4JW+BE$O,:%LRARY
M5HK5RAO>? _K.ISY31S,(IUAX3]!H1(],MMC+;[LX\I&9;"(3,0)3<RG  8D
M' ;(M6!075%G) N,J[>KE2 I)'!LF<?^HC"5%_<)4SF";][ZF0#+8%66R<+O
MJ4/B\)+F;#?;N< #;+9L7.M^Y&12NH."4.YI'Z ?2U E&:+]0* B"LY+'Y[;
M*!K9Z A+G\Y)- D<'F;B?J.4' 9KY 4?"^'?ZP$OA$VTX)@:IIM$L)RM-IQ^
M]TINR4FK$V9T]KO-.4V7%%I5PQ\HS[BOW::M&*?E2AK9&$$ '5BVX%#=BCEA
M9L<H7W6':G_P1VR_[!NX_='A;=U09"[V&CLE_RX[,Y. [?59+30G+!-2W<P;
M=J2HIRP(@ &'2=%=!;:T4&HRH-&VA9"L-7B@8Z94/T)RC#@IO1'HZI7<!5-5
M:5!>)FDET0L*2!MA@<70)5^,NY3BM'-D-E$;%CPALYTR^J4$T#GLUE]F7<YM
MX@$0L",HW"U&A\H@+\=>K2 0DD33<%[,VE"2_:5&:+7<8;?FJ@/8B;Q4S06U
MJ0NXLC/28Z(HY'PN$$M9PX4$=#?-06@R*)8L5Y:"(5?2<"#BQJQ%8G+6/! X
M2@2\])RZA2"D&5<55X14-5EJ515P'Z$:YF9J- MEN-QZVZRD43+!Y21UZ<TC
MB[ZNFD'G&6 J >\C2@3Q]T57TO<)-H@Z_Q8Y=CHMY=OB IN=?+^2.:N&]G>L
M6+R\3\5BOY5-V,G<61X4V]OGO&L[V'0VJMTG8#>NZAL(SD#:2+#V4-(/N9=-
MX/5=[.0S]"HC J$7YDVL<JU<;YS3(9Q1'!V=4[)J M/NVRC&$PURDL9F>:N3
MU?HK&I!M?A[.FM.U[=.Z [Q6727+.I:ZBYP]:'-@ BGC;+W^V@AD1O"'2=W
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MYP4#P:9D\8ZHL__^MS,@OJ/%L+VU^=LF@]KKU_]N_-^RE/7TY>#9BP9EW<7
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MQC*'LDCO5\II $>08UK7YF4^AHESRC7X'6=E@CT!0$T3#8 GR2U@^8:@)Y-
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MM:[+=VK^ON:?(,N^:?56DZP?6E+,(5)CGQT#TTF$//6FP>@%@74W91[9OY\
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M.F=_ U!+ 0(4 Q0    ( &U$9UG"EL=/N0L  '!B   1              "
M 0    !A<')E+3(P,C0P.3,P+GAS9%!+ 0(4 Q0    ( &U$9UDIZU^R)PD
M +UO   5              "  >@+  !A<')E+3(P,C0P.3,P7V-A;"YX;6Q0
M2P$"% ,4    " !M1&=9"S?:M"T9   @>P$ %0              @ %"%0
M87!R92TR,#(T,#DS,%]D968N>&UL4$L! A0#%     @ ;41G63=OS"TN.P
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M<F4M,C R-# Y,S!X97@Q,&0Q+FAT;5!+ 0(4 Q0    ( &U$9UG#"&%OP @
M 'DH   8              "  6QF P!A<')E+3(P,C0P.3,P>&5X,S%D,2YH
M=&U02P$"% ,4    " !M1&=9U\L1:P<)  "7*0  &               @ %B
M;P, 87!R92TR,#(T,#DS,'AE>#,Q9#(N:'1M4$L! A0#%     @ ;41G6>V?
ME&2U!0  ?AH  !@              ( !GW@# &%P<F4M,C R-# Y,S!X97@S
M,F0Q+FAT;5!+ 0(4 Q0    ( &U$9UEI%PH@RP4  *L:   8
M  "  8I^ P!A<')E+3(P,C0P.3,P>&5X,S)D,BYH=&U02P4&      L "P#L
) @  BX0#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>apre-20240930x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:apre="http://aprea.com/20240930"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="apre-20240930.xsd" xlink:type="simple"/>
    <context id="As_Of_9_30_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8visgBbaHUi1WL8smvF9Lg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">apre:ConvertiblePreferredStockSeriesaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_vRazHx54bUee8EgCl6bZxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">apre:ConvertiblePreferredStockSeriesaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_MQGoU-f5K02GZ9PlM-yOkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">apre:ConvertiblePreferredStockSeriesaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_liwNe_OrZkuTHNDpnZcmag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">apre:ConvertiblePreferredStockSeriesaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_7IVaogKI6UuHMaADrJkhsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">apre:ConvertiblePreferredStockSeriesaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_m1QoLrlDGE-p35iHaQN70A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">apre:ConvertiblePreferredStockSeriesaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_7gGY2uLNAUOrIeOyl0Yu3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">apre:ConvertiblePreferredStockSeriesaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_R6HjfKfj2kC0Dts-tFsRHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">apre:ConvertiblePreferredStockSeriesaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_rhWtSSOwCkCaEzpIAh-drA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">apre:ConvertiblePreferredStockSeriesaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8CsMqAUtn0GBba1hxVBFiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">apre:ConvertiblePreferredStockSeriesaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_Paz762NlyEuz8le-TUK-tw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_oHdcOW4hiEyfgESy4f5Jzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uk8mlSyVokKTP3XSCE6G2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bnRcQIiX2Eip-CUgrzN4Ag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SIsBYxIs2kWHjyNmgCyPrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_sqNgwBmbiUi7e68XTiWaJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GS2DrbBqyE-0nKgeaspqPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7APo5uzuAUeE_AwHD_aDyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_w6HcF2RyJ0OwVohdYcyrWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_mLJ_odBxZ0OgdXDNP5Doaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3OjBHmrFdEqql1a9Qd1d4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_z5h7zepvB0S3yMqUDLxYRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_kRMbWJwEh0W2ZdxtrlSp2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ZePgtrw-B0izH24xd1d8mw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wfx449lO0kKvBkD-ftLx7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Wi8LbADSoE6H9bs8u0MVsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_lCnJPy7l60uydEVcNxwm6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_Zvq5nTZZy0aWnnp0Yr_H1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mNt4s5ToekueR3QLxsxleQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GQCbRqVK3kuaSwxkX6qMKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_yLYKKEjvoUy7Hx5o25CtFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ibhlFLDIRka5MzPbpPpzAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6rGZcRyRUEmEmilgCL28PA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Ezbxq8ZdSkqMSQnvf2yPiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mlp_Zv_4RkCOvMMVab-nCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_yt6vg4-7Hk-CNT47e35gSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_VtyWAB_w50KEUnNv-Oaekg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_Lr_RTA-Vhk-vAvhygDZlMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_XHftf8DOMkW2QPF25BFt1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_DvSHu5RNCU269rSppFYYgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3R6cMW1KKUK6IIoYqDNzqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_slQjcR-CEUatMT3-GnhwQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_-el1flLwfkGvk1hb4s7jRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_X-C6_R8tJE29iS3my5-mwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fJbOuezCP0ukeyIR7_AUvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Omg5HL2Zk0iyUrhlyHkYzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_pTVYFBxdF0KO7SAVt4uiIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BOEuDXy_ZUeMtyMb1W31eg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tUhQ63t-YU-t2nhI1MP0bg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jAvkAIbuQECJ-En9TI9QOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5KgXuLcFS0y6eld2ApcJhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jLLZztnJSEaM57oF94_7xQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ep_zwMxd8Uy2Rb83GGZtEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_2_28_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_apre_ShelfRegistrationStatementMember_UBxEuMVTak-jJ5nG9mM16A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:ShelfRegistrationStatementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="Duration_2_1_2023_To_2_28_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_apre_ShelfRegistrationStatementMember_LaEYUb2hjkW2KGU-74xlQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:ShelfRegistrationStatementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_fSqftKDYcEGIBNux4uAuoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_wNRC8dghckiqZHMJ2Qab2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fmrXxlAg8k2LTPqbZsdqQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_alO13T8cuE2PUKMnkFcK4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ZYusih75WEqqXs5jfU46kA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_BnvW7lwu70SqT0ZU3Hyn2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ZDYsshJEZkqk3c9XgeoP5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jqM4BFBbeUqa02lyUgxwnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_SbTatJBJOUiFH1taEFtwHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_pA-2oAPYMEqk86sHU18u8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_JK8xHrjZfkqa45FOBphUpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_NMOLLFp0TUWc89OurulIXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hNmUQDanvk2hr1a2pdyeMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_WAR5SHVFkE6tbDGoKuqOZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_Do28_zwKEkmVihgrJpKe5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-11</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_XHHJ56Sb40GzY2_iFyVSmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_8FQi5hYCckGx-AAVXCTMIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_18zK2B__vkKA8IrK9I5aKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_BniNzMIFNESCAEERHrL4Qg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_lWBjcVjr5UKoPSricaY5kw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_-xdRwU9xSUiPNwUETulTXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_V6BVG1ivukSZDtIV_eHuyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_I-_Nu9K7KEKrfxHT-XiE6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_z_oRFQwZ_U2_FPccUncU4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ddh4E4AbBEerRzR7f0tdRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_00YNAPouPUS3eodKEdKUZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_fAYnBVLhzUG8aJvV8WQWcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JmDXfNDeoU-A7sBdCGSkpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_k6qmi3YCyUeoj4EzQWmoYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_44A8CawaA0CwnlBa7i0axg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5LQIj-xrt0am4-0q7OB9Gw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_P0QiqJFu3ku16O4sijWHpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_60CYeoJMNkOFtTQ-EB4jYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_zTcMywQwh0-rXqoAlfNCWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_11_7_2024_rCC5Lx28V0yL1CVfxqJ0aQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
        </entity>
        <period>
            <instant>2024-11-07</instant>
        </period>
    </context>
    <context id="As_Of_11_12_2020_us-gaap_SubsidiarySaleOfStockAxis_apre_ShelfRegistrationStatementMember_ARwQ47H460ieVrWA3BWUnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:ShelfRegistrationStatementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-12</instant>
        </period>
    </context>
    <context id="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice9.1125PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_G-a6RTBX2E2Sy0VISZQI2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:PreFundedWarrantsExercisePrice9.1125PerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-11</instant>
        </period>
    </context>
    <context id="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice7.29PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_lx_pDgysWkWXlV3jLs59hg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:PreFundedWarrantsExercisePrice7.29PerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-11</instant>
        </period>
    </context>
    <context id="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_srt_StatementScenarioAxis_apre_AtEventOfElectionOfHolderMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_jryn2JxtuUiScam-ie0pMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">apre:AtEventOfElectionOfHolderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-11</instant>
        </period>
    </context>
    <context id="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_5KoUULH39EatBTbigzb7Nw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-11</instant>
        </period>
    </context>
    <context id="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice9.1125PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_zOEchtkouU6yqqanDoFo6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:PreFundedWarrantsExercisePrice9.1125PerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-11</startDate>
            <endDate>2024-03-11</endDate>
        </period>
    </context>
    <context id="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice7.29PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_2erKOwIbbU-vg-0HBwM-Ew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">apre:PreFundedWarrantsExercisePrice7.29PerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-11</startDate>
            <endDate>2024-03-11</endDate>
        </period>
    </context>
    <context id="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_NhXjTaJGO0qzpt50WX1aQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:CertainPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">apre:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-11</startDate>
            <endDate>2024-03-11</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_1_26_2024_srt_CounterpartyNameAxis_apre_HCWainrightCoLlcMember_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarket2024OfferingMember_M05-gKo8P0qhKNNnCJ2ynA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">apre:HCWainrightCoLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:AtMarket2024OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-26</instant>
        </period>
    </context>
    <context id="As_Of_1_26_2024_us-gaap_SubsidiarySaleOfStockAxis_apre_ShelfRegistrationStatement2024Member_hof9NYm7h0ub2MpXywHosA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:ShelfRegistrationStatement2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-26</instant>
        </period>
    </context>
    <context id="As_Of_11_12_2020_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_gmVaaYo2B0i-Fejiwesclg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-12</instant>
        </period>
    </context>
    <context id="Duration_11_12_2020_To_11_12_2020_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_MJWqDGoHuUiO0gnEMhlZUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">apre:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-12</startDate>
            <endDate>2020-11-12</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001781983</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <unit id="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_psC0V7jouEy1pdZ9EBR0Hw">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_Vote_xLAtZ3mDNEadoQnTSpr_cQ">
        <measure>apre:Vote</measure>
    </unit>
    <unit id="Unit_Standard_lease_uug6S_kQsEij919rCVEEeQ">
        <measure>apre:lease</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">
        <measure>shares</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      id="Hidden_-zPpJ3bRgkyQ0nxFFzF5lw"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg"
      id="Hidden_GlMZNwmHW0qzOUsp9CRjlg"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Tc_XKnPpj0gkkCLXqbRAjdmRA_1_1">0001781983</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Tc_napIRieUEU25LorZQCOpFA_2_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Tc_CwTW4B8KwEOKj1yJhkVIpw_3_1">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Tc_GrlxfBf1qEet2t2j3Gc_lQ_4_1">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Tc_XX9aeEqGc0uSOa5ZWi8sjw_5_1">false</dei:AmendmentFlag>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      decimals="INF"
      id="Hidden_81GrG1sLMEy1hqocEcqz_A"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">5434903</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg"
      decimals="INF"
      id="Hidden_RER4QCFRiEqM4rJJHJIF8Q"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">3736673</us-gaap:CommonStockSharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_9_30_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_vRazHx54bUee8EgCl6bZxg"
      decimals="INF"
      id="Hidden_T0es8AYRy0ahzFENb_YA5A"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">56227</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_m1QoLrlDGE-p35iHaQN70A"
      decimals="INF"
      id="Hidden_CwFh2Lkz30mFTRIyKnV_og"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">56227</us-gaap:TemporaryEquitySharesOutstanding>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g"
      id="Hidden_crGT9flIcE6p7KBQXNYKVQ">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g"
      id="Hidden_bgQIm2SdUki9zLB3cPayVA">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g"
      id="Hidden_iA1bmvAgEkabBTZ1yPfd7g">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g"
      id="Hidden_gT6Ck3ksFUm3M-K_GoMkjg">false</ecd:NonRule10b51ArrTrmntdFlag>
    <apre:LesseeOperatingLeaseAnnualBaseRentObligationAfterCurrentYear
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      decimals="0"
      id="Hidden_dXY0fqi6LUqjrBt7mcO_tw"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">0</apre:LesseeOperatingLeaseAnnualBaseRentObligationAfterCurrentYear>
    <dei:DocumentType
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Narr_3EyfGtKt4keo4c6_fk73Ow">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Narr_w0gcbDq8Y0-lDVN_QGJFAQ">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Narr_sB7B1yXT1Eqi7OUmWRRDtQ">2024-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Narr_G22wCT5rC025ytYgtEnqmw">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Narr_PSzfweh-q0CmlEk6Zbmp8Q">001-39069</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Narr_ojBHyRfuIU-yLfD0HkKXaQ">Aprea Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Tc_6ssEvX4HFUyAOw6CPms7vA_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Tc_Gu69SdIOok67RdkC-ejIiQ_1_1">84-2246769</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Tc_wzLS2aVhnEC2xb4qSAXwGQ_4_0">3805 Old Easton Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Narr_y41Qg7TG1kWkTvWB3OXf6w">Doylestown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Narr_wJasxAZpW0S0wgLumzRR_Q">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Tc_8vVtiqNlCE2DSygFL1Kpqg_5_1">18902</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Narr_QKJzOCR1TU-hJgn6stk4AA">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Narr_9_TxHZu_NUyLDP9q1WS0aQ">463-9385</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Tc_P-tu_nVO6kWUmpn-GsQfsQ_1_0">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Tc_PhsGREJQbEa0tMgS88zNvg_1_2">APRE</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Narr_rCNJGzOx60WSYn1O8RinCw">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Narr_GiAzFkMRv0qtBZ8AX32WkQ">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Narr_iJmIp6IRTU2w2xJCdKj7yQ">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Narr_qba514AAzU67n8DjTcaNXQ">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Narr_yc7KsLwGeEmXF9XOThvrWg">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Narr_Xq-YVpI1VUWxoJlez3dpfw">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Narr_Yzrqj7RULESeNk-F_INK8Q">true</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Narr_R4epJb8DE0CZFJUxC-6_vg">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_11_7_2024_rCC5Lx28V0yL1CVfxqJ0aQ"
      decimals="INF"
      id="Narr_W0_o68Wrn06Hp7RFBRwVVA"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">5434903</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      decimals="0"
      id="Tc_xwW35TRHikG2gd6kqiwslg_5_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">26249625</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg"
      decimals="0"
      id="Tc_6hmNAX_vfUypXc_dxTxKjw_5_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">21606820</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      decimals="0"
      id="Tc_GpJBH-ibME6L-u3Ws7q0aA_6_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">234195</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg"
      decimals="0"
      id="Tc_3VirJ-6dL0-b7By9btMguw_6_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">914275</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      decimals="0"
      id="Tc_-HQ_7mI41kepF7tIDOMqaA_7_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">26483820</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg"
      decimals="0"
      id="Tc_jX2RmYFcFE6K8PsTZ6lanA_7_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">22521095</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      decimals="0"
      id="Tc_1q29ya2eskWzxSky3GfJEA_8_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">86950</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg"
      decimals="0"
      id="Tc_66ZnmiQRqUee3WJnATLdgg_8_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">88362</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      decimals="0"
      id="Tc_sGmvdS1hlUuxk6d_MEa-ng_9_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">41537</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg"
      decimals="0"
      id="Tc_SobIJs2yb06zlLhf3Kvv0A_9_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">40717</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      decimals="0"
      id="Tc_CMsk6td60Ea1lYvFIXuT-Q_10_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">281662</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      decimals="0"
      id="Tc_L9XfP9CCb0mieKdOOVB_Zg_11_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">26893969</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg"
      decimals="0"
      id="Tc_610Ua_jG1UWQ53-i2cBZ0g_11_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">22650174</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      decimals="0"
      id="Tc_G8SMTKHz-EC9CD1sUoSmtw_14_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">1153880</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg"
      decimals="0"
      id="Tc_j2RnaRuAiUSIXNpDgE-yNg_14_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">1670369</us-gaap:AccountsPayableCurrent>
    <apre:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      decimals="0"
      id="Tc_DvCf-6xvzUSkG_4mtHOv9A_15_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">2482008</apre:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent>
    <apre:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg"
      decimals="0"
      id="Tc_WPDBb7I7_kiVHr1GMM2HBQ_15_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">2186262</apre:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg"
      decimals="0"
      id="Tc_syxRxJg3KEaTYZIRFop_DQ_16_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">528974</us-gaap:DeferredRevenueCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      decimals="0"
      id="Tc_nWTxQJptnUe7nDNsE5KWmA_17_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">3635888</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg"
      decimals="0"
      id="Tc_kLb6H9SqkU6vWVGatza3_A_17_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">4385605</us-gaap:LiabilitiesCurrent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_9_30_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_vRazHx54bUee8EgCl6bZxg"
      decimals="INF"
      id="Narr__V9i4AW9_k6mRdXL-u5v2g"
      unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_m1QoLrlDGE-p35iHaQN70A"
      decimals="INF"
      id="Narr_ww2NYHLCo02p73H7Zokt4g"
      unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_9_30_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_vRazHx54bUee8EgCl6bZxg"
      decimals="INF"
      id="Narr_fIcmEaL62Eee5WP5DnxjeQ"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">40000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_m1QoLrlDGE-p35iHaQN70A"
      decimals="INF"
      id="Narr_T_CcTl9AsEilG_lqrjgXlw"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">40000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_9_30_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_vRazHx54bUee8EgCl6bZxg"
      decimals="INF"
      id="Narr_Q-UyHMcmO0SXkeRavtxDKw"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">56227</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_m1QoLrlDGE-p35iHaQN70A"
      decimals="INF"
      id="Narr_AMl_s0_W7EKGp5DesUOxDQ"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">56227</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_9_30_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_vRazHx54bUee8EgCl6bZxg"
      decimals="0"
      id="Tc_7EHv4_rGN0aztZpi02rVYQ_19_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">1311063</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_m1QoLrlDGE-p35iHaQN70A"
      decimals="0"
      id="Tc_FRVEsfynN0S5OW42AsVqgg_19_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">1311063</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      decimals="INF"
      id="Narr_IzFUVydXVEqY14-FurjyBw"
      unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg"
      decimals="INF"
      id="Narr_sRx6OH7OEUyR4jywFXrn9A"
      unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      decimals="INF"
      id="Narr_RHAFHvIrg0e4XRZ15Fw_sA"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg"
      decimals="INF"
      id="Narr_Utdo9x2l8Eq0_JHzixqffg"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      decimals="INF"
      id="Narr_CeoWckkCGkC6kFFbaqU6Xg"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">5434903</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg"
      decimals="INF"
      id="Narr_02rt8iZOK0WyuG6e8v9Xvg"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">3736673</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      decimals="0"
      id="Tc_IB9CDappAUeSQeUyuvd7rw_21_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">5435</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg"
      decimals="0"
      id="Tc_hn7wXOOUmEy1bRtO2pQVMw_21_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">3736</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      decimals="0"
      id="Tc_p82MmbT6-0-t28Gb2HJ1lw_22_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">350693403</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg"
      decimals="0"
      id="Tc_k9oFhNleUkynEB1A7rfDjw_22_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">335644204</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      decimals="0"
      id="Tc_UDrU77dll0uPN7MBnSPaXQ_23_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-10604747</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg"
      decimals="0"
      id="Tc_x8t1Lq8Evk20wrORScWGKA_23_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-10611273</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      decimals="0"
      id="Tc_R8mtH81G00-s4AqKkVIK9g_24_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-318147073</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg"
      decimals="0"
      id="Tc_Ia9vhyWi8kCx5yEU55i_IA_24_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-308083161</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      decimals="0"
      id="Tc_MyabgoqC40S8zY8Uqwhf_Q_25_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">21947018</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg"
      decimals="0"
      id="Tc_kqyHzXa8WUKQi1oMbl84wQ_25_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">16953506</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      decimals="0"
      id="Tc_G6d0rDvyI06c4U_RnSaZEg_26_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">26893969</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg"
      decimals="0"
      id="Tc_dhYvgRCBnkue2QssJiEqQg_26_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">22650174</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g"
      decimals="0"
      id="Tc_7y_Xx6ROoEuyq-rLuifFIQ_3_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">354621</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug"
      decimals="0"
      id="Tc_ddvt6rKo4kKAztQ5EVTCcQ_3_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">319468</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      decimals="0"
      id="Tc_ZJCmpVXFWUKB0E2md9d5lQ_3_9"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">1296764</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA"
      decimals="0"
      id="Tc_s6oBQp0UJ06rQNpG8kmt3g_3_12"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">569156</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g"
      decimals="0"
      id="Tc_yITcHZEuqk-fAY00aoF2bg_5_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">2846399</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug"
      decimals="0"
      id="Tc_oOoDLeUmzE-e81Mihua7hQ_5_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">2122603</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      decimals="0"
      id="Tc_YzR9eCMJTkODSf5km1tJIQ_5_9"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">7004451</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA"
      decimals="0"
      id="Tc_EQl2UFcYo0eq5ymgj675kg_5_12"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">5581802</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g"
      decimals="0"
      id="Tc_iQkcGfVGTU-p2_dxc0jAnw_6_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">1605238</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug"
      decimals="0"
      id="Tc_3e0K-4Cqs0qO8ANBNNFHhw_6_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">1719715</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      decimals="0"
      id="Tc_Rb8ynzCUYk2bjmG-pfr-mA_6_9"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">5385923</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA"
      decimals="0"
      id="Tc_Y7VuOiY1E0Oln5mHOe0wLA_6_12"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">6784388</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g"
      decimals="0"
      id="Tc_pJ0Swk21b0qyxkjlB4FUrQ_7_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">4451637</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug"
      decimals="0"
      id="Tc_vGqvNxYTQkam4wsOmgxbHA_7_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">3842318</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      decimals="0"
      id="Tc_6PD9TGIr10Wy_K7_jDWmyQ_7_9"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">12390374</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA"
      decimals="0"
      id="Tc_Twcp66QJG06omA2ntD4KSw_7_12"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">12366190</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g"
      decimals="0"
      id="Tc_cACtO86oEE-nb6IbfvgyTg_8_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-4097016</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug"
      decimals="0"
      id="Tc_GiSotAG6ZkmOxUyLeQFNuQ_8_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-3522850</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      decimals="0"
      id="Tc_GORYa6gDJkC-7STYIRofeg_8_9"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-11093610</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA"
      decimals="0"
      id="Tc_jcbyP1wD0UWshqU1k_2AUQ_8_12"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-11797034</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g"
      decimals="0"
      id="Tc_lQ4wsYYrGEuW_RQ2_j9ulw_10_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">348741</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug"
      decimals="0"
      id="Tc_teuSu4Qnk0CKYgS_O78cPw_10_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">321215</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      decimals="0"
      id="Tc_PnU4y0h67kKwJphCx8_fAg_10_9"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">1014518</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA"
      decimals="0"
      id="Tc_EneG2cUihkSjL1BnOAxjIw_10_12"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">913846</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g"
      decimals="0"
      id="Tc_r0pOf9nJskmUOmyZEcVzBA_11_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-35494</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug"
      decimals="0"
      id="Tc_5wR7RpAhP0K8Ez-W50MOsA_11_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-2880</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      decimals="0"
      id="Tc_DHm_G4UGbkyashh7Isyjvw_11_9"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">15180</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA"
      decimals="0"
      id="Tc_bT7QhfdONkqJlfvZRp-ptQ_11_12"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">39686</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g"
      decimals="0"
      id="Tc_yAnRuydnYkyb0CGyPXQbug_12_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">313247</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug"
      decimals="0"
      id="Tc_-7vTNQR0FEmjqKxWgDSaiA_12_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">318335</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      decimals="0"
      id="Tc_XCKY8Z0E00mY9z6bUhCuoQ_12_9"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">1029698</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA"
      decimals="0"
      id="Tc_nm0lEou1OECjoHCHEUFynw_12_12"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">953532</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g"
      decimals="0"
      id="Tc_Gjx7df3vpESV5TgwiUz1uQ_13_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-3783769</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug"
      decimals="0"
      id="Tc_-a1dYDSGp0GuU331YUjksA_13_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-3204515</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      decimals="0"
      id="Tc_d31DbBKb3kGC94AfWlFjIg_13_9"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-10063912</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA"
      decimals="0"
      id="Tc_JFuC-qrg_UKGciO0ZaSHgA_13_12"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-10843502</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g"
      decimals="0"
      id="Tc_SYY3bec_dUWcbhBEYcY-1w_15_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">23557</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug"
      decimals="0"
      id="Tc_w0unpQdUKkiylkn65epYNg_15_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-1002</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      decimals="0"
      id="Tc_GIeEB23lDUiwYoYF0da5KQ_15_9"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">6526</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA"
      decimals="0"
      id="Tc_q8rhOJU62kmU7GPxJ8IyWw_15_12"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-12466</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g"
      decimals="0"
      id="Tc__MEf_cTHNEu_Hl2hpPslMQ_16_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-3760212</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug"
      decimals="0"
      id="Tc_uNjUnw3Ve0ez35gYCOxGeg_16_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-3205517</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      decimals="0"
      id="Tc_YMyG7bqgdE2bpYpgNdy_Kg_16_9"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-10057386</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA"
      decimals="0"
      id="Tc_u47a4RwY5U2VFB_zGIw70w_16_12"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-10855968</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g"
      decimals="2"
      id="Tc_BYOISHvoVUGifAaOX-50UQ_17_3"
      unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A">-0.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g"
      decimals="2"
      id="Tc_BYOISHvoVUGifAaOX-50UQ_17_3_2"
      unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A">-0.64</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug"
      decimals="2"
      id="Tc_M413Etpf_k2VfBcfXzr6xg_17_6"
      unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A">-0.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug"
      decimals="2"
      id="Tc_M413Etpf_k2VfBcfXzr6xg_17_6_2"
      unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A">-0.86</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      decimals="2"
      id="Tc_a1vxov7CUkqlRXZkxgJWhA_17_9"
      unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A">-1.88</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      decimals="2"
      id="Tc_a1vxov7CUkqlRXZkxgJWhA_17_9_2"
      unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A">-1.88</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA"
      decimals="2"
      id="Tc_uFaRapRVrkaHM6IeJFMuzQ_17_12"
      unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A">-3.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA"
      decimals="2"
      id="Tc_uFaRapRVrkaHM6IeJFMuzQ_17_12_2"
      unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A">-3.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g"
      decimals="0"
      id="Tc_CCzNvXdEUUiLCd_TvgLd7Q_18_3"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">5939755</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g"
      decimals="0"
      id="Tc_CCzNvXdEUUiLCd_TvgLd7Q_18_3_2"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">5939755</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug"
      decimals="0"
      id="Tc_WW9VMFFrZk-O6AyGbnvl8w_18_6"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">3735176</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug"
      decimals="0"
      id="Tc_WW9VMFFrZk-O6AyGbnvl8w_18_6_2"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">3735176</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      decimals="0"
      id="Tc_F7BRbzPD80S8-oz_3y-hnQ_18_9"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">5360579</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      decimals="0"
      id="Tc_F7BRbzPD80S8-oz_3y-hnQ_18_9_2"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">5360579</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA"
      decimals="0"
      id="Tc_BnLGV-j-R0-7QFwEjdrhJg_18_12"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">3577482</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA"
      decimals="0"
      id="Tc_BnLGV-j-R0-7QFwEjdrhJg_18_12_2"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">3577482</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8CsMqAUtn0GBba1hxVBFiQ"
      decimals="INF"
      id="Tc_rYJnYlIKmUKtoEbZyzKBIA_5_2"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">56227</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8CsMqAUtn0GBba1hxVBFiQ"
      decimals="0"
      id="Tc_N2MD-RF8jkSpkz38eNGJfg_5_5"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">1311063</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ep_zwMxd8Uy2Rb83GGZtEA"
      decimals="INF"
      id="Tc_gJby4NOGZECrbmsenrs6PQ_5_7"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">2655269</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ep_zwMxd8Uy2Rb83GGZtEA"
      decimals="0"
      id="Tc_-2Om3geWA0O1M_K-ORrjNQ_5_10"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">2655</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_X-C6_R8tJE29iS3my5-mwA"
      decimals="0"
      id="Tc_9d9ygiS_w0y1W6tg8g9UoA_5_13"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">330060836</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fJbOuezCP0ukeyIR7_AUvw"
      decimals="0"
      id="Tc_slq1pKZNUEODjk_BsxvddA_5_16"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-10623408</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_-el1flLwfkGvk1hb4s7jRQ"
      decimals="0"
      id="Tc_8YssXp_NaUKhCTUE3tMH2w_5_19"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-293796405</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_XHHJ56Sb40GzY2_iFyVSmw"
      decimals="0"
      id="Tc_lZUwz_OJNU-XfcXFiyAjjQ_5_22"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">25643678</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GS2DrbBqyE-0nKgeaspqPg"
      decimals="INF"
      id="Tc_Gl5Jw6b1K0KaOQ8gfa6YJg_6_7"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">1050000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GS2DrbBqyE-0nKgeaspqPg"
      decimals="0"
      id="Tc_2H0ieNUHA0q_5h48fejfrg_6_10"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">1050</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_60CYeoJMNkOFtTQ-EB4jYg"
      decimals="0"
      id="Tc_TZGzhsoFyUqSuIhx-dmeng_6_13"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">4870815</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_3_31_2023_zTcMywQwh0-rXqoAlfNCWw"
      decimals="0"
      id="Tc_AKXS8MAmZ0WBIBzv2VmRNg_6_22"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">4871865</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_sqNgwBmbiUi7e68XTiWaJg"
      decimals="INF"
      id="Tc_UdVYTxVTSUaEMpC70fC7XA_7_7"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">26302</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_sqNgwBmbiUi7e68XTiWaJg"
      decimals="0"
      id="Tc_V18kTdRnZkmMl77TRVVV-w_7_10"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">26</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_Paz762NlyEuz8le-TUK-tw"
      decimals="0"
      id="Tc_-iXtGOiaNkWLa6jCfJkx_A_7_13"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">268099</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_oHdcOW4hiEyfgESy4f5Jzw"
      decimals="0"
      id="Tc_EaFVj2x9mkCxNURHwrwVpg_7_22"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">268125</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_60CYeoJMNkOFtTQ-EB4jYg"
      decimals="0"
      id="Tc_PFH4BHd6h0KJBkzIKaqf_Q_8_13"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">16244</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_3_31_2023_zTcMywQwh0-rXqoAlfNCWw"
      decimals="0"
      id="Tc_dJWMkckVaUmdBOl875FRtg_8_22"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">16244</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ZDYsshJEZkqk3c9XgeoP5A"
      decimals="0"
      id="Tc_SjPP6aTTgkS05x-qSm5NPw_9_16"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">61956</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2023_To_3_31_2023_zTcMywQwh0-rXqoAlfNCWw"
      decimals="0"
      id="Tc_VkER0-aLIUevgH2-CvS-RA_9_22"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">61956</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_hNmUQDanvk2hr1a2pdyeMA"
      decimals="0"
      id="Tc_5o2H9TRwxEOqgQHM-B2SFQ_10_19"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-4379890</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_3_31_2023_zTcMywQwh0-rXqoAlfNCWw"
      decimals="0"
      id="Tc_TGKL6ZusVE2f7rzg231IRA_10_22"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-4379890</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_rhWtSSOwCkCaEzpIAh-drA"
      decimals="INF"
      id="Tc_ax8xvdRxF0eHxkNWD0mZug_11_2"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">56227</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_rhWtSSOwCkCaEzpIAh-drA"
      decimals="0"
      id="Tc_cQZrGvEYBkywD5SKZwTOQA_11_5"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">1311063</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jLLZztnJSEaM57oF94_7xQ"
      decimals="INF"
      id="Tc_weAIF-6ElkeBrm7XfK_mdw_11_7"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">3731571</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jLLZztnJSEaM57oF94_7xQ"
      decimals="0"
      id="Tc_Aovzn_X7FEafSPcd28Iheg_11_10"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">3731</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_DvSHu5RNCU269rSppFYYgw"
      decimals="0"
      id="Tc_Fc8IdYziZESdPJaa3i_m_A_11_13"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">335215994</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3R6cMW1KKUK6IIoYqDNzqg"
      decimals="0"
      id="Tc_xE8GTP80uUyDk_lWj8c_Dg_11_16"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-10561452</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_XHftf8DOMkW2QPF25BFt1A"
      decimals="0"
      id="Tc_RiDIs5sja0GNKeUHXdcZqQ_11_19"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-298176295</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_slQjcR-CEUatMT3-GnhwQA"
      decimals="0"
      id="Tc_goFTpJ-bqkyAM_WDqnuJmw_11_22"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">26481978</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5LQIj-xrt0am4-0q7OB9Gw"
      decimals="0"
      id="Tc_58jUGNEagEePu-xAEliPWQ_13_13"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">269323</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2023_To_6_30_2023_P0QiqJFu3ku16O4sijWHpw"
      decimals="0"
      id="Tc_LQlZ1Ff090Sb8U08__ehcg_13_22"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">269323</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_BnvW7lwu70SqT0ZU3Hyn2A"
      decimals="0"
      id="Tc_QKPz9QPc-EWM_xmRZPegug_14_16"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-73420</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_4_1_2023_To_6_30_2023_P0QiqJFu3ku16O4sijWHpw"
      decimals="0"
      id="Tc_Zjqu9LP7fESb5GM0eZCUnQ_14_22"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-73420</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_NMOLLFp0TUWc89OurulIXA"
      decimals="0"
      id="Tc_qh0QxN4nCUuFwMDwCEC93Q_15_19"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-3259097</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2023_To_6_30_2023_P0QiqJFu3ku16O4sijWHpw"
      decimals="0"
      id="Tc_AQclITxQsUKS2bY7XStwoQ_15_22"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-3259097</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_R6HjfKfj2kC0Dts-tFsRHg"
      decimals="INF"
      id="Tc_Qy7_somJ9kKqceTu_sFS_Q_16_2"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">56227</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_R6HjfKfj2kC0Dts-tFsRHg"
      decimals="0"
      id="Tc_SOUY8tHo50y9PZTec3oyQQ_16_5"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">1311063</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5KgXuLcFS0y6eld2ApcJhw"
      decimals="INF"
      id="Tc_iwUFYWVYbkef2rSENk55tQ_16_7"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">3731571</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5KgXuLcFS0y6eld2ApcJhw"
      decimals="0"
      id="Tc_3jR6znR6CEyW92w2SpPLXw_16_10"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">3731</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_yt6vg4-7Hk-CNT47e35gSQ"
      decimals="0"
      id="Tc_UPhKSI5wqk68OoCsIE0Exg_16_13"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">335485317</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_VtyWAB_w50KEUnNv-Oaekg"
      decimals="0"
      id="Tc_To-LrBbqL0SntT7i3xuKKg_16_16"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-10634872</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mlp_Zv_4RkCOvMMVab-nCw"
      decimals="0"
      id="Tc_gr3nUHCt-U-ndU61DuXAEA_16_19"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-301435392</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_Lr_RTA-Vhk-vAvhygDZlMw"
      decimals="0"
      id="Tc_Zws_CVYYuUuctysOk2rndw_16_22"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">23418784</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bnRcQIiX2Eip-CUgrzN4Ag"
      decimals="INF"
      id="Tc_1zUeHAdhj0-Zb-qnnmj17Q_18_7"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">5102</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bnRcQIiX2Eip-CUgrzN4Ag"
      decimals="0"
      id="Tc_aHEyEDRYaUaN1TSGso7f9g_18_10"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">5</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_44A8CawaA0CwnlBa7i0axg"
      decimals="0"
      id="Tc_EdHlBaf9RUCC3xuEnz1kaQ_18_13"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-5</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_44A8CawaA0CwnlBa7i0axg"
      decimals="0"
      id="Tc_lpYT2VV7mUitWgULN5vpyw_19_13"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">76031</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug"
      decimals="0"
      id="Tc_XSvVt1gRd0ap1cQ-G4yzrw_19_22"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">76031</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ZYusih75WEqqXs5jfU46kA"
      decimals="0"
      id="Tc_YZYNCDMUyUSAWi0suFHm0g_20_16"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-1002</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug"
      decimals="0"
      id="Tc_PW4wOvLU30K9RhNyQnKXEw_20_22"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-1002</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_JK8xHrjZfkqa45FOBphUpw"
      decimals="0"
      id="Tc_qJ3gZrut5kODQ9BzObcRbQ_21_19"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-3204515</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug"
      decimals="0"
      id="Tc_a9x6kAVYFk-FmQhtDTAznQ_21_22"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-3204515</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_9_30_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_7gGY2uLNAUOrIeOyl0Yu3Q"
      decimals="INF"
      id="Tc_SxJCi4wonUywZFiHkOj65w_22_2"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">56227</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_9_30_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_7gGY2uLNAUOrIeOyl0Yu3Q"
      decimals="0"
      id="Tc_dB85EOhWdUKHn2B12msSww_22_5"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">1311063</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jAvkAIbuQECJ-En9TI9QOw"
      decimals="INF"
      id="Tc_63Oo28tpwkuX4A7n0YEvHA_22_7"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">3736673</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jAvkAIbuQECJ-En9TI9QOw"
      decimals="0"
      id="Tc_jsnxbIRC7Ua8ifbTRgTt0A_22_10"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">3736</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6rGZcRyRUEmEmilgCL28PA"
      decimals="0"
      id="Tc_eanh1mR0qkK6ozZ6En7NFw_22_13"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">335561343</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Ezbxq8ZdSkqMSQnvf2yPiw"
      decimals="0"
      id="Tc_IpgLjsbQLUuxkhSv45w_jw_22_16"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-10635874</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ibhlFLDIRka5MzPbpPpzAQ"
      decimals="0"
      id="Tc_uhMDXllJwkuNE8kTdLPO-g_22_19"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-304639907</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_8FQi5hYCckGx-AAVXCTMIQ"
      decimals="0"
      id="Tc_EI6K793eBkOT5QzbaLq78g_22_22"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">20289298</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_7IVaogKI6UuHMaADrJkhsA"
      decimals="INF"
      id="Tc_is5H_HkXDEaQRTyApAsJpA_24_2"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">56227</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2023_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_7IVaogKI6UuHMaADrJkhsA"
      decimals="0"
      id="Tc_uuBemZZmx0-T-IZKni1PEA_24_5"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">1311063</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tUhQ63t-YU-t2nhI1MP0bg"
      decimals="INF"
      id="Tc_f7UbBznXp0qSGFYOYeo8GQ_24_7"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">3736673</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tUhQ63t-YU-t2nhI1MP0bg"
      decimals="0"
      id="Tc_502LkiTAOEKLfBBnRit3_g_24_10"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">3736</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GQCbRqVK3kuaSwxkX6qMKA"
      decimals="0"
      id="Tc_NEUS4kCIkUGCZtK1Mf_Tpw_24_13"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">335644204</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_yLYKKEjvoUy7Hx5o25CtFw"
      decimals="0"
      id="Tc_TuZyCX6LekSK3FcKPUk9rw_24_16"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-10611273</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mNt4s5ToekueR3QLxsxleQ"
      decimals="0"
      id="Tc_eRzrSu0qVkmXSE4wCmwm8Q_24_19"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-308083161</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg"
      decimals="0"
      id="Tc_txOc2BkAQE-746oI_IigeA_24_22"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">16953506</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SIsBYxIs2kWHjyNmgCyPrQ"
      decimals="INF"
      id="Tc_JtN92iCFXE253ZvLNvCs-Q_25_7"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">1687712</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SIsBYxIs2kWHjyNmgCyPrQ"
      decimals="0"
      id="Tc_-GtKXuNoJES_Oh2l543NGQ_25_10"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">1688</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JmDXfNDeoU-A7sBdCGSkpw"
      decimals="0"
      id="Tc_b_2Cc4onAka7mYa8yZwnlg_25_13"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">14708017</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_3_31_2024_k6qmi3YCyUeoj4EzQWmoYg"
      decimals="0"
      id="Tc_CQO3rWVbEEqYhkFz0y0Wgw_25_22"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">14709705</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SIsBYxIs2kWHjyNmgCyPrQ"
      decimals="INF"
      id="Tc_s0BkeOazmkKLs1_bilfYGA_26_7"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">5830</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SIsBYxIs2kWHjyNmgCyPrQ"
      decimals="0"
      id="Tc_bEuV6eerHE-8_rmot_Vjrw_26_10"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">6</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JmDXfNDeoU-A7sBdCGSkpw"
      decimals="0"
      id="Tc_J_NnGop33ECcL-Xis1lrnw_26_13"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-6</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JmDXfNDeoU-A7sBdCGSkpw"
      decimals="0"
      id="Tc_bi9HuC2pqkSj4H9A3i-OdQ_27_13"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">85830</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_3_31_2024_k6qmi3YCyUeoj4EzQWmoYg"
      decimals="0"
      id="Tc_INs23ZkBr0-bnLHKk2E2PA_27_22"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">85830</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_alO13T8cuE2PUKMnkFcK4Q"
      decimals="0"
      id="Tc_C1p-HqRkqUSsh96ddf9OfQ_28_16"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-15083</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2024_To_3_31_2024_k6qmi3YCyUeoj4EzQWmoYg"
      decimals="0"
      id="Tc_2V0hjTGqFUWHA66-afbUUw_28_22"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-15083</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_pA-2oAPYMEqk86sHU18u8Q"
      decimals="0"
      id="Tc_mLcBVJw9GEqM14aB6TRuig_29_19"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-2810091</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_k6qmi3YCyUeoj4EzQWmoYg"
      decimals="0"
      id="Tc_RwnYD04C0UCmTyultyETnw_29_22"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-2810091</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_3_31_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_liwNe_OrZkuTHNDpnZcmag"
      decimals="INF"
      id="Tc_oLxASaoHiUKHeXnWnCoU0A_30_2"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">56227</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_3_31_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_liwNe_OrZkuTHNDpnZcmag"
      decimals="0"
      id="Tc_DF0PTZU_uUOh0BIzg2vv9w_30_5"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">1311063</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BOEuDXy_ZUeMtyMb1W31eg"
      decimals="INF"
      id="Tc_Rj-Ucl0f0UqsJHArFKZaEQ_30_7"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">5430215</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BOEuDXy_ZUeMtyMb1W31eg"
      decimals="0"
      id="Tc_20TxZIpBJkaaB6UW_Yq-Tw_30_10"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">5430</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Wi8LbADSoE6H9bs8u0MVsQ"
      decimals="0"
      id="Tc_dIBOXoQAdEOW1r7iaUqwVQ_30_13"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">350438045</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_lCnJPy7l60uydEVcNxwm6g"
      decimals="0"
      id="Tc_PhGDturCZka3LhawtgdD8A_30_16"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-10626356</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wfx449lO0kKvBkD-ftLx7w"
      decimals="0"
      id="Tc_wDHGrFlnkUWT9q0ee9t9_g_30_19"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-310893252</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_Zvq5nTZZy0aWnnp0Yr_H1w"
      decimals="0"
      id="Tc_cetyQA1NdkCwYjZHJJ2_6A_30_22"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">28923867</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_00YNAPouPUS3eodKEdKUZQ"
      decimals="0"
      id="Tc_ELSTK5OGVkiepBqLX7gHfw_32_13"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">21060</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_4_1_2024_To_6_30_2024_fAYnBVLhzUG8aJvV8WQWcQ"
      decimals="0"
      id="Tc_W2OCHiciskGAx_Q-smyp3Q_32_22"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">21060</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_00YNAPouPUS3eodKEdKUZQ"
      decimals="0"
      id="Tc_gXw8mwKWlU6LRhsTVFXIXw_33_13"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">128488</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2024_To_6_30_2024_fAYnBVLhzUG8aJvV8WQWcQ"
      decimals="0"
      id="Tc_oLJpawGesESlVmuxgjoobQ_33_22"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">128488</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fmrXxlAg8k2LTPqbZsdqQw"
      decimals="0"
      id="Tc_rLRxlXmfTE228VQibOQ7yw_34_16"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-1948</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_4_1_2024_To_6_30_2024_fAYnBVLhzUG8aJvV8WQWcQ"
      decimals="0"
      id="Tc_VFM1Q7atxk-LyWeIYbwflg_34_22"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-1948</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_SbTatJBJOUiFH1taEFtwHQ"
      decimals="0"
      id="Tc_BCgAz4PX8ECdxHIomRtlxA_35_19"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-3470052</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2024_To_6_30_2024_fAYnBVLhzUG8aJvV8WQWcQ"
      decimals="0"
      id="Tc_8nlOTVObRUS7svFJ1WkXqg_35_22"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-3470052</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_6_30_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_MQGoU-f5K02GZ9PlM-yOkA"
      decimals="INF"
      id="Tc_ZQVfN2jzY0SChWCPBqkOBA_36_2"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">56227</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_6_30_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_MQGoU-f5K02GZ9PlM-yOkA"
      decimals="0"
      id="Tc_VeHMKDZVnUmYYxij1Wcpkg_36_5"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">1311063</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_pTVYFBxdF0KO7SAVt4uiIg"
      decimals="INF"
      id="Tc_qbk8jpjWNUOgI4Jd3e59hg_36_7"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">5430215</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_pTVYFBxdF0KO7SAVt4uiIg"
      decimals="0"
      id="Tc_90JYYeMYKkOEwkLiE6Bl7Q_36_10"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">5430</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_z5h7zepvB0S3yMqUDLxYRQ"
      decimals="0"
      id="Tc_DrECCqGVS0eKehXfyfAH4g_36_13"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">350545473</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_kRMbWJwEh0W2ZdxtrlSp2g"
      decimals="0"
      id="Tc_3oaFCXqwJESVIWVbw8TU9w_36_16"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-10628304</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3OjBHmrFdEqql1a9Qd1d4w"
      decimals="0"
      id="Tc_aRs8y1oe6k606zdmcjwkeQ_36_19"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-314363304</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_ZePgtrw-B0izH24xd1d8mw"
      decimals="0"
      id="Tc_nAUYZ59yN0ixEdyV6uq6yQ_36_22"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">25559295</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ddh4E4AbBEerRzR7f0tdRQ"
      decimals="0"
      id="Tc_qqTVArkW_EKD6wDcc49_XA_38_13"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">1155</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g"
      decimals="0"
      id="Tc_SfxR5orYmkqu1C1xYuuu_A_38_22"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">1155</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uk8mlSyVokKTP3XSCE6G2g"
      decimals="INF"
      id="Tc_KIwqepWFSEurnCt61t_htw_39_7"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">4688</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_uk8mlSyVokKTP3XSCE6G2g"
      decimals="0"
      id="Tc_N1-gr3wjUUmZQzopvK7AVA_39_10"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">5</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ddh4E4AbBEerRzR7f0tdRQ"
      decimals="0"
      id="Tc_dbn6qIPNeUm-k-GoeJjxkw_39_13"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-5</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Ddh4E4AbBEerRzR7f0tdRQ"
      decimals="0"
      id="Tc_sJUng0xS1kWa26TT1ttK8g_40_13"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">149090</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g"
      decimals="0"
      id="Tc_uO2DP1y5Tk-o8k77X6k_rA_40_22"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">149090</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_wNRC8dghckiqZHMJ2Qab2A"
      decimals="0"
      id="Tc_ihOf5Z-JdkmitOkqCugwUQ_41_16"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">23557</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g"
      decimals="0"
      id="Tc_LhSz1FXEFEquHwmIJr070Q_41_22"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">23557</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jqM4BFBbeUqa02lyUgxwnw"
      decimals="0"
      id="Tc_CBja0fVZhUirP3pnJa70jQ_42_19"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-3783769</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g"
      decimals="0"
      id="Tc_5yPaoXcW1U2U5_FrMmwTfw_42_22"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-3783769</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_9_30_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8visgBbaHUi1WL8smvF9Lg"
      decimals="INF"
      id="Tc_SIU0NfKtAUOJYofxOJx4eQ_43_2"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">56227</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_9_30_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_8visgBbaHUi1WL8smvF9Lg"
      decimals="0"
      id="Tc_LNQK1zSDK0OCFEMWQmA5RA_43_5"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">1311063</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Omg5HL2Zk0iyUrhlyHkYzQ"
      decimals="INF"
      id="Tc_zhjCrA09TkGlEH4SzdYCvQ_43_7"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">5434903</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Omg5HL2Zk0iyUrhlyHkYzQ"
      decimals="0"
      id="Tc_wOdablRwJUWW1ykGVWhTqw_43_10"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">5435</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_w6HcF2RyJ0OwVohdYcyrWg"
      decimals="0"
      id="Tc_i3KFprF0gE-ftkZJfLVbng_43_13"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">350693403</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_mLJ_odBxZ0OgdXDNP5Doaw"
      decimals="0"
      id="Tc_NlitUHHPYUmQZl-ab1S4HQ_43_16"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-10604747</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7APo5uzuAUeE_AwHD_aDyQ"
      decimals="0"
      id="Tc_BxTBDTKQBU2fhKBuLA1bXw_43_19"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-318147073</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      decimals="0"
      id="Tc_iwwPbiox6E2qUizsV8Yl0A_43_22"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">21947018</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      decimals="0"
      id="Tc_E6xUcTdyakuJbGtov2eIaQ_4_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-10063912</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA"
      decimals="0"
      id="Tc_R8Knvky9EkOReX2iuNX-Sw_4_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-10843502</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      decimals="0"
      id="Tc_wMC1oh2qE067hY-7gf47rA_6_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">16890</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA"
      decimals="0"
      id="Tc_xS-cmM5RcUS6z8RB_9K7Yg_6_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">2066</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      decimals="0"
      id="Tc_aVimeM__bkaUhjnF6upm7g_7_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">363408</us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash
      contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA"
      decimals="0"
      id="Tc_kKNvnMy8x0uaejvkej2ROw_7_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">361598</us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      decimals="0"
      id="Tc_2lEC7ksPrUKDtpBfD3ZASw_8_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">15180</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA"
      decimals="0"
      id="Tc_a6O_7wYhrUaO65kKAbyF_w_8_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">39686</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      decimals="0"
      id="Tc_9Koi3yWe_USOujYy23nyPQ_10_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-398531</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA"
      decimals="0"
      id="Tc_ayc7qxDpnEKDSC5haHJWdQ_10_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-1077138</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      decimals="0"
      id="Tc_FhjMNFpPz0e5xD4cv5Dt_w_11_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-515964</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA"
      decimals="0"
      id="Tc_Ax9FROEw6ECueY8hxbjq6Q_11_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">21873</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      decimals="0"
      id="Tc_7_eNzTsIt0qa4nCVgVJyqA_12_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">299387</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA"
      decimals="0"
      id="Tc_nxvdP25JkU6kzIxvJtWHlw_12_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">982563</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      decimals="0"
      id="Tc_VMKFVvl94EGcyanBhHOfhA_13_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-528974</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      decimals="0"
      id="Tc_8aSI2cRW3UCU6SvDW6g-Zw_14_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-10045814</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA"
      decimals="0"
      id="Tc_9WMCVT0CI0idQDC1mHVacA_14_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-8437950</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      decimals="0"
      id="Tc_3078a0AMJ0C8aLuZa9QkEA_16_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">15478</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA"
      decimals="0"
      id="Tc_MdnOIdkB7EK9gdtXOoHzAw_16_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">85943</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      decimals="0"
      id="Tc_FU9-x1wnV0WLjyoZb-pZBw_17_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-15478</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA"
      decimals="0"
      id="Tc_RFVoCFxkGU2TQ3j9JoeLQw_17_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-85943</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      decimals="0"
      id="Tc_ve8iv9D9zkGM_KbOpDeNDw_19_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">15999598</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA"
      decimals="0"
      id="Tc_XP4SmZ4CUESJJjMRIlad_w_19_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">5788918</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      decimals="0"
      id="Tc_GS2eKvY0fEWLSDcEcQ1Mtg_20_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">1312108</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA"
      decimals="0"
      id="Tc_KS-TISJsBEiIHaB_SGxApA_20_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">648928</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      decimals="0"
      id="Tc_21HEAg_oS0KpYh-nYm0rzw_21_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">14687490</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA"
      decimals="0"
      id="Tc_EGEHlyoq_UClxeF8W2oVAg_21_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">5139990</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      decimals="0"
      id="Tc_xnNRDbyUMUmYGC_A9nLvVw_22_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">4626198</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA"
      decimals="0"
      id="Tc_NFXWDFP4S0SwJCYnDSSWjQ_22_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-3383903</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      decimals="0"
      id="Tc_UA3AZJRhdEqDwmW_ntNd5Q_23_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">17427</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA"
      decimals="0"
      id="Tc_0WZZc6xVk0SJNu6k35WfOA_23_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">-8782</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg"
      decimals="0"
      id="Tc_YLm40TYIEkO4yUUHoxni2w_24_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">21647537</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_XHHJ56Sb40GzY2_iFyVSmw"
      decimals="0"
      id="Tc_17qOXeXOCEqBkufiqi0gXA_24_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">28786647</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      decimals="0"
      id="Tc_ah3Z_wHXtEaEG75XmY6pGA_25_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">26291162</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2023_8FQi5hYCckGx-AAVXCTMIQ"
      decimals="0"
      id="Tc_lQa3zhiJ-EufanUosTfIPA_25_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">25393962</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      decimals="0"
      id="Tc_uAH4rAPjEkqvT0PBo0s8Hw_28_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">26249625</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2023_8FQi5hYCckGx-AAVXCTMIQ"
      decimals="0"
      id="Tc_UM7ZHtXWS0mDfmePnNEbvg_28_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">25353513</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      decimals="0"
      id="Tc_yGKDC_AP3E2LwXJ8z5IrkA_29_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">41537</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="As_Of_9_30_2023_8FQi5hYCckGx-AAVXCTMIQ"
      decimals="0"
      id="Tc_Ty6yjJITAE6QaPW7lZFd8w_29_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">40449</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      decimals="0"
      id="Tc_a6qNa-ezyEGLWn3I4HZiQw_30_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">26291162</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2023_8FQi5hYCckGx-AAVXCTMIQ"
      decimals="0"
      id="Tc_e09gepk1Uk2wKqkDYeH13w_30_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">25393962</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Tb_4hMiYW5Kv0uZlXk3aNT0EQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;1. Nature of business and basis of presentation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nature of business&lt;/b&gt;&lt;span style="white-space:pre-wrap;"&gt;&#x2014;Aprea Therapeutics, Inc. (the &#x201c;Company&#x201d;) is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company began principal operations in 2006 and is headquartered in Doylestown, Pennsylvania.  Prior to the acquisition of Atrin Pharmaceuticals Inc. (&#x201c;Atrin&#x201d;) in May 2022, the Company was engaged in the clinical development of cancer therapeutics that reactivate the mutant p53 tumor suppressor protein. In December 2020, the Company announced that its pivotal Phase 3 myelodysplastic syndromes trial failed to meet its predefined primary endpoint of complete remission (CR) rate. Given these results, FDA feedback and the costs of continuing the APR-246 development program, the Company shifted focus of its activities to the assets acquired in the May 2022 acquisition of Atrin. The Company&#x2019;s two clinical programs are a novel oral macrocyclic ATR inhibitor, ATRN-119, and our next-generation oral inhibitor of the WEE1 kinase, APR-1051. Both programs are the cornerstones of our pipeline of synthetic lethality-based cancer therapeutics and were internally discovered, developed, and evaluated by our dedicated team of chemists, scientists, and clinicians.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Basis of presentation and management plans&lt;/b&gt;&#x2014;The accompanying financial statements are prepared in conformity with accounting principles generally accepted in the United States (&#x201c;U.S.&#160;GAAP&#x201d;). The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Since its inception, the Company has devoted substantially all of its efforts to business planning, clinical operations, research and development, recruiting management, technical staff, raising capital and has financed its operations through the issuance of convertible preferred stock and common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is subject to risks common to companies in the biopharmaceutical industry. There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s intellectual property will be maintained, that any therapeutic products developed will obtain required regulatory approval or that any approved or consumer products will be commercially viable. Even if the Company&#x2019;s development efforts are successful, it is uncertain when, if ever, the Company will generate significant product sales.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company believes that the September&#160;30,&#160;2024 cash balance of approximately $26.2 million will be sufficient to fund the Company&#x2019;s operating expenses and capital expenditure requirements through at least twelve months from the date of issuance of these condensed consolidated financial statements. In the event that additional funds are not available thereafter, management would expect to significantly reduce expenditures to conserve cash, which would involve scaling back or curtailing new development activity.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      decimals="-5"
      id="Narr_qFKatj8cIEOKUvJPAYFZcw"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">26200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Tb_V89E-hcq5k2vWo_LtPPkEA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2. Summary of significant accounting policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company's complete listing of significant accounting policies are described in Note 2 to the Company's audited consolidated financial statements as of December&#160;31,&#160;2023 included in its annual report on Form 10-K filed with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Principles of consolidation&lt;/b&gt;&#x2014;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries Aprea Therapeutics AB, which was incorporated in May 2009, Aprea US,&#160;Inc., which was incorporated in June&#160;2016 and ATR Pharmaceuticals LLC which was incorporated in May 2022. Management has concluded it has a single reporting segment for purposes of reporting financial condition and results of operations. All intercompany transactions and balances have been eliminated.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unaudited interim consolidated financial statements&lt;/b&gt;&#x2014;The accompanying unaudited interim condensed consolidated financial statements have been prepared by the Company in accordance with U.S. GAAP for interim information and pursuant to the rules and regulations of the SEC for reporting on Form 10-Q. Accordingly, certain information and footnote disclosure normally included in financial statements prepared in accordance with U.S. GAAP have been &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;condensed or omitted pursuant to such rules and regulations. These unaudited condensed interim financial statements should be read in conjunction with the audited financial statements and related notes included in the Company&#x2019;s annual report on Form 10-K for the year ended December&#160;31,&#160;2023 filed with the SEC.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The unaudited interim consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements, and in management&#x2019;s opinion, include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of the financial information for the interim periods have been made. The results of operations for the three and nine months ended September&#160;30,&#160;2024 are not necessarily indicative of the results to be expected for the full fiscal year or any future period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Use of estimates&lt;/b&gt;&#x2014;The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses as of and during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates. Significant items subject to such estimates and assumptions, are used for, but not limited to, include stock-based compensation and accounting for research and development costs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Foreign currency and currency translation&lt;/b&gt;&#x2014;The functional currency for Aprea Therapeutics AB is the Swedish Krona. Assets and liabilities of Aprea Therapeutics AB are translated into United States dollars at the exchange rate in effect on the balance sheet date. Operating expenses are translated at the average exchange rate in effect during the period. Unrealized translation gains and losses are recorded as a cumulative translation adjustment, which is included in the consolidated statements of stockholders&#x2019; equity as a component of accumulated other comprehensive loss. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other income, net in the condensed consolidated statements of operations and comprehensive loss as incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash and cash equivalents&#x2014; &lt;/b&gt;The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restricted cash&#x2014; &lt;/b&gt;The Company has restricted cash of $41,537 and $40,717 at September&#160;30,&#160;2024 and December&#160;31,&#160;2023, respectively, that is securing the Company&#x2019;s credit card program.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value of financial instruments&lt;/b&gt;&#x2014;The accounting standard for fair value measurements provides a framework for measuring fair value and requires expanded disclosures regarding fair value measurements. Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic 820, Fair Value Measurement (&#x201c;ASC 820&#x201d;), establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The hierarchy defines three levels of valuation inputs, of which the first two are considered observable and the last is considered unobservable:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;1 inputs: Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;2 inputs: Inputs other than quoted prices included within Level&#160;1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;3 inputs: Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use in pricing the asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s financial instruments consist of cash, cash equivalents, restricted cash, accounts payable and accrued expenses. The carrying amount of accounts payable and accrued expenses is considered a reasonable estimate of fair value due to the short-term maturity.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series A Convertible Preferred Stock&lt;/b&gt;&#x2014;The Company classifies the Series A Preferred Stock as temporary equity outside of stockholders&#x2019; equity on the accompanying condensed consolidated balance sheets&#160;due to certain events that are not within the Company's control.&#160;The Series A Preferred Stock was recorded at fair value upon the acquisition of Atrin in May 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accounting for leases&lt;/b&gt;&#x2014;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified asset(s), if any, and the Company&#x2019;s control over the use of the identified asset(s), if applicable. Operating lease liabilities and their corresponding right of use assets are recorded based on the present value of future lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"&gt;The Company has elected not to separate lease and non-lease components as a single component. Operating leases are recognized on the balance sheet as right of use (ROU) lease assets, lease liabilities current and lease liabilities non-current. Fixed rents are included in the calculation of the lease balances while variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis. The Company has also elected the short-term lease exemption for all leases with an original term of less than 12&#160;months.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Research and development costs&lt;/b&gt;&#x2014;Research and development costs are charged to expense as incurred. Research and development expenses incurred in performing research and development activities, include salaries and benefits, materials and supplies, preclinical expenses, stock-based compensation expense, depreciation of equipment, contract services, and other outside expenses. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development. Deposits made by the Company with certain service providers that are to be applied to future payments due under the service agreements or returned to the Company if not utilized are recorded in the consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue recognition&lt;/b&gt;&#x2014; The Company&#x2019;s revenue is primarily generated through grants from government and non-government organizations. Grant revenue is recognized during the period that the reimbursable research and development services occur, as qualifying expenses are incurred or conditions of the grants are met. Grant revenue received in advance is recorded as deferred grant revenue and recognized as revenue once the conditions for revenue recognition are met. Associated expenses are recognized when incurred as research and development expenses. The Company concluded that payments received under these grants represent conditional, nonreciprocal contributions, as described in ASC&#160;&lt;i style="font-style:italic;"&gt;958,&lt;/i&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;Not-for-Profit Entities, and that the grants are&#160;&lt;i style="font-style:italic;"&gt;not&lt;/i&gt;&#160;within the scope of ASC&#160;&lt;i style="font-style:italic;"&gt;606,&lt;/i&gt;&#160;Revenue from Contracts with Customers, as the organizations providing the grants do&#160;&lt;i style="font-style:italic;"&gt;not&lt;/i&gt;&#160;meet the definition of a customer. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Stock-based compensation&lt;/b&gt;&#x2014;The Company measures stock options and other stock-based awards granted to employees and directors based on their fair value on the date of the grant and recognize compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective award. The Company applies the straight-line method of expense recognition to all awards with only service based vesting conditions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;For stock-based awards granted to non-employees, compensation expense is recognized over the period during which services are rendered by such non-employees until completed in accordance with ASC 718. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company estimates the fair value of each stock option grant on the date of grant using the Black Scholes option pricing model, which uses as inputs the fair value of the Company&#x2019;s common stock and assumptions the Company makes for the volatility of its common stock, the expected term of its stock options, the risk-free interest rate for a period that approximates the expected term of its stock options and its expected dividend yield. The Company elects to account for forfeitures when they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company also awards restricted stock units (&#x201c;RSUs&#x201d;) to employees and directors. RSUs are generally subject to forfeiture if employment terminates prior to the completion of the vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse.&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net loss per share&lt;/b&gt;&#x2014;The Company has reported losses since inception and has computed basic net loss per share attributable to common stockholders by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company computes diluted net loss per common share after giving consideration to all potentially dilutive common shares, including options to purchase common stock, outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential common shares have been anti-dilutive and basic and diluted loss per share have been the same. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Included within weighted average common shares outstanding for the three and nine months ended September&#160;30,&#160;2024 are 507,076 common shares issuable upon the exercise of certain warrants, which are exercisable at any time for nominal consideration, and as such, the shares are considered outstanding for the purpose of calculating basic and diluted net loss per share attributable to common stockholders.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine months ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:67.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Convertible preferred stock (as converted)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 28,112&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 28,112&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:67.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 734,131&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 582,641&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:67.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,194,788&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:67.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 36,442&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 23,870&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:67.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total shares of common stock equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,993,473&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 634,623&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recently issued accounting pronouncements&#x2014;&lt;span style="font-weight:normal;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) or other standard setting bodies that the Company adopts as of the specified effective date. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 will improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses on an interim and annual basis. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods after December 15, 2024, with early adoption permitted. The adoption of this standard is not expected to have a material impact on the Company&#x2019;s condensed financial statements at adoption date.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Tb_XjMNNj98okKG-FrxmVh3Vw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Principles of consolidation&lt;/b&gt;&#x2014;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries Aprea Therapeutics AB, which was incorporated in May 2009, Aprea US,&#160;Inc., which was incorporated in June&#160;2016 and ATR Pharmaceuticals LLC which was incorporated in May 2022. Management has concluded it has a single reporting segment for purposes of reporting financial condition and results of operations. All intercompany transactions and balances have been eliminated.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <apre:UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Tb_aC6XweIQFEalESnViFaknA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unaudited interim consolidated financial statements&lt;/b&gt;&#x2014;The accompanying unaudited interim condensed consolidated financial statements have been prepared by the Company in accordance with U.S. GAAP for interim information and pursuant to the rules and regulations of the SEC for reporting on Form 10-Q. Accordingly, certain information and footnote disclosure normally included in financial statements prepared in accordance with U.S. GAAP have been &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;condensed or omitted pursuant to such rules and regulations. These unaudited condensed interim financial statements should be read in conjunction with the audited financial statements and related notes included in the Company&#x2019;s annual report on Form 10-K for the year ended December&#160;31,&#160;2023 filed with the SEC.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The unaudited interim consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements, and in management&#x2019;s opinion, include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of the financial information for the interim periods have been made. The results of operations for the three and nine months ended September&#160;30,&#160;2024 are not necessarily indicative of the results to be expected for the full fiscal year or any future period.&lt;/p&gt;</apre:UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Tb_vFBQmcYH-0mD_l3znCrj0g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Use of estimates&lt;/b&gt;&#x2014;The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses as of and during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates. Significant items subject to such estimates and assumptions, are used for, but not limited to, include stock-based compensation and accounting for research and development costs.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Tb_M96s1MFyGk6iJYD7hgzl5A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Foreign currency and currency translation&lt;/b&gt;&#x2014;The functional currency for Aprea Therapeutics AB is the Swedish Krona. Assets and liabilities of Aprea Therapeutics AB are translated into United States dollars at the exchange rate in effect on the balance sheet date. Operating expenses are translated at the average exchange rate in effect during the period. Unrealized translation gains and losses are recorded as a cumulative translation adjustment, which is included in the consolidated statements of stockholders&#x2019; equity as a component of accumulated other comprehensive loss. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other income, net in the condensed consolidated statements of operations and comprehensive loss as incurred.&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Tb_L73sOzHNz0230_5eTcJZgQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash and cash equivalents&#x2014; &lt;/b&gt;The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restricted cash&#x2014; &lt;/b&gt;The Company has restricted cash of $41,537 and $40,717 at September&#160;30,&#160;2024 and December&#160;31,&#160;2023, respectively, that is securing the Company&#x2019;s credit card program.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCash
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      decimals="0"
      id="Narr_fWqVjhkG50uqb4ZLcr9rgQ"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">41537</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg"
      decimals="0"
      id="Narr_Qbo363oR2UquJ4T9znP7Iw"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">40717</us-gaap:RestrictedCash>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Tb_yhFNXp6ewkCvQnkSJAGsgQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value of financial instruments&lt;/b&gt;&#x2014;The accounting standard for fair value measurements provides a framework for measuring fair value and requires expanded disclosures regarding fair value measurements. Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic 820, Fair Value Measurement (&#x201c;ASC 820&#x201d;), establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The hierarchy defines three levels of valuation inputs, of which the first two are considered observable and the last is considered unobservable:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;1 inputs: Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;2 inputs: Inputs other than quoted prices included within Level&#160;1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;3 inputs: Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use in pricing the asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s financial instruments consist of cash, cash equivalents, restricted cash, accounts payable and accrued expenses. The carrying amount of accounts payable and accrued expenses is considered a reasonable estimate of fair value due to the short-term maturity.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <apre:TemporaryEquityPolicyTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Tb_Z4sTgrNbjUWp3QuFbuEz6g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series A Convertible Preferred Stock&lt;/b&gt;&#x2014;The Company classifies the Series A Preferred Stock as temporary equity outside of stockholders&#x2019; equity on the accompanying condensed consolidated balance sheets&#160;due to certain events that are not within the Company's control.&#160;The Series A Preferred Stock was recorded at fair value upon the acquisition of Atrin in May 2022.&lt;/p&gt;</apre:TemporaryEquityPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Tb_tXkYhFMRikGB5pdJMLjmsw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accounting for leases&lt;/b&gt;&#x2014;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified asset(s), if any, and the Company&#x2019;s control over the use of the identified asset(s), if applicable. Operating lease liabilities and their corresponding right of use assets are recorded based on the present value of future lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"&gt;The Company has elected not to separate lease and non-lease components as a single component. Operating leases are recognized on the balance sheet as right of use (ROU) lease assets, lease liabilities current and lease liabilities non-current. Fixed rents are included in the calculation of the lease balances while variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis. The Company has also elected the short-term lease exemption for all leases with an original term of less than 12&#160;months.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Tb_lm-LuDqijkiPbw8RMSQdug">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Research and development costs&lt;/b&gt;&#x2014;Research and development costs are charged to expense as incurred. Research and development expenses incurred in performing research and development activities, include salaries and benefits, materials and supplies, preclinical expenses, stock-based compensation expense, depreciation of equipment, contract services, and other outside expenses. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development. Deposits made by the Company with certain service providers that are to be applied to future payments due under the service agreements or returned to the Company if not utilized are recorded in the consolidated balance sheets.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Tb_6e7awdMBe0iNuaPD1_vpOA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue recognition&lt;/b&gt;&#x2014; The Company&#x2019;s revenue is primarily generated through grants from government and non-government organizations. Grant revenue is recognized during the period that the reimbursable research and development services occur, as qualifying expenses are incurred or conditions of the grants are met. Grant revenue received in advance is recorded as deferred grant revenue and recognized as revenue once the conditions for revenue recognition are met. Associated expenses are recognized when incurred as research and development expenses. The Company concluded that payments received under these grants represent conditional, nonreciprocal contributions, as described in ASC&#160;&lt;i style="font-style:italic;"&gt;958,&lt;/i&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;Not-for-Profit Entities, and that the grants are&#160;&lt;i style="font-style:italic;"&gt;not&lt;/i&gt;&#160;within the scope of ASC&#160;&lt;i style="font-style:italic;"&gt;606,&lt;/i&gt;&#160;Revenue from Contracts with Customers, as the organizations providing the grants do&#160;&lt;i style="font-style:italic;"&gt;not&lt;/i&gt;&#160;meet the definition of a customer. &lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Tb_i7F0ViNjwUaJAIef_wiDOQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Stock-based compensation&lt;/b&gt;&#x2014;The Company measures stock options and other stock-based awards granted to employees and directors based on their fair value on the date of the grant and recognize compensation expense of those awards over the requisite service period, which is generally the vesting period of the respective award. The Company applies the straight-line method of expense recognition to all awards with only service based vesting conditions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;For stock-based awards granted to non-employees, compensation expense is recognized over the period during which services are rendered by such non-employees until completed in accordance with ASC 718. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company estimates the fair value of each stock option grant on the date of grant using the Black Scholes option pricing model, which uses as inputs the fair value of the Company&#x2019;s common stock and assumptions the Company makes for the volatility of its common stock, the expected term of its stock options, the risk-free interest rate for a period that approximates the expected term of its stock options and its expected dividend yield. The Company elects to account for forfeitures when they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company also awards restricted stock units (&#x201c;RSUs&#x201d;) to employees and directors. RSUs are generally subject to forfeiture if employment terminates prior to the completion of the vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse.&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Tb_4sz1AHPQj02e79BwnX2c1A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net loss per share&lt;/b&gt;&#x2014;The Company has reported losses since inception and has computed basic net loss per share attributable to common stockholders by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company computes diluted net loss per common share after giving consideration to all potentially dilutive common shares, including options to purchase common stock, outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential common shares have been anti-dilutive and basic and diluted loss per share have been the same. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Included within weighted average common shares outstanding for the three and nine months ended September&#160;30,&#160;2024 are 507,076 common shares issuable upon the exercise of certain warrants, which are exercisable at any time for nominal consideration, and as such, the shares are considered outstanding for the purpose of calculating basic and diluted net loss per share attributable to common stockholders.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine months ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:67.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Convertible preferred stock (as converted)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 28,112&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 28,112&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:67.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 734,131&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 582,641&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:67.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,194,788&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:67.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 36,442&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 23,870&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:67.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total shares of common stock equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,993,473&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 634,623&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_WAR5SHVFkE6tbDGoKuqOZg"
      decimals="INF"
      id="Narr_WzzAmbQQGESkqcjHWta9AQ"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">507076</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_WAR5SHVFkE6tbDGoKuqOZg"
      decimals="INF"
      id="Narr_Spd-Nyl6QEmiwb8CTG_pqQ"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">507076</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Tb_A5FgWA2sNUSG2-wLVEygCA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine months ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:67.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Convertible preferred stock (as converted)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 28,112&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 28,112&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:67.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 734,131&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 582,641&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:67.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,194,788&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:67.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 36,442&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 23,870&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:67.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total shares of common stock equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,993,473&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 634,623&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_-xdRwU9xSUiPNwUETulTXA"
      decimals="INF"
      id="Tc_dHoO9S3DAECwCnBMMTXB5Q_3_2"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">28112</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_z_oRFQwZ_U2_FPccUncU4Q"
      decimals="INF"
      id="Tc_o140uOgmv069dOK6ee9zdQ_3_4"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">28112</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_lWBjcVjr5UKoPSricaY5kw"
      decimals="INF"
      id="Tc_EJnzFr7X3kqmucT6tZvArQ_4_2"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">734131</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_I-_Nu9K7KEKrfxHT-XiE6A"
      decimals="INF"
      id="Tc_EFqoR1A6_U-vWv_yDW79GQ_4_4"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">582641</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_18zK2B__vkKA8IrK9I5aKw"
      decimals="INF"
      id="Tc_oXG3Z3xwREOFxQ2-PiiVVg_5_2"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">2194788</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_BniNzMIFNESCAEERHrL4Qg"
      decimals="INF"
      id="Tc_nrY1GN7oEEu_BxDU8Kj6rw_6_2"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">36442</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_V6BVG1ivukSZDtIV_eHuyA"
      decimals="INF"
      id="Tc_I69oiOiFkUi7kZL6Ogdakw_6_4"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">23870</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      decimals="INF"
      id="Tc_8gN_vzHN7U6p34LPk7lgxQ_7_2"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">2993473</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA"
      decimals="INF"
      id="Tc_SGtdBuQN8ketXUU79aHE2g_7_4"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">634623</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Tb_xynWj9Ix50madTBHF8oxtg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recently issued accounting pronouncements&#x2014;&lt;span style="font-weight:normal;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) or other standard setting bodies that the Company adopts as of the specified effective date. &lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <apre:LeaseDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Tb_F7z5NAA9wE-bn6V8JqcErw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;3. Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is party to one operating lease for office and laboratory space. The Company&#x2019;s finance leases are immaterial both individually and in the aggregate. The Company has elected to apply the short-term lease exception to all leases of one&#160;year or less. Rent expense for each of the three months ended September&#160;30,&#160;2024 and 2023 was $19,998. Rent expense for each of the nine months ended September&#160;30,&#160;2024 and 2023 was $59,993, which is included in operating expenses. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company has an annual operating lease for office and laboratory space in Doylestown, Pennsylvania which was amended in October 2024 and is currently set to expire on October 31, 2025. Rent expense under this lease is $110,000 annually and the Company has applied the short-term exception to this lease. The Company has &lt;span style="-sec-ix-hidden:Hidden_dXY0fqi6LUqjrBt7mcO_tw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;no&lt;/span&gt;&lt;/span&gt; lease obligations beyond October 2025.&lt;/p&gt;</apre:LeaseDisclosureTextBlock>
    <apre:LesseeOperatingLeaseNumberOfOperatingLeases
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      decimals="INF"
      id="Narr_7vN6DwcjMEOnCWtuLC2ucw"
      unitRef="Unit_Standard_lease_uug6S_kQsEij919rCVEEeQ">1</apre:LesseeOperatingLeaseNumberOfOperatingLeases>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug"
      decimals="0"
      id="Narr_Whqcbb5tk0KBJ6hKx611qg"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">19998</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g"
      decimals="0"
      id="Narr_HY4MxuLRdE-GswImWSQseA"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">19998</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA"
      decimals="0"
      id="Narr_VWvYSTE2V0i-e_rU9Jc1kA"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">59993</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      decimals="0"
      id="Narr_Elt3eS_utEK_FEpLO9T9kw"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">59993</us-gaap:OperatingLeaseExpense>
    <apre:LesseeOperatingLeaseAnnualBaseRent
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      decimals="INF"
      id="Narr_3zlvYhneYkWYPGssS7s8GA"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">110000</apre:LesseeOperatingLeaseAnnualBaseRent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Tb_7eXRpuTclUSB76UXwctvbQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;4. Accrued expenses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;Accrued expenses consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Professional&#160;fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 168,225&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 138,601&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Compensation, severance&#160;and&#160;benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 673,322&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,016,960&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research&#160;and&#160;development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,582,173&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 856,575&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 58,288&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 174,126&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total&#160;accrued&#160;expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,482,008&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,186,262&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Tb_TwTWdpTvXUuVN41oDaz6HQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Professional&#160;fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 168,225&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 138,601&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Compensation, severance&#160;and&#160;benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 673,322&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,016,960&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research&#160;and&#160;development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,582,173&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 856,575&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 58,288&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 174,126&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:72.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total&#160;accrued&#160;expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,482,008&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,186,262&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      decimals="0"
      id="Tc_fM_CVDb7rEy1tSk0OnYIbA_3_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">168225</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg"
      decimals="0"
      id="Tc_Ylr8QPMDZEGCIte88zu-rQ_3_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">138601</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      decimals="0"
      id="Tc_4Jg9WbXbDkeSRmVoe68acg_4_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">673322</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg"
      decimals="0"
      id="Tc_9eGEWAt5PUS6HynRPdoCZg_4_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">1016960</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <apre:ResearchAndDevelopmentRelatedLiabilitiesCurrent
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      decimals="0"
      id="Tc_mHNN4GwhSUu5HhEZBFEAOg_5_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">1582173</apre:ResearchAndDevelopmentRelatedLiabilitiesCurrent>
    <apre:ResearchAndDevelopmentRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg"
      decimals="0"
      id="Tc_97GjH06PP0eOzkF486ilYA_5_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">856575</apre:ResearchAndDevelopmentRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      decimals="0"
      id="Tc_dd9dHVwueECnV8Aq34xfJw_6_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">58288</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg"
      decimals="0"
      id="Tc_AOpvp2KcPkactpQuCCiNmg_6_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">174126</us-gaap:OtherAccruedLiabilitiesCurrent>
    <apre:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      decimals="0"
      id="Tc_HyqeikMXYUaB-pwOnNQvfA_7_3"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">2482008</apre:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent>
    <apre:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg"
      decimals="0"
      id="Tc_trDCJsT1yUmhOicnSSKvRg_7_6"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">2186262</apre:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent>
    <apre:CommonStockTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Tb_vmWvwuyPH0ONwH5iVSZSTA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;5. Stockholders&#x2019; equity &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The total number of shares of all classes of capital stock that the Company is authorized to issue is 440,000,000 shares, consisting of 400,000,000 shares of common stock, par value $0.001 per share and 40,000,000 shares of preferred stock, par value $0.001 per share.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Series A Preferred Stock&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;As of September&#160;30,&#160;2024, a total of 56,227 shares of Series A Preferred Stock remained outstanding, which are convertible into 28,112 shares of common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Common Stock&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;The holders of common stock are entitled to one&lt;span style="white-space:pre-wrap;"&gt; vote for each share of common stock.  In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, after the payment or provision for payment of all debts and liabilities of the Company, the holders of common stock shall be entitled to share in the remaining assets of the Company available for distribution, if any.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Shelf Registration Statement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;On November 12, 2020, the Company filed a universal shelf registration statement with the SEC for the issuance of common stock, preferred stock, warrants, rights, debt securities and units up to an aggregate of $350.0 million (the &#x201c;2020 Shelf Registration Statement&#x201d;). On November 30, 2020, the 2020 Shelf Registration Statement was declared effective by the SEC and on November 30, 2023, the 2020 Shelf Registration Statement expired. The 2020 Shelf Registration Statement included an at-the-market offering program with SVB Leerink LLC (the &#x201c;SVB ATM Program&#x201d;) and the Company filed a Prospectus Supplement dated September 2, 2022, for the sale of up to $14,744,728 of shares of the Company&#x2019;s common stock pursuant to its ATM offering program. The Company agreed to pay a commission of 3% &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;of the gross proceeds of any common stock sold in connection with the SVB ATM Program. During the nine months ended September&#160;30,&#160;2023, the Company issued and sold 26,302 shares of common stock under the ATM offering program resulting in net proceeds to the Company of approximately $0.3 million after deducting approximately $8,000 in issuance costs. The SVB ATM Program has terminated and is no longer effective.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;In February 2023, the Company issued and sold 1,050,000 shares of common stock at a public offering price of $5.25 per share pursuant to the 2020 Shelf Registration Statement resulting in net proceeds to the Company of approximately $4.9 million, after deducting underwriting discounts and offering expenses of approximately $0.6 million. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;On January 26, 2024, the Company filed a new shelf registration statement (the &#x201c;2024 Shelf Registration Statement&#x201d;) with the SEC for issuance of common stock, preferred stock, warrants, rights, debt securities and units up to an aggregate of $150 million, including a prospectus for the sale of $1&lt;span style="white-space:pre-wrap;"&gt; million of shares of our common stock under the ATM Agreement, as defined below, which was declared effective on February 2, 2024.  The Company subsequently filed a prospectus supplement to the 2024 Shelf Registration Statement for the sale of up to &lt;/span&gt;$2&lt;span style="white-space:pre-wrap;"&gt; million of shares of common stock pursuant to the ATM Agreement.  On January 26, 2024, the Company entered into an At the Market Offering Agreement (the &#x201c;ATM Agreement&#x201d;) with H.C. Wainwright &amp;amp; Co., LLC (&#x201c;HCW&#x201d;).  Pursuant to the ATM Agreement and the prospectus supplement filed in connection therewith, the Company was able, from time to time, in its sole discretion, to issue and sell through HCW, acting as sales agent and/or principal, up to &lt;/span&gt;$2&lt;span style="white-space:pre-wrap;"&gt; million of shares of common stock.  The Company did not make any sales under the ATM Agreement and in March 2024, the Company terminated the ATM Agreement with HCW.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;March 2024 Private Placement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;On March 11, 2024, the Company entered into a securities purchase agreement with certain purchasers (the &#x201c;Purchasers&#x201d;) pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement offering exempt from registration under the Securities Act of 1933, as amended, or the Securities Act, and the Purchasers agreed to purchase from the Company (i) 1,687,712 shares of the Company&#x2019;s common stock at a purchase price of $7.29 per share (the &#x201c;Shares&#x201d;), (ii) pre-funded common stock purchase warrants at a purchase price of $7.289 to purchase an aggregate of up to 507,076 shares of the Company&#x2019;s common stock at an exercise price of $0.001 per share (the &#x201c;Pre-Funded Shares&#x201d;), (iii) tranche A common stock purchase warrants to purchase up to 1,097,394 shares of the Company&#x2019;s common stock at an exercise price of $7.29 per share (the &#x201c;Tranche A Warrants&#x201d;), and (iv) tranche B common stock purchase warrants to purchase up to 1,097,394 shares of the Company&#x2019;s common stock at an exercise price of $9.1125 per share (the &#x201c;Tranche B Warrants&#x201d;). The Tranche A Warrants will be exercisable until the earlier of (i) the three-year anniversary of issuance and (ii) 30 days after the Company announces the recommended Phase 2 dose for ATRN-119, and, following such announcement, the daily volume weighted average price of the Company&#x2019;s common stock equals or exceeds $14.58 for 30 consecutive trading days. The Tranche B Warrants will be exercisable until the earlier of (i) the five-year anniversary of issuance and (ii) 30 days after the Company announces the recommended Phase 2 dose for APR-1051 and, following such announcement, the daily volume weighted average price of the Company&#x2019;s common stock equals or exceeds $18.225 for 30 consecutive trading days. To the extent that the exercise of a Tranche A Warrant or Tranche B Warrant would result in the holder beneficially owning greater than 4.99% (or, at the election of the holder, greater than 9.99%) of the Company&#x2019;s outstanding common stock immediately following such exercise, the holder will instead receive pre-funded warrants in substantially the same form as the pre-funded warrants issued at closing. The aggregate upfront gross proceeds from the issuance of common stock and pre-funded common stock purchase warrants totaled approximately $16.0 million, before deducting placement agent fees and offering costs of approximately $1.3 million. The gross proceeds from potential future warrant cash exercises are expected to be up to approximately $18.0 million, before deducting placement agent fees. In April 2024, we registered on Form S-3 the resale of the Shares, the Pre-Funded Shares and the shares underlying the Tranche A Warrants and Tranche B Warrants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company evaluated the terms of the warrants issued and determined that they should be classified as equity instruments within additional paid-in capital. As of September&#160;30,&#160;2024, none of the pre-funded warrants, Tranche A Warrants or Tranche B Warrants have been exercised.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Stock-Based Compensation Expense&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company recorded stock-based compensation expense of $149,090 and $76,031 for the three months ended September&#160;30,&#160;2024 and 2023, respectively. The Company recorded stock-based compensation expense of $363,408 and $361,598 for the nine months ended September&#160;30,&#160;2024 and 2023, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</apre:CommonStockTextBlock>
    <apre:StockSharesAuthorized
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      decimals="INF"
      id="Narr_QZu8urIr0EKJ73whMmVbWQ"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">440000000</apre:StockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      decimals="INF"
      id="Narr_vWWwbpaaskOTtXoi4trUVQ"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      decimals="INF"
      id="Narr_8g71vJPrp0yKNCir8EBPOA"
      unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      decimals="INF"
      id="Narr_0VZTxjGcAEafGLd55Aa7RQ"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">40000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      decimals="INF"
      id="Narr_p_ZjpFsgdkK5t5w5imxgZQ"
      unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_9_30_2024_us-gaap_StatementClassOfStockAxis_apre_ConvertiblePreferredStockSeriesaMember_vRazHx54bUee8EgCl6bZxg"
      decimals="INF"
      id="Narr_KtspceqDQUm0dDTGuRkVwQ"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">56227</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      decimals="INF"
      id="Narr_snotvY5h1ku8ujGfCZdjkg"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">28112</us-gaap:PreferredStockConvertibleSharesIssuable>
    <apre:CommonStockNumberOfVotingRightsPerShare
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      decimals="INF"
      id="Narr_cvQRoMHp8UyckKt0jJx4KA"
      unitRef="Unit_Standard_Vote_xLAtZ3mDNEadoQnTSpr_cQ">1</apre:CommonStockNumberOfVotingRightsPerShare>
    <apre:UniversalShelfRegistrationMaximumAmountToBeIssued
      contextRef="As_Of_11_12_2020_us-gaap_SubsidiarySaleOfStockAxis_apre_ShelfRegistrationStatementMember_ARwQ47H460ieVrWA3BWUnQ"
      decimals="-5"
      id="Narr_sn82W6G5wk6A1GjKXlNT3w"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">350000000.0</apre:UniversalShelfRegistrationMaximumAmountToBeIssued>
    <apre:AtMarketOfferingProgramMaximumAmountToBeIssued
      contextRef="As_Of_11_12_2020_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_gmVaaYo2B0i-Fejiwesclg"
      decimals="INF"
      id="Narr_1ZfIWiluHEu6pMHUQ5eB_w"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">14744728</apre:AtMarketOfferingProgramMaximumAmountToBeIssued>
    <apre:AtMarketOfferingCommissionPayableAsPercentageOfGrossProceedsFromSaleOfCommonStock
      contextRef="Duration_11_12_2020_To_11_12_2020_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_MJWqDGoHuUiO0gnEMhlZUg"
      decimals="2"
      id="Narr_yLVhCbvlWUayp8flg4Digg"
      unitRef="Unit_Standard_pure_psC0V7jouEy1pdZ9EBR0Hw">0.03</apre:AtMarketOfferingCommissionPayableAsPercentageOfGrossProceedsFromSaleOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_fSqftKDYcEGIBNux4uAuoQ"
      decimals="INF"
      id="Narr_b0paR4ld40ilt31kP6SzFA"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">26302</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_fSqftKDYcEGIBNux4uAuoQ"
      decimals="-5"
      id="Narr_imHQ-IOC_0mefw3cDDrwug"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">300000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarketOfferingMember_fSqftKDYcEGIBNux4uAuoQ"
      decimals="0"
      id="Narr_0qKLOh0FtU6_6MENb7UI1Q"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">8000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_2_1_2023_To_2_28_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_apre_ShelfRegistrationStatementMember_LaEYUb2hjkW2KGU-74xlQw"
      decimals="INF"
      id="Narr_ZSDuAEh0REmQHqLohaG8Mw"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">1050000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="As_Of_2_28_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_apre_ShelfRegistrationStatementMember_UBxEuMVTak-jJ5nG9mM16A"
      decimals="INF"
      id="Narr_qBB9itCmnEuwYlzcsSU3nw"
      unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A">5.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_2_1_2023_To_2_28_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_apre_ShelfRegistrationStatementMember_LaEYUb2hjkW2KGU-74xlQw"
      decimals="-5"
      id="Narr_U_HoenttBk61_BfGqwFoRA"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">4900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_2_1_2023_To_2_28_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_apre_ShelfRegistrationStatementMember_LaEYUb2hjkW2KGU-74xlQw"
      decimals="-5"
      id="Narr_RFTZsCEQwUy89T7mDosMVw"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">600000</us-gaap:PaymentsOfStockIssuanceCosts>
    <apre:UniversalShelfRegistrationMaximumAmountToBeIssued
      contextRef="As_Of_1_26_2024_us-gaap_SubsidiarySaleOfStockAxis_apre_ShelfRegistrationStatement2024Member_hof9NYm7h0ub2MpXywHosA"
      decimals="-6"
      id="Narr_sBAc6OcYNE6jYYAH-E1Lpw"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">150000000</apre:UniversalShelfRegistrationMaximumAmountToBeIssued>
    <apre:AtMarketOfferingProgramMaximumAmountToBeIssued
      contextRef="As_Of_1_26_2024_us-gaap_SubsidiarySaleOfStockAxis_apre_ShelfRegistrationStatement2024Member_hof9NYm7h0ub2MpXywHosA"
      decimals="-6"
      id="Narr_lsBrLnDOcEqQ1yP5-if3QQ"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">1000000</apre:AtMarketOfferingProgramMaximumAmountToBeIssued>
    <apre:AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement
      contextRef="As_Of_1_26_2024_us-gaap_SubsidiarySaleOfStockAxis_apre_ShelfRegistrationStatement2024Member_hof9NYm7h0ub2MpXywHosA"
      decimals="-6"
      id="Narr_c-Tt8ZOo8kmqoQWYAjmGrw"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">2000000</apre:AtMarketOfferingProgramMaximumAmountToBeIssuedSupplement>
    <apre:AtMarketOfferingProgramMaximumAmountToBeIssued
      contextRef="As_Of_1_26_2024_srt_CounterpartyNameAxis_apre_HCWainrightCoLlcMember_us-gaap_SubsidiarySaleOfStockAxis_apre_AtMarket2024OfferingMember_M05-gKo8P0qhKNNnCJ2ynA"
      decimals="-6"
      id="Narr_XASu58PP4kyxjQqTBSzJHg"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">2000000</apre:AtMarketOfferingProgramMaximumAmountToBeIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_NhXjTaJGO0qzpt50WX1aQA"
      decimals="INF"
      id="Narr_4wFMh3Hm2UygYmc1PEXfqg"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">1687712</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_5KoUULH39EatBTbigzb7Nw"
      decimals="2"
      id="Narr_Yp2Mt13lBEyYGrKXOdKJ6w"
      unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A">7.29</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_Do28_zwKEkmVihgrJpKe5A"
      decimals="INF"
      id="Narr_AZ5Dpst84UWfBana4ROO-w"
      unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A">7.289</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_Do28_zwKEkmVihgrJpKe5A"
      decimals="INF"
      id="Narr_lx37ipP1b02rqdR6Z8INuQ"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">507076</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_5KoUULH39EatBTbigzb7Nw"
      decimals="3"
      id="Narr_72NJDpCz7USaaz6wsBzS9g"
      unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice7.29PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_lx_pDgysWkWXlV3jLs59hg"
      decimals="INF"
      id="Narr_RAohUyRidUKVs6iN0m9iYQ"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">1097394</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice7.29PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_lx_pDgysWkWXlV3jLs59hg"
      decimals="2"
      id="Narr_X7wiODn4hk2MZSWCnVKRoA"
      unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A">7.29</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice7.29PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_lx_pDgysWkWXlV3jLs59hg"
      decimals="INF"
      id="Narr_kQePR8Xab0q-qctPB6rCoQ"
      unitRef="Unit_Standard_shares_sSDE7Woa5kmBB7-iZ39Wcg">1097394</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice9.1125PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_G-a6RTBX2E2Sy0VISZQI2A"
      decimals="4"
      id="Narr_AgXIBW9IcEaeX1oG-9R8rA"
      unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A">9.1125</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <apre:StockIssuanceAnniversaryPeriod
      contextRef="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice7.29PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_2erKOwIbbU-vg-0HBwM-Ew"
      id="Narr_NIqIXRlCR0i6UddLUmfLIw">P3Y</apre:StockIssuanceAnniversaryPeriod>
    <apre:NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119
      contextRef="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice7.29PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_2erKOwIbbU-vg-0HBwM-Ew"
      id="Narr_VtxT4GNeg02rOqDHIebX5g">P30D</apre:NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119>
    <apre:SharesIssuedVolumeWeightedAveragePricePerShare
      contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice7.29PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_lx_pDgysWkWXlV3jLs59hg"
      decimals="2"
      id="Narr_jsDtz-sRGEOwaEsCBMo4xA"
      unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A">14.58</apre:SharesIssuedVolumeWeightedAveragePricePerShare>
    <apre:NumberOfConsecutiveTradingDays
      contextRef="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice7.29PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_2erKOwIbbU-vg-0HBwM-Ew"
      id="Narr_A7s7oYjDF0KbKhhYrIfc-w">P30D</apre:NumberOfConsecutiveTradingDays>
    <apre:StockIssuanceAnniversaryPeriod
      contextRef="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice9.1125PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_zOEchtkouU6yqqanDoFo6w"
      id="Narr_DkqjriLx8k6iqOz3dgG4Dg">P5Y</apre:StockIssuanceAnniversaryPeriod>
    <apre:NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119
      contextRef="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice9.1125PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_zOEchtkouU6yqqanDoFo6w"
      id="Narr_vtgg1lGcikipppKDmlc6JQ">P30D</apre:NumberOfDaysAfterCompanyAnnouncesRecommendedPhase2DoseForAtrn119>
    <apre:SharesIssuedVolumeWeightedAveragePricePerShare
      contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice9.1125PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_G-a6RTBX2E2Sy0VISZQI2A"
      decimals="3"
      id="Narr_lFPeZfyx7kSjJnvGa89kJA"
      unitRef="Unit_Divide_USD_shares_jFtjfubESUepDXxJCjGa7A">18.225</apre:SharesIssuedVolumeWeightedAveragePricePerShare>
    <apre:NumberOfConsecutiveTradingDays
      contextRef="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_ClassOfWarrantOrRightAxis_apre_PreFundedWarrantsExercisePrice7.29PerShareMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_2erKOwIbbU-vg-0HBwM-Ew"
      id="Narr_9vckXgciA0mQLpDGZlttAg">P30D</apre:NumberOfConsecutiveTradingDays>
    <apre:PercentageOfOutstandingShares
      contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_5KoUULH39EatBTbigzb7Nw"
      decimals="4"
      id="Narr_Kjbh-J4pRkulaOG2Dy-fJg"
      unitRef="Unit_Standard_pure_psC0V7jouEy1pdZ9EBR0Hw">0.0499</apre:PercentageOfOutstandingShares>
    <apre:PercentageOfOutstandingShares
      contextRef="As_Of_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_srt_StatementScenarioAxis_apre_AtEventOfElectionOfHolderMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_jryn2JxtuUiScam-ie0pMg"
      decimals="4"
      id="Narr_Pu_2GbairkqlQHmRuKKjfQ"
      unitRef="Unit_Standard_pure_psC0V7jouEy1pdZ9EBR0Hw">0.0999</apre:PercentageOfOutstandingShares>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_NhXjTaJGO0qzpt50WX1aQA"
      decimals="-5"
      id="Narr_eZPhhR4d6ESEXBadaj8FfA"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">16000000.0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_NhXjTaJGO0qzpt50WX1aQA"
      decimals="-5"
      id="Narr_OYO4Wf_YGk-fw3yvMsEY7w"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">1300000</us-gaap:PaymentsOfStockIssuanceCosts>
    <apre:ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise
      contextRef="Duration_3_11_2024_To_3_11_2024_srt_CounterpartyNameAxis_apre_CertainPurchasersMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_us-gaap_TypeOfArrangementAxis_apre_SecuritiesPurchaseAgreementMember_NhXjTaJGO0qzpt50WX1aQA"
      decimals="-5"
      id="Narr_acup2Ik8kUWCtIzB_WGojg"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">18000000.0</apre:ExpectedGrossProceedsFromPotentialFutureWarrantCashExercise>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      decimals="0"
      id="Narr_I1JD4_la00-3mgUZfCT_sQ"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g"
      decimals="0"
      id="Narr_f_VG65IQw0SMk3rq4pDEGw"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">149090</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug"
      decimals="0"
      id="Narr_nHJyNfPc20a4o26OgXbB4g"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">76031</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      decimals="0"
      id="Narr_Fn9k7rW7XEC5fB1GMDzHxg"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">363408</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA"
      decimals="0"
      id="Narr_gTjEYJTPVkOZQkvXavuVlQ"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">361598</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Tb_sHCYOpUYgU2woPy89oquTQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;6. Income Taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has no income tax expense due to operating losses incurred for the three and nine months ended September&#160;30,&#160;2024 and 2023. The Company has provided a valuation allowance for the full amount of the net deferred tax assets as, based on all available evidence, it is considered more likely than not that all the recorded deferred tax assets will not be realized in a future period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Realization of the future tax benefits is dependent on may factors, including the Company&#x2019;s ability to generate taxable income within the net operating loss carryforward period.  Under the provisions of the U.S. Internal Revenue Code and Sweden tax law, certain substantial changes in the Company&#x2019;s ownership, including a sale of the Company or significant changes in ownership due to sales of equity, may have limited, or may limit in the future, the amount of net operating loss carryforwards that could be used annually to offset future taxable income.  For U.S. and Swedish income tax purposes, the Company has not completed a study to assess whether a change of control has occurred or whether there have been changes of control since the Company&#x2019;s formation due to the complexity and cost associated with such study and because there could be additional changes of control in the future.  As a result, the Company is not able to estimate the effect of the change in control, if any, on the Company&#x2019;s ability to utilize U.S. or Swedish net operating losses or other tax attribute carryforwards in the future.  For Swedish income tax purposes, the Company&#x2019;s net operating losses may be subject to limitations in accordance with the country&#x2019;s group contribution restriction laws.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company files tax returns in Sweden, the United States, Massachusetts and Pennsylvania. Income tax returns prior to 2020 in the United States and Massachusetts are no longer subject to examination and income tax returns prior to 2017 are no longer subject to examination in Sweden. The Company is not currently under examination by the IRS or any other jurisdictions for any tax years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As tax law is complex and often subject to varied interpretations, it is uncertain whether some of the Company&#x2019;s tax positions will be sustained upon examination. Tax liabilities associated with uncertain tax positions represent unrecognized tax benefits, which arise when the estimated benefit recorded in the Company&#x2019;s financial statements differs from the amounts taken or expected to be taken in a tax return because of the uncertainties described above. Substantially all of these unrecognized tax benefits, if recognized, would benefit the Company&#x2019;s effective income tax rate.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As of September&#160;30,&#160;2024 and December&#160;31,&#160;2023, the Company had approximately $0.1 million of liabilities related to uncertain tax positions. As the Company&#x2019;s uncertain tax positions can be offset by available net operating losses, the Company did not recognize interest and penalties for 2024 and 2023.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2023_To_9_30_2023_k8UUUYOybEqporASv5v9wA"
      decimals="-6"
      id="Narr_KnJrh0lZN0KcN0pU3Q4VNQ"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2023_To_9_30_2023_v-LjngAKfEy_IbC8lBSzug"
      decimals="-6"
      id="Narr_C769ns_V-EqYxrvi4Y2_Pg"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      decimals="-6"
      id="Narr_v6TxUCPxwkaqej36HDME1Q"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2024_To_9_30_2024_6517Mi394ES2VFIg34L93g"
      decimals="-6"
      id="Narr_ceYO5sEWcEW_VYwb9WNYQw"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:LiabilityForUncertainTaxPositionsNoncurrent
      contextRef="As_Of_9_30_2024_B-SqioY7F0Cr4CUP1IEowQ"
      decimals="-5"
      id="Narr_2QEUnkXDnUyMdKnyJ8zKKQ"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">100000</us-gaap:LiabilityForUncertainTaxPositionsNoncurrent>
    <us-gaap:LiabilityForUncertainTaxPositionsNoncurrent
      contextRef="As_Of_12_31_2023_agvJLElEFkGptfHsxeyYBg"
      decimals="-5"
      id="Narr_5i_WbmqNC0OS_71tYUhsNg"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">100000</us-gaap:LiabilityForUncertainTaxPositionsNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      id="Tb_6XdxMGekK0eoUYSC-W2INw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;7. Commitments and contingencies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company records a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. As of September&#160;30,&#160;2024, the Company has not recorded a provision for any contingent losses.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualProvision
      contextRef="Duration_1_1_2024_To_9_30_2024_evSZpCMaEkSRtn4RjrAQdA"
      decimals="0"
      id="Narr_QIzVBwuwjEuF-USauq9oag"
      unitRef="Unit_Standard_USD_kvBPk_S4wkKFTfsbG_xqAw">0</us-gaap:LossContingencyAccrualProvision>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
